

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA
HONORABLE ANDREW J. GUILFORD, JUDGE PRESIDING
HSINGCHING HSU,)
)
)
)
Plaintiff,)
)
)
)
Vs.) No. SACV15-0865-AG
)
)
)
PUMA BIOTECHNOLOGY, ET AL,)
)
)
)
Defendants.)
)
)
_____)

REPORTER'S TRANSCRIPT OF PROCEEDINGS
JURY TRIAL, DAY 3
SANTA ANA, CALIFORNIA
THURSDAY, JANUARY 17, 2019

MIRIAM V. BAIRD, CSR 11893, CCRA
OFFICIAL U.S. DISTRICT COURT REPORTER
411 WEST FOURTH STREET, SUITE 1-053
SANTA ANA, CALIFORNIA 92701
MVB11893@aol.com

A P P E A R A N C E S

IN BEHALF OF THE PLAINTIFF,
HSINGCHING HSU:

TOR GRONBORG
JASON FORGE
SUSANNAH R. CONN
PATRICK COUGHLIN
ROBBINS GELLER RUDMAN &
DOWD LLP
655 WEST BROADWAY, SUITE
1900
SAN DIEGO, CA 92101

IN BEHALF OF THE DEFENDANT,
PUMA BIOTECHNOLOGY, ET AL:

COLLEEN SMITH
MICHELE JOHNSON
ANDREW CLUBOK
SARAH TOMKOWIAK
LATHAM AND WATKINS LLP
12670 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130

INDEXWITNESS:PAGE:

<u>Alan Auerbach, witness, previously sworn</u>	31
<u>DIRECT EXAMINATION (RESUMED)</u>	31
<u>CROSS-EXAMINATION</u>	158

EXHIBITS:

Exhibit 384 received	32
Exhibit 451 received	34
Exhibit 393 received	36
Exhibit 394 received	40
Exhibit 396 received	44
Exhibit 398 received	47
Exhibit 475 received	51
Exhibit 1067 received	60
Exhibit 1068 received	62
Exhibit 494 received	65
Exhibit 175 received	70
Exhibit 1012 received	71
Exhibit 1014 received	74
Exhibit 460 received	75
Exhibit 1008 received	80
Exhibit 1048 received	83
Exhibit 773 received	85
Exhibit 567 received	86
Exhibit 491 received	87
Exhibit 492 received	98
Exhibit 528 received	102
Exhibit 753 received	103
Exhibit 506 received	109
Exhibit 505 received	111
Exhibit 739 received	112
Exhibit 221 received	121
Exhibit 1007 received	122
Exhibit 480 received	150
Exhibit 1014 received	170
Exhibit 987 received	170
Exhibit DX1 marked for identification	187
Exhibit 115 received	188
Exhibit 952 received	193
Exhibit 119 received	197
Exhibit 979 received	201
Exhibit 300 received	205

1	Exhibit 922 received	207
	Exhibit 766 received)	219
2	Exhibit 482 received	49
	Exhibits 481 and 795 received	157

1 SANTA ANA, CALIFORNIA; THURSDAY, JANUARY 17, 2019; 8:45 A.M.

2 ---

3 THE COURT: Okay. Are we ready to begin?

4 MS. JOHNSON: Yes, Your Honor.

5 MR. GRONBORG: Good morning.

6 THE COURT: So we might need to go over the 9:00
7 hour on the deposition issues. Let's first focus on the
8 exhibits referenced by the defense.

9 My question today is what it was yesterday. Show
10 me where in the exhibits there is a reference to the
11 litigation that would be inappropriate or why the exhibits
12 require you to bring up the litigation.

13 MS. JOHNSON: Thank you, Your Honor. We're down to
14 two exhibits. Plaintiff has withdrawn one. Let me start
15 with Exhibit 482.

16 THE COURT: Yes.

17 MS. JOHNSON: In the second paragraph three lines
18 down, four lines down --

19 THE COURT: I'm looking at 482. I see one
20 paragraph on the first page. You're looking on the second
21 page?

22 MS. JOHNSON: Yes. I'm on the attachment.

23 THE COURT: Okay.

24 MS. JOHNSON: With the attachment is a letter from
25 Mr. Auerbach to Pfizer. He references in that second

1 paragraph that Pfizer has sent an extremely detailed list of
2 questions regarding the data. Then he, Mr. Auerbach, says,
3 we e-mailed you stating we would be supplying you with that
4 data, but most of the requested data did not exist.

5 We understand and expect that plaintiffs will use
6 these documents to say, number one, data he says he had did
7 not exist; and two, data that he provided to Pfizer was
8 different than what he had said in the conference call.

9 In order to explain why neither of those things is
10 true or nefarious, the entire context of the dispute --

11 THE COURT: That's what I'm not understanding.
12 You're cutting right to the chase. I'm not understanding
13 why -- and I even suggested yesterday there may be reasons
14 why you have to bring it up, but I'm not understanding why
15 you can't just say this was a demand from someone. You don't
16 need to know why.

17 You don't even need to tell them you don't need to
18 know why. It could have been their great uncle wanting the
19 information and not providing it. I need to know why your
20 excuse relates to the litigation.

21 MS. JOHNSON: Because the timing is important.

22 THE COURT: Keep going. I'm not there yet.

23 MS. JOHNSON: Right. They are asking for a
24 detailed list of information in the context of a legal
25 dispute with lawyers on the e-mails with lists of information

1 being requested, with advice of counsel being solicited and
2 provided on both sides regarding --

3 THE COURT: Where does it say advice of counsel? I
4 mean, let's cut to the chase. If you're telling me
5 litigation counsel said don't give it to them -- I just need
6 to hear something that relates to the case. I'm hearing
7 broad generalities. Time is important.

8 I need to know why a specific reference to the case
9 is necessary by you, and I'm not getting it. We need to cut
10 this off and move on to the deposition quickly.

11 MS. JOHNSON: I understand. Can I just say is --

12 THE COURT: Sure you can.

13 MS. JOHNSON: -- we are put in the untenable
14 position in this timed trial of listing out the previous
15 correspondence. You need -- they're asking for different
16 data. They're asking for --

17 THE COURT: I'm not getting the relationship to the
18 motion in limine. If you're now making a different objection
19 from the motion in limine, my brain will shift.

20 MS. JOHNSON: If they don't have the -- if the jury
21 does not have the context of this dispute, this long --

22 THE COURT: Why is what I need to know, I keeping
23 asking. Have a conversation there.

24 MS. JOHNSON: Okay. One second.

25 (Counsel conferring)

1 THE COURT: We need to move on to the deposition
2 unless I can get a specific statement about why I'm putting
3 you in the position where you have to bring up the
4 litigation.

5 MS. JOHNSON: It's prejudicial to say they are
6 asking for this data. We are saying it doesn't exist without
7 explaining the context of the dispute.

8 THE COURT: I -- Ms. Johnson, you said that a few
9 times. I get it. Tell me why, why you have to bring up the
10 litigation.

11 MS. JOHNSON: Because if you don't understand the
12 context of what Pfizer is asking for and why -- they've just
13 been embarrassed on a public conference call. Their CEO is
14 on an analyst call and he got a question saying Cougar turned
15 out to be a big success. Pfizer is embarrassed. Pfizer says
16 we're going to pursue all of our legal rights and remedies.

17 That colors and couches and explains what they're
18 asking for, why there is this dispute, and why this data is
19 different from what he was articulating in the conference
20 call. If they do not have that background of leading up to
21 the dispute and why these things are being asked for, they
22 will get confused or there is a high likelihood about what he
23 is saying in response.

24 THE COURT: Okay. The objection to the exhibits is
25 overruled. Now let get to the transcript. Again, I

1 mentioned earlier and perhaps not everyone was here, we might
2 have to go a little bit after 9:00 because I understand why
3 these points are important, and they get a little complicated
4 in the context of a deposition transcript.

5 Let me just say, my overall view which I think kind
6 of controls various notions is, you know, based on an
7 analysis, the hearsay rule. So let's be clear. This whole
8 deposition is hearsay, yet the parties have decided that the
9 witness is unavailable or whatever, and that provides the
10 first exception to the hearsay rule concerning the
11 deposition.

12 But within the deposition there are out-of-court
13 statements beyond just the deposition that I find
14 occasionally are subject to granting the hearsay objection.
15 Part of it is, gosh, that's a pretty broad statement that
16 hurts a particular side and the particular side ought to be
17 able to cross-examine the person who made that statement.

18 Now, you don't get to cross-examine the witness in
19 the deposition because that comes in through an exception.
20 But, gosh, maybe you should get to cross-examine the writer
21 of the memo that gets referenced. That's where it comes down
22 to.

23 The further complication is questions to this
24 witness like, did you find this ambiguous, well, that's not
25 hearsay. That's just asking the witness, did you find it

1 ambiguous. If the question is about a word in the e-mail,
2 then it gets a little complicated about referencing what he's
3 talking about.

4 To that extent the e-mail or the document would be
5 offered just to give context to the later direct statement to
6 the witness, is this a true statement, or, was it ambiguous.
7 So it gets complicated on when I might let a little bit of an
8 e-mail to come in to give context to the direct question
9 like, what do you think of this phrase.

10 I hope that was somewhat clear. I want us to make
11 sure we're talking about the same thing.

12 So I think the best way to proceed -- and then I do
13 commend the objections. I didn't get the boilerplate, which
14 I could recite in my sleep -- foundation, relevance, hearsay,
15 privilege. I got hearsay, I think, every time as I recall.

16 So I appreciate the thought that went into that,
17 but sometimes the hearsay objection applies to, you know,
18 say, 25 lines, some of which are direct questions to the
19 witness. Was it ambiguous? I'm just throwing that as an
20 example -- unrelated to the document or to any other hearsay
21 statement, and I think that comes in.

22 So on some of these I had to parse the overall
23 hearsay objection down to, say, if there was a specific
24 question within the broad statement, did you find it
25 ambiguous. I think that's an appropriate question and I

1 allowed it.

2 So we have to be very careful about what we allow
3 and what we don't allow.

4 With that, I would like assistance to make sure I
5 don't skip over anything. I believe the first objection
6 appears on -- oh, one other thing. I do not believe the
7 plaintiff ever objected to designating something as rebuttal.
8 I don't think that happened. I didn't rule on whether any of
9 the rebuttals were inappropriate because not part of the rule
10 of completeness or for some other reason.

11 I'm just saying I didn't rule on that. If you want
12 me to rule on rebuttals, I didn't do so. I'm only ruling on
13 the objections provided by the defense which are uniformly
14 hearsay and I believe start on 126.

15 Does anyone have -- am I right, starting on 126
16 where I first see an objection?

17 MS. CONN: Yes, Your Honor.

18 THE COURT: Okay. Now, this says Exhibit 316 is an
19 e-mail from you to Gross dated whatever; subject line, major
20 stock upside increasingly dependent on M&A Cowen and Company.
21 That is an out-of-court statement that I would be inclined to
22 sustain.

23 What is the argument, if any, on that?

24 MS. CONN: Thank you, Your Honor. I would just
25 like to emphasize that for this objection and also for the

1 remaining objections, the analyst who's being deposed, his
2 analyst reports have already been admitted into evidence. We
3 agreed to waive our hearsay objection to those reports, but
4 we do think it's important to also give the --

5 THE COURT: Oh, I thought you were admitting the
6 analyst reports. Did I miss something?

7 MR. COUGHLIN: No, Your Honor. We're admitting the
8 analyst reports with the limiting instruction.

9 MS. CONN: Correct.

10 THE COURT: I thought you were asking that they be
11 admitted.

12 MS. CONN: That's correct, Your Honor.

13 THE COURT: Then I'm a little -- you are asking
14 that they be admitted, so I don't understand your argument.
15 Sorry. If you were asking that they were admitted, I don't
16 know how that cuts with this is more evidence.

17 Go ahead.

18 MS. CONN: The point I was trying to make is that
19 the analyst reports are coming into evidence. We think it's
20 important to give the context of his state of mind when he
21 was writing those reports. And as --

22 THE COURT: Okay. That's --

23 MS. CONN: -- referenced, there's a limiting
24 instruction for the reports. We think the e-mail should also
25 come in with a similar limiting instruction.

1 THE COURT: Okay. I understand that argument.
2 Give me a moment to think about it.

3 Okay. You're not offering that to prove the truth
4 or falsity. You're offering it for state of mind. I get
5 that. State of mind is much abused and not as broad as some
6 people would like, but you want this to come in on state of
7 mind.

8 Just a moment. I understand the argument.
9 Anything further on this first question on page 128?
10 Anything further from the plaintiff -- I'm sorry, 126.
11 Anything further from the plaintiff on that?

12 MS. CONN: No, Your Honor.

13 THE COURT: Okay. I am going to sustain the
14 objection to that statement.

15 Next, page 128. I have myself sustaining up to
16 line 16 but then overruling after line 16. So when it says
17 you go on to say, quote, I think we always knew that Alan is
18 incapable of launching, et cetera, I believe that's an
19 out-of-court statement offered to prove the truth of that
20 point, that Alan is incapable. So I'm sustaining.

21 But then on line 17 you say: Could you elaborate
22 on that? Did you believe that the M&A excerpt was the
23 primary driver of Puma stock evaluation? I think that can
24 get answered.

25 MR. CLUBOK: We agree, Your Honor. That's

1 appropriate.

2 THE COURT: Okay. Thank you. So that's the issue
3 I always said. And I would look and see, does the plaintiff
4 need the context of what it says to understand this. This
5 question, who asked this question by the way? I mean, it's
6 well asked.

7 MR. CLUBOK: I'm not certain. Someone --

8 THE COURT: All right.

9 MS. CONN: Our counsel in the back.

10 MR. CLUBOK: Marco asked it.

11 THE COURT: You asked a good follow-up question
12 which you would ask a witness: Do you believe that the M&A
13 stock was the primary driver? You can ask that.

14 MR. CLUBOK: And, Your Honor, just to be clear,
15 just because the objection, compound, vague, we have waived
16 that objection.

17 THE COURT: Oh, I didn't see an objection.

18 MR. CLUBOK: It's in there, but I just --

19 THE COURT: Where is it in there? In my version I
20 don't see it.

21 MR. CLUBOK: Your Honor, it's just in the
22 transcript, if you look at the --

23 THE COURT: Oh, I see it.

24 MR. CLUBOK: We're not making that. You are
25 correct to note that we are not trying to claim that here.

1 THE COURT: Okay. So I would tell the videographer
2 to remove the objection.

3 MR. CLUBOK: Yes. We have the capability to do
4 that.

5 THE COURT: So you should remove objections stated
6 on the record.

7 All right. So on page 128, sustained up to line
8 17. Overruled from 17 to line 2. That gets us to 130,
9 page 130.

10 All right. I would overrule the objection through
11 line 10 on the next page. And then I have sustained the
12 objection lines 11 through 19 and overruled the objection for
13 the rest of the input, the rest of the designation.

14 So stated differently, I am sustaining lines 11
15 through 19 on page 131, and I am overruling the objection for
16 everything else. So I guess I need to look to the plaintiff
17 to talk me out of allowing everything but lines 11 through 19
18 on page 131.

19 Feel free to make your argument.

20 MS. CONN: I think we're fine with that, Your
21 Honor.

22 THE COURT: Who said that?

23 MS. CONN: I did.

24 THE COURT: Okay. So that's what we'll do.

25 MR. CLUBOK: I'm sorry, Your Honor. May I just

1 respond to the part that you're allowing in?

2 THE COURT: Yes, please.

3 MR. CLUBOK: So I think, if I have it right, you
4 are sustaining lines 11 through 19 and letting in the
5 previous lines. We agree with that. The problem we have,
6 Your Honor, is when you pick up with line 20, it's really
7 multiple hearsay. It's -- he's basing it on --

8 THE COURT: I'm sorry. I misspoke when I asked the
9 plaintiff. I should have been asking the defense.

10 MR. CLUBOK: Oh, excuse me.

11 THE COURT: My mistake. Go ahead.

12 MR. CLUBOK: That's okay.

13 THE COURT: So now let's look at this carefully
14 because -- yes. Okay. So looking at line 20, go ahead.

15 MR. CLUBOK: Right. So line 20 he's -- this is
16 hearsay within hearsay, I think, or at least double. He's
17 reporting conversations he supposedly had --

18 THE COURT: Okay. Forgive me for interrupting,
19 but, you know, discussions with investors, consensus appeared
20 to be around four percent. I'm interpreting that as not
21 offered to prove that it's around four percent but offered to
22 prove what the investors were thinking independent of the
23 facts.

24 So that's a typical hearsay exception. Tell me why
25 I'm wrong on that. I could be wrong on that because I don't

1 fully grasp all the necessary context. Why is that not
2 offered to prove but just offered to -- you know, if the
3 investors said this is really important to us, four percent,
4 four percent is irrelevant. The fact is that is important to
5 them.

6 MR. CLUBOK: So, Your Honor, the more hearsay
7 within hearsay you go, the further away you get from being
8 able to cure this by referring to the state of mind or the
9 other exceptions to hearsay.

10 THE COURT: Not offered to prove.

11 MR. CLUBOK: Yes. So if this will appear to the
12 jury -- and we do not think a limiting instruction can
13 properly cure it -- as if these other investors actually said
14 it. We can't cross those other investors on what they said,
15 whether it's really true that other investors are saying it
16 and which other investors.

17 By the way, Your Honor, this exchange is with
18 Mr. Gross, a very -- an investor that has a troubled
19 relationship with Puma. There were some accusations against
20 Mr. Gross.

21 THE COURT: Is this Bill Gross?

22 MR. CLUBOK: No, no, not that Gross, Your Honor. I
23 think it's Phil Gross. So it rhymes with Bill. But --

24 THE COURT: I understand what -- I might change my
25 mind on this. Let me look more carefully. Tell me about

1 multiple hearsay you see in line 20. Who are the different
2 declarants?

3 MR. CLUBOK: Unnamed investors that we can't
4 cross-examine who supposedly made these statements out of
5 court that I understand why they would like to say a limiting
6 instruction can cure it, but the jury will surely take this
7 as truth that investors are saying this.

8 When he's talking to -- and particularly in this
9 conversation he's talking to Phil Gross, an investor who is
10 constantly complaining -- and we could get into an
11 explanation of why Phil Gross's statements are not true.

12 He's trying to -- whether or not Mr. Schmidt is
13 trying to curvy favor with Phil Gross is another sideshow.
14 But certainly when he tells Phil Gross to sort of placate him
15 that, oh, yes, other investors are saying this, the jury is
16 going to believe that that is true, and there's lots of
17 reasons why it may not be. But we certainly can't
18 cross-examine those other investors and prove that it's not.

19 So this is where a limiting instruction we just do
20 not believe will sufficiently cure it. The jury will take
21 this as being true. They will not just take it as this is
22 what he thought. They'll take it as he's telling the truth
23 and truthfully reporting the content of these out-of-court,
24 unnamed, untimed discussions with whoever investors we don't
25 know. That's the big problem here.

1 THE COURT: All right. Anything further on the
2 designations on 131, 132, 133?

3 MS. CONN: Your Honor, if I may --

4 THE COURT: Actually I want to hear from the
5 defense here.

6 MS. CONN: I'm sorry.

7 MR. CLUBOK: I'll just say one other thing. He
8 reports with what these investors supposedly say, then he
9 reports what they supposedly believed. He goes on to say,
10 well, why did they say that? And he says, oh, it's because
11 of what Alan said.

12 He's reporting a lot of what supposedly they said
13 and supposedly why they believed it. And all of it is going
14 to seem like he's reporting a truthful report of these
15 unnamed conversations that we can't properly rebut, and a
16 limiting instruction doesn't cure that in this case, we
17 think.

18 THE COURT: Okay. I think the cross-examination
19 you seek would be cross-examination of Mr. Schmidt: Did the
20 investors think this? Are you sure about that, et cetera?
21 And I am going to stick with my ruling.

22 So on the designation beginning on page 130 and
23 going through 133, it's all allowed except for 11 through 19
24 on page 131.

25 MR. CLUBOK: And may I just add one thing for the

1 record, Your Honor? I assume Your Honor knows this, but
2 obviously Mr. Schmidt is not being called as a witness here.

3 THE COURT: Well, yeah, I know that.

4 MR. CLUBOK: Okay. Thank you.

5 THE COURT: Then on page 134 I'm sustaining lines 2
6 through 6. Yeah, you need to cross-examine Mr. Sanayha
7 [phonetic] as to what he meant by that, and you don't get a
8 chance to do that. I'm sustaining lines 2 through 6 on page
9 134.

10 Any response?

11 MS. CONN: No, Your Honor.

12 THE COURT: And then I'm overruling lines 14
13 through 17, which may become irrelevant since I am then
14 sustaining through line 6. So 18 through line 6, line 18
15 through line 6, yeah, I'm sustaining all of that.

16 So any response to me sustaining that objection
17 through line -- actually through line 5?

18 MS. CONN: No, Your Honor.

19 THE COURT: Okay. Then I'm going to overrule the
20 objection 6 through 25, and I invite defense to tell me where
21 I'm wrong on that.

22 MR. CLUBOK: That's fine, Your Honor. Given the
23 other rulings you've made, we would agree with that.

24 THE COURT: Okay. Good. All right. Then moving
25 on, page 138, I'm sustaining that. Again it's an exhibit

1 with a significant subject line, and I'm sustaining that.

2 Any objection? Any response?

3 MS. CONN: No, Your Honor.

4 THE COURT: Okay. On 140, I am overruling as to
5 the statements on 140 and 141. You know, direct question
6 from our friend in the back there: Is there anything else
7 that you can think of that may have been the cause of that
8 drop? That's an appropriate question.

9 There's a slight reference to a document that the
10 deponent wrote at the beginning, but that's being provided
11 just to give context to what else is said. So that's what
12 I'm ruling on page 140 to 141.

13 Any response from the defense? Feel free. Take
14 your time, because there's a lot of little statements --

15 Mr. CLUBOK: I appreciate that, Your Honor.

16 THE COURT: For example, there's a reference to
17 Mr. Gordon on line 21 that's not a statement offered to prove
18 the truth of the matter. That's a statement that gives
19 context to the response.

20 Go ahead.

21 MR. CLUBOK: I guess my only question is, does that
22 mean that you are allowing this statement to be read but not
23 the underlying document to be admitted?

24 THE COURT: Oh, I'm not allowing the document.

25 MR. CLUBOK: Okay. In that case, Your Honor, then

1 I think we won't have an objection. If you just give me one
2 moment.

3 THE COURT: Feel free. Again, it gets a little
4 dicey in there.

5 MR. CLUBOK: Yeah. We appreciate that. And it's
6 through line? I apologize, Your Honor.

7 THE COURT: Say again.

8 MR. CLUBOK: The whole thing you're allowing in?

9 THE COURT: Yes.

10 MR. CLUBOK: Okay.

11 THE COURT: Anytime there's a reference to another
12 person's statement, I believe that's being offered not to
13 prove the truth of any assertion but to establish context.

14 MR. CLUBOK: Okay. Your Honor, we understand your
15 ruling.

16 THE COURT: Okay. Then --

17 MR. CLUBOK: And we --

18 THE COURT: By the way, that's a good thing to say.
19 I don't want you to waive your objection on appeal.

20 MR. CLUBOK: Yes.

21 THE COURT: Seriously.

22 MR. CLUBOK: We appreciate that.

23 THE COURT: Saying you understand -- be careful in
24 these kinds of discussions, also in jury instructions.
25 Sometimes your statement might be deemed a waiver. I like

1 the notion, we understand, without saying that's okay.

2 You're not saying that's okay.

3 MR. CLUBOK: That's what meant, Your Honor. Thank
4 you.

5 THE COURT: I agree with you.

6 Okay. Page 153, I'm sustaining all of that. It's
7 an exhibit with an interesting subject line. Yeah, the
8 defense ought to be able to cross-examine the guy that wrote
9 that subject line and parse what it means or doesn't mean.
10 So I'm sustaining page 153.

11 Any response from the plaintiff?

12 MS. CONN: Just to be clear, Your Honor, this is an
13 e-mail that Mr. Schmidt himself was the author of, so there
14 was the opportunity to cross-examine him on that.

15 THE COURT: That's a very good point.

16 MS. CONN: I would also like to, if I could,
17 revisit the issue of the underlying documents. I know you
18 referenced with respect to the last designation that you're
19 not inclined to allow the e-mails in. I would just --

20 THE COURT: I've not looked at that issue at all.

21 MS. CONN: Okay. I just want to --

22 THE COURT: I hope it will come up at a different
23 time. Right now I want to focus on the transcripts so we can
24 get moving along. I wasn't asked anything about the
25 admission of documents.

1 MS. CONN: Okay.

2 THE COURT: And I understand of the defense is
3 going to object, and I can't make a ruling on that.

4 MS. CONN: That's fine, Your Honor.

5 THE COURT: Okay. You know, here we get into
6 notions of prior consistent statement. Just because the
7 person on the stand has a prior consistent statement doesn't
8 always or necessarily allow it to come in. Here under the
9 record -- under the record made to me, I'm going to sustain
10 that objection.

11 Moving on to pages 155, I'm overruling all of that
12 on page 155.

13 MR. CLUBOK: Nothing further from the defense on
14 that objection, Your Honor.

15 THE COURT: That all comes in. And we move on to
16 157. I'm overruling everything on 157 and sustaining on 158.

17 So I'd ask the defense to look carefully at what
18 I'm overruling on 157 and give me a response. He asked a
19 specific question: You believe his credibility was shot
20 after this announcement? The answer is yep. So I'm allowing
21 the first part in for context and the last part in because
22 it's a direct statement from the deponent.

23 What does the defense say?

24 MR. CLUBOK: We understand your ruling, Your Honor.

25 THE COURT: I got it. Okay. I got it.

1 Then I'm sustaining 158. Any response from the
2 plaintiff?

3 MS. CONN: No, Your Honor.

4 THE COURT: Okay. Then 160, I'm sustaining on what
5 he goes on to write here. I'm sustaining up until line 20,
6 and then I'm allowing line 20 on because he is confirming the
7 response. So the response is giving context, and what's
8 being offered to prove is his confirmation of that.

9 So page 160 to 161, sustained through line 20 and
10 overruled as to line 20 on. You could suggest that him
11 reading his response is a hearsay statement, but it's offered
12 in context and it largely becomes moot, in fact indeed
13 becomes moot because he accepts it there while he is
14 speaking.

15 So that's my ruling. Any response?

16 MR. CLUBOK: We understand.

17 THE COURT: You understand. Good. All right.
18 Moving on. We're getting close here, folks.

19 Okay. Page 178, sustained. Again it's a re line,
20 Cowen report. I'm sustaining that, but I'm overruling pages
21 179 through 180. If I'm right on this, that is a statement
22 that defense wants to present since it's in yellow and the
23 plaintiff is objecting.

24 MR. CLUBOK: This was our provisional rebuttal in
25 case you overruled some of our objections. So we now have it

1 in here.

2 MS. CONN: No, Your Honor. Plaintiffs are not
3 objecting.

4 THE COURT: So actually it was defense's objection
5 to their own rebuttal? You mentioned that yesterday.

6 MR. CLUBOK: I'm sorry. Maybe I misunderstood.

7 THE COURT: Let's make sure we're clear here.
8 Pages 179 and 180, in my book it is yellow. It means that
9 the defense is offering it, which would suggest the objection
10 comes from the plaintiff. But maybe the plaintiff is saying
11 you didn't object. The defense objected to their own lines.

12 The explanation might be that the defense was being
13 careful, et cetera, et cetera, and contingent. So just talk
14 amongst yourselves over there. I'm allowing all of that in,
15 which should be a good thing for the defense.

16 MR. CLUBOK: There's no objection, Your Honor.

17 THE COURT: All right. Moving on. Okay. Good.
18 We're getting close. Page 188 -- and the poor videographer,
19 I hope you're making proper notes. I'm trying to be as clear
20 as possible. And I can hand you my version which I think
21 pretty much reflects what I'm saying. All right. 138 [sic],
22 overruled.

23 MR. CLUBOK: I beg your pardon? What page?

24 THE COURT: I'm on page 189. Excuse me, 189 says,
25 I'm handing you what's been marked as Exhibit 329. I'm

1 allowing that in, but I'm sustaining on page 190 beginning at
2 line 10 down to line 19. Here Thomas Reuters is asking,
3 quote: How are you? PBYI is down a bunch for the second day
4 in a row, et cetera, et cetera. I'm sustaining all that.
5 It's what Thomas Reuters is asking. So I'm sustaining down
6 to line 19. Stated again, everything on 189 is acceptable.
7 Objections overruled. On page 190, sustained down to
8 line 20. I'm allowing, so are you aware, et cetera, Puma
9 stock price dropped, on page 190 through 191. I'm allowing
10 that.

11 You can ask the witness: Are you aware that the
12 stock dropped? That's my ruling there. Any response from
13 anyone?

14 MR. CLUBOK: No, Your Honor.

15 THE COURT: Hearing none, we're moving on. And I
16 believe that takes --

17 MS. CONN: That was the last one.

18 THE COURT: Excuse me? I think that takes care of
19 all the objections. So there we have it.

20 Folks, I don't think I altered my rulings here. I
21 don't know if it would be helpful for the videographer to see
22 the notes I took last night.

23 MR. CLUBOK: May I add one final --

24 THE COURT: Please.

25 MR. CLUBOK: In context now, and I appreciate now

1 that we've seen it all, I'm going to just revisit slightly if
2 I may the one that we had the vigorous exchange about, which
3 is at the bottom of page 131 where he's purporting to report
4 the consensus from discussions with investors and then what
5 those investors supposedly based those discussions on.

6 At the very least, Your Honor, can we get a
7 limiting instruction?

8 THE COURT: Oh, you absolutely get a limiting
9 instruction. Remind me to give the limiting instruction. I
10 think at the conclusion of the videotape, the limiting
11 instruction should come if you request it, and I would say
12 this isn't offered to prove -- well, when do you think I
13 should make it?

14 MR. CLUBOK: This one has to be more there's no
15 proof he had those discussions. There's no truth that they
16 actually said that. He said he's reporting what --

17 THE COURT: What page are you on?

18 MR. CLUBOK: This is the bottom of page 131 through
19 page 132.

20 THE COURT: Okay.

21 MR. CLUBOK: I think this particular limiting --

22 THE COURT: I'm going to instruct the videographer
23 to stop at 131, line 19. I will say: We're about to receive
24 information that is not offered to prove the truth of the
25 information but is offered to prove what people thought might

1 or might not be true.

2 If you want to expand on that, let me know.

3 MR. CLUBOK: Your Honor, that is proving the truth
4 of something, to prove he -- he is saying --

5 THE COURT: Hold on. Now you're switching gears on
6 you. I just want to be clear. Back to the merits and not to
7 what I'm going to say.

8 MR. CLUBOK: I'm sorry, Your Honor.

9 THE COURT: It's all right.

10 MR. CLUBOK: The limiting instruction I think is
11 not going to cure the problem. That's the way I should have
12 phrased it.

13 THE COURT: Okay. I understand. Okay. On
14 page 131, line 20, the videographer is to stop and I will say
15 something. But my ruling is that it is as it is.

16 Anything else from anyone before we begin?

17 MS. CONN: No, Your Honor.

18 THE COURT: Okay. I hope someone got a hold of
19 Mr. Coughlin's coffee this morning and put in a little decaf.

20 MR. COUGHLIN: Your Honor, before the jury comes
21 out, maybe I could ask this. When I apologized to the court
22 reporter yesterday, she indicated that it wasn't how fast we
23 were talking but it was that we were talking over each other.

24 So I will try not to talk over Mr. Auerbach and
25 just maybe try to stop him versus talking over him. And if

1 we could do the same, it would help.

2 THE COURT: Was the issue just talking over or
3 speed?

4 Let me just say, do you know how many pages we got
5 yesterday? In the normal course of the trial, we usually get
6 225 or so. Yesterday we had 290, which suggests to me it's a
7 speed issue.

8 MR. COUGHLIN: Understand.

9 THE COURT: Speed isn't necessarily a problem. As
10 I said, I married someone because she spits it out quickly
11 and I get it and I move on. But here, gosh, I could try and
12 figure out the percentage of 290 to 225. It's a big
13 percentage increase. So it's not just talking over. I think
14 it's also speed, based on the page estimate.

15 So with that, I think we're ready to go.

16 MS. CONN: Your Honor, my videographer would like
17 your transcript.

18 THE COURT: Yes.

19 (Court and clerk conferring)

20 THE COURT: If you have any questions -- you know,
21 I'm putting marks. When I put -- actually I put overruled
22 with a down arrow, and it looks like I'm making a male
23 symbol. But it really is overruled, with a down arrow.

24 (Open court - jury present)

25 THE COURT: Welcome back, folks. Sorry for the

1 delay. I really don't like having jurors sit out there. We
2 actually started well before the 9:00 hour to go over some
3 evidentiary issues where both sides are making excellent
4 points on issues about what should be admitted and what
5 shouldn't be admitted.

6 I was hoping it would last until 9:00. It
7 obviously lasted until 9:25. So I apologize for that.

8 You may continue, counsel.

9 MR. COUGHLIN: Thank you, Your Honor.

10 **Alan Auerbach, witness, previously sworn**

11 **DIRECT EXAMINATION (RESUMED)**

12 BY MR. COUGHLIN:

13 Q. Good morning, Mr. Auerbach.

14 A. Good morning.

15 Q. If you take a look at the binder and open up to
16 Exhibit 384, I'm going to ask you some questions about that.

17 MR. COUGHLIN: I'm going to ask that this exhibit
18 with no objection to it be admitted into evidence.

19 THE COURT: Okay. So for starting off, let me just
20 say that there was in the pretrial conference order reference
21 to objections or non-objections. When counsel tells me there
22 is no objections, I'm accepting that and I will simply say
23 admitted without objection.

24 That may require the defense to hustle and check
25 and double-check. If I make that statement and all of a

1 sudden you think there's a mistake, speak up. But if you're
2 not objecting, we'll just move on.

3 So when I say admitted without objection, I'm
4 assuming there's not an objection. That doesn't mean that
5 three later you might say, Your Honor, wait. There is an
6 objection. It's just a way to move it along.

7 Go ahead.

8 Admitted without objection --

9 **(Exhibit 384 received)**

10 MR. COUGHLIN: Thank you, Your Honor.

11 THE COURT: -- on January 17th. Good.

12 BY MR. COUGHLIN:

13 Q. Mr. Auerbach, if you could take a look at this document.
14 It's from Bin Yao. Who is Bin Yao?

15 A. Bin Yao is the head of biostatistics at Puma.

16 Q. Okay. And he writes to you on July 24th, 2014; is that
17 correct?

18 A. Yes. That's correct.

19 Q. Okay. And first he tells you, I guess he's excited
20 about the increase, the 295 percent increase in the stock,
21 and then he talks about access to the results. Did he have
22 access to the results, can you recall, on July 22, 2014, the
23 date of the conference call?

24 A. I don't recall if he had access to the unblinded data.
25 I know he had access to the entire data set because he had

1 confirmed the number of events in the study. I believe that
2 was blinded data.

3 I don't recall if at this juncture he had access to
4 the unblinded data.

5 Q. He certainly had access to some data; is that correct?

6 A. I think that's correct, yes.

7 Q. Okay. So let's take a look down at what he's asking
8 about some things, some things to do. I'd like to focus
9 basically on the last two bullet points. There he asked
10 that -- some things to do, and he talks about the DFS,
11 DFS-DCIS by interval, the top two lines, by node HR status,
12 region HR2 status, grade of tumor, and other factors.

13 I assume he's talking about doing analysis of those
14 various subgroups; is that correct?

15 A. I believe that's correct, yes.

16 Q. Okay. And then the next he talks about the DF curves
17 beyond the two-year truncation: Granted, it may be biased,
18 but if one believes the information available is random, the
19 curves beyond two years may still be indicative of the truth.
20 We have probably eight events in the past two years that were
21 not included in the primary DFS analysis, and these are not
22 enough to provide much additional information. But at the
23 formal data lock, there may be more.

24 Do you see that?

25 A. Yes, I do.

1 Q. Does that refresh your recollection about how many
2 events that you had going out beyond two years?

3 A. I believe he's making an estimate of it, I don't know,
4 where he says we probably have eight events past two years.
5 But I don't think he actually has the number.

6 Q. Okay. Let's flip over of the next -- let's flip over to
7 the next page. Here it's August 13th, and this is Alvin
8 Wong. And who is -- well, wait a second.

9 MR. COUGHLIN: The next document is 451, and I
10 don't believe there's any objection to this document, Your
11 Honor. I'd move it to be admitted.

12 THE COURT: Without objection 451 is admitted.

13 **(Exhibit 451 received.)**

14 BY MR. COUGHLIN:

15 Q. Who is Alvin Wong, if you could tell us?

16 A. Alvin Wong is the senior vice president of clinical
17 sciences at Puma.

18 Q. Okay. And he's talking about amendment nine in this
19 document. Can you refresh our recollection about what
20 amendment nine was?

21 A. Amendment nine was the truncation of the study that was
22 performed by Pfizer prior to Puma licensing the drug.

23 Q. It was the cutoff at two years, 28 days, right?

24 A. Correct.

25 Q. And he says: There's very few patients who we have data

1 in the clinical database with follow-up for three years. But
2 then he goes on and he charts that data in the next two
3 pages; is that correct?

4 A. I need to review this document. I do see he says
5 approximately 50 percent did have some exams over the
6 two-year period but fell short of the three. So I'm assuming
7 what that means is we had data out past two years but not out
8 past three years.

9 Q. Yes. And I think the chart on the next page shows some
10 of that.

11 A. Okay.

12 Q. Okay. If you take a look down there, the chart -- let's
13 say past 24 months you start seeing the lines on the chart as
14 they drop down for the data and about the data that you have.
15 And then down below when we talk about randomization and DFS
16 events, it has 73 and 113. And the numbers we looked at
17 yesterday were 70 and 109. Do you recall that?

18 A. I seem to remember there were roughly 179 in the
19 two-year data, so this would be 186. That would be an
20 increase of seven events.

21 Q. Right, seven events in the third year?

22 A. Right.

23 Q. Okay. So that's about -- does that refresh your
24 recollection now in August about how many dates you had going
25 out into the third year -- events?

1 A. Yes.

2 Q. Okay. Now, let's take a look at Exhibit 393 --

3 MR. COUGHLIN: -- which there is no objection to,
4 Your Honor, and I would like to admit into evidence.

5 THE COURT: Without objection 393 is admitted.

6 **(Exhibit 393 received.)**

7 BY MR. COUGHLIN:

8 Q. This is a document dated September 10, 2014, from Bin
9 Yao, the head of your biostatistics. If I could have you
10 take a brief look at this document.

11 A. (Witness complies.)

12 Q. And where I want to direct your attention is to page 11
13 of 23. Do you see this proportional hazard assumption?

14 A. Yes.

15 Q. You understand what that is, right?

16 A. Yes.

17 Q. Okay. And in the second dash, it says: When the
18 assumption is violated, interpretation of a single hazard
19 ratio may not be adequate. Additional implication of a
20 non-constant hazard ratio over time is the extrapolation
21 beyond two years and will be more tenuous given the current
22 data or truncated at two years. Do you see that?

23 A. Yes, I do.

24 Q. If you flip over to the next page, there's an
25 investigation that was done to the hazard estimates over

1 time. Do you see that?

2 A. Yes.

3 Q. And what Mr. Yao has done is he has taken -- at about
4 six-month intervals he has calculated what the hazard ratios
5 are going out for the data that you have. Do you understand
6 that?

7 A. Yes, I do.

8 Q. Okay. And do you see in the last six months that the
9 hazard ratios cross; that the neratinib arm crosses the
10 placebo?

11 A. Correct.

12 Q. And that indicates that the hazard ratio has been
13 violated; is that correct?

14 A. I believe that's correct. I know Dr. Yao will be a
15 witness in this. He is much more able to discuss this than I
16 am.

17 Q. We'll talk more about it with him. Okay.

18 And if we flip back to the last page I believe of
19 that document, which is page 23 -- well, let's go back to
20 that chart for a second. So that chart basically shows that
21 all of the efficacy for neratinib basically occurs in the
22 first six months; is that correct?

23 A. Can you explain how you are coming to that conclusion?

24 Q. I'm looking at the neratinib arm which is up above .003.
25 I'm sorry. It's down at the bottom. And the placebo arm

1 starts up at .003. And there's a widening right there at
2 those curves, and then they come together in the last six
3 months of the two-year study.

4 A. Again, the goal of neratinib is to prevent breast cancer
5 recurrence. Right? So if your hazard ratio in the neratinib
6 arm is lower than that in the placebo arm, that can be
7 generally viewed as neratinib having efficacy.

8 If I look at those two curves, it appears that the
9 hazard rates of the neratinib arm is lower than the placebo
10 arm for the first -- I'm estimating that at 18 months.

11 Q. I would give it 20 months.

12 A. And then after of that period is where the hazard
13 changes.

14 Q. Understand. I just wanted to make sure we were on the
15 same page.

16 And if we take a look now at next steps at the back
17 of the page -- and that's page 23 of 23 -- Mr. Yao is talking
18 about next steps to be done?

19 A. Uh-huh.

20 Q. And he's talking about extrapolating DFS curves beyond
21 two years. Do you see that?

22 A. Yes.

23 Q. You hadn't had any curves done before this time frame;
24 is that correct?

25 A. No, that is incorrect. Claire Sherman, who is our other

1 statistician -- in the company we had both Bin Yao and we had
2 Claire Sherman. Claire Sherman and Bin were at the same
3 level, if you will. Claire is the one who had done all of
4 the analyses of the ExteNET data. Bin then, I believe,
5 requested access so he could do his own analyses of it. So
6 you have two different statisticians doing analyses.

7 Claire I believe was the one who did the first
8 three-year analyses, and now Bin is asking that he do them as
9 well.

10 Q. Right -- the ones that we don't have and can't find?

11 A. I believe we have been able to recreate those --

12 Q. In 2018?

13 A. -- in the exact same data set that was available in July
14 of 2014.

15 Q. And do you know when Claire was first asked, she said
16 she didn't do it. You know that?

17 A. I believe she said later in her deposition that she
18 actually may have done it and needed to think about it,
19 something to that extent.

20 Q. But she would have kept a record of it, right?

21 A. I -- I don't know the answer to that.

22 Q. Okay. Let's flip over to the next page -- sorry. I
23 mean Exhibit 394.

24 MR. COUGHLIN: There's no objection, Your Honor, so
25 I'd move for its admission.

1 THE COURT: 394 is admitted.

2 **(Exhibit 394 received.)**

3 BY MR. COUGHLIN:

4 Q. Mr. Auerbach, I'd like you to take a look at this. This
5 is Bin Yao in October 4, 2014, and this is a communication
6 from you to him. Do you see this?

7 A. Yes, I do.

8 Q. Okay. If I asked you to take a look at this document,
9 it appears if we go down to the bottom of the document it
10 says: Lastly we discussed trying to simulate a three-year
11 DFS curve using the same trends that we have seen in the data
12 thus far and continuing them. When do you anticipate being
13 able to do this?

14 Do you see that?

15 A. Yes, I do.

16 Q. Now, you said you had already seen the real ones, right?

17 A. Correct. However, the real ones that we saw were based
18 on a very low number of events. So our curiosity was whether
19 there would be a way to take the recurrence patterns, so, you
20 know, take the patterns we've seen for the breast cancer
21 coming back in these patients, and if there would be a way to
22 perform simulations called Monte Carlo simulation where you
23 kind of look at, you know, assuming the current recurrence
24 rate, assume a lower recurrence rate, assume a higher one,
25 and see what the three-year curves would look like.

1 Q. Is Monte Carlo the gambling type simulations?

2 A. I don't know if there is a correlation between these
3 statistical Monte Carlo simulation and the casino. I don't
4 know the answer to that, but it's a statistical term called
5 the Monte Carlo simulation.

6 Q. Okay. If you take a look at the top, it says -- and you
7 ask him for a timeline, and he tells you, you know, that it
8 should be next Wednesday, and this timeline will work fine
9 with you. When do the three-year simulations you can do for
10 both the DFS -- that's the topline results, right?

11 A. Correct.

12 Q. And the other topline DFS-DCIS, right?

13 A. That's correct.

14 Q. If we switch over to the next page, 394, you actually
15 sent him a list of things that you want done -- 394, page 3
16 of 5. And I'd like to direct your attention to the top of
17 that page.

18 A. Correct.

19 Q. In those you're asking him to do some curves one, two,
20 and three years out; is that correct?

21 A. Hang on. Yes, correct.

22 Q. And down below you're asking him to do some similar
23 analysis on the various subgroups that we were talking about
24 yesterday; is that correct?

25 A. Can you show me where you're --

1 Q. I'm talking about subgroup and sensitivity analysis.

2 I'm talking about the third paragraph down, subgroup and

3 sensitivity analysis.

4 A. Yes.

5 Q. You're asking him to do some of the same analysis there?

6 A. That is correct.

7 Q. Okay. Now, if we switch to the last page of that

8 document, 5 of 5, I'd like to take a look at that chart.

9 That chart comes out of the efficacy analysis that I believe
10 you received on July 17th?

11 A. Correct.

12 Q. Okay. And yesterday we were talking about dropouts
13 versus discontinuation, and we had looked at some numbers of
14 discontinuation. We had first looked at discontinuation due
15 to diarrhea. I think it was 16.8. And then discontinuation
16 for all AEs, and that was 27.6.

17 Here if you take a look at the number of subjects
18 that discontinued before completing part A, we have a 16.6
19 number. Do you see that there? It's 16.3. I'm sorry.

20 A. Yes.

21 Q. So is that the number that discontinued before
22 completing part A?

23 A. That's discontinued the drug. It's not dropped out of
24 the study.

25 Q. So this is just -- it's not the dropout number?

1 A. No.

2 Q. Okay. You don't know the dropout number; is that what
3 you're saying?

4 A. No. From the data we discussed yesterday, if you
5 remember, the dropout due to diarrhea I believe was
6 1.6 percent.

7 Q. The dropout rate for diarrhea alone -- you're talking
8 about discontinuation due to diarrhea?

9 A. No. There's two different things.

10 Q. Yes. The dropout rate is 1.6.

11 A. There's discontinuation due to diarrhea. The patient
12 discontinues but they continue to go visit their doctor every
13 three months and get checked to see whether or not their
14 cancer has come back. Dropout means they've physically left
15 the study and we get no more data from them.

16 Q. They didn't ever show back up. That's what you mean?

17 A. Correct.

18 Q. And they did that as a result of an adverse event,
19 correct?

20 A. Their reason stated for why they were dropping out of
21 the study, and we never got any more data past that time
22 period. It is an adverse event, yes.

23 Q. Right. So we have the discontinuation rate, and that's
24 the 16.8. And then we have the discontinuation rate for
25 diarrhea, discontinuation rate for all adverse events, and

1 that's 27.6, right?

2 A. Right.

3 Q. And then we have a lack of follow-up, and that's 1.6; is
4 that right?

5 A. Correct.

6 Q. Okay. And you knew that as of -- those three numbers
7 you knew as of July 17th; is that correct?

8 A. Yes, correct.

9 Q. Let's flip to Exhibit 396.

10 MR. COUGHLIN: I believe 396 has been admitted. I
11 mean, not admitted. I'm moving for its admission. There's
12 no objection.

13 THE COURT: 396 is admitted without objection.

14 **(Exhibit 396 received.)**

15 BY MR. COUGHLIN:

16 Q. So in October, a couple months after the call, you're
17 asking him to do these simulations, and he does the
18 simulation for you. Can you take a look through 396 and
19 refresh your recollection?

20 A. Yes. (Witness complies.)

21 Q. Let's flip over on the first page. That's 3 of 8 of
22 Exhibit 396. So if we look at the first page of this
23 document, which is 3 of 8, where the charts are, that chart
24 right there is the topline event chart for the KM curves for
25 study; is that right?

1 A. Correct.

2 Q. Okay. And that's the 93.9 and the 91.6, which gives us
3 the absolute difference of 2.3 percent, correct?

4 A. Correct.

5 Q. And then he's broken it down per six-month intervals.
6 Do you see this down here at the bottom that Mr. Bin Yao has
7 done?

8 A. Yes. That's correct.

9 Q. Okay. So you get a 17, hazard ratio of 17 percent in
10 the first six months, right?

11 A. Correct.

12 Q. Okay. Then .83. Then it drops back down to .63. Then
13 it goes back up to 1.5. Do you see that?

14 A. Yes.

15 Q. And that's what the chart was showing us back before
16 where the hazard ratios were crossing, correct?

17 A. That's correct.

18 Q. And then he does it for the 12-month intervals which you
19 had done for the efficacy report that you had seen on
20 July 17th, and he has got a hazard ratio in the second year
21 of .94. Do you see that?

22 A. That's correct.

23 Q. So we flip over to the next page. Mr. Yao decides to
24 run out the simulations for the third year into the seventh
25 year using the optimistic, the .67. Now, the optimistic is

1 your actual hazard ratio, right, that you actually reached in
2 the two years for the overall study? Right?

3 A. I believe that's correct.

4 Q. Okay. And then he has a pessimistic number which he
5 says is the same as the hazard ratio of the second year in
6 the 12-month hazard rate table, which is the page before,
7 right, the .947?

8 A. Uh-huh. Yes.

9 Q. And then he picks a middle ground to run that, a .80
10 hazard ratio. Do you see that?

11 A. Yes.

12 Q. The lower the hazard ratio, the better, right?

13 A. That is correct.

14 Q. Okay. The trend that you were seeing in the second year
15 is that your hazard ratio in the last six months went over
16 one, and in the last year was approaching one at .947,
17 correct?

18 A. Correct. I seem to remember this was influenced by some
19 censoring that was occurring at the last month.

20 Q. You can explain it to your counsel --

21 A. Okay.

22 Q. -- about why it's happening. I'm just asking, that's
23 what was happening?

24 A. Correct. But just to make it -- if I can make it clear.
25 Is that okay?

1 Q. Your counsel can talk to you about that, and then you
2 can make it really crystal clear.

3 A. Okay.

4 Q. But that's what was happening. That's what your
5 understanding of the data showed, correct?

6 A. Yes, with the caveat that there was some noise at the
7 end of the curve that was influencing, making that hazard
8 ratio go higher than the real signal would suggest.

9 Q. Okay. And he ran those curves for you, is that correct,
10 on those -- well, he actually ran the data for those three
11 scenarios in this document; is that correct?

12 A. That is correct.

13 Q. Okay.

14 If we flip over to the next document,
15 Exhibit 398 --

16 MR. COUGHLIN: I would move the admission of 398.
17 I don't believe there's any objection.

18 THE COURT: Without objection 398 is admitted.

19 **(Exhibit 398 received.)**

20 BY MR. COUGHLIN:

21 Q. This is a document dated a couple days after that last
22 document. It's October 12th. And you're responding to
23 Mr. Bin Yao, and you're asking that the -- can you print out
24 a hazard ratio, would be after three years in the p-value and
25 the DFS and DFS-DCI curves. Do you see that?

1 A. Yes.

2 Q. Okay. And you want it for the optimistic scenario; is
3 that correct?

4 A. Yes, correct.

5 Q. Okay. So if we flip in to this document, again we start
6 at page 4 of 11. We have your original results, the 2.3; is
7 that correct?

8 A. That is correct.

9 Q. Okay. And then we have the optimistic scenario results
10 carrying the charts out, and we have to flip over to page 10
11 of 11.

12 If we take a look at that chart on 10 of 11, which
13 goes out to 36 months under the optimistic scenario, we end
14 up with the rates of .916 over .888. Do you see that?

15 A. Yes, I do.

16 Q. So that gives you an absolute difference of 2.8 percent.
17 Do you see that?

18 A. Yes, I do.

19 Q. Okay. And that's under the optimistic scenario using
20 the .67 carrying out throughout the time period, right?

21 A. Correct.

22 Q. Okay. Let's flip over to document 482. I believe it is
23 now --

24 MR. COUGHLIN: There was an objection, but I
25 believe that we're past that. So I believe it's now admitted

1 with the objection preserved.

2 THE COURT: What number?

3 MR. COUGHLIN: 482.

4 THE COURT: You stated it correctly. Objections
5 are preserved, but 482 is admitted.

6 **(Exhibit 482 received.)**

7 BY MR. COUGHLIN:

8 Q. If you could take a look at this, Mr. Auerbach. This
9 document is dated September 19th, so it's a few weeks before
10 those simulations were run. Do you see that?

11 THE COURT: Before you get too deep into this, on
12 the exhibit list I have this document and other documents
13 near it have an R after it. What does the R mean? Does
14 anyone know?

15 MR. FORGE: Yes, Your Honor. This is the R
16 document. The black marks on it are the -- is what the R
17 stands for. Redacted.

18 THE COURT: Revised -- redacted.

19 MR. FORGE: Yes.

20 THE COURT: Okay. Good.

21 BY MR. COUGHLIN:

22 Q. And this says you're sending some information to your
23 licensor, Pfizer; is that correct?

24 A. That's correct.

25 Q. Okay. And if we flip into the second page, 2 of 4, they

1 had asked you some questions about sending some curves to
2 them, and you respond over on the next page, 3 of 4, you say
3 you're still in the process of fully validating this data; is
4 that correct?

5 A. That is correct.

6 Q. Okay. Now, they're asking for efficacy data. Wasn't
7 that validated as of July 17th?

8 A. Yes. There's a little more context to this discussion.
9 May I discuss that, please?

10 Q. You can discuss it with your counsel. Let me ask my
11 questions. They can ask you then.

12 A. This is a different data set they were asking for than
13 what was validated previously.

14 Q. Okay. Let's take a look. It appears based on our
15 preliminary analysis that the absolute difference in the DFS
16 curves is separating by approximately .5 percent a year; is
17 that correct?

18 A. Yeah. So again there's more context to this. May I
19 discuss that, please?

20 Q. I'm going to give you a chance to discuss that. I want
21 to know if that's what you wrote.

22 A. Yes, but it's a different data set than what was
23 presented and discussed with investors in July of 2014.

24 Q. And when we actually look at that data set in the curve,
25 then I'll let you explain. How's that?

1 A. Thank you very much.

2 Q. Okay. So that's what you were sending to Pfizer, that
3 it was up .5 percent per year for the next year; is that
4 right?

5 A. Correct.

6 Q. If we take a look several weeks later, November 5th,
7 2014 --

8 MR. COUGHLIN: This Exhibit 475, again an objection
9 is preserved, but this document is now to be admitted.

10 THE COURT: 475?

11 MR. COUGHLIN: Yes.

12 THE COURT: 475 is admitted.

13 **(Exhibit 475 received.)**

14 MS. JOHNSON: Wait. We're noticing that 475 is
15 missing the second to the last two pages of the attachment.
16 So the objection is incomplete.

17 THE COURT: I don't know what that last sentence
18 means. The objection is incomplete?

19 MS. JOHNSON: Incompleteness.

20 THE COURT: I don't know what that means. I just
21 don't know. Where are the last two pages?

22 MR. COUGHLIN: I'll get them for you, Your Honor.
23 I thought I had them all in my binder.

24 THE COURT: Okay, which binder? I think this
25 witness now has two binders, three binders, and there's 25

1 other binders. In which binder can we find the last two
2 pages?

3 MR. COUGHLIN: Well, I thought I had them all in my
4 binder, but I must have miscopied.

5 MR. FORGE: Your Honor, just for the record, 475
6 should be three pages long. Is that what the defense has?

7 MS. JOHNSON: It's five.

8 MR. FORGE: Your Honor, may I confer?

9 THE COURT: I must say, it says plaintiffs'
10 Exhibit 475, page 1 of 3.

11 MR. FORGE: Correct.

12 THE COURT: What I admitted was a three-page
13 document. How long a document are you now admitting?

14 MR. COUGHLIN: A three-page document.

15 THE COURT: Okay.

16 MR. COUGHLIN: I don't have another two pages to
17 this document that was produced to us.

18 THE COURT: All right. So what we argued about and
19 what we're admitting is a three-page document.

20 Is the defense now wanting the other two pages as
21 part of this?

22 MS. JOHNSON: Yes, Your Honor.

23 THE COURT: Is there any objection?

24 MR. COUGHLIN: No objection.

25 THE COURT: All right. Then the other two pages

1 will be a part of this.

2 Let me just say that there are many, many, many
3 documents. The Court staff and I do our best to be as
4 accurate as possible. On something like this, I don't have
5 the two extra pages. I don't know what we're talking about.
6 That means -- listen carefully. It's up to both sides to
7 make sure that the documents submitted to the jury reflect
8 the Court's ruling. The Court is now ruling that it is a
9 five-page document, but the Court apparently doesn't have the
10 five-page document and the Court won't do the extra effort at
11 the end to figure out and attach it.

12 It's up to the parties to make sure that happens.
13 If that doesn't happen, it is the fault of the parties. A
14 five-page document, Exhibit 475, is admitted.

15 Go ahead.

16 MR. COUGHLIN: Thank you, Your Honor.

17 MR. FORGE: Your Honor, just for the record, and I
18 apologize. I'm not trying to deflect responsibility. Right
19 now as far as we know, it is only three pages. So I'm going
20 to go step outside and see if I can get it clarified.

21 THE COURT: All right.

22 MR. FORGE: In other words, we don't have pages 4
23 and 5.

24 MR. CLUBOK: For the record, we have -- we're
25 having copies made very quickly.

1 THE COURT: Your microphone is not on.

2 Good. Go ahead. Five-page document, 475.

3 Go ahead.

4 BY MR. COUGHLIN:

5 Q. If you take a look at this document, Mr. Auerbach, 475,
6 which we have as three pages, dated November 5th, 2014; is
7 that correct.

8 A. Yes, that is correct.

9 Q. And you're sending Pfizer -- if you look at the bottom
10 of that: Please find attached to this e-mail the
11 Kaplan-Meier curve for the ExteNET trial. Do you see that?

12 A. That is correct.

13 Q. The first document shows the curves using a scale of .0
14 to 1.0. The second document shows the curves with the same
15 -- with the scale from .8 to 1.0?

16 A. That is correct.

17 Q. Okay. And if you flip over to the first page, to the
18 first curve that you're sending, what you're showing is a
19 36-month curve; is that correct?

20 A. Yes, that's correct.

21 Q. Okay. And that is -- and that shows a 2.8 absolute
22 difference, doing the math we just did in the previous
23 document?

24 A. Correct.

25 Q. And those are the documents you sent Pfizer for the

1 going out to three years?

2 A. That is correct.

3 Q. You didn't send them the document that Claire Sherman
4 created showing the actual data you had; is that correct?

5 A. That was not what they had requested.

6 Q. They hadn't requested a simulation from you?

7 A. May I -- as I mentioned earlier, there's more context to
8 this. May I please go into that now?

9 Q. You can go into it some.

10 A. Thank you very much. We received the ExteNET data in
11 July of 2014. Pfizer is the company who we licensed this
12 drug from, and we've had a wonderful relationship with them.
13 They're really great people, and we're very pleased that they
14 allowed us to license this asset.

15 In August of 2014 I flew to New York and we
16 discussed the ExteNET data with them, and we also went
17 through a, you know, an update on the company as a whole. We
18 had discussed with them that, you know, we were obviously
19 eager to look at the longer-term curves, three years,
20 four years, five years, et cetera.

21 Our goal with this drug is to reduce a woman's risk
22 of the breast cancer coming back. Being able to do that at
23 two years is wonderful, but these are young women. These are
24 women who were 40 years old. They don't want to have their
25 cancer come back. They're very young women. They have

1 babies, and their dream is to watch those babies grow up and
2 produce babies of their own.

3 Reducing their breast cancer recurrence at two
4 years is wonderful. Obviously we want to look at the longer
5 term as well. So we had discussed with them that we were
6 performing simulations where we were taking the existing
7 hazard ratio and assuming that that would apply to the future
8 events as well.

9 And that was what they had requested of a gentleman
10 by the name of Vatnak Vat-Ho, I believe, who I believe was
11 included in this e-mail as well. So they had requested that
12 we provide them with these simulations because they found
13 them very interesting. And specifically Vatnak had asked
14 that we produce the simulations because he found them very
15 intriguing and he wanted to see where they went. That is the
16 reason we supplied these.

17 Q. Okay. So he didn't ask for the real data that you had
18 left, the data you said you saw and the data that you relied
19 on on the conference call?

20 A. I believe we had shown that to them. As a recall, we
21 had actually shown them the data with the caveat of the
22 patient numbers were dropping off very dramatically. My
23 recollection of this is we had our face-to-face meeting. We
24 should them the data where the patient numbers were dropping
25 off quite dramatically as we went out two years, three years,

1 et cetera.

2 Then we had mentioned to them that we were doing
3 the simulations as well, and this is what they had requested.

4 Q. Okay. They wanted simulations. They didn't want to see
5 the real data?

6 A. We had already shown them the real data.

7 Q. You have no record of showing them the real data. That
8 chart does not exist anywhere.

9 A. We had a face-to-face meeting with them, and it was
10 produced to them in a PowerPoint slide show. How that was,
11 you know, why there is no record of that being done, I'm not
12 quite sure how there could be of that record.

13 Q. And you flew out there in August to do this?

14 A. That would have been August right after we got the data,
15 August 2014.

16 Q. Okay. And you flew out there and showed them this, but
17 there's no electronic record anywhere, not from the person
18 who sent it to you, not to you showing it to them. Did
19 Claire Sherman go with you?

20 A. No. She was not there.

21 Q. So you had it on your computer?

22 A. In some way, shape, or form. I remember showing it to
23 them. I don't know if we showed it to them as a piece of
24 paper, if it was shown to them on a slide. At some point it
25 was definitely shared with them.

1 Q. And who else was with you at that meeting?

2 A. My attorneys.

3 Q. From Latham?

4 A. I don't remember which attorneys we had with us.

5 Q. Well, who was with you?

6 A. One of the attorneys for the company.

7 Q. What's the name of the attorney?

8 A. I don't remember who was with me.

9 Q. Okay. So you can't remember if it was a Latham attorney
10 or not?

11 A. It may have been a Latham attorney or it may not have
12 been. I don't remember.

13 Q. So you took an attorney to this meeting and you showed
14 them the actual data, and they said, we'd like to see
15 simulations out for three years?

16 A. They had specifically requested the work we were doing
17 with the simulations.

18 Q. Okay. So when you show them -- when you sent them the
19 simulations, you say in the note that you sent them: Please
20 find attached the Kaplan-Meier curves for the ExteNET trial.
21 Do you see that?

22 A. Yes.

23 Q. Okay. You don't say, please find the simulations
24 attached for the original intent-to-treat population; is that
25 correct?

1 A. You know, again, this is what they had requested, and
2 this is what we had sent to them.

3 Q. Okay. So nowhere on this document do you say that these
4 are simulations.

5 A. It was discussed not with Kathy but with Vatnak.

6 Q. Okay. And you some removed the patient populations from
7 these documents before you sent them, too; is that correct?

8 A. When you say removed had the patient populations, what
9 do you refer to?

10 Q. When Daniell first did the simulations for you, you
11 asked him to remove the patient populations at the bottom.
12 Do you remember that?

13 A. Oh, the patients at risk.

14 Q. Yes.

15 A. The patients at risk was meaningless because they
16 weren't real patients. They were simulations.

17 Q. So you took them off?

18 A. We had taken them out because it was misleading. It was
19 difficult to see the patients at risk because you were making
20 assumptions you didn't have.

21 Q. And did Pfizer ask you about that and say, hey, we want
22 to see the patient populations?

23 A. We never got a request from Pfizer asking for the
24 patients at risk.

25 Q. They never followed up and said, hey, we can't figure

1 out these curves?

2 A. I don't remember getting any type of communication from
3 Pfizer where they said that they wanted to see the number of
4 patients at risk on the X axis.

5 Q. Okay. And nowhere on this document where you say it's
6 the original intent-to-treat population do you label these as
7 simulations; is that correct?

8 A. As I recall the meeting in August, this was what they
9 had requested.

10 Q. So that's what you sent them?

11 A. Correct.

12 Q. Let's take a look at Exhibit 1067. Do you recognize
13 what 1067 is?

14 A. I apologize. I need to refresh my memory.

15 Q. Okay.

16 MR. COUGHLIN: Your Honor, I don't believe there's
17 any objection to Exhibit 1067, so I'd like to move for its
18 admission.

19 THE COURT: 1067 is admitted without objection.

20 **(Exhibit 1067 received.)**

21 THE WITNESS: Yes, I remember this.

22 BY MR. COUGHLIN:

23 Q. Okay. And this is an October 13, 2014, document, and
24 you're writing Claire Sherman who we've just been talking
25 about?

1 A. That is correct.

2 Q. And you're asking for the HR positive and HR negative
3 subgroups to be broken out into KM curves; is that correct?

4 A. Correct. So I believe, if you look at the bottom of
5 this e-mail, please.

6 Q. That's where I was looking at. Yes: I apologize if I
7 I've already asked for this information --

8 A. So you will notice I say the words, I apologize if I
9 have already asked for this information, but do you have --
10 it is quite common that I will ask for things multiple
11 times --

12 Q. Understood.

13 A. -- even if they've been shown to me in the past, because
14 sometimes they're not shown to me in a manner where I can,
15 you know -- may be on a piece of paper, may be on a computer
16 where I visually see it, but I don't have a tangible copy of
17 it.

18 Q. Now, she says -- she replies to that, that forest plots
19 were produced to examine the hormone-receptor subgroups. Do
20 you see that?

21 A. Yes.

22 Q. Okay. And she can modify the programs to produce the
23 Kaplan-Meier plots you are asking for. Do you see that --
24 you are requesting?

25 A. Correct.

1 Q. Okay. So she hadn't done that before?

2 A. She may not have. Someone else may have.

3 Q. Somebody else had done these Kaplan-Meier curves you're
4 now asking her to do?

5 A. Yeah. After -- I mean, before July 2014 Claire had
6 access to the data, and I believe someone else did as well,
7 perhaps Judy Bebchuk. There were other statisticians who had
8 access to the database.

9 Q. Okay. So Claire wouldn't have known that those had
10 already been done?

11 A. You know, Claire is up in our San Francisco office. We
12 have an entire team down in Los Angeles as well. I don't
13 know if they communicate on a minutely basis as to what
14 analyses are being gone. So I don't know the answer to that.

15 Q. Okay. So she says she will create the two-year --
16 create the tables with the two-year DFS, DFS-DCI rates. Do
17 you see that?

18 A. Yes. Yes, I do.

19 Q. And if we take a look at the next document dated
20 October 17, 2014 --

21 MR. COUGHLIN: I'd move for the admission of
22 document 1068. I don't believe there's any objection to it,
23 Your Honor.

24 THE COURT: 1068 is admitted without objection.

25 **(Exhibit 1068 received.)**

1 BY MR. COUGHLIN:

2 Q. So it appears these are the materials that she creates,
3 the KM curves for you for the HR negative and HR positive; is
4 that correct?

5 A. That appears to be correct. Please let me review.

6 Yes, that is indeed correct.

7 Q. And this is the estrogen, progesterone, the HR negative
8 and HR positive; is that correct?

9 A. Yes. The estrogen receptor or progesterone receptor, if
10 the tumor has that, that is known as hormone-receptor
11 positive.

12 Q. And in the first table we get a .2 absolute
13 difference -- if we flip over to the next page, I'm sorry.
14 First chart inside that document is 6594, the table?

15 A. Yes. That is correct.

16 Q. And then the curve is drawn on the next page, 6595?

17 A. That is correct.

18 Q. Okay. Then we -- if we flip to the next, we have HR
19 positive? And this was where neratinib had a high
20 statistical significance, is that correct, in the HR
21 positive?

22 A. Correct. It was where we saw the majority of the
23 efficacy. If you looked at those two subgroups, there was
24 more efficacy in the hormone-receptor positive.

25 Q. And that's a subgroup of your intent-to-treat

1 population; is that correct?

2 A. Correct. It made up about between 65 to 70 percent of
3 the patients that I remember.

4 Q. Okay. And it has an absolute difference of 4.1 percent;
5 is that correct?

6 A. That is correct.

7 Q. Okay. And we flip over to the last page where we -- I'm
8 sorry. Before we go from that previous one, the hazard ratio
9 for that was .51; is that correct?

10 A. Yes, that is correct.

11 Q. So it had a better hazard ratio than the overall
12 population of .67?

13 A. That is correct.

14 Q. And finally, if we flip to the back page that I said,
15 6600, that's the ER PR plus. So that's both plus; is that
16 correct?

17 A. No. That is the same analysis that you just referenced
18 previously. However, this time it's --

19 Q. Oh, it's the ductal?

20 A. The DFS-DCIS, as we discussed yesterday, includes the
21 premalignant tumors but not the noncancerous tumors.

22 Q. And they had an improved rate of 4.7, correct?

23 A. That's correct.

24 Q. And to your knowledge that was the first time that
25 Claire had produced those curves; is that correct?

1 A. I don't know if Claire -- someone in the company had
2 produced them. I don't remember if it was Claire or another
3 statistician.

4 Q. Well, she said she had never produced them. She said
5 she had only done forest plots?

6 A. As I said Claire, may not have done them. Other
7 statisticians may have done them.

8 Q. But those other reports were not produced to us?

9 A. I'm -- I'm not aware of what was produced to you and not
10 produced to you. I do know that back in July of 2014,
11 someone had produced those curves because I remember seeing
12 them.

13 Q. Let's take a look at the next exhibit, Exhibit 494. It
14 might not be the next exhibit but next in line.

15 THE COURT: Is it admitted?

16 MR. COUGHLIN: It's admitted without objection,
17 Your Honor.

18 THE COURT: Oh, that means it hasn't been admitted?

19 MR. COUGHLIN: No, it hasn't been admitted.

20 THE COURT: You move its admission?

21 MR. COUGHLIN: I'd move its admission.

22 THE COURT: Admitted without objection, 494.

23 **(Exhibit 494 received.)**

24 BY MR. COUGHLIN:

25 Q. This is in March of 2015?

1 A. That is correct.

2 Q. And you're asking Mr. Bin Yao to produce a chart on the
3 centrally confirmed; is that correct?

4 A. Yes.

5 Q. And it's a KM curve?

6 A. Correct. This had been -- so we have two different
7 statistical team, if you will. At the time one was headed up
8 by Bin and one was headed up by Claire. I was asking Bin to
9 produce this for me. I believe Claire or someone on her team
10 had produced it previously.

11 Q. Previously to when she was doing these other ones in
12 October -- September and October?

13 A. No. It had been produced in July of 2014.

14 Q. It had been produced -- so these are reports that had
15 been produced in July? You're saying --

16 A. When we -- I'm sorry. Please go ahead. I didn't mean
17 to interrupt you.

18 Q. These same curves had been producing to you in July?

19 A. I remember seeing these curves in July of 2014, and it
20 was part of the presentation that had been done. I don't
21 remember who did the presentation, and I didn't ask on every
22 slide that was shown to me who was the statistician who did
23 this.

24 Q. And there's no record. You haven't seen it in
25 preparation of this litigation. You haven't seen those

1 curves in July; have you?

2 A. I am not aware of what has been produced regarding this
3 topic in this litigation, so I don't know that I can answer
4 that.

5 Q. Well, none of those curves have been produced to us.
6 You've been involved in the litigation. You've been asked to
7 produce those documents, your company has. But we haven't
8 seen any of those curves that were -- back in July. This is
9 like the fourth thing that you said existed. Did you have a
10 computer shutdown or something and the documents just
11 disappeared?

12 A. I'm not aware of a computer shutdown where documents
13 disappear, but we are a small company and we are an
14 entrepreneurial company. Oftentimes we don't save everything
15 or files get deleted or people leave and take their computers
16 with them and we don't have access to them. Again, we're a
17 small company. These things happen.

18 Q. So you're saying --

19 THE COURT: I must say, counsel keeps saying the
20 documents aren't there. The documents aren't there. The
21 documents disappeared. That may be true. It may not be
22 true. But you're not the witness and you're not sworn.

23 I am just reminding folks.

24 MR. COUGHLIN: I understand, Your Honor.

25 THE COURT: The issue of missing documents always

1 presents a challenge in proving it. But, go ahead.

2 MR. COUGHLIN: It's tough to prove the negative.

3 THE COURT: Yes, indeed. I understand your
4 position.

5 BY MR. COUGHLIN:

6 Q. So this centrally confirmed, you understood at this time
7 even at this late date that you were missing 60 percent of
8 the data?

9 A. I believe, if I remember this correctly -- hang on one
10 second. I don't remember -- hang on. I thought I saw this
11 in one of your earlier -- I don't remember. I remember that
12 we had centrally confirmed testing that was still being done
13 from the samples from the patients back in July, but I
14 thought this analysis was, for lack of a better word,
15 complete enough that we felt confident in it.

16 Q. Even if you were missing 40 percent of the overall data?

17 A. I don't know that the number was that high. I need to
18 refresh my memory on how high that number was. I remember it
19 was enough that we felt confident in it. And again, you
20 know, we had data, so it was, you know, worth reporting.

21 Q. You would agree that if you were missing 40 percent of
22 data at this time, in March, that would be a problem?

23 A. It could be a problem or it could not be a problem. The
24 40 percent of the data was similar in its results to what we
25 has seen -- I mean, 60 percent is a lot of data.

1 If it was 10 percent, I would agree with you that
2 the results had a high potential for error. If you're
3 talking about 60 percent of the date, you know, the next
4 40 percent might agree with your 60 percent or it might not.
5 So I can't answer that.

6 Q. But this is because you had quit collecting the data two
7 years before; is that correct? We saw that document off the
8 safety?

9 A. I don't know that we quit collecting the centrally
10 confirmed. The bio marker data, which has nothing to do with
11 this where we're looking for, you know, genetic mutations and
12 things like that, if that work had been stopped, yes.

13 The centrally confirmed, I don't remember that that
14 was actually specifically stopped. I seem to remember that
15 we had it and it was still being processed.

16 Q. Well, that's what the slide deck said, is that you had
17 quit collecting it. The slide deck that you got on the
18 safety data before the conference call said you had quit
19 collecting that data with amendment number nine.

20 A. I don't remember that.

21 Q. Okay. Let's take a look at the next exhibit,
22 Exhibit 179 -- sorry, 175.

23 MR. COUGHLIN: There's no objection to this
24 document, Your Honor, so I would move for its admission.

25 THE COURT: 975?

1 MR. COUGHLIN: 175.

2 THE COURT: I misheard. 175 is admitted.

3 **(Exhibit 175 received.)**

4 BY MR. COUGHLIN:

5 Q. So this is about two months later, May 27th, 2015?

6 A. Yes.

7 Q. Okay. And here you are talking to Al Lalani; is that
8 correct?

9 A. Yes.

10 Q. Again if we flip in to page 3 of 6, it says: Am I
11 correct that to date the central HER2 testing has been done
12 on 60 percent of the patients?

13 A. Correct, 1,704 out of 2,840.

14 Q. Does that refresh your recollection that it was
15 60 percent?

16 A. Yes.

17 Q. Let's take a look at our next in line exhibit,
18 Exhibit 1012. I'm going to step back in time, Mr. Auerbach,
19 back to August 25th, 2014, if that's all right.

20 A. Sure.

21 MR. COUGHLIN: There's been no objection to this
22 document, Your Honor, so I would move for its admission.

23 MS. JOHNSON: We just preserve our objections under
24 MIL four. Otherwise, no objection.

25 THE COURT: Give me the document again.

1 MR. COUGHLIN: The document is 1012, Exhibit 1012.
2 I understand the preservation of their objection, Your Honor,
3 but now there's no objections to its admission. They've
4 preserved their objection to what it does.

5 THE COURT: Yes. Okay. Now I'm understanding.
6 1012 is admitted over objection.

7 **(Exhibit 1012 received)**

8 BY MR. COUGHLIN:

9 Q. Can you take a look at this document, Mr. Auerbach?

10 A. Yes.

11 Q. After you got your results, you wanted to get what they
12 call a breakthrough designation from the FDA; is that
13 correct?

14 A. That is correct. We discussed it with them.

15 Q. And that's what this document deals with, this document
16 that you're editing; is that correct?

17 A. I believe that's correct, yes.

18 Q. Okay. And it says here -- and you're writing to
19 Christine Woods; is that right?

20 A. Yes.

21 Q. You're saying that you would like to -- you made a few
22 edits onto that document. Let's turn to those edits if we
23 could, to page 4 of 7. At the top of the page we see an edit
24 by you, node positive or node negative. You added that?

25 A. That's correct.

1 Q. Okay. And down below we have the actual tables and the
2 results for the DFS topline, and that's done in the reverse
3 this time of 6.1, which gives you the 93.9, and the 8.4,
4 which gives you the 91.6, for the absolute difference of 2.3.
5 Do you see that?

6 A. Yes, I do.

7 Q. So these are the actual results of the ExteNET study
8 going to the FDA?

9 A. That is correct.

10 Q. Okay. And these are the KM curves on the next page,
11 page 5 of 7?

12 A. That is correct.

13 Q. And you were involved in that process trying to get the
14 breakthrough designation?

15 A. Yes. I was involved in the call that we had with the
16 FDA to discuss this.

17 Q. Okay. And that -- that breakthrough designation allows
18 you certain benefits of speeding up the approval process; is
19 that correct?

20 A. There's a little more context than that. May I discuss
21 that, please?

22 Q. Yes. You can discuss it in all the detail you want with
23 your counsel. But it does give you an advantage as you're
24 trying to seek approval, right?

25 A. I believe on the FDA website it states that the

1 breakthrough designation is meant for -- is ideally meant for
2 drugs that have not yet started a phase III trial. So as you
3 know, with ExteNET, ExteNET was a phase III trial. So to
4 answer your question, it is meant to expedite phase II drugs
5 that would like to get approval before doing their phase IIIs
6 because they achieve efficacy that is, you know, so much
7 greater than what the current standard of care would.

8 Q. Right. And you had completed phase III, so you were a
9 step beyond?

10 A. Yeah. Late, yeah.

11 Q. And it still gives you benefits to expedite things, and
12 that's why you sought it, right?

13 A. I don't know that that was the case. As I remember
14 this, the breakthrough designation came out from FDA. They
15 first introduced this sometime in 2012, 2013. And it wasn't
16 quite clear what it was, but our regulatory group had said
17 that, you know, they felt it would be good if we attempt --
18 if we discussed it with them.

19 I don't know that it would have given us any
20 advantages over the path, otherwise we would have taken it.

21 THE COURT: We're at a good breaking time. Okay?

22 MR. COUGHLIN: Yes, Your Honor.

23 THE COURT: We're going to break now, and we will
24 come back in 15 minutes. Thank you.

25 THE CLERK: All rise.

1 (Recess taken from 10:28 a.m. until 10:45 a.m.)

2 THE CLERK: All rise.

3 (Open court - jury present)

4 THE COURT: All right.

5 Please continue, Mr. Coughlin.

6 BY MR. COUGHLIN:

7 Q. Mr. Auerbach, if you could turn to Exhibit 1014.

8 MR. COUGHLIN: Your Honor, I believe there's an
9 objection, but they're preserving the objection and this
10 document can be admitted.

11 THE COURT: 1014 is admitted over objection.

12 **(Exhibit 1014 received.)**

13 BY MR. COUGHLIN:

14 Q. If you take a look at this document, this is Ms. Woods
15 sending on the request for breakthrough, the breakthrough
16 request to the FDA. Do you see that?

17 A. That is correct.

18 Q. If we just flip in to the document to page 6 of 7, we
19 see that document contains your edit from node positive or
20 node negative --

21 A. Correct.

22 Q. -- at the top? And it has the absolute difference
23 charts down at the bottom?

24 A. Yep.

25 Q. And the KM curves on the next page, correct?

1 A. That is correct.

2 Q. If we can flip to Exhibit 460, we're going to flip in to
3 this exhibit page 78 of 128.

4 MR. COUGHLIN: I don't believe there's any
5 objection to this.

6 THE COURT: Without objection 460 is admitted.

7 **(Exhibit 460 received.)**

8 BY MR. COUGHLIN:

9 Q. If we turn to page 78 of 128.

10 A. (Witness complies.)

11 Q. Mr. Auerbach, who is Judith Bebachuk Segal?

12 A. Judy Bebachuk is a statistician in my company.

13 Q. And you had mentioned her name before, somebody possibly
14 doing some of the curves and things like that?

15 A. That's correct. She was involved in the ExteNET trial.

16 Q. Okay. And she's got her notes dated September 23rd,
17 2014, and it's the breakthrough request meeting with the FDA.
18 Do you see that?

19 A. Yes, I do.

20 Q. Okay. And we talked a little bit about what the
21 breakthrough would do. Correct me if I'm wrong. My
22 understanding is that the breakthrough -- the breakthrough
23 drug is intended alone or in combination with one or more
24 other drugs to treat a serious or life-threatening disease or
25 condition. Was that your understanding?

1 A. That's the indication, yes. As I mentioned earlier, the
2 FDA on their website also says that the time they would like
3 you to meet with them is before you have started your
4 phase III trials.

5 Q. And it says preliminary clinical evidence indicates that
6 the drug may demonstrate substantial improvement. Is that
7 your understanding of what they -- what they're considering,
8 if it may demonstrate substantial improvement?

9 A. I don't have the FDA definition in front of me, so I
10 can't answer that.

11 Q. But does it sound like what it was?

12 A. It may be what it is.

13 Q. We'll look at it.

14 A. Okay.

15 Q. So this is a meeting September 23rd, 2014, and it lists
16 the attendees, or I guess it's probably a phone call. Do you
17 remember this meeting?

18 A. Yes, I do.

19 Q. Okay. And it talks about the different questions that
20 were asked --

21 A. Uh-huh.

22 Q. -- and different people that were asking questions and
23 responding. And if we go down to the bottom, her final notes
24 are: 2.3 percent improvement in DFS not enough for
25 breakthrough. Need safety. Worried about censoring.

1 Do you see that?

2 A. I'm sorry. That cuts off there. If we can continue on
3 to the next page so we can see that, please.

4 Q. Yes.

5 A. Thank you. That's perfect. Yes. So as I read -- may I
6 read this?

7 Q. Yes.

8 A. Thank you very much. As I read this, it says,
9 2.3 percent improvement in DFS not enough for breakthrough.
10 Need safety. Worry about censoring. Does not have
11 implication on NDA.

12 So just to clarify, an NDA is the formal FDA filing
13 where you apply for approval of your drug.

14 Q. The new drug?

15 A. New drug application is what it stands for, yes. So in
16 the part below there which is not being highlighted, I
17 believe it says: Does not have implications on NDA. Only
18 afflicts breakthrough.

19 And that is mentioned by someone named Patricia.
20 Patricia is Patricia Cortazar, who was the heard of the
21 breast cancer group at the FDA. So we were quite encouraged
22 in this meeting because they were essentially telling us,
23 encouraging us to file our NDA, which would be the
24 application for the FDA approval of the drug.

25 Q. Right. But they denied you breakthrough designation at

1 this time?

2 A. As I recall this meeting, when we discussed the concept
3 of breakthrough designation, they reiterated to us that it is
4 meant for drugs -- you have three phases of clinical trials,
5 phase I, phase II, and phase III. Phase I is where you look
6 for your initial safety. Phase II is where you look for your
7 initial efficacy. Phase III is either a very large study
8 where you compare the efficacy of your drug to whatever the
9 standard of care is.

10 What they had mentioned to us, as I remember this,
11 was that this breakthrough designation was a way for a
12 phase II drug that was very promising to leapfrog phase III
13 and get approval while still running the phase III trials.
14 It was an early window for approval for earlier drugs.

15 So I remember them telling us that we were a little
16 bit late. Then I also seem to remember that they had
17 mentioned to us that if someone did do a large phase II
18 trial -- so let's say they did a smaller version of ExteNET
19 but it was a phase II study, the bogie, if you will, the
20 number they would look for, would be a hazard ratio of 0.5, I
21 remember them telling us, and we were at 0.67. So we just
22 kind of barely missed it.

23 Q. I see. So you're saying you were further along. You
24 had done a big clinical trial that had covered years and
25 years, and they denied you breakthrough because you were too

1 far along?

2 A. So the -- as I understand --

3 Q. Mr. Auerbach, could you just answer that question?

4 That's really your testimony, right?

5 A. That was --

6 Q. You were too far along?

7 A. My recollection was --

8 MS. JOHNSON: Objection, Your Honor, to the
9 compound question. He has to be allowed to finish his
10 testimony.

11 BY MR. COUGHLIN:

12 Q. Were you too far along?

13 THE COURT: When there's an objection, it's my job.
14 I gotta respond. You said, like, three things. You said
15 compound. You said he has to be allowed to finish. I'm not
16 sure where we are.

17 MS. JOHNSON: It was --

18 THE COURT: What's your objection?

19 MS. JOHNSON: That the question was compound.

20 THE COURT: All right.

21 Rephrase your question. Proceed.

22 BY MR. COUGHLIN:

23 Q. Ms. Bebachuk doesn't write anything in here about you
24 being too far along; is that correct?

25 A. These are Judy's notes. This is actually the first time

1 I've seen them. So I would probably venture to guess that
2 this is not a direct transcript of every word that was said
3 at the meeting.

4 Q. Thank you, Mr. Auerbach.

5 If we go to the next exhibit, Exhibit 1008.

6 MR. COUGHLIN: Your Honor, there was an objection
7 here. The objection is preserved. But with that caveat,
8 we'd move 1008 in.

9 THE COURT: Admitted as described. 1008, right?

10 MR. COUGHLIN: Yes.

11 **(Exhibit 1008 received.)**

12 BY MR. COUGHLIN:

13 Q. Mr. Auerbach, this is September 24th, or one day later.
14 Maybe even the same, later that day: We do not intend to
15 submit a formal breakthrough therapy designation request for
16 this neratinib indication. Do you see that?

17 A. Yes. That is correct.

18 Q. And in this document you're asking for a nonclinical
19 type C meeting request and briefing package, is what you're
20 submitting; is that correct?

21 A. That is indeed correct.

22 Q. Okay. And this was for more -- you could probably
23 explain it better -- follow-up studies on the cancer risks;
24 is that correct?

25 A. No, not exactly. May I describe that?

1 Q. Yes.

2 A. Thank you very much.

3 So when it comes to applying for FDA approval of a
4 drug, they ask you to do clinical studies which is where in
5 actual patients you're testing that your drug is safe and
6 effective. But there's also nonclinical studies.
7 Nonclinical studies are studies done on animals, so rats and
8 things like that, where you're testing various things that
9 you couldn't really test in humans very easily.

10 Specifically the ones we're testing here is what is
11 called carcinogenicity. What carcinogenicity is, is does
12 your drug cause cancer. So, for example, here we have a drug
13 which has shown efficacy in preventing breast cancer, but
14 what if it causes lung cancer or it causes brain cancer or it
15 causes non-Hodgkins lymphoma or something?

16 THE COURT: Causes what?

17 THE WITNESS: Non-Hodgkins lymphoma. So this is
18 what you're testing in these studies. The way you do these
19 studies is that you give your drug to rats because rats are
20 known to develop spontaneous tumors much quicker than humans.

21 So you usually do very long studies for a period of
22 two years where you'll take a number of rats, give them a
23 large quantity of your drug at various doses and then a large
24 quantity of a placebo, so just a dummy pill. And you'll see
25 whether or not there's a difference in between the number of

1 cancers caused in the rats who get your drug versus the ones
2 who get the placebo.

3 You're usually looking for large differences,
4 doubling, tripling, things like that. If you see that, it
5 would imply your drug has the risk of causing cancer in
6 humans. If you don't see that and the two are basically the
7 same, then you can feel quite comfortable that your drug
8 likely does not cause other cancers.

9 BY MR. COUGHLIN:

10 Q. You were quite comfortable with neratinib at this time
11 because of all the studies that had been done before that you
12 wouldn't have a problem in that area; is that correct?

13 A. We -- well, until you do the testing, you can't be
14 certain of that. Some of the initial studies that we had
15 done -- not these two-year rat studies. Some of the initial
16 studies that we had done certainly did not give us any
17 concerns that neratinib would indeed cause other cancers.

18 Q. So you were asking that some of these longer studies
19 with the rats and the other animals, that they would be
20 allowed to be submitted after you had made your NDA
21 application, your new drug application; is that correct?

22 A. So that is correct. The two-year rat studies had not
23 been completed at the time we were hoping to file for FDA
24 approval of this drug. So the purpose of this meeting was to
25 request of the FDA that we could be allowed to apply for FDA

1 approval and then submit that data afterwards.

2 Q. Okay. And in this application you include the topline
3 results of the ExteNET study; is that correct?

4 A. Let me --

5 Q. Flip to page 27 of 47.

6 A. Yes, that is correct.

7 Q. Page 27 of 47. And again we have the topline DFS of
8 2.3 percent in the reverse; is that correct?

9 A. That is correct.

10 Q. And on the next page, 28 of 47, we have the Kaplan-Meier
11 curves; is that correct?

12 A. That is correct.

13 Q. Okay. Now, if we flip to the next exhibit,
14 Exhibit 1048, dated November 24th, 2014, this appears to be
15 the teleconference setting up the teleconference meeting for
16 the call the next day with the FDA at the end of
17 November 2014; is that correct?

18 A. Correct.

19 MR. COUGHLIN: I should move this in with the same
20 caveat. The objection is preserved. And other than that,
21 the document can come in.

22 THE COURT: State the document.

23 MR. COUGHLIN: 1048.

24 THE COURT: 1048 is admitted.

25 **(Exhibit 1048 received.)**

1 BY MR. COUGHLIN:

2 Q. And if we flip in to this document and first go to page
3 7 of 21, this document has some of the FDA's preliminary
4 comments to Puma; is that correct?

5 A. I believe that's correct, yes.

6 Q. Okay. And it has this table with the top line there of
7 neoplasms, malignant, and has some rates?

8 A. Correct.

9 Q. And the next page has the topline results from the
10 ExteNET study if we go to page 8 of 21; is that correct?

11 A. That is correct.

12 Q. Okay. And then it has the forest chart, the next page,
13 9 of 21?

14 A. That is correct.

15 Q. And here's where you ask the FDA whether you can submit
16 those studies after you submit -- if we look at question
17 number two, page 7 of 10 --

18 A. Uh-huh.

19 Q. -- they ask -- you ask if you could admit those studies
20 later, and the FDA's response to you is, no, you've got to
21 submit them with your application; is that correct?

22 A. Yes. That was the initial response, correct.

23 Q. Let's take a look at Exhibit 773.

24 MR. COUGHLIN: I'd move for the admission of this
25 document 773, with the objection preserved.

1 THE COURT: 773 is so admitted.

2 **(Exhibit 773 received.)**

3 BY MR. COUGHLIN:

4 Q. And Christine Woods on December 15th, 2014, appears to
5 be distributing the FDA's -- the minutes from the meeting
6 from Jeannette O'Donnell from the FDA; is that correct?

7 A. Yes, that is correct.

8 Q. Okay. And you received a copy of these?

9 A. Yes. I'm on the e-mail list. I did.

10 Q. Turn to page 6 of 15. It has that same chart that had
11 been part of the discussion, the telephonic discussion,
12 right?

13 A. That is correct.

14 Q. Okay. And 7 of 15 are the ExteNET topline results; is
15 that correct?

16 A. That is correct.

17 Q. Okay. Then if we take a look at page 10 of 15, we now
18 have the FDA's response. Again, no study reports from the
19 carcinogenicity studies should be included in an NDA
20 submission. Do you see that?

21 A. Yes, I do.

22 Q. You received this on 12/15; is that correct?

23 A. That is correct.

24 Q. Okay.

25 Let's turn to Exhibit 569 [sic].

1 MR. COUGHLIN: There's no objection to this
2 exhibit, I believe, 567. I'd move to admit, Your Honor.

3 THE WITNESS: You said earlier 569.

4 MR. COUGHLIN: No, it's 567. Thank you.

5 THE COURT: 567 is admitted.

6 **(Exhibit 567 received.)**

7 BY MR. COUGHLIN:

8 Q. Who is Bradley Wolff?

9 A. Bradley Wolff is the managing director of healthcare
10 investment banking for the investment banking firm of Bank of
11 America Merrill Lynch.

12 Q. Okay. And they were going to do an offering for Puma;
13 is that correct?

14 A. That is correct.

15 Q. Okay. So they were starting to undertake their due
16 diligence here in October; is that correct?

17 A. Yes, that is correct.

18 Q. And they had asked you for recent FDA correspondence, if
19 any; revised license agreement; and an IP update, if any. Do
20 you see that?

21 A. Yep. That is correct.

22 Q. Okay. And did you provide them with those materials?

23 A. Yes, I did.

24 Q. Okay. Let's turn to Exhibit 491.

25 MR. COUGHLIN: I'd like to move for the admission

1 of 491. I don't believe -- well, there's an objection. So
2 subject to the objection.

3 THE COURT: Can we hear the objection?

4 MR. COUGHLIN: No. It's on the record, Your Honor.

5 THE COURT: Well, when you say it's on the record
6 and I admit it, if it's a viable objection, we could get
7 reversed.

8 MR. COUGHLIN: No. It's an objection to a whole
9 line of questioning. So they're preserving their objection.

10 THE COURT: Have I had a chance to rule on the
11 merits of the objection?

12 MR. COUGHLIN: Yes.

13 THE COURT: I want to make sure I have the chance
14 to rule on the merits of any objection made by a party.

15 All right. So 491 is admitted.

16 MR. COUGHLIN: Thank you, Your Honor.

17 **(Exhibit 491 received)**

18 BY MR. COUGHLIN:

19 Q. Who is William Hicks?

20 A. William Hicks or Bill Hicks is the attorney who was
21 acting as what's called underwriter's counsel, which means
22 that he acts as the lawyer for the underwriters, which here
23 would be Bank of America Merrill Lynch.

24 Q. He was --

25 A. Sorry.

1 Q. He was mentioned in the previous document, that he would
2 be reaching out to you to do the due diligence; is that
3 correct?

4 A. Yes, that is correct.

5 Q. Okay. And here you are providing him with some
6 materials that he requested; is that correct?

7 A. Yes, that is correct.

8 Q. Okay. And this is January 7th, 2015; is that right?

9 A. Yes, that is correct.

10 Q. Okay. And you wish him Happy New Year. Then, please
11 find attached the minutes from our recent meeting with the
12 FDA for neratinib which is being provided to you for
13 regulatory diligence in advance of our update call on Friday;
14 is that right?

15 A. That is correct.

16 Q. Okay. And then you talk about there is no other legal
17 or IP diligence items; is that correct?

18 A. Correct.

19 Q. And then you provide him with the FDA report that is
20 attached to this e-mail; is that correct?

21 A. That is correct.

22 Q. Now, you understand today that this FDA report that
23 you're providing him that was supposedly sent by Jeannette
24 O'Donnell in 2015 is different than the report that you
25 received from Christine Woods back in December of 2014,

1 right?

2 A. Yes. I became aware of this at my deposition, which was
3 in January of 2018.

4 Q. Okay. Let's compare these two reports. If we could
5 compare Exhibit 773 with Exhibit 491. Exhibit 773 with the
6 exhibit number at the bottom is on the left. Exhibit 491 is
7 on the right. Okay.

8 The one you sent to Mr. Hicks is the one on the
9 right. The one that is on the left is the one you received
10 from Ms. Woods; is that correct?

11 A. Yes, correct.

12 Q. Okay. If we flip in to the first page, we see that both
13 these reports are the same; is that correct?

14 A. Yes.

15 Q. And the second page, they are the same, correct?

16 A. That appears to be correct.

17 Q. Okay. On the third page they are the same?

18 A. That appears to be correct, yes.

19 Q. Okay. On the fourth page, still seem to be the same,
20 right?

21 A. That is correct.

22 Q. Let's go to the fifth page. Let's go to the top two
23 columns on the fifth page. The one on the top is from the
24 report that you received on 12/15, and the one on the bottom
25 is the report you sent Mr. Hicks on January 7th. Do you see

1 that?

2 A. Yes, I do.

3 Q. Do you see how the numbers are changed so that the
4 neratinib arm no longer goes above the placebo arm?

5 A. Yes.

6 Q. It's your testimony you didn't make that change?

7 A. I have no recollection of making that change. I have no
8 recollection of asking anyone to make that change.

9 Q. Okay. Let's go to the next page in each document. I'm
10 sorry, let's go back to page 6. On the bottom of that page,
11 there's also a missing sentence on the original, the sentence
12 that begins, the placebo group. Do you see that, right on
13 the right on the original document? That sentence is no
14 longer in the document that Mr. Hicks received. Do you see
15 that?

16 A. Yes, I do.

17 Q. Let's flip to the next page of both documents. Do you
18 see that the next page of the document on the right that you
19 sent Mr. Hicks no longer contains the ExteNET results?

20 A. Yes, I see that.

21 Q. Somebody has removed those results. Do you see that?

22 A. Yes, I see that.

23 Q. Okay. Let's go to the next page. Do you see that also
24 the forest chart has been removed?

25 A. Yes, I see that.

1 Q. It's your testimony you didn't remove that chart?

2 A. I have no recollection of removing that chart, and I
3 have no recollection of asking anyone to remove that chart.

4 Q. I'd like to go to question number two in the document,
5 in the original document 10 of 15. Here the question -- let
6 me get them both up there first. Question number two from
7 the one, the document that you sent Mr. Hicks on January 7th,
8 the question seems to have been changed. Did you change
9 that?

10 A. I have no recollection of changing that, and I have no
11 recollection of asking anyone to change that.

12 Q. Okay. Are you denying that you made these changes?

13 A. I have no recollection of making any of these
14 modifications.

15 Q. Okay. Now, you understand that -- let's go to 491. The
16 metadata of that document shows that it was created on
17 January 6, 2015, at 11:15 at night, page 12 of 12?

18 A. I'm sorry. Where are you looking?

19 Q. At the end of that document, of 491. You can just flip
20 to it.

21 A. Yes. Correct.

22 Q. That document was created on January 6, 2015; do you see
23 that?

24 A. Yes.

25 Q. And that you're listed as the author of that document,

1 correct?

2 A. Correct.

3 MR. FORGE: Hold on.

4 BY MR. COUGHLIN:

5 Q. So are you denying that you created this document?

6 MR. FORGE: Hold on one second. We've got to get
7 this up on the screen.

8 MR. COUGHLIN: It was easier when I could use the
9 elmo.

10 MR. FORGE: Why don't you use the elmo?

11 MR. COUGHLIN: It's all right.

12 BY MR. COUGHLIN:

13 Q. You can see that document; is that correct?

14 THE COURT: By the way, you can still use the elmo.
15 I tell everyone that. The elmo is that document just to its
16 left. You slap a document on and it goes on the screen and
17 you can point to it and you can have fun with it.

18 But most of the time counsel these days put all
19 their documents on computers, which has its advantage. They
20 quickly hit a button and it shows. But you can't point to
21 things. Old timers like the elmo. That would be me but not
22 necessarily Mr. Coughlin.

23 MR. COUGHLIN: I like the elmo.

24 THE COURT: Go ahead.

25

1 BY MR. COUGHLIN:

2 Q. So you understand the metadata shows you were the author
3 of that document, correct?

4 A. Yes. My understanding of this is that the metadata
5 shows I am the author of the pdf, but it is not showing that
6 I am the author of the Microsoft Word document that is
7 located toward the bottom there.

8 Q. And you understand that we were informed by your counsel
9 that Alan's flash drive, that this came from your flash
10 drive? And then it supports the metadata that this is the
11 e-mail that was sent and that the actual document itself was
12 not on any Puma drive and that it was only provided by you in
13 this e-mail on Puma's system and that it comes from your
14 flash drive?

15 A. That is incorrect information. There was a version of
16 this document that was found on my flash drives. It was
17 saved on February -- early February 2018. At my deposition
18 this is the first time I was shown that there was a
19 difference between these two documents, the one that was sent
20 to Mr. Hicks and the one that we received from the FDA.

21 And I was asked to go investigate where this -- how
22 this was caused, et cetera, et cetera. I opened the e-mail
23 to Mr. Hicks to get the version that had been sent to him,
24 and I saved it on my flash drive.

25 My deposition, if I remember correctly, was

1 January 28-29, 2018. And I believe the date the document was
2 saved on my flash drive was somewhere around February 1st or
3 2nd of 2018. So the document that you're referring to on my
4 flash drive was saved after my deposition. It would not be a
5 diversion that would apparently have been sent back in
6 January of 2015.

7 Q. So you're not denying that you sent this to Mr. Hicks?

8 A. This document was indeed sent to Mr. Hicks, but the one
9 that you're referring to which was on my flash drive is the
10 same document. I believe actually on the flash drive it
11 actually denotes that it's a copy of this file.

12 Q. So you think somebody got in and changed this document
13 and took all the important information out of it that would
14 have indicated that you had a 2.3 absolutely difference and
15 altered the document, and that's the document you sent
16 Mr. Hicks for his due diligence?

17 A. So I first became aware that the document that was sent
18 to Mr. Hicks was different from the version that had been
19 sent to the FDA at my deposition in January of 2018.

20 We then went back to look for reasons, et cetera.
21 I don't know. I certainly did not alter this document and I
22 did ask anyone to alter this document.

23 Q. Mr. Auerbach, actually I thought you said you don't
24 recall altering it. At every juncture you said: I don't
25 recall --

1 A. I don't have any recollection of altering this document.
2 I don't have any recollection of asking anyone to alter this
3 document.

4 Q. You'd certainly remember if you had altered the
5 document, right?

6 A. I certainly would've remembered. I assume that I would
7 have remembered if I had altered this document, and I assume
8 I would have remembered if I had asked someone to alter it.

9 Q. So your testimony is you didn't alter this document?

10 A. I have no recollection of having altered this document.
11 What I can say is that my recollection of this was that I had
12 asked my team to give me copies of all recent FDA
13 correspondence so I could send them to Mr. Hicks.

14 I have a team. I trust that team. Does that team
15 make mistakes? That team does make mistakes.

16 Q. So somebody else at Puma took all the important
17 information out and sent it to you, the CEO, to send on for a
18 \$200 million offering for the due diligence?

19 A. Well, when I requested from my team that they send me
20 copies of all of our recent FDA correspondence, I did not
21 mention to them that it was for a financing. It was -- I
22 just asked them for copies of our recent communications with
23 the FDA.

24 Now, it is common practice in the company that
25 after we have meetings with the FDA, we will oftentimes edit

1 those notes, edit those meeting notes to reflect any changes
2 that may have occurred since that meeting or to also discuss
3 anything that may have been different from our perception of
4 what happened at that meeting versus what they're writing in
5 writing.

6 So we typically will maintain an internal version
7 of the meeting notes that includes our own annotations, et
8 cetera. In terms of the content of the meeting notes that
9 were sent to Mr. Hicks, all of the information in there is
10 indeed accurate. It reflects exactly what was discussed at
11 the meeting with the FDA.

12 If you would like, I would be more than happy to go
13 through each page if you'd like --

14 Q. You're going to get a chance to do that, Mr. Auerbach.

15 A. Okay.

16 Q. All of the tables, though, from your ExteNET study that
17 show how efficacious neratinib was have been taken out of
18 this document.

19 A. Can we go back to the meeting notes, please?

20 Q. You can go back with your counsel.

21 Are any of those -- have those tables been taken
22 out of this document?

23 A. They were -- out of the internal version of the notes,
24 we took them out because when we attempted to discuss with
25 the FDA the clinical data, they made it clear to us that this

1 was a nonclinical meeting, which, that was the reason I
2 wanted to go back to the notes. If you'll notice, it says at
3 the top nonclinical meeting.

4 So the reason for us doing this is that it was a
5 nonclinical meeting. When we tried to discuss the clinical
6 data with them -- again, what we were trying to do is get
7 them to allow us to not use the carcinogenicity studies, not
8 have to file them, and file them after because we didn't want
9 to delay applying for FDA approval by two years.

10 So we were attempting to use the clinical data to
11 sway that opinion, and we --

12 Q. That's no reason to take out --

13 MS. JOHNSON: Your Honor, I would just object that
14 he's asking him complicated questions and not letting the
15 witness finish his answer.

16 MR. COUGHLIN: I've let him --

17 THE COURT: We are timing this matter, and to some
18 extent his further responses and review of further documents
19 and such is best timed against his defense team. And it is
20 cross-examination.

21 I'm going to allow counsel to ask the next
22 question, please.

23 BY MR. COUGHLIN:

24 Q. Actually, Mr. Auerbach, I'm going to ask you to go to
25 Exhibit 492.

1 A. Correct.

2 Q. Do you have that?

3 A. Yes, I do.

4 MR. COUGHLIN: I'm going to move for the admission
5 of 492.

6 THE COURT: Any objection to 492?

7 MR. COUGHLIN: No objection.

8 THE COURT: Who said that?

9 MR. COUGHLIN: It's the same caveat.

10 MS. JOHNSON: With the same --

11 THE COURT: Okay.

12 MR. COUGHLIN: I should have said that, with the
13 same caveat as to these documents.

14 THE COURT: All right. 492 is admitted.
15 Proceed.

16 **(Exhibit 492 received.)**

17 BY MR. COUGHLIN:

18 Q. And this is Mr. Hicks following up on January 9th to ask
19 you if there's been anything more, any other correspondence
20 with the FDA; is that correct?

21 A. That is correct.

22 Q. Okay. And you say: Hi, Bill. And he actually says --
23 I think it says that he has -- he didn't get any FDA
24 correspondence update in November; is that correct?

25 A. Correct.

1 Q. Had you sent him any update for the breakthrough denial?

2 A. No, we did not. That was the -- first of all, the
3 meeting we had with the FDA on the breakthrough was what they
4 termed a not-formal meeting. There was no meeting minutes.
5 It was just a call to discuss whether or not we should or
6 should not apply for it.

7 Second, it had no relevance to what investors cared
8 about, which was the potential FDA approval of neratinib. I
9 mean, if anything, as you saw in the notes, the FDA actually
10 encouraged us to file the NDA.

11 Q. You're saying that the investors would not have had an
12 interest in an expedited approval of neratinib?

13 A. There is nothing to state that a breakthrough
14 designation would have been an expedited approval or any
15 quicker than the path we took.

16 Q. Isn't that the whole purpose of the breakthrough
17 designation, is to get a quicker approval?

18 A. For phase II drugs, yes. We were not a phase II drug.

19 Q. But you had gone already through phase III, so it would
20 be that much quicker, right?

21 A. The FDA always prioritizes drugs that are post phase
22 III. You have thousands of companies trying to request
23 meetings with the FDA, and the biggest problem you have is
24 them trying to schedule this because they're very busy and
25 unfortunately quite under-resourced.

1 So one of the reasons for the breakthrough is
2 through all of those earlier stage drugs -- this is an
3 industry that has a very, very high rate of failure.

4 Q. Mr. Auerbach --

5 A. Can you please let me continue?

6 Q. No. I would like to ask you a question. You wanted to
7 get this drug expedited --

8 MS. JOHNSON: I'll object for the record.

9 THE COURT: You may continue, counsel.

10 BY MR. COUGHLIN:

11 Q. You wanted to get this drug expedited with the FDA,
12 right?

13 A. Our goal was to get this to patients as quickly as
14 possible, yes.

15 Q. So even though you had gone through phase III, you went
16 to the FDA and sought breakthrough because you wanted to get
17 it expedited, right?

18 A. No. The breakthrough designation does not have impact
19 on your timing of FDA approval or the quickness of the
20 review. What you're referring to is the difference between
21 priority review, accelerated approval, and things like that.
22 The breakthrough designation is a completely different
23 entity.

24 Q. So the -- off the website, the FDA will expedite the
25 development of the review, is incorrect?

1 A. There is no statistics that show that the breakthrough
2 designated drugs go through quicker than others.

3 Q. Why apply then? Why did you apply?

4 A. It was an early program. They had just come out within
5 2012. We didn't -- our regulatory group wasn't even clear
6 what the benefit would be, but we figured we would apply.

7 Q. Okay.

8 A. There was absolutely no guarantee of anything that would
9 make it quicker.

10 Q. So you didn't notify Mr. Hicks of the denial of the
11 breakthrough?

12 A. There was no formal denial. There's no -- there's no
13 meeting minutes from that meeting.

14 Q. But they had told you that you wouldn't get
15 breakthrough, and you didn't tell Mr. Hicks, right?

16 A. I believe we told him that we had a meeting with the
17 FDA. I don't remember if we said it was on the breakthrough,
18 but we did mention that in our informal meeting with the FDA,
19 that they had encouraged the NDA submission.

20 Q. Okay.

21 Let's go to Exhibit Number 108, please.

22 THE COURT: Do you move its admission?

23 MR. COUGHLIN: I do. I don't believe there's any
24 objection.

25 MS. JOHNSON: Wait --

1 MR. COUGHLIN: Oh, wait. There is an objection.
2 I'll pass 108.

3 THE COURT: Okay. 108 is not admitted.

4 MR. COUGHLIN: I'm going to Exhibit 528.

5 THE COURT: Any objection?

6 MS. JOHNSON: No, Your Honor.

7 THE COURT: 528 is admitted.

8 **(Exhibit 528 received.)**

9 BY MR. COUGHLIN:

10 Q. Mr. Auerbach, do you recognize what this document is?

11 A. Yes, I do.

12 Q. Okay. And this project Panthera, that was your
13 follow-on offering; is that right?

14 A. That is correct.

15 Q. If we flip in to page 6 of 62, if we look at the bottom,
16 of the key issues for commitments, committee consideration.
17 It says: Puma has not disclosed details of new data that
18 they recently discovered. While the company plans to
19 disclose this information in the near future, possibly at an
20 upcoming conference, they have decided not to reveal the data
21 with any of the banks involved in this transaction.

22 Do you see that?

23 A. Yes, I do.

24 Q. And Mr. Hicks was supposed to do the due diligence for
25 the banks; is that correct?

1 A. Yes, and he did do that due diligence.

2 Q. Okay.

3 MR. COUGHLIN: Let's turn to the next exhibit,
4 Exhibit Number 753.

5 There's no objection to 753, Your Honor. We'd move
6 for its admission.

7 THE COURT: 753 is admitted without objection.

8 **(Exhibit 753 received.)**

9 BY MR. COUGHLIN:

10 Q. This is the release January 27th for the offering, the
11 \$218 million public offering; is that correct?

12 A. Yes, that is correct.

13 Q. And that went out at, I think, \$190 a share; is that
14 right?

15 A. Yes, that is correct.

16 Q. Okay. Now, you had a meeting with Mr. Hicks following
17 that exchange of the FDA minutes; is that correct?

18 A. We had a meeting face to face in January of 2015.
19 That's correct.

20 Q. Okay. And did you send Mr. Hicks the materials before
21 the meeting?

22 A. No. We -- it was a face-to-face meeting, so I just
23 gave -- presented -- it was to present him the ExteNET data,
24 and I presented him the data at that meeting.

25 Q. And that was off your computer; is that right?

1 A. That is correct.

2 Q. A slide deck?

3 A. Yeah. It was the -- so this meeting took place in
4 January of 2015. In December of 2014, the prior month,
5 there's a medical conference which is called the San Antonio
6 Breast Cancer Symposium. At that meeting we had shared the
7 ExteNET data with a number of breast cancer physicians. So
8 we shared that same data slide deck with Mr. Hicks.

9 Q. And that was the academic steering committee that you
10 were talking about?

11 A. No. It was larger than that. So it was important to us
12 to, you know, get feedback from the breast cancer community
13 as to what they thought of the ExteNET data. So we put --
14 I'm ball-parking here, but it was tens if not a hundred -- we
15 probably put tens of doctors under a confidentiality
16 agreement and then showed them the ExteNET data.

17 So, yes, you're correct. We showed it to the
18 academic steering committee, but we also showed it to a
19 number of other breast cancer doctors as well.

20 Q. So you didn't provide Mr. Hicks a hard copy of what you
21 showed him?

22 A. He did not request one. I had the meeting with him, and
23 afterwards I believe I asked him, do you want me to e-mail
24 you this? He was, no, I'm good.

25 Q. So he didn't bring anything to the meeting either? He

1 didn't bring any documents or anything like that to share
2 with you and talk to you about?

3 A. The purpose of the meeting was that the banks had put
4 together a system so we could protect the confidentiality of
5 the ExteNET data where Mr. Hicks signed a confidentiality
6 agreement, and then I shared the data with Mr. Hicks.

7 In terms of him bringing, yes, he brought, you
8 know, obviously a large notepad and pen, and he took, you
9 know, copious notes as I was presenting the data to him.

10 Q. And you knew Mr. Hicks had no background to understand
11 some of the technical terms in the ExteNET date; is that
12 correct? That he had a partner that he was sending on the
13 reports to review that you sent him?

14 A. I don't agree with that statement. Mr. Hicks has been
15 in this industry a long time. He did work with my prior
16 company 10 to 15 years prior. He knows this industry very
17 well.

18 In terms of him, as you said, not qualified, I
19 would disagree with that statement.

20 Q. Maybe I misspoke about qualification. He was sending it
21 on to somebody he was working with that had expertise in this
22 area to review the FDA stuff that you had sent him. Did he
23 inform you of that?

24 A. I was not aware of that.

25 Q. He didn't tell you that?

1 A. No.

2 Q. Okay. Let's take a look at the next exhibit,
3 Exhibit 503. I believe this is the copy we've agreed on.
4 Good. Take a look at 503, please.

5 MR. COUGHLIN: And I don't believe there's any
6 objection to this, so we'd move for its admission.

7 THE COURT: I believe it was admitted yesterday.

8 MR. COUGHLIN: Okay. Thank you, Your Honor.

9 BY MR. COUGHLIN:

10 Q. Can you tell us what this is, Mr. Auerbach?

11 A. Yes. So when you apply to have your data presented at a
12 medical conference -- and this was ASCO, which stands for the
13 American Society of Clinical Oncology meeting -- you will
14 usually --

15 THE COURT: Hold on. The American Society of
16 Clinical Oncology meeting, did you say?

17 THE WITNESS: Yes. That is correct.

18 THE COURT: One at a time. Continue.

19 THE WITNESS: So you will usually submit an
20 abstract. What an abstract is, is a short summary, kind of a
21 preview, if you will, of the data that you're going to be
22 presenting. It's usually a one-page summary, and that's what
23 gets submitted to the conference.

24 This would be the submission we made. I believe
25 this was made in either January or February of 2015 to the

1 ASCO meeting. They receive thousands of these abstracts
2 because this is a very large medical conference and everyone
3 would like to present at it. They will usually categorize
4 them in three generic categories. One is that you're not
5 allowed to physically present the data at the meeting, but
6 they'll publish it in the book they put out, which, the book,
7 I used to use the analogy it's the size of a phone book, but
8 I don't think they put those out anymore. But if you have
9 remember the old Yellow Pages --

10 THE COURT: Hold on. Hold on.

11 MR. COUGHLIN: I didn't want to interrupt.

12 THE COURT: You're going way too fast.

13 THE WITNESS: I'm sorry.

14 BY MR. COUGHLIN:

15 Q. If we could look at Exhibit 503.

16 THE COURT: I do have to ask since I interrupted.
17 Did you finish your answer?

18 THE WITNESS: Yes.

19 BY MR. COUGHLIN:

20 Q. If we take a look at the bottom of 503 and take a look
21 at some of the results you reported, if we take a look at the
22 last sentence, efficacy results are shown below, do you see
23 that sentence?

24 A. Yes, I do.

25 Q. And it goes over to the next page and it talks about

1 hazard ratios for the centrally confirmed group.

2 A. Uh-huh. Yes.

3 Q. And there's another group that is being presented for;
4 is that correct? You're adding two different subgroups here;
5 is that right?

6 A. Yes. That is correct. So we are adding the
7 hormone-receptor positive patients, which would be referred
8 to as ER/PR positives. And then we are adding the centrally
9 confirmed HER2.

10 Q. And the hazard ratio for the first group ER/PR positive
11 is .51; is that correct?

12 A. That is correct.

13 Q. And for the centrally confirmed it's .52?

14 A. That's correct.

15 Q. Now, you don't disclose in the abstract here the
16 absolute difference for those two subgroups; do you?

17 A. No, we do not. You're unfortunately leaving out --

18 Q. No, Mr. Auerbach. I just asked you if you disclose.

19 A. No, we do not.

20 Q. Okay. But you do disclose the absolute difference for
21 the intent-to-treat population, the topline results; is that
22 correct?

23 A. Correct. We were limited for space.

24 Q. Okay. If we take a look at the next exhibit, 506.

25 MR. COUGHLIN: There's no objection to 506, Your

1 Honor, so we would move for its admission.

2 THE COURT: Without objection 506 is admitted.

3 **(Exhibit 506 received.)**

4 BY MR. COUGHLIN:

5 Q. Do you recognize what this document is, Mr. Auerbach?

6 A. Yes, I do.

7 Q. Okay. And we saw some of these names the other day.

8 Howard Liang, do you remember Mr. Liang? He's an analyst?

9 A. That's correct.

10 Q. And you're actually giving him over this e-mail the
11 absolute differences between the HR-plus population as well
12 as the centrally confirmed population; is that correct?

13 A. My recollection of this is that -- if we can go down in
14 the e-mail, please.

15 Q. Certainly.

16 A. No. Can you go to what's listed as page 2 of 3, please.

17 Q. Yes.

18 A. Okay. So I believe this was after the abstract had been
19 made public information --

20 Q. Correct.

21 A. -- and I had spoken to them on the phone. These Wall
22 Street analyst groups have quite a sophisticated ability to
23 do analyses. They have statisticians in-house. They have
24 software packages that, you know, are extremely robust.

25 So while I was on the phone with them, they were

1 recreating the KM curves, which apparently there's an ability
2 to do that based on the data we gave and the hazard ratios we
3 gave. And as I was speaking to them, they were coming up
4 with the differences.

5 Q. And you wanted to make sure they got the right numbers,
6 so you reported exactly what the numbers were, right?

7 A. No. Those were the numbers they told me on the phone,
8 because I remember I had written them down as they were doing
9 them because I was actually quite impressed that they were
10 able to do these curves so quickly. So I had written them
11 down. This was the back and forth of that conversation.

12 Q. I'm looking at the top where you write back 4.2 percent
13 at the top of one of three. 4.2 percent is for HR-plus
14 population, right?

15 A. So they were -- when I was on the phone with them, they
16 were both talking over each other, and they were getting the
17 HR positive -- again, they were doing the calculations and
18 they were getting the HR positive DFS magnitude and centrally
19 confirmed mixed.

20 So when they e-mailed me -- and again, they were
21 doing the calculations. I had just written them down. They
22 were then e-mailing me back because obviously they were
23 trying to write a report and they each had different numbers
24 written.

25 Q. And you wanted to make sure they got the right numbers?

1 A. Based on their analyses, not based on anything we had
2 done.

3 Q. So you corrected them or made sure they had the right
4 analyses and the right numbers --

5 A. Based on their analyses.

6 Q. Let's turn to Exhibit 505.

7 MR. COUGHLIN: I'd move for the admission of 505.
8 There's no objection.

9 THE COURT: 505 is admitted.

10 **(Exhibit 505 received.)**

11 BY MR. COUGHLIN:

12 Q. So those absolute difference numbers that you were
13 conferring with those analysts about, they were not in the
14 abstract. And then you received this Adam Feuerstein note;
15 is that correct?

16 A. I received this e-mail, correct.

17 Q. All right. And he's a columnist for the The Street; is
18 that correct?

19 A. Yeah. I believe that's a website of some sort.

20 Q. Okay. And he is asking you if you did talk to these
21 analysts. He said: Did you speak with Leerink and UBS
22 analysts last night? And if yes, did you provide the analyst
23 with the DFS percentage point difference in the subset of
24 patients with central lab determination of HR-2 status? Do
25 you see that?

1 A. Yes, I do.

2 Q. Those Leerink and UBS notes say that the difference
3 between neratinib and placebo for the central lab cohort of
4 patients was approximately four percentage points. That data
5 is not contained in the ASCO abstract released last night.
6 And he asked: Did you provide the analyst with that data?

7 Do see that?

8 A. Yes, I do.

9 Q. It's your testimony you didn't provide it. You were
10 just correcting them?

11 A. My recollection of this is as I was on the phone with
12 both here Leerink and UBS analysts, that they had their
13 statisticians on the phone as well and they were using a
14 software program -- I thought it was SAS. I could be
15 wrong -- where they were somehow able to calculate these
16 numbers based on what we had already made public.

17 Q. Okay. Let's take a look at the next exhibit,
18 Exhibit 739.

19 MR. COUGHLIN: I'd move for the admission of this
20 exhibit. There's no objection.

21 THE COURT: Number again?

22 MR. COUGHLIN: 739.

23 THE COURT: 739 is admitted.

24 **(Exhibit 739 received.)**

25

1 BY MR. COUGHLIN:

2 Q. So this is after the abstract went out and you received
3 this from -- who is Benjamin M. Matone?

4 A. Ben Matone works for NASDAQ.

5 Q. And he's letting you know that after the abstract went
6 out and that the placebo was -- that absolute difference was
7 different, that that's the reason that at least the market
8 has a selloff?

9 A. I believe what he said and you've very nicely
10 highlighted there is that there's a comment on Twitter which
11 says -- may I read this?

12 Q. Yes.

13 A. Thank you. There's a comment on Twitter that says that
14 investor expectations for absolute neratinib DFS improvement
15 over --

16 THE COURT: Hold on. Slow down. When you read,
17 people read fast, and there's some difficult words.

18 THE WITNESS: I'll restate this.

19 The Twitter comment is investor expectations for
20 absolute neratinib DFS improvement over PLO was three to
21 four percent, actual delta, 2.3 percent, hence tonight's
22 selloff. So I believe he's referring to a comment on
23 Twitter.

24 BY MR. COUGHLIN:

25 Q. That's right, and that difference is the difference

1 we've been talking about this whole trial, the difference
2 that you had led the market to believe three to four percent
3 versus 2.3 percent, right?

4 A. We did not lead the market to believe it was three to
5 four percent. We gave the guidance of a range between one
6 and six percent, and both the intent-to-treat population and
7 the centrally confirmed population, both fell within that
8 range.

9 Q. And the stock was hit with a 32 percent decline; is that
10 correct? Do you remember that, your stock going down
11 32 percent that night?

12 A. I don't remember what -- it was -- I'm sorry. It was
13 after-hours trading. So, yeah, I don't remember what it was
14 doing.

15 MR. COUGHLIN: Now, I'd like to turn to
16 Exhibit 701. There's an objection to this exhibit, Your
17 Honor. I'd like to lay the foundation to have it moved in.

18 MS. JOHNSON: The objection is hearsay, Your Honor.

19 MR. COUGHLIN: This is a document in the ordinary
20 course of business that Phil Gross sent to Mr. Auerbach who
21 received this document. Phil Gross's company, Adage Capital,
22 is the second largest shareholder and --

23 THE COURT: Just a moment. Let's get the document.

24 MR. COUGHLIN: 701.

25 THE COURT: Okay. I'm looking at Auerbach exhibit

1 book. The numbers aren't in order. They start at
2 Exhibit 1034. Shall I go to the 16 volumes, or what else
3 shall I do?

4 MR. COUGHLIN: That's the -- 1043 is your first
5 exhibit. It's right at the back.

6 THE COURT: 1034 is my first exhibit.

7 THE WITNESS: The numbers don't line up.

8 THE COURT: Are there two volumes of Auerbach?

9 MR. COUGHLIN: Yes.

10 THE COURT: Okay. I'm looking in the wrong volume.
11 It's a little difficult because, again, the numbers are not
12 in order. Now I'm looking at the second volume.

13 MR. FORGE: Your Honor, may I approach with 741?

14 THE COURT: I'm sorry. I didn't hear you. Would
15 you say that again near a microphone.

16 MR. FORGE: May I approach to provide you with a
17 copy of 701?

18 THE COURT: Not if you've given it to me in one of
19 the two books you've provided.

20 MR. FORGE: I'm sorry. I was just trying to
21 expedite things.

22 THE COURT: I'm looking in Volume 2 for this
23 witness, and I'm looking for 701?

24 MR. COUGHLIN: I would go all the way near the
25 back, Your Honor.

1 THE COURT: All right. I now have 701.

2 You move its admission. The defense says hearsay.

3 Give me a chance to look at it for a moment.

4 MR. COUGHLIN: I will, Your Honor.

5 THE COURT: All right. So I see in the first line
6 a hearsay statement by the declarant, Mr. Gross. Is
7 Mr. Gross going to be a witness subject to cross-examination?

8 MR. COUGHLIN: No, Your Honor. He was a large
9 shareholder.

10 THE COURT: Let's just start, then, with that first
11 line and tell me why that's not hearsay and why I shouldn't
12 sustain the objection on hearsay without repeating what it
13 says.

14 MR. COUGHLIN: Because Mr. Gross was writing in the
15 ordinary course of business to Mr. Alan Auerbach, who
16 received this --

17 THE COURT: Stop. Stop. Let's just break it down.
18 When you say in the ordinary course of business, you're
19 saying this is a business record?

20 MR. COUGHLIN: I am.

21 THE COURT: It's not a business record.

22 MR. COUGHLIN: Okay. Your Honor, I'm not offering
23 it for the truth of the matter asserted because you raised a
24 hearsay objection. I'm offering it for the state of mind
25 that between the largest -- the second largest shareholder in

1 Puma communicating with the largest shareholder in Puma, both
2 at about 20 percent, okay, talking to them about the market
3 reaction as a result of the release of this ASCO thing and
4 the market selloff.

5 So these are two of the biggest owners of this
6 company talking about what's happening and why. So it is
7 very relevant. And if Your Honor considers it not a business
8 record, which I think it is and it might even be, you know,
9 an adoption, then it's at least for state of mind.

10 THE COURT: Hold on. Okay. I want to break it
11 down. You can't just give me an aside and say adoption.

12 MR. COUGHLIN: Okay.

13 THE COURT: What is your adoption argument?

14 MR. COUGHLIN: My adoption argument is that
15 Mr. Auerbach receives this and does not respond to this
16 e-mail. And therefore --

17 THE COURT: Well, why don't we begin by you just
18 asking this live witness the information you want from this
19 document.

20 MR. COUGHLIN: Okay.

21 THE COURT: And we'll see where it goes. It might
22 turn into an impeachment document.

23 MR. COUGHLIN: Okay.

24 THE COURT: So for now the objection to the exhibit
25 is sustained.

1 MR. COUGHLIN: Okay.

2 BY MR. COUGHLIN:

3 Q. Mr. Auerbach, did you receive this exhibit from
4 Mr. Gross?

5 A. Yes, I did.

6 Q. Okay. And the information contained in it, you read the
7 this e-mail; is that correct?

8 A. I believe I did, yes.

9 Q. Okay. And in this e-mail certain of your quotes are
10 quoted; is that correct?

11 A. Yes. It appears to.

12 Q. Okay. And the first quote is: We would anticipate --

13 THE COURT: Hold on. No.

14 MR. COUGHLIN: Okay. I'll step back.

15 THE COURT: Just ask him that information.

16 MR. COUGHLIN: Okay.

17 BY MR. COUGHLIN:

18 Q. Did you say at any --

19 THE COURT: Nope.

20 BY MR. COUGHLIN:

21 Q. Okay. Was the diarrhea rate in line of 29 to 30 percent
22 that has been seen in prior studies of neratinib as a mono
23 therapy?

24 A. We were referring to the first cycle effect. And, yes,
25 in this trial the first cycle effect was roughly 28 percent.

1 Q. And is the response from Mr. Gross is that diarrhea rate
2 was actually 40 percent?

3 MS. JOHNSON: Objection, Your Honor.

4 THE COURT: Sustained.

5 BY MR. COUGHLIN:

6 Q. And what was the actual diarrhea rate at this time in
7 August in --

8 A. In the trial --

9 THE COURT: Hold on. Don't talk over each other.

10 BY MR. COUGHLIN:

11 Q. What was the diarrhea rate that you reported in the ASCO
12 release?

13 A. It was 39.9 percent.

14 Q. And then there's some questions about DFS.

15 THE COURT: Don't refer to the document. Just ask
16 this witness questions.

17 BY MR. COUGHLIN:

18 Q. Were you comfortable with the number 86 percent in the
19 placebo arm?

20 A. I believe the conversation was mid to high 80s, around
21 86 percent or so.

22 Q. And the actual rate in the control arm, it was 91.6; is
23 that correct?

24 A. That is correct.

25 Q. And as far as the neratinib arm, did you believe that

1 you could get to that number of 90 to 91 with a 33 percent
2 improvement?

3 A. Again, the range we were endorsing was mid to high 80s
4 for the placebo arm and 90 to 91 for the neratinib arm. That
5 would be endorsing a range of between one and six percent.

6 Q. In fact, neratinib was only 2.3 percent; is that
7 correct?

8 A. That's correct, and that would be within the one to
9 six percent range.

10 Q. And the actual range for that was 93.9 percent versus
11 91.6 percent, right?

12 A. That is correct.

13 MR. COUGHLIN: I'd still move for the admission for
14 this document.

15 THE COURT: Any objection?

16 MS. JOHNSON: Yes, Your Honor. Hearsay.

17 THE COURT: Sustained.

18 BY MR. COUGHLIN:

19 Q. Did you talk to Mr. Gross about the falloff, the dropoff
20 in the stock that night?

21 A. I believe I spoke with Mr. Gross when the abstract first
22 became public that evening, and I also met with him at the
23 actual ASCO conference.

24 Q. And he was upset that he felt he had been misled; isn't
25 that correct?

1 A. That was not the context of our conversation.

2 Q. But he was upset because he had been misled, and he told
3 you that, right?

4 A. I do not remember him saying that he was upset because
5 he had been misled. May I expand on that, please?

6 Q. You can expand on it with your counsel.

7 You don't remember him being upset?

8 A. I remember him being upset. I do not remember him being
9 upset about being misled.

10 Q. Okay. If we flip to the next document, Exhibit
11 Number 221.

12 MR. COUGHLIN: There's no objection to Exhibit 221,
13 Your Honor.

14 MS. JOHNSON: No objection.

15 THE COURT: 221 is admitted.

16 **(Exhibit 221 received.)**

17 BY MR. COUGHLIN:

18 Q. Do you recognize this as the news release on June 1st
19 for the neratinib study to be presented at the ASCO
20 conference?

21 A. Yes. That is correct.

22 Q. And it actually contains the actual numbers to be
23 presented; is that correct?

24 A. I'm sorry. Can you clarify that question?

25 Q. It actually contains the absolute differences to be

1 presented for all of the arms at the ASCO conference; is that
2 correct?

3 A. Yeah. There's a detailed description of the trial and
4 of both the safety and the efficacy results.

5 Q. Okay. And that was to be presented on June 1st at ASCO,
6 too; is that correct?

7 A. As I remember this, this release went out at the exact
8 same time that the data was actually presented at the ASCO
9 meeting in Chicago. So, yes, it was the data that was being
10 presented as this came out.

11 Q. If we flip over to the next page, Exhibit 1007.

12 MR. COUGHLIN: I'd move for the admission of 1007,
13 Your Honor.

14 THE COURT: Any objection?

15 MS. JOHNSON: No objection.

16 THE COURT: 1007 is admitted.

17 **(Exhibit 1007 received.)**

18 BY MR. COUGHLIN:

19 Q. This is an e-mail dated May 18th, 2015, from you to
20 Arlene Chan. I think we already talked about who Dr. Chan
21 was, how she was going to present it. She was the head of
22 the committee presenting ExteNET; is that correct?

23 A. Yes, that is correct. She was the head of the academic
24 steering committee.

25 Q. And in the first paragraph, in the middle of the

1 paragraph, you were talking to her about what slides she was
2 going to present; is that correct?

3 A. No, that is not correct.

4 Q. Okay. Well, let's talk about it. It says: Also
5 remember that the grade-three diarrhea rate in ExteNET is
6 extraordinarily high at 40 percent. Do you see that?

7 A. Yes. There's more context to this. May I discuss that?

8 Q. Not yet. You can do it with your counsel. I just want
9 to ask you: And you wanted to adjust the slide and put in
10 ongoing studies suggest loperamide prophylaxis significantly
11 reduces incidence in severity, grade-three diarrhea 0 to
12 17 percent with intensive prophylaxis be put back into the
13 slides. Isn't that what you said?

14 A. She had originally had that statement in the slides
15 because we wanted -- again, it was important for us to
16 communicate that we had a drug that had efficacy; however, in
17 the ExteNET trial nothing was done to prevent the diarrhea.
18 There was no Imodium prophylaxis as we've been discussing.

19 Q. Stop there for a second. If I might --

20 A. Sure.

21 Q. -- ask you. We know that 84 percent of the patients
22 were on Imodium?

23 A. After the diarrhea occurred.

24 Q. From day one?

25 A. The diarrhea occurs -- it could occur on day one.

1 Q. So you want to put back into the slides this statement
2 that she had taken out?

3 A. So initially that statement was in the slides, and
4 Arlene's comment which I respected was that the results of
5 those studies that showed that we could reduce the
6 grade-three diarrhea to 0 to 17 percent was not part of the
7 ExteNET study. She felt she should be more of a purist, if
8 you will, and just present ExteNET data and not present data
9 from other trials in this presentation.

10 My comment to her was that, you know, the reason
11 that we present these studies at medical conferences is so
12 that doctors can get comfortable using this drug in their
13 patients and know that this drug has efficacy that can
14 prevent this deadly disease from coming back.

15 But since we knew that there was a way to deliver
16 this to patients in a safer manner, we should be
17 communicating that to doctors to protect the safety of the
18 patients. That was the point I was a hinting to get across
19 here.

20 Q. And she didn't want to include it because it was not
21 part of the ExteNET study, and she also didn't want to
22 include it because of the size of the patient population in
23 those studies; isn't that correct?

24 A. I don't remember her being concerned about the size of
25 the studies. I remember that the conversation was she said

1 she would not put it in the slides but she would just mention
2 it orally in her talk.

3 My comment to her, which I'm going through in the
4 first few lines up there, is that, number one, often people
5 are distracted, so it's helpful to have it on the screen.
6 But also a lot of times people don't attend the presentation
7 and instead they download the slides later. And if they
8 download the slides later, they wouldn't see that.

9 Q. And you knew that the population of these different
10 studies was six people, 41 people, 14 people, and 13 people
11 of the four different studies that you're referring to; is
12 that correct?

13 A. I don't remember if that was the numbers at that time.

14 Q. Okay.

15 MR. COUGHLIN: Your Honor, I think this might be a
16 good time to break. I don't have much more, but it would be
17 shorter if we take the break now.

18 THE COURT: Good timing, sir. It is almost
19 straight up noon. We'll be back at 1:30.

20 Thank you for your attention. Remember, don't
21 discuss the case. Don't research the case. Keep an open
22 mind. We'll see you at 1:30. Stay dry.

23 THE CLERK: All rise.

24 (Open court - jury not present)

25 THE COURT: All right. See you all at 1:30.

1 (Recess taken from 12:02 p.m. until 1:33 p.m.)

2 THE COURT: Let's go on the record.

3 MR. COUGHLIN: There are four documents that I'd
4 like to use for impeachment. They were in dispute earlier.

5 THE COURT: Let's cut this short. What do you want
6 me to do right now?

7 MR. COUGHLIN: I'd like you to look at four
8 documents, and I'd like to use them for impeachment of
9 Mr. Auerbach.

10 THE COURT: Why don't you just -- why don't we just
11 rule on them as they come in?

12 MR. COUGHLIN: Okay.

13 THE COURT: Tell me what the documents are. I'll
14 take a look.

15 MR. COUGHLIN: I'll hand you a copy because they're
16 not in the book. They're impeachment.

17 THE COURT: Well, I'm not crazy about that, but
18 we'll have to --

19 MR. COUGHLIN: I didn't know he was going to say
20 what he said.

21 THE COURT: All right. Give me the four documents
22 you intend to use for impeachment. Just come around this
23 way. Thank you. Okay.

24 Actually, let's just have a brief discussion of
25 impeachment. Do you know what these documents are?

1 MS. JOHNSON: No, Your Honor.

2 THE COURT: They're not on the exhibit list?

3 MR. COUGHLIN: Yes, Your Honor. They were in
4 dispute in the Pfizer matter, and they do not reference the
5 dispute. But Mr. Auerbach testified --

6 THE COURT: I'm not interested in that. They're on
7 the exhibit list I have in front of me?

8 MR. COUGHLIN: Yes.

9 THE COURT: And the defense objects to them?

10 MS. JOHNSON: They were excluded by your motion in
11 limine. I will check specifically, but your motion in limine
12 regarding Pfizer listed out the Pfizer documents and you
13 excluded them.

14 MR. COUGHLIN: And these four documents have to
15 deal with -- Mr. Auerbach said he had gone in August of 2014
16 and provided the information to Pfizer, and these four
17 documents indicate that that was not correct, that he had not
18 provided that. They were still asking for that information
19 in September and October.

20 And in -- actually on the last document,
21 Exhibit 486, Mr. Auerbach states in an e-mail to himself that
22 he prepared to send out if Pfizer had commented that Pfizer
23 has not seen the disease-free survival data.

24 THE COURT: When do you think you'll get to these?

25 MR. COUGHLIN: Right now. I'm not going to do any

1 more. I'm just going to do the impeachment and be done.

2 THE COURT: Well, then, that's different.

3 MR. COUGHLIN: Your Honor, I can even do this
4 after. I didn't want to sit down --

5 THE COURT: After what?

6 MR. COUGHLIN: After they go. I didn't want to sit
7 down and not have brought this up. Because this is
8 impeachment material, I thought I should bring it up while
9 I'm standing up.

10 THE COURT: Let's make a ruling on them right now.
11 So it's 480, 481, and --

12 MR. COUGHLIN: 795 and 486. And I can go over them
13 briefly.

14 THE COURT: Hold on just a moment. Okay. We're
15 looking at 480.

16 Now, Ms. Johnson, you said something about these
17 were referenced in the motion in limine?

18 MS. JOHNSON: I believe that they were, Your Honor.

19 THE COURT: Okay. What is your objection to 480?

20 MS. JOHNSON: That it is subject to motion in
21 limine number two.

22 THE COURT: It references the Pfizer litigation?

23 MR. COUGHLIN: No.

24 THE COURT: Where does it -- I'm asking her what
25 her argument is.

1 MS. JOHNSON: Your Honor, they've redacted specific
2 references to the dispute resolution, but this was my worry
3 earlier when they -- they cannot open the door by asking
4 questions of the witness and back-door in documents around
5 your --

6 THE COURT: Maybe this has information they're
7 entitled to get in that could be completely independent of
8 Pfizer. You can't exclude harmful information that doesn't
9 reference Pfizer or that you say you will have to reference
10 Pfizer on your own.

11 I get back to my previous question to you. Why do
12 you have to mention Pfizer? What in 480 are you going to
13 refer to?

14 MR. COUGHLIN: I'm going to refer to the fact that
15 there was request in September for the tables summarizing the
16 data that was presented, you know, in the ExteNET conference
17 call. They -- Mr. Auerbach testifies earlier this morning
18 that in August 2014, that he had gone to New York and he --

19 THE COURT: I don't need to get into that much
20 detail.

21 MR. COUGHLIN: It does not mention --

22 THE COURT: Where about 480 implicates the motion
23 in limine concerning the Pfizer litigation?

24 MS. JOHNSON: First of all, it was referenced in
25 the motion. Second of all, it -- you're not -- this is what

1 I was trying to explain earlier.

2 THE COURT: No. It's like you didn't get a chance
3 to explain it earlier. I fully understood what you were
4 saying, and I kept asking why you have to implicate Pfizer,
5 and I just never got an answer on that.

6 So I don't know what more I can say, then. You
7 need to tell me how it implicates Pfizer.

8 MS. JOHNSON: It's not persuading --

9 THE COURT: The Pfizer litigation, I should say.
10 Excuse me.

11 Go ahead.

12 MS. JOHNSON: At the risk of repeating the
13 arguments, this is such a long story if you don't have
14 context for it. He says they asked for this --

15 THE COURT: You've said that before, and I keep
16 asking: Why do you need the context of the litigation? I
17 have asked you. Was it withheld because it was privilege?
18 Was it withheld as part of litigation strategy? Was it --
19 you haven't said any of that.

20 MS. JOHNSON: Because they were asking for --
21 within the context of the litigation, they were asking for
22 different types of data, different runs.

23 THE COURT: But they could have been asking for
24 that for investment purposes or whatever else. Okay.
25 Anything else on 480? I just need something that ties it in

1 to the Pfizer litigation.

2 MS. JOHNSON: The context informs what they were
3 asking for, why, when they asked for it, what the resolution
4 was. Mr. Auerbach testified there were lawyers at that
5 meeting. It's all -- to understand what they were asking for
6 and why, and what he provided and why, it necessarily
7 implicates the litigation.

8 THE COURT: Yeah. I'm not -- that's what I keep
9 asking, and then I don't see that. Would your argument be
10 the same on 481, 486, and 795? Or can you show me specific
11 things that implicates the litigation?

12 MS. JOHNSON: If you can give us one minute since
13 we just received these.

14 THE COURT: Sure.

15 MR. COUGHLIN: I don't believe 481 does have
16 anything about the litigation. I know it doesn't. What it
17 does have is a table stuck to the back with the absolute
18 delta, the key data removed from the middle of the chart on
19 the fourth page.

20 He says he'd gone in August -- and this is dated
21 September 16th. He says he'd gone in August and shown them
22 that data and even shown them the Bin Yao separating curves
23 data.

24 THE COURT: Go ahead.

25 MS. JOHNSON: That is exactly why you need the full

1 context in order to understand.

2 THE COURT: I'm not understanding right now. Tell
3 me why you need the full context.

4 MS. JOHNSON: He's misleading the jury by
5 simplifying the story. He's misleading the jury by --

6 THE COURT: Let me ask you again. Why do you need
7 to reference the Pfizer litigation to give this context?
8 I've thrown out five different options, and I'm not hearing
9 any of them coming back at me.

10 MS. JOHNSON: No. That's correct. But if you are
11 in a business negotiation or a request for information and
12 you're under a CDA, that is one context for providing
13 information.

14 If you're in litigation and there are lawyers on
15 every e-mail, lawyers in every meeting, that is a different
16 context for understanding.

17 THE COURT: Can't you ask him: Did this request
18 for information have anything to do with investors? No.

19 You can even ask if you want: Does it have to do
20 with unrelated litigation where there was contentions going
21 on? I think you could ask that if you wanted, and we
22 wouldn't get into the concerns I have about the Pfizer motion
23 in limine.

24 It wouldn't be accusations against you. It would
25 just be other litigation where lawyers are involved. I would

1 allow you to get into that if you wanted to explain perhaps
2 he had a level of caution you shouldn't have in responding to
3 investors.

4 What about that?

5 MS. JOHNSON: The concern about doing that, it
6 would bring up the exact -- well, one of the issues that we
7 had in bringing the motion in limine in the first place, that
8 there was a dispute. The jury may misunderstand, and Pfizer
9 is not here.

10 THE COURT: Well, I can only do so much. I bought
11 the trial within a trial, but whenever you have a motion in
12 limine, there's evidence that doesn't go to the trial. It
13 goes to another significant point here.

14 When I excluded it, it was out of concern about a
15 trial within a trial, and it's not fair to say you are
16 getting -- were you sued by Pfizer?

17 MS. JOHNSON: No.

18 THE COURT: Well, then, maybe that motion in limine
19 was wrong. But instead of getting into all of that
20 lawsuit -- that's why I granted the motion in limine, but
21 that has nothing to do with whether he withheld documents
22 that were requested. I think that's an important point that
23 plaintiff should be able to show.

24 MS. JOHNSON: And I --

25 THE COURT: And you can't protect your client from

1 that by saying, oh, it mentions Pfizer.

2 MS. JOHNSON: I'm actually concerned by
3 Your Honor's question because that is the implication that
4 counsel is trying to raise, that --

5 THE COURT: What is the implication?

6 MS. JOHNSON: That Puma withheld information --

7 THE COURT: Is there any doubt about that?

8 MS. JOHNSON: There is absolutely doubt.

9 THE COURT: No, no. Is there any doubt that that's
10 what he wants to do?

11 MS. JOHNSON: No.

12 THE COURT: Okay. So my raising the obvious point
13 of why he wants it in, you shouldn't be concerned about that.
14 We all know that's why he wants it in.

15 MS. JOHNSON: And I'm concerned that the jury will
16 get the misimpression that there was something wrong with
17 what Puma did vis-à-vis Pfizer. That is the subject of the
18 litigation. We would have to litigate that it was an
19 arbitration.

20 THE COURT: I've been asking over and over and over
21 again, what is your explanation for this that necessarily
22 requires you to get into the litigation?

23 MS. JOHNSON: If you are -- so this was a dispute
24 resolution process pre-arbitration under the licensing
25 agreement. If a person -- if parties are in a dispute

1 resolution process, which is basically litigation or
2 pre-litigation, that context explains their interaction. It
3 explains why there might be certain timing of information
4 requests, which this exhibit is, and information provided.

5 There might explain why you have meetings with
6 lawyers to discuss the exchange of information rather than
7 just providing what one has. That explains the sequence here
8 and the timing, and it explains that there in fact was not
9 any withholding of information, at least not any improper
10 holding of information, which is the implication counsel
11 seeks to bring out.

12 THE COURT: I think you can do all of that without
13 asking questions that implicate the concerns I had in
14 granting your motion in limine. Were you in litigation?
15 Yes. Were there lawyers involved? Yes. You can ask those
16 questions. The concerns I had about the motion in limine are
17 just not implicated.

18 I mean, I suggested what plaintiff is trying to do.
19 It's possible defense wants to say Pfizer and let bad stuff
20 out that aren't going to implicate Pfizer or the Pfizer
21 arbitration.

22 MS. JOHNSON: And I guess my concern is if I don't
23 explain what was going on in the litigation, documents will
24 be taken out of context by the jury to suggest that something
25 was withheld or going on or wrong.

1 THE COURT: Tell me why it wasn't wrong? I mean,
2 that's the core issue. Why wasn't it wrong?

3 MS. JOHNSON: Because it wasn't wrongfully
4 withheld.

5 THE COURT: Tell me why it wasn't wrongfully
6 withheld.

7 MS. JOHNSON: Because it was part of the dispute
8 resolution process provided for by the licensing agreement
9 that they would go through this process --

10 THE COURT: And that allowed them to withhold
11 documents in response to requests? I don't understand.

12 MS. JOHNSON: That's what I would I have to --

13 THE COURT: That's what I'm asking you.

14 MS. JOHNSON: I would have to put on witnesses to
15 say no.

16 THE COURT: Well, you haven't even told me that
17 yet. I mean, if you told -- I suggested to you five
18 different arguments, and you haven't taken up any of them.

19 MS. JOHNSON: Correct.

20 THE COURT: What would you say? I'm still asking.
21 Why weren't these documents produced?

22 MS. JOHNSON: There were many documents produced.
23 What was produced was what was required.

24 THE COURT: You're staying these documents weren't
25 required?

1 MS. JOHNSON: Correct.

2 THE COURT: What do you say to that?

3 MR. COUGHLIN: That's absolute hogwash.

4 THE COURT: I'm not -- why weren't they required?

5 MS. JOHNSON: Of course he would say hogwash
6 because we --

7 THE COURT: Why weren't they required?

8 MS. JOHNSON: Because the license agreement
9 required certain things. Those certain things were provided.
10 Then Pfizer asked for different things. There was a dispute
11 about whether they were entitled to those things under the
12 license agreement.

13 If I could lay out that whole story, the jury would
14 see, hear at the end when Pfizer is asking for things that
15 under the license agreement, those things were not required
16 to be provided to Pfizer.

17 THE COURT: This is the closest you've come to
18 answering the question I've been asking since this morning.

19 Go ahead. Did you want to have a conversation, or
20 what did you want to do?

21 MR. CLUBOK: I'm sorry, Your Honor.

22 THE COURT: You can speak.

23 MR. CLUBOK: I appreciate it. I think the trouble
24 here is that there is no duty to provide Pfizer any documents
25 except what they're entitled to under the contract. If we

1 are -- if we are able to provide the whole story if we're
2 required to to rebut the false implication that they withheld
3 something improperly, we would show that everything that was
4 required to be produced under the agreement was produced.

5 There was a dispute over what they were entitled
6 to. That dispute gets resolved. Pfizer doesn't sue. So we
7 can tell them, you know, that Pfizer originally complained
8 that they weren't getting what they were entitled to, but
9 here they ended up getting it.

10 Mr. Coughlin will say, oh, that's hogwash. Pfizer
11 didn't get what they were entitled to. Now we will put on a
12 witness from Pfizer to show that they did get what they were
13 entitled to.

14 And by the way, there was Ropes & Gray involved.
15 There was Latham & Watkins --

16 THE COURT: I don't know how that helps.

17 MR. CLUBOK: Because there's lots of lawyers
18 involved. So which of the witnesses will we be induced to
19 call to prove that at the end of the day -- I mean, the proof
20 is in the pudding that Pfizer did not sue. You could argue
21 that.

22 But to tell the whole story -- and by the way, to
23 explain why there's some negative comments in these
24 documents, it's not because they're true. It's because
25 Pfizer started this off by having an aggressive position

1 because their CEO was surprised at a conference call about
2 how good the results were, not about how bad they were.

3 So Pfizer then says, well, gee, we want to see this
4 data. And they threatened litigation. That's why the
5 lawyers get involved. That's why people are super careful
6 about what's provided.

7 They ultimately do provide everything that's
8 required, but misleadingly. A snippet of this makes it seem
9 like they're not because they take this document that Pfizer
10 is writing in a litigation context like lawyers often do when
11 they say you're not giving me what I'm entitled to.

12 Then the two sides either, you know, go to a judge
13 or an arbitrator to prove that they're not, or they resolve
14 it. So this whole story we're being sucked into responding
15 to, that's the trial within the trial.

16 Ultimately there is no lawsuit. Pfizer doesn't
17 make a claim --

18 THE COURT: I got it. I'm not there.

19 What's your response to what we just heard?

20 MR. COUGHLIN: This has nothing to do with what
21 Pfizer was required to give over or get or anything else like
22 that, or what Mr. Auerbach was required to send over or not.
23 Okay?

24 Our assertion here is that he didn't send Pfizer
25 the true data. He sent them simulations because he didn't

1 want anybody to know that he had lied on that conference
2 call. He says here -- wholly apart from any Pfizer dispute,
3 he says here this morning that: In August of 2014, I flew to
4 New York and I provided them two things. I provided them the
5 real data. He says that. He also provided them with the
6 curves going out that we talked about Bin Yao. These
7 documents show that Pfizer a month later had not gotten that
8 data and were asking for it.

9 So it shows that what he said this morning, wholly
10 apart from any Pfizer litigation or any long, lengthy
11 explanation, that what he did was he deleted key tables. He
12 said he showed them the real data.

13 Why would you delete the key efficacy table if you
14 had shown them the real data in August when you flew to
15 New York? Why in September would you do that? Just the same
16 reason he did it with the FDA stuff. He's hiding it -- could
17 I finish? He's hiding it from the market.

18 Okay. He's hiding it from other people like
19 Pfizer. He's keeping this data only to himself because he
20 doesn't want it out there. And this -- and he lied about it
21 this morning, okay, because he didn't show them this data,
22 and they kept asking for it. He said he did it in August.

23 That's ripe -- that's all ripe for us to impeach
24 him now with this document -- wholly and apart from anything
25 else that might have happened with Pfizer.

1 THE COURT: Response?

2 MR. CLUBOK: If I may, Your Honor, he didn't say
3 that. What he said was they agreed at that meeting that they
4 would get -- they agreed either at that meeting -- I can't
5 remember if it was at that meeting or as a follow-up call --
6 that they would get the simulation curves, which they sent.

7 I'm sorry, Your Honor.

8 MR. COUGHLIN: I have it right here, Your Honor.
9 In August of 2014, he says he flew to New York to share with
10 them this data. Okay. And they requested had requested
11 certain things. Okay.

12 I asked: Okay. Did you show them the real data
13 that you had left, the data that you had seen, you know, in
14 the July snapshot, the data relying on the conference call,
15 that you relied on in the conference call? I brought it back
16 to the conference call.

17 And he says: I believe we had shown that to him.
18 Okay. As I recall, we had shown them the data with the
19 caveat that the patient numbers were dropping off. Now he's
20 talking about the three-year Bin Yao curve. Okay. Very
21 dramatically, my recollection of this is we were in a
22 face-to-face meeting. We showed them the data where the
23 patient numbers were dropping off quite dramatically. We
24 went out two years, three years, et cetera.

25 Then had mentioned to them we were doing the

1 simulations as well, and this is what they requested. They
2 wanted simulations. They didn't want to see the real data?
3 Answer: We had shown them the real data. And that is
4 absolutely false in these request documents, because they --
5 they attached the data he shows them. He sends them back the
6 false data and he cuts out the key data.

7 MR. CLUBOK: Your Honor, the questions were
8 incredibly confusing. But cut through all of that, what
9 Mr. Auerbach would testify to is that the data set that he
10 had available to him in July of 2012 [sic] was the data from
11 which he talked on the conference call about the preliminary
12 data. That's what he was talking about. Point one.

13 Point two, the data from which these simulated
14 curves that were sent to Pfizer comes from is that same data
15 set informed by a few additional months.

16 Point three -- can you turn that off for one
17 second?

18 THE COURT: That's not going to help.

19 MR. CLUBOK: It's okay. Your Honor, I'm sorry.
20 The flashing light distracted me from the most important
21 point. If you would give me a second -- but that's a good
22 technique.

23 Let me think for one second where I was in the
24 middle of it. Plaintiffs' counsel in the midst of all this
25 has repeatedly represented that they don't have this same

1 data set. All of this is an ultimate sideshow because this
2 exact data set that both what Mr. Auerbach told the people in
3 the conference call on July 22nd about and that these
4 simulated curves were from and the curves we've done now, it
5 all comes from the exact same data set that was provided to
6 plaintiffs over a year ago.

7 So this whole thing has become impossibly
8 incomprehensible on an issue that is designed to confuse the
9 jury as --

10 THE COURT: You have not -- I didn't hear you
11 mention the Pfizer litigation.

12 MR. CLUBOK: Oh, sorry. I apologize.

13 THE COURT: Hold on. I thought you were finished.
14 Now you seem to be making other arguments, and I just have a
15 compartmentalizing mind here. So I'm going to give you a
16 little more time to make any additional arguments and then
17 I'm going to rule.

18 Go ahead.

19 MR. CLUBOK: There was a dispute resolution
20 pre-litigation -- at least they called it litigation
21 process -- where Pfizer suggested that they -- they had
22 suggested and in the course of that exchange were suggesting
23 that they were not getting information, as if Mr. Auerbach
24 was hiding.

25 There was a dispute resolution process that Puma

1 successfully demonstrated to Pfizer that it had given it all
2 of the data that it was entitled to under the license
3 agreement. By the way, the claim in that litigation was that
4 the data was so good and that's why it was being, quote,
5 hidden. So they're claiming it's being hidden
6 inappropriately. It's not.

7 THE COURT: That's why we have --

8 MR. CLUBOK: Understood, but --

9 THE COURT: Let me finish. Gosh, I'm listening a
10 lot and I'm only talking a very little bit here. That's why
11 you get a chance to ask questions on direct or whatever we
12 call it.

13 MR. CLUBOK: That's right.

14 THE COURT: You get to clear it up that way. They
15 get to raise implications on the evidence before them and you
16 get to refute the implications.

17 MR. CLUBOK: You're right. But Your Honor had
18 previously said when they raised these implications, don't
19 you think that we're going to have to respond? And once we
20 start telling the story, we tell a little bit more about the
21 story, like a meeting, that then causes them to say, well,
22 now we have to rebut what he said about that. Then we have
23 to rebut what they said about that.

24 Now we're litigating over what was happening in the
25 Pfizer litigation, exactly what Your Honor was worried or

1 anticipated would happen.

2 THE COURT: No.

3 All right. I'm ready to rule. You don't have to
4 implicate the Pfizer litigation. You can talk about -- let
5 me start from the beginning.

6 I think plaintiff obviously is making a case about
7 withheld documents, not surprisingly. It's not earth
8 shaking. Is that what you're doing?

9 MR. COUGHLIN: I am, Your Honor.

10 THE COURT: Yeah. I think that is part of your
11 theory of the case, and I think there's been a lot of
12 mourning on that. I think you're allowed to present evidence
13 that supports that theory. I think the defense is allowed to
14 refute that evidence. And I believe the defense can do all
15 their refuting without mentioning the fact of this Pfizer
16 litigation.

17 I've suggested to you you can say, and the witness
18 is here and he's listening, you can say that was part of a
19 dispute and everyone came away from that dispute happy. You
20 can say that.

21 MR. CLUBOK: And may I just ask about one -- we've
22 talked about several of the documents. Can I raise a
23 specific issue?

24 THE COURT: Well, it's a little late to be raising
25 a specific issue because we've been at this for 25 minutes.

1 You'll note my modus operandi is to identify the issues and
2 address them, not let the issues move on to others.

3 Go ahead.

4 MR. CLUBOK: I appreciate that. Exhibit 486 is a
5 draft e-mail that Mr. Auerbach is writing to himself in the
6 course of this litigation to explain what he's doing here
7 would require -- he's at the time working with attorneys.
8 He's preparing drafts internally, and --

9 THE COURT: Your objection?

10 MR. CLUBOK: -- this never gets publicly disclosed
11 to anyone. This certainly is the kind of thing that to
12 explain it, I do think we would have to explain why he's
13 writing it and what it means. And it's going to seem
14 suspicious when it's not, particularly since it never goes
15 anywhere outside of his draft folder.

16 THE COURT: Okay. So your objection to 486 is on
17 what grounds?

18 MR. CLUBOK: On the grounds that -- first of all,
19 this was specific --

20 THE COURT: Let me ask again. Your objection to
21 486 on what grounds?

22 MR. CLUBOK: 403, 402, relevance, the prejudicial
23 value.

24 THE COURT: You said 402.

25 MR. CLUBOK: Relevance, and that it would require

1 us to bring in issues unrelated to the case in order to have
2 a chance to properly rebut the false implication that they
3 want to use this document for.

4 THE COURT: Okay. Let me read it to myself.

5 (Court reading document)

6 THE COURT: We have four documents in front of us.
7 I do think 486 from what has been presented to me gets the
8 closest to the concerns that have been presented. I think I
9 said to Ms. Johnson this is an issue of strategy for the
10 litigation, et cetera. This e-mail sort of looks like issues
11 of strategy and what they're doing.

12 MR. COUGHLIN: I would -- I would propose, Your
13 Honor, if you feel that way, because this goes right to the
14 heart of it, he says Pfizer has not seen the disease-free
15 survival data, nor has Pfizer seen the Kaplan-Meier curves
16 for the ExteNET trial. I would take off the next two
17 sentences and delete anything about legal. It just has to do
18 with that he made a representation --

19 THE COURT: Very good point. Thank you. That
20 sentence doesn't necessarily -- in fact, it doesn't seem to
21 implicate what I had concerns about.

22 So 486 as presently stated is the objection is
23 sustained. If you want to ask the witness: As of
24 October 27th, 2014, had Pfizer seen the disease-free survival
25 rate? You know, just ask that question without even

1 referencing this document.

2 MR. COUGHLIN: Got it, Your Honor.

3 THE COURT: And if he disagrees with that, I think
4 you've got some effective impeachment with that sentence.

5 MR. COUGHLIN: Got it.

6 THE COURT: That's what we need to do. So 486, for
7 now the objection is sustained.

8 MR. CLUBOK: Your Honor, because I knew you were
9 reading and I didn't want to say anything, but let me add.
10 This was created definitely in anticipation of litigation.

11 THE COURT: Say again.

12 MR. CLUBOK: This was also -- it's part of the
13 litigation process. He's anticipating what they're going to
14 say and helping form his legal strategy, even the first two
15 sentences. I wanted to say that for the record.

16 THE COURT: Yes. Understood. That's why 486 is
17 excluded. Perhaps it could come up as an impeachment.

18 Are we then prepared to proceed?

19 Let's call the jury in, Ms. Bredahl.

20 THE CLERK: All rise.

21 (Open court - jury present)

22 THE COURT: Welcome back, folks.

23 Again, we've been dealing with some issues outside
24 your presence so this will proceed more smoothly.

25 You may continue with your examination.

1 MR. COUGHLIN: Thank you.

2 BY MR. COUGHLIN:

3 Q. Good afternoon, Mr. Auerbach.

4 A. Good afternoon.

5 Q. This morning we were talking about some documents that
6 you had sent to licensor, Pfizer; is that correct?

7 A. That is correct.

8 Q. You said you had gone in August of 2014 to meet with
9 Pfizer in New York, Mr. Vatnak; is that correct?

10 A. Correct.

11 Q. And that you provided Mr. Vatnak with the real data that
12 you had presented on June 22nd, 2014, on the analyst call.
13 And that you had also provided him with the curves going out,
14 the Bin Yao simulation -- the Ben Yao curves going out, not
15 the simulation curves; is that correct?

16 A. That is what I said this morning, yes.

17 Q. Okay. Let me show you what has been marked as document,
18 Exhibit 480. Do you see that document?

19 A. Yes, I do.

20 Q. Do you see that it is referencing a discussion in August
21 -- I mean, in September 12, 2014?

22 A. Correct.

23 Q. And there's a request. There's a request for documents;
24 is that correct?

25 A. Yes, a very extensive request.

1 MR. COUGHLIN: I'd move for Exhibit 480 to come in,
2 Your Honor.

3 THE COURT: Over objection 480 is admitted.

4 **(Exhibit 480 received.)**

5 BY MR. COUGHLIN:

6 Q. And in that request Pfizer is requesting table -- if you
7 go down to the baseline data and the primary efficacy
8 analysis, do you see that on the second page, page 2 of 4?

9 A. Yes.

10 Q. Pfizer is requesting that information; is that correct?

11 A. That would be correct.

12 Q. And that's -- and earlier you testified that you had
13 already provided that information in August of 2014; is that
14 correct?

15 A. We had shown -- my recollection of this is that in the
16 August 2014 meeting, we had shown this to them, but we didn't
17 leave them with any formal copy of it. We didn't give them
18 any hard copy of it. This appears to be a very extensive
19 list of requests from them for data analyses that includes
20 what we had shown to them but more than that.

21 Q. Okay. You said -- and you believe you had shown them
22 the efficacy tables; is that correct?

23 A. That was my recollection, yes.

24 Q. Okay. I'd ask you to turn to Exhibit 481, and I'd ask
25 you to flip in to page 6 of 7. Now, this is an efficacy end

1 point summary chart. Do you recognize it?

2 A. Yes, I do.

3 Q. And it takes out the Kaplan-Meier rates. Do you see
4 that?

5 A. I don't remember if they had -- in between all of these
6 e-mails documentations, I seem to remember calls with them
7 because, as I recollect, they had sent us this huge list of
8 things they wanted.

9 We had asked them -- which were kind of the high
10 points they wanted because this was, you know, quite a lot of
11 work to get done. I seem to remember them kind of triaging
12 this, if you will, in terms of here's what we really need
13 right now and you can get us the rest later.

14 I seem to remember this table was high on that
15 list, which is why it's likely being provided.

16 Q. Let's take a look at Exhibit, I believe it's, 123. It's
17 already been admitted into evidence. Let's go into the
18 table. Find 123. Let's go into the efficacy charts.

19 Let's go in to page, if we might, page 8 of 35.

20 A. I apologize. I don't have that exhibit in front of me.
21 Can you please provide it?

22 Q. We're going to show it on the screen.

23 A. Okay.

24 Q. Do you see that table there?

25 A. Yes.

1 Q. Okay. That is the table that you were given on July 17,
2 2014; is that correct?

3 A. Correct.

4 Q. Okay. And now let's go back to -- and that has -- that
5 has the KM rates where you can figure out the absolute delta
6 of 2.3 percent; is that correct?

7 A. That's correct.

8 Q. Okay. Let's go back to Exhibit 481, page 6.

9 In this document those -- that -- those KM rates,
10 those rates in the absolute delta table are cut out. Do you
11 see that?

12 A. Yes, correct.

13 Q. You're saying that's what Pfizer wanted?

14 A. In between these calls -- so you'll notice on the e-mail
15 from --

16 Q. Could you just answer that question, Mr. Auerbach. Then
17 you can explain with your counsel if you want to go through
18 this document. I just asked that question. Is that what
19 Pfizer wanted? Yes or no?

20 A. So what was communicated to me when we had said to them,
21 you sent us this long list, can we triage this so we can kind
22 of get to the stuff you want right now, right away, this was
23 what they had said they wanted.

24 Q. They wanted you to cut a table out --

25 A. Communications were between the various parties, as you

1 can see on the screen, including our attorneys at Latham, and
2 this is how it was communicated to me. So this is what we
3 sent.

4 Q. Okay. Let's go to the next, document 795.

5 Mr. Auerbach, before get to that document, if you
6 presented all this documentation to them in August 2014, why
7 are you cutting out certain information in September and
8 October?

9 A. Again, what we presented to them was a presentation,
10 right, where we showed it to them. We didn't leave them an
11 actual physical copy of it. When they sent us this list, my
12 assumption was they wanted an actual physical copy of it,
13 which, I understand that request.

14 The list was extremely long, and obviously we had
15 just gotten phase III data, so we were excited to go start
16 moving this toward FDA approval. So we had just asked them,
17 listen, we're short-staffed. What do you -- can we triage
18 this? Can you tell me what is the highest propriety things
19 you want and what are the lower priority things so we can get
20 this to you in a timely fashion.

21 Q. And let me stop you. So it was quicker to cut a table,
22 to have somebody actually cut a table out of results, topline
23 results that you received, and send it to Pfizer? That was
24 more efficient?

25 A. That is what was communicated to me that they wanted to

1 see.

2 Q. Weren't you keeping it from them because you couldn't
3 tell anybody outside your company what the real results were?
4 Isn't that the reason you cut that table out?

5 A. That is absolutely not the reason that that table is not
6 in that document. We were more than happy to provide that
7 data --

8 Q. Mr. Auerbach, let's go on --

9 THE COURT: Just a moment. Here under the
10 circumstances I'm going to let you finish your answer.

11 Go ahead.

12 THE WITNESS: We were more than happy to provide
13 that data to numerous breast cancer physicians, to the FDA,
14 and to other parties who asked for it. There is -- I'm not
15 aware of anyone who asked for that data who was under
16 confidentiality agreement that we did not show that data to.

17 BY MR. COUGHLIN:

18 Q. Well, you didn't show it to Mr. Hicks when you sent him
19 the FDA data; did you?

20 A. We did show it to him in a meeting in January of 2015,
21 which I believe he has testified he saw. And I believe the
22 underwriters have also said, testified that he saw.

23 Q. I think that you're misquoting that testimony, but we're
24 going to hear that testimony about what he remembers seeing
25 then. Okay? Let's go next to Exhibit Number 795.

1 Mr. Auerbach, you testified this morning that you
2 had shown them curves, the Bin Yao curve simulation, the real
3 data, going out from two to three years. Do you remember
4 that testimony this morning?

5 A. We had shown them the preliminary curves.

6 Q. Okay. And then this is a document dated September 17,
7 2014. Okay. And they have three bullet point requests. It
8 says: In response to a question from Mr. Werber, Dr. Werber,
9 that we heard on the conference call regarding DFS rates,
10 Alan implied that he knew the DFS rates of the active and
11 control arms.

12 You said you had given them that data in August,
13 and here they are wondering about that data in September; is
14 that correct?

15 A. We had shown them the data. We did not leave them a
16 physical copy. I interpreted this when we got this that they
17 just wanted to have a physical copy of it.

18 Q. Okay. Next question. In response to a question by
19 Howard Liang regarding long-term follow-up, Alan implied
20 knowledge of DFS rates beyond two years and alluded to
21 continued separation of curves; is that correct?

22 A. Again, this had been shown to them. My interpretation
23 of this is they were asking for a physical copy of it.

24 Q. And you say you already had shown them a copy, and they
25 were just asking -- this is them asking for a physical copy

1 saying that you had implied knowledge of this beyond.

2 A. Well --

3 Q. Doesn't this indicate that they had never seen anything
4 like that?

5 A. I don't think that implies that at all. The people who
6 we met with were only two of the members of Pfizer on this
7 list. You have, it looks like, five or six, so this may be
8 one of the five or six who were not at that meeting
9 requesting that.

10 Q. You can explain with your counsel. In the final bullet
11 point in response to a follow-up question by Howard Liang
12 regarding subgroup analysis, something we went over extensive
13 this morning, Alan implied knowledge of efficacy in
14 prospectively defined subgroups and that a number of those
15 subgroups were extremely differentiating.

16 Is it your testimony that you had already shown
17 them that and they wanted a hard copy?

18 A. My recollection of this is that we had shown them this
19 but they were asking for more information on it.

20 Q. Thank you. No more further questions, Your Honor.

21 THE COURT: All right. Thank you, counsel.

22 MS. JOHNSON: Thank you, Your Honor.

23 MR. COUGHLIN: I meant to move all these into
24 evidence, Your Honor, those three documents.

25 THE COURT: I'm afraid you can't just say all these

1 three.

2 MR. COUGHLIN: I'm Sorry?

3 THE COURT: I think you did move them into
4 evidence.

5 MR. COUGHLIN: I thought I had.

6 THE COURT: Let's just confirm it. Document what?

7 MR. COUGHLIN: 480 I know I did.

8 THE COURT: That's in.

9 MR. COUGHLIN: Exhibit 795.

10 THE COURT: I think you might not have done that.

11 MR. COUGHLIN: And Exhibit --

12 THE COURT: Just a moment. It's also good to let
13 the jury know that they're going to see it.

14 MR. COUGHLIN: Yes.

15 THE COURT: All right. Next was what?

16 MR. COUGHLIN: 481.

17 THE COURT: No. You said seven something.

18 MR. COUGHLIN: 795.

19 THE COURT: 795 you didn't mention. Now you did.
20 And what's last?

21 MR. COUGHLIN: 481.

22 THE COURT: Okay. That's in. Go ahead.

23 **(Exhibits 481 and 795 received.)**

24 MR. COUGHLIN: Thank you.

25 MS. JOHNSON: Can we approach with the witness

1 binder?

2 THE COURT: Please.

3 Ms. Johnson, looking at various estimates, I
4 believe you will take this witness to the end of the day?

5 MS. JOHNSON: I expect so, yes.

6 THE COURT: Yes, I think so. Just letting the jury
7 know and the others know. And he'll be back with us on
8 Tuesday, correct?

9 MS. JOHNSON: Correct.

10 THE COURT: Okay.

11 **CROSS-EXAMINATION**

12 BY MS. JOHNSON:

13 Q. Good afternoon, Mr. Auerbach.

14 A. Good afternoon.

15 Q. You were asked quite a few questions that you wanted to
16 expound on and follow up on, and we'll do that and I'll ask
17 you about those.

18 I wanted to start by perhaps asking you to back up
19 and introduce a bit about yourself, starting with what did
20 you found Puma in order to accomplish?

21 A. The goal of Puma when I founded it is the same as the
22 goal of my prior company, Cougar, that it's very simply to
23 help cancer patients.

24 Q. Why was that mission important to you?

25 A. So I don't know if we discussed this earlier, but I'm

1 actually a former Wall Street analyst. I was a biotech
2 analyst on Wall Street for six years specifically dealing
3 with small and mid-size companies who develop drugs for the
4 treatment of cancer.

5 Unfortunately in 2002 my father was diagnosed with
6 terminal cancer, and I made the conscious decision to stop
7 being an analyst and to do something to help cancer patients,
8 and more specifically to help their families. It was
9 devastating what occurred in my family with the loss of my
10 father, and I wanted to do everything I could to help the
11 cancer patients and to help their families.

12 So in 2003 I founded my first company, Cougar
13 Biotechnology. We developed the drug Abiraterone, now known
14 as Zytiga, which ended up being the drug in prostate cancer
15 showing the greatest survival benefit ever in the history of
16 prostate cancer.

17 When that was done, I wanted to relive that
18 experience, and so Puma was founded immediately after the
19 completion of Cougar.

20 Q. All right. A couple of questions leading up to Cougar.
21 Where did you grow up?

22 A. I'm born and raised in Chicago.

23 Q. Did you go to college?

24 A. Yeah. I have an undergraduate degree from Boston
25 University.

1 Q. How did you pay for Boston University?

2 A. I was fortunate to receive many scholarships,
3 fellowships, grants, et cetera.

4 Q. Did you go to graduate school?

5 A. Yes. I received a -- my bachelor's degree was in
6 biomedical engineering. USC gave me a fellowship which was
7 full tuition, et cetera, where I received my master's degree
8 in biomedical engineering.

9 Q. And what was your first job after you graduated?

10 A. I worked for a company in Los Angeles known as
11 Diagnostic Products Corporation, also known as DPC. They're
12 a diagnostics company. More specifically, they make blood
13 tests for the treatment of cancer. And I ran the clinical
14 trials of all of those cancer diagnostics.

15 Q. And then what was your next job after that?

16 A. I then went to Wall Street and became a Wall Street
17 analyst where I worked with small and mid-size companies
18 developing treatments for cancer.

19 Q. And through those two work experiences, did you gain
20 experience with clinical trials for oncology products?

21 A. Yes, absolutely. We were running clinical trials when I
22 was at DPC. Then when I was a Wall Street analyst, all of
23 the companies that I dealt with were developing drugs for the
24 treatment of cancer. So were analyzing those trials, and I
25 was there working with the companies that did.

1 Q. Then you've explained a little bit about this already.
2 Can you please slowly explain to the jury how you came to
3 found Cougar.

4 A. So when my father was diagnosed with cancer in 2002, it
5 was unfortunately extremely advanced, and unfortunately my
6 family and I recognized we were going to lose him. And I
7 started to realize that there was a lot of companies that
8 were developing drugs that for whatever reason they either
9 internally determined that they didn't have the money for,
10 perhaps they had changed their priorities. But for whatever
11 reason, they abandoned these programs.

12 I became very angry with that because I realized
13 that these were drugs that possibly could keep my dad alive,
14 and they weren't being developed. So they were just sitting
15 on the shelves.

16 So I had the idea to go to these companies and see
17 if they would sell the rights to them or license the rights
18 to them to an entrepreneur like myself where we could then
19 take the drugs, take them off the shelves and start to
20 develop them and help the cancer patients and their families.

21 That was how Cougar was founded, and the first drug
22 that we actually bought, which was Abiraterone, as I
23 mentioned, had previously been developed by a company in the
24 United Kingdom. The company is called BTG -- B as in boy, T
25 as in Tom, G as in Gail. And that stands for British

1 Technology Group.

2 They had developed the drug Abiraterone, and it was
3 sitting on a shelf for about three and a half years. I found
4 it through the medical literature and through talking to
5 doctors. I bought the rights to it. I was in the UK, so we
6 brought it here to Los Angeles.

7 We built the company from there, and I'm very, very
8 proud of the fact that it has had a pronounced effect in the
9 lives of prostate cancer patients.

10 Q. Briefly on Cougar, did you raise money to start Cougar
11 for the purposes that you've told us about?

12 A. Yes, we did. When I decided to leave my career as an
13 analyst, I went to all the investors who I had built
14 relationships with and told them exactly what I was going to
15 do.

16 They liked the idea. They thought it was a very
17 innovative idea. And when I bought the drug, they found the
18 technology to be very intriguing. So when I first acquired
19 the asset, we raised money around that, and then we raised
20 money over the course of the company as well.

21 Q. And what did you do with that money? What did you do to
22 develop Abiraterone?

23 A. All the money we raised was put forward just for running
24 the clinical trials and doing the research to bring the drug
25 to the market for cancer patients. So in the history of the

1 company I think we raised somewhere in the neighborhood of
2 \$200 million, I believe, and all of that was put forward just
3 for developing that drug for cancer patients.

4 Q. And then what happened with Cougar and its drug product?

5 A. While we were in the middle of doing clinical trials, we
6 got approached by the large pharmaceutical company Johnson &
7 Johnson. Johnson & Johnson had an interest in building out
8 their cancer portfolio. They did not have very much at the
9 time, but they were interested in doing so.

10 And we as a small company, at that point we were in
11 phase III, and I believe we had two very large phase IIIs
12 that were running, and we had to start moving toward building
13 up our manufacturing facilities, building out our sales and
14 marketing force, and the costs were starting to get, you
15 know, quite large.

16 Also the amount of, you know, people we would have
17 to hire would get quite large as well. So when Johnson &
18 Johnson approached us, they had approached us with the idea
19 of them acquiring the company. They obviously have a lot
20 more resources. They have huge manufacturing facilities, so
21 it was very easy for them to do this.

22 Again, my goal was do what is best for the cancer
23 patients and to put the drug in the hands of someone who is
24 much more experienced, has much more capital, and can
25 certainly guarantee that this drug gets to the patients as

1 quick as possible. It made a lot of sense. So Johnson &
2 Johnson ended up acquiring the company in, I believe it was,
3 somewhere around July of 2009.

4 Q. Did you stay on with Cougar after the acquisition by
5 Johnson & Johnson?

6 A. Yes. After Johnson & Johnson acquired Cougar, they had
7 asked me to stay on because, you know, these people are my
8 family. My employees are my family, and I wanted to make
9 sure they were all taken care of.

10 In the contract with Johnson & Johnson, I put a
11 stipulation in there that they could not terminate any Cougar
12 employee I believe it was somewhere in the range of two to
13 three years.

14 And I stayed with the company for six months to
15 make sure the employees were okay. I wanted to make sure
16 they all saw me there every day and that nobody was
17 negatively impacted. So I ended up staying until January of
18 2010.

19 I left on a Friday, and by that next Monday I was
20 already talking to investors about starting Puma.

21 Q. Did Abiraterone end up getting FDA approval?

22 A. Yes, it did. It is now called Zytiga, and it is spelled
23 Z-y-t-i-g-a. It has been available to prostate cancer
24 patients since approximately 2011.

25 MR. COUGHLIN: Your Honor, I think we're going

1 pretty far afield here for relevance.

2 THE COURT: Yes. I -- it's a timed trial, so I
3 provide some leeway. How much more on -- before we get to
4 the merits?

5 MS. JOHNSON: That was my last question on Cougar.

6 THE COURT: Well, not just Cougar.

7 MS. JOHNSON: And on Puma, now we're going to turn
8 to the development of neratinib.

9 THE COURT: Proceed.

10 BY MS. JOHNSON:

11 Q. After you sold Cougar, you came to found Puma. Did you
12 raise money from investors to start trials on neratinib?

13 A. Yes, we did.

14 Q. And how did you go about doing that?

15 A. After Cougar had been acquired, I had gone to all the
16 investors and that them that I loved everything about this
17 experience and I loved what I had done taking, you know,
18 drugs that had been sitting on a shelf and taking that and
19 translating that into something that was great for patients.

20 I told them I wanted to do it again, and they were
21 all very eager for me to do that again. So once I obtained
22 the rights to neratinib, I went back to the exact same
23 investors and raised money again to start Puma.

24 Q. How many people does Puma employ currently?

25 A. Somewhere between 300 and 350.

1 Q. And how many of those employees are in California?

2 A. The large majority are in California. Our field force
3 obviously is out in the field. The in-house people are
4 pretty much evenly split between Northern California and
5 Southern California.

6 Q. And quickly, can you describe what neratinib looks like
7 physically for the jury?

8 A. Sure. Neratinib is an oral pill. It's a very small
9 pill that is taken by mouth once a day by the patient.

10 Q. And briefly, how does neratinib work to prevent breast
11 cancer in HER2-positive patients?

12 A. So in patients who have HER2-positive breast cancer,
13 which means that they have the HER2 gene, the cancer cell
14 will have a part that is outside the cell and a part that's
15 inside the cell.

16 You heard a lot earlier about a drug called
17 Herceptin. Herceptin works by binding to the outside of the
18 cell. Now, unfortunately cancer is very smart, and when you
19 block it one way, it finds another way to go. So usually
20 when you block cancer on the outside, it returns on the -- it
21 relies on the internal mechanism to keep itself growing.

22 Neratinib hits that internal mechanism, and more
23 specifically an area called the tyrosine kinase, which is
24 what neratinib binds to.

25 Q. I'd like to jump right into questions you were asked

1 about breakthrough designation for neratinib.

2 A. Yes.

3 Q. Do you recall that line of questioning?

4 A. Yes, I do.

5 Q. If you still have the plaintiffs' binders in front of
6 you, would you turn to Exhibit 1014. It's in the second
7 binder, I believe.

8 A. Yes.

9 Q. And you were asked questions about preparing to submit a
10 breakthrough request designation to the FDA for a meeting
11 that you had with the FDA?

12 A. That is correct.

13 MS. JOHNSON: If we could put up 1014,
14 Exhibit 1014.

15 BY MS. JOHNSON:

16 Q. Anyway, so plaintiffs showed this to you in your
17 questioning. The exhibit says in its second paragraph: That
18 way, if you're able to schedule an informal teleconference
19 with Puma, the call can be coordinated.

20 Is this a document that was submitted to the FDA by
21 Puma in advance of a teleconference meeting with the FDA?

22 A. That is correct.

23 Q. And did you participate in that meeting?

24 A. Yes, I did.

25 Q. What happened at the meeting?

1 A. So during the meeting for the breakthrough
2 designation -- again, this was an informal meeting for us to
3 determine whether or not we should or should not file for
4 breakthrough designation.

5 What the FDA discussed with us was that the
6 breakthrough designation was meant as a way for earlier stage
7 companies to leapfrog the process and get approval earlier.
8 So as I was referring to earlier, typically when you run
9 clinical trials, there are three phases of clinical trials.

10 There is phase I, which is where you get your
11 initial safety data. There is phase II, where you will start
12 to get initial efficacy data. Then phase III, which is the
13 large randomized trials where you will do a head-to-head
14 against whatever the standard of care is for your disease.

15 The breakthrough designation was a way for the
16 companies who had completed phase II to jump ahead to
17 approval before running their entire phase III program.

18 So what was explained to us was they tended to want
19 companies who were after phase II but before phase III, so
20 they didn't feel it was appropriate for us. And they also
21 mentioned to us that if a company had done a phase II
22 adjuvant study like what we had done in a phase III, the bar
23 they would have typically liked to have seen for the
24 breakthrough designation to allow them to leapfrog phase III
25 would have been a hazard ratio of 0.50, so a 50 percent

1 improvement.

2 Ours was a hazard ratio of 0.67, so a 33 percent
3 improvement, so it was a little bit below the bar they had
4 wanted to see. But they were also very clear with us that
5 they encouraged us to file the NDA, which was the application
6 for the approval of the drug.

7 Q. Does whether a drug receives breakthrough treatment have
8 any impact on whether it is ultimately approved?

9 A. No, it does not. We've actually seen a number of drugs
10 with phase II data that obtained breakthrough designation
11 that actually failed their phase III trials.

12 So again, I commend the desire to have a way to
13 fast-track these drugs to the market like this and leapfrog,
14 but there has unfortunately been a very high failure rate of
15 the drugs that have received this breakthrough designation.

16 Q. Did Puma end up filing a formal application with the FDA
17 for breakthrough designation?

18 A. No, we did not.

19 Q. Why not?

20 A. It didn't appear to be a path that was going to result
21 in the drug getting to the market any earlier, and the
22 commentary from the FDA was just go right to your NDA.

23 Q. You testified earlier about breakthrough therapy being
24 for phase II drugs --

25 A. Uh-huh. Correct.

1 Q. -- and you talked about the FDA's guidance on that
2 point. We've marked for identification purposes Exhibit 987
3 at the front of the binder.

4 MS. JOHNSON: I'm reminded that 1014 is not in
5 evidence, so I'd move 1014 into evidence if there's no
6 objection.

7 THE COURT: Without objection 1014 is admitted.

8 **(Exhibit 1014 received)**

9 BY MS. JOHNSON:

10 Q. And 987 marked for identification is guidance for
11 industry expedited programs for serious conditions, drugs,
12 and biologics.

13 THE COURT: 987?

14 MS. JOHNSON: 987.

15 THE COURT: I don't have that on my list.

16 MS. JOHNSON: You don't because it was brought up
17 by testimony, and we wanted --

18 THE COURT: Is there any objection to 987?

19 MR. COUGHLIN: No, Your Honor.

20 THE COURT: 987 is admitted.

21 **(Exhibit 987 received.)**

22 THE COURT: Again, counsel needs to assure we are
23 accurate in our identification, particularly since this isn't
24 on my list.

25 Go ahead.

1 MS. JOHNSON: We will do so, Your Honor.

2 Thank you.

3 So if you could put up 987.

4 BY MS. JOHNSON:

5 Q. Again, it's guidance for industry, and if you could turn
6 to page 8. This is page 8 of that guidance document. At the
7 top of that page the line -- it's a chart, and it says when
8 to submit request. Do you see that?

9 A. Yes.

10 Q. And then under the column for breakthrough therapy, what
11 does it say about when to submit a breakthrough therapy
12 request?

13 A. It says in the highlighted right there on the right, the
14 far right right there: Ideally no later than end of phase II
15 meeting. So exactly as I was mentioning this morning, they
16 would ideally like you to file for breakthrough designation
17 after you've completed phase II and before you have started
18 your phase III trial.

19 Q. The first bullet point says with IND. What does that
20 refer to?

21 A. Your IND is the first application you're asking the FDA
22 to start human trials. So that's before you've ever tested
23 the drug in humans.

24 Q. How an IND already been filed for neratinib?

25 A. Yes, back in 2003.

1 Q. And had neratinib already proceeded through the end of
2 phase II meeting?

3 A. Yes. That had occurred in 2008, I believe.

4 Q. So for a phase III drug what, if any, implication would
5 achieving breakthrough therapy have on your FDA approval
6 process?

7 A. Well, according to this, they want you to talk to them
8 before you start your phase II, so it's not clear. I mean,
9 you can see on the screen here there's a lot of different
10 columns -- fast track, accelerated approval, priority review.
11 Those are more of the paths you would take post your
12 phase III data.

13 Q. All right. Mr. Coughlin showed you notes from Judy
14 Segal. You mentioned you hadn't seen those before. I wanted
15 to put those up again and ask you some questions about it.
16 It's Exhibit 460. And he directed your attention to page
17 438.

18 MS. JOHNSON: And, Your Honor, before we get there,
19 I'd like to move Exhibit 987 into evidence.

20 MR. COUGHLIN: No objection.

21 THE COURT: I thought we already did. It's in
22 evidence.

23 MS. JOHNSON: All right. Thank you. Just making
24 sure.

25

1 BY MS. JOHNSON:

2 Q. All right. Is this -- go down to the bottom. We talked
3 about the first little paragraph there that spans the two
4 pages, and then you pointed out the other paragraph that
5 says, does not have implications on NDA. What's an NDA?

6 A. So an NDA is the formal FDA application where you ask
7 them to approve your drug based on the data from your
8 clinical trial. So this meeting where it says -- Patricia is
9 listed as having that comment. Patricia is Patricia
10 Cortazar. Dr. Patricia Cortazar at the time was the head of
11 the FDA breast cancer group.

12 Q. And then after the meeting that you described and
13 Ms. Segal is describing, did the FDA's guidance on
14 breakthrough therapy have any implication for the NDA?

15 A. No, it did not.

16 Q. Did it have any implication for the filing of the NDA?

17 A. No, it did not. We were still able to file our NDA.

18 Q. And did it have any implication for the FDA's acceptance
19 of that NDA?

20 A. No, it did not.

21 Q. We had some questions early in the trial about the cost
22 of neratinib. Does Puma have a policy for patients who want
23 neratinib but may be unable to afford it?

24 A. Yes, we do. The policy we have is that we always put
25 the patient's interests first. So if there is a patient who

1 has insurance and can afford their copayment, that's great.

2 If there is a patient who has insurance and can't
3 afford their copayment, we provide them with copayment
4 assistance. So we pay that down to very low amount. I
5 believe it's, if I recollect, it's \$10 a month or something.

6 If the patient is uninsured, then we give them the
7 drug for free. There is no patient who has ever wanted
8 neratinib that did not get neratinib. We always put the
9 patients first.

10 Q. All right. Let's talk -- we've talked a lot about the
11 ExteNET trial here and I won't repeat questions that you've
12 already been asked, but when did the ExteNET trial originate.

13 A. The ExteNET trial originated, if I remember correctly,
14 it was April of 2009 under Wyeth, who was the original
15 developer of the drug.

16 Q. How many clinical trials of neratinib have there been?

17 A. I don't know the exact number. My estimation would be
18 somewhere in the range of 10 to 20.

19 Q. Were all of those started when Puma had ownership of the
20 drug, or some before?

21 A. The majority of those were started before Puma got the
22 drug. But because neratinib is a very active drug, there
23 were still patients who had been taking it for many, many
24 years.

25 Q. And what do you mean by active drug?

1 A. The drug has efficacy in the treatment of breast cancer.
2 So, you know, when we first acquired this asset from Pfizer,
3 I believe there was, like, 14 or so clinical trials, many of
4 which had been started, you know, five plus years prior to us
5 licensing it.

6 But this is an active drug, and it has a very
7 dramatic impact on breast cancer patients. So if you started
8 with, you know, a hundred patients five years ago, you move
9 forward and you still have patients who are responding to it.
10 So they were still on trial and, you know, we were happy to
11 see them continuing to respond to it.

12 Q. How important was ExteNET in particular as a study of
13 neratinib?

14 A. ExteNET was a very important study. You know, this is a
15 group of patients who are very young, especially patients who
16 are early stage and newly diagnosed HER2-positive breast
17 cancer. These are very young patients. These are
18 40-year-old patients.

19 They're extremely young and they've got children
20 and they want to see those children grow up and have children
21 of their own. And when they get breast cancer, you know, it
22 unfortunately jeopardizes that dream. So we have a drug here
23 that, you know, we thought had the potential to prevent that
24 deadly disease from coming back. So it was a very important
25 trial to us.

1 Q. We've reviewed the outcome of the ExteNET trials.
2 That's Exhibit 123 in evidence. And we've looked at page
3 6 -- if we can put that up -- that has some of the efficacy
4 results from the ExteNET trial. Do you recall seeing this a
5 number of times?

6 A. Yeah. Yes.

7 Q. And you've walked us through the different data
8 populations. I want to jump right into what else Puma had,
9 what other results Puma had as of July 2014 from the ExteNET
10 data. What was the volume, if you could describe, of the
11 data that Puma had access to as of July 2014?

12 A. So as of July 2014, we had a very large database with,
13 you know, over 2,800 patients in there. Some of those
14 patients had been followed, you know, well more than, you
15 know, two years.

16 I think we had several hundred patients who had
17 been followed for more than two years. So we had a very, you
18 know, large complete database of patients who had been
19 followed for quite a long period of time.

20 Q. Does Puma still have the database that existed as of
21 July 2014 in its possession today?

22 A. Yes, we do. We took what's called a snapshot, which
23 means we kind of saved the clinical database, as of
24 July 2014, and that was the data that was used in our
25 presentations to ASCO and in our presentations to investors.

1 So that database in that format we have of
2 July 2014 we still have in our possession.

3 Q. And what is your understanding of whether that snapshot
4 was provided to the plaintiffs in this litigation?

5 A. So my understanding of this is that, you know, we
6 obviously recognized that that database was something that
7 was very important to this litigation, and my understanding
8 is that we provided that database containing all of the data
9 that we had as of July 2014 to the plaintiffs and allowed the
10 plaintiff to be able to do any and all analyses that they
11 wanted to do on that database which is exactly the data we
12 had as of July 2014.

13 Q. Were you and your team personally involved in providing
14 that data snapshot to us for production to the plaintiffs in
15 this litigation?

16 A. Yes, we did.

17 Q. All right.

18 Were there additional analyses other than these
19 topline results that could be performed in that data snapshot
20 as it existed in July of 2014?

21 A. Yes, there was.

22 Q. Did you at the time ask anyone to provide analyses in
23 addition to the data that is existing in this page 6 of
24 Exhibit 123?

25 A. Yes. There were analyses that the statistical team had

1 done themselves and a lot that I specifically asked for that
2 they performed as well.

3 Q. We've talked about a couple of those additional
4 analyses, and we've heard about a group of patients called
5 centrally confirmed?

6 A. That's correct.

7 Q. What does that mean?

8 A. So the test to see if you are HER2-positive or not is a
9 test to see if you have the HER2 gene present in your tumor.
10 The way patients entered the ExteNET trial was they had to
11 have that test done in their doctor's office.

12 Unfortunately the tests that are done in the
13 doctor's office have a high degree of inaccuracy to them,
14 meaning if there's a false positive rate, meaning that the
15 doctor will say your cancer is HER2-positive, but in effect
16 it's not.

17 The false positive rate can be anywhere between 15
18 and 20 percent. So the way of making sure the patient is
19 indeed HER2-positive and has the HER2 gene present is by
20 doing what we called a centrally confirmed study.

21 This means the test is sent out to a central lab.
22 So your doctor sends it off to a central lab, and that lab
23 specializes in this test and therefore and confirm the
24 presence of the HER2 gene.

25 So for all the patients in ExteNET, we had the

1 local test done, which meant their doctor's office said they
2 had the HER2 gene, but then we also sent the sample out for
3 central confirmation as well.

4 Q. Was it required in order to participate in the ExteNET
5 study that a person's HER2-positive status be centrally
6 confirmed?

7 A. No. We allowed the patients to enter the study if their
8 test at their doctor's office, which was the local test, said
9 they were HER2-positive.

10 Q. Did the study track those two types of diagnoses, if
11 that's the right word, of the HER2-positive gene?

12 A. Yes, it did.

13 Q. All right. Did you ask for an analysis of the centrally
14 confirmed patient population back in July of 2014?

15 A. Yes, we did.

16 Q. You were asked questions about centrally confirmed
17 analyses that were done later in time. Do you recall that?

18 A. Correct.

19 Q. Did you ask Puma statisticians to conduct that same type
20 of analysis in the July 2014 time period?

21 A. Yes. The analysis in July of 2014 looked at whatever
22 data we had at that time on the centrally confirmed
23 population. They had done this because the prior drug we
24 were talking about, Herceptin, which is the drug that's used
25 in the year before neratinib, all of their clinical trials

1 only allowed patients to enter if they had centrally
2 confirmed disease.

3 They didn't do like we did, that if your doctor's
4 office said you had it, you could enter. So it was important
5 for us to be able to kind of do the apples-to-apple
6 comparison in comparing our results to theirs. So it key for
7 us to be able to get those centrally confirmed results. So,
8 yes, we did perform that in July of 2014.

9 Q. By the way, how many biostatisticians does Puma have or
10 did Puma have in this time period?

11 A. Oh, I don't know the exact number because we used a lot
12 of contractors and things like that. My ballpark would be 20
13 to 30 if I had to take a guess at it.

14 Q. Let's talk about the press release that we've seen
15 before. Did you make plans, once you had the ExteNET data
16 available, to make those results public?

17 A. Yes, we did.

18 Q. And Exhibit 102, which is in evidence, is that press
19 release. I want to walk through it just briefly. We've seen
20 it before.

21 This press release announces results from the
22 phase III clinical trial noted as ExteNET. Is this the press
23 release that announced the topline results of the ExteNET
24 trial?

25 A. Yes, it is.

1 Q. And the third paragraph talks about the results that are
2 being announced in this press release. I just want to read
3 two of the sentences: The results of the trial demonstrated
4 that treatment with neratinib resulted in a 33 percent
5 improvement in disease-free survival versus placebo.

6 Did you see that?

7 A. Yes.

8 Q. Has that information ever been corrected?

9 A. No. It remains accurate today.

10 Q. The next sentence is: The hazard ratio was determined
11 to be 0.67, which was statistically significant with a
12 p-value of 0.0046.

13 Do you see that?

14 A. Yes.

15 Q. Has that information ever been corrected?

16 A. No. That continues to be accurate.

17 Q. A couple of other data points are disclosed here talking
18 about the secondary end point: The results of the trial
19 demonstrated that treatment with neratinib resulted in a
20 37 percent improvement in disease-free survival, including
21 ductal carcinoma in situ versus placebo.

22 What does that statistic refer to?

23 A. So as we had mentioned yesterday as well as earlier this
24 morning, there are breast cancer tumors that are actually
25 malignant, meaning they're cancerous.

1 Then there are also precancerous lesions, and those
2 precancerous lesions are referred to as ductal carcinoma in
3 situ. These are precancerous lesions that can become
4 cancerous. Obviously there's something that you also would
5 like to prevent, so this is the definition that would include
6 those premalignant tumors.

7 Q. And the hazard ratio for that population is .63?

8 A. That's correct.

9 Q. Was that -- was that correct, that that population was a
10 secondary end point of the trial?

11 A. Yes. It was the main secondary end point of the trial.

12 Q. The press release then says: Based on these results
13 from the ExteNET study, Puma plans to file for regulatory
14 approval of neratinib in the extended adjuvant setting in the
15 first half of 2015.

16 Was that the plan as of this July 22nd press
17 release?

18 A. Yes, that was the plan as of the July press release.

19 Q. And then the full results according to the press release
20 will be presented at a future scientific meeting.

21 We've heard about this a bit before, but what
22 future scientific meeting did the ExteNET results get
23 presented at?

24 A. Well, at the time this press release came out, that was
25 not something that we, Puma, determined. We have an outside

1 group of, like, of doctors called the academic steering
2 committee, and they had the right to choose which cancer
3 conference this data was presented.

4 The one they ended up presented to was what we
5 referred to as the American Society of Clinical Oncology
6 meeting, which is also known under the acronym ASCO, A-S-C-O.

7 Q. Let's look at the back of the press release. We've seen
8 the front. There is a second page to the press release, and
9 it contains a number of risk warnings. I'd like to ask you
10 about a couple of them that are highlighted here.

11 The company warned in this press release that
12 results could differ materially from the statements due to a
13 number of factors. Do you see that?

14 A. Yes, I do.

15 Q. What did you intend that risk warning to refer to?

16 A. These press releases are meant for investors, and we
17 always put forward these type of, you know, forward-looking
18 statements and risk factors so that investors understand the
19 risks of investing in development-stage, small biotech
20 companies like Puma.

21 Q. And one more risk factor. There's a number here, but I
22 wanted to ask you about one more, the risk that the results
23 of clinical trials may not support the company's drug
24 candidate claims. What did you intend by that risk
25 disclosure?

1 A. Again it was a risk factor for the investors which --
2 there you go. It was a risk factor for the investors which
3 essentially was exactly what it says on the screen.

4 Q. Fair enough. Let's talk a little bit about ASCO. The
5 conference that you presented at was in 2015, correct?

6 A. That is correct.

7 Q. And what generally happens at these types of medical
8 conferences?

9 A. So these medical conferences -- and ASCO is an extremely
10 large one. I think the attendance at ASCO is usually
11 approximately 30,000 people, so this is quite a large
12 conference.

13 Usually they get thousands of research studies
14 being submitted to the conference. They have a whole panel
15 of individuals who review these, and they kind of give them a
16 rating. And the ones that get the highest ratings get to be
17 presented at the conference.

18 So they kind of have three groups that they
19 generally categorize the studies into. One is that they just
20 publish them in a large book that they put out as part of the
21 conference. The second is they have what I refer to as
22 poster presentations. These are very large rooms where they
23 have posters where you, you know, put them up against the
24 walls, if you will, and people come in and can talk to you
25 about them.

1 And then kind of the highest tier, what we refer to
2 as oral presentations, these are done in very large rooms
3 that can hold hundreds if not thousands of people. And
4 they're big presentation with giant screens where you speak
5 for 20 minutes and go through a PowerPoint presentation. And
6 then there's usually an open question-and-answer period where
7 doctors who are in the audience can come up and ask you
8 questions.

9 So we submitted the ExteNET study to ASCO, and we
10 were very pleased when it got accepted and specifically got
11 accepted for an oral presentation.

12 Q. Did you personally -- you said you were pleased that it
13 was accepted for oral presentation. Why were you pleased?

14 A. When you have a drug that has completed phase III -- you
15 know, this is an industry that has a very, very, very high
16 failure rate. For every 10,000 drugs that get discovered,
17 one makes it to the market. So you're talking about an
18 industry with a 99.9 percent failure rate.

19 So when you have a successful phase III, you know,
20 as you can imagine, you feel very fortune. And especially
21 when it's a drug that helps cancer patients, you have a great
22 deal of excitement about it because you're now going to go
23 head to market. You know, you've been successful, and now
24 you get to do all the things that you want to do, which is
25 help cancer patients.

1 So for us a very key step in that process was
2 presenting it at a big conference where we could educate the
3 breast cancer doctors about this drug and show them about the
4 efficacy so they could, you know, hopefully one day use it in
5 their patients. Also about the safety and how to control the
6 side effects so that it didn't cause any harm to their
7 patients.

8 The best way to do that is in these large oral
9 presentations because these are, you know, big rooms that can
10 hold, as I said, hundreds if not thousands of people. And
11 it's the best way to educate the group as a whole.

12 MS. JOHNSON: I'd like to put up Exhibit 983, not
13 move it into evidence but as a demonstrative.

14 THE COURT: Any objection?

15 MR. COUGHLIN: One second, Your Honor.

16 MR. FORGE: No objection as a demonstrative, Your
17 Honor.

18 THE COURT: Demonstrative just means they're going
19 to demonstrate, but it's not in evidence.

20 MS. JOHNSON: Just wanted to look at a picture
21 after so many words.

22 BY MS. JOHNSON:

23 Q. Is this a picture of the actual ASCO conference in 2015?

24 A. Yes, it is.

25 Q. And you were obviously in attendance?

1 A. Correct.

2 Q. How many people attended ASCO, this 2015 conference, if
3 you know?

4 A. The number is somewhere in the range of, I believe,
5 30,000 to 33,000 people or so.

6 Q. All right.

7 MS. JOHNSON: I'll mark this as demonstrative
8 Exhibit 1, DX1. Again, we're not moving it into evidence.

9 **(Exhibit DX1 marked for identification.)**

10 BY MS. JOHNSON:

11 Q. All right. What was the process for submitting the
12 ExteNET trial to ASCO for presentation at the conference?

13 A. So as I mentioned earlier, we had a group of outside
14 breast cancer doctors known as the academic steering
15 committee. We had gotten them all together at a meeting that
16 takes place in December in San Antonio, Texas, which is
17 called the San Antonio breast cancer meeting.

18 We went to them, showed them the data, and then
19 turned it over to them to, what do you think would be the
20 best conference for us to present this data at. They made
21 the determination at that conference that they felt this
22 would be ideal for ASCO.

23 And so we then went forward with putting together
24 what's called an abstract, which is kind of a shortened
25 summary of it that gets submitted to the conference and they

1 determine whether or not to accept it or to reject it.

2 Q. All right. Let's take a look at Exhibit 115, the ASCO
3 submission form for getting the abstract into the conference.

4 MS. JOHNSON: I believe there's no objection on
5 Exhibit 115 in evidence?

6 THE COURT: Without objection 115 is admitted.

7 **(Exhibit 115 received.)**

8 MS. JOHNSON: It's hard to read until we blow it
9 up, so let's blow up the first part of it.

10 BY MS. JOHNSON:

11 Q. Did you assist with filling out this form to get the
12 ExteNET abstract in to ASCO?

13 A. Yes, that is correct.

14 Q. And the box on the left -- if you could blow it up -- it
15 provides the date of submission. If we can see it,
16 February 1st, 2015. Was that the date that you submitted the
17 ExteNET abstract to be considered by ASCO for presentation?

18 A. Yes. That's correct.

19 Q. All right. On page 3 of this document it has a
20 confidentiality policy. Do you see that --

21 A. Yes.

22 Q. -- once we get there, page 3? And there's a box that's
23 checked there saying, I agree to a particular confidentiality
24 policy. Do you see that?

25 A. Yes.

1 Q. And if you can tell us, basically what is the
2 confidentiality policy of getting into ASCO?

3 A. So in order to be able to present your data at any
4 medical conference, you have to check a box very similar to
5 the one you see on the screen which states that this data is
6 confidential and it's never been presented in any public
7 forum and will not be presented in any public forum prior to
8 this meeting.

9 Q. Did you understand that -- let me ask you. The
10 confidentiality policy applies when you submit the abstract
11 for consideration, right?

12 A. The confidentiality policy is basically saying that as
13 of the date I am submitting this, I have not made this data
14 public information, that it is indeed confidential. You're
15 also agreeing to keep it confidential until the meeting.

16 Q. All right. Let's talk about the process for getting
17 ready for the ASCO conference.

18 You testified about this earlier, so I wanted to
19 walk through it. Were there people outside of Puma that you
20 submitted the ExteNET data to in getting ready for the ASCO
21 conference?

22 A. Yes, absolutely. So in addition to the academic
23 steering committee, we had shown this data to somewhere in
24 the range of, you know, 50 or so breast cancer doctors. And
25 we did this at the meeting I previously referenced, which was

1 the San Antonio breast cancer meeting which had been in
2 December.

3 And we had scheduled one-on-one meetings with each
4 of these individuals, usually about a half hour in length.
5 We did this over the course of a week where we, you know,
6 just kept bring in doctor after doctor, showing them the data
7 and getting their thoughts on it.

8 THE COURT: When is a good time for a break?

9 MS. JOHNSON: Right now.

10 THE COURT: All right. That's what I thought.

11 So we'll break and come back at 3:15. Thank you.

12 THE CLERK: All rise.

13 (Open court - jury not present)

14 (Recess taken from 3:01 p.m. until 3:19 p.m.)

15 (Open court - jury present)

16 THE COURT: Ms. Johnson.

17 MS. JOHNSON: Thank you, Your Honor.

18 BY MS. JOHNSON:

19 Q. Mr. Auerbach, I was asking you if there were people
20 outside of Puma that saw the data leading up to the ASCO
21 conference, and you described an academic steering committee,
22 right?

23 A. Yes. That is correct.

24 Q. Remind us again what the academic steering committee is.

25 A. The academic steering committee is a group of outside

1 breast cancer doctors who have been involved with the trial
2 from inception, and the academic steering committee was meant
3 to advise Puma on the trial and to also help -- they were the
4 ones who originally helped design the study.

5 They were also the ones who had the mandate as to
6 determining where and which medical conference this study
7 would be presented at.

8 Q. And did you meet with the academic steering committee
9 ahead of ASCO to discuss the ExteNET trial data?

10 A. Yes, we did. We first met with them at the San Antonio
11 breast cancer meeting which was in December. That was the
12 point at which we made the determination or they made the
13 determination that this data should be presented to ASCO.

14 We then later got together with them where we had
15 them all fly to Los Angeles in January where we sat down for
16 an entire day in order to put together the abstract.

17 Q. How many doctors make up the academic steering
18 committee?

19 A. I don't remember the exact number off the top of my
20 head. It would be somewhere in the range of 10 to 15, if I
21 remember correctly.

22 Q. Are any of them Puma employees?

23 A. No. They are all outside physicians.

24 Q. Does Puma pay them for their work to oversee the trials?

25 A. No. We do not provide them any compensation. They just

1 do this for the purpose of helping cancer patients. And they
2 certainly don't want to have any conflicts of interest such
3 that if they did present this data at a conference, you know,
4 someone could imply that the only reason they're doing this
5 is because they're getting paid. So, no, we do not pay them.

6 Q. And not in money, not in stock?

7 A. We don't give them any cash. They don't own any stock
8 in Puma. We don't give them any stock in Puma. They are
9 free and clear of all conflicts.

10 Q. And who is the head of the academic steering committee?

11 A. The head of the academic steering committee is
12 Dr. Arlene Chan. She is a breast cancer physician in
13 Australia.

14 Q. And are all my payment questions true for her as well?
15 Puma doesn't pay her?

16 A. That's correct. We do not provide her with any
17 compensation.

18 Q. All right. And before ASCO did you show the full
19 ExteNET trial data to specifically the academic steering
20 committee?

21 A. Yes, we did.

22 Q. All right. Let's turn to 952.

23 MS. JOHNSON: Don't publish it yet.

24 I believe there's no objection to 952, and we'd
25 move it into evidence.

1 MR. COUGHLIN: No objection.

2 THE COURT: Without objection 952 is in.

3 MS. JOHNSON: Correct.

4 **(Exhibit 952 received.)**

5 MS. JOHNSON: So 952, starting at the first slide
6 is ExteNET academic steering committee, San Antonio,
7 December 9, 2014.

8 BY MS. JOHNSON:

9 Q. Is this the meeting that you were referring to?

10 A. Yes, it is.

11 Q. Who from Puma attended this meeting?

12 A. So from Puma I remember that I was at this meeting.
13 Dr. Richard Bryce -- Bryce is spelled B-r-y-c-e -- who is our
14 chief medical officer was at this meeting. Then I believe
15 also Dr. Susan Moran -- Her last name is spelled M-o-r-a-n --
16 was at this meeting as well. I also believe that Dr. Alvin
17 Wong -- W-o-n-g is his last name -- may also have been
18 present at that meeting.

19 Q. And you as well, of course?

20 A. Correct.

21 Q. Did you present this slide deck to the academic steering
22 committee at that meeting?

23 A. Yes, we did.

24 MS. JOHNSON: If we could turn to slide nine.

25 BY MS. JOHNSON:

1 Q. There is a summary of the efficacy information for the
2 ITT population. Was this one of the slides that you
3 presented to the steering committee?

4 A. Yes. This is correct.

5 Q. And does it include the DFS for the entire ITT
6 population with the difference of 91.6 to 93.9?

7 A. Yes. That is correct.

8 Q. In addition to a number of other topline analyses of the
9 data, right?

10 A. That is correct.

11 Q. And two slides later there's a picture of the
12 Kaplan-Meier curves showing the entire ITT population. Was
13 that a slide that you walked through with the academic
14 steering committee in December of 2014?

15 A. Yes, that is correct.

16 Q. All right. And then let's -- I guess there's a number
17 of other slides here. I don't want to necessarily go through
18 all of them, but did you also present the diarrhea rates?

19 A. Yes, we did. I think it's a few slides forward.

20 Q. All right. Most frequent adverse events, 15 percent or
21 greater. Is the 39.9 percent number for diarrhea presented
22 in this slide deck?

23 A. Yes, it is.

24 Q. Among a number of other safety results, and then a few
25 slides later do we have the 16.8 percent -- actually the next

1 slide, 16.8 percent for treatment discontinuation.

2 Do you see that?

3 A. Yes. Correct.

4 Q. Among a number of other pieces of information.

5 First of all, were you worried about getting kicked
6 out of ASCO for presenting this data to the steering
7 committee?

8 A. No. ASCO's policy is that the data cannot be presented
9 in a public forum. This was under confidentiality. All of
10 the doctors who are on our academic steering committee signed
11 a confidentiality agreement, a CDA, with Puma. So they
12 agreed to keep this confidential. So this would be a
13 confidential discussion.

14 Q. And what were the reactions of the academic steering
15 committee to the presentation of this data?

16 A. We were very encouraged by their feedback. The number
17 one comment that we heard from the academic steering
18 committee was we need this for our patients. And that was
19 very encouraging to hear from them.

20 Q. Did you discuss the likelihood of FDA approval?

21 A. They had asked us at the time what our plans were, not
22 just for the FDA but worldwide, because the academic steering
23 committee is made up of doctors from the United States but
24 also from Europe, from South America, Central America, places
25 like that. Then obviously Asia Pacific, such as Dr. Arlene

1 Chan.

2 So they were asking us for our plans for filing for
3 FDA approval but then also for filing in Europe and other
4 countries as well.

5 Q. Did any of these doctors tell you that any of these data
6 were troubling?

7 A. No. We did not hear from any physician that this data
8 in any way caused any concerns or was in any way troubling to
9 them.

10 Q. Did any of the doctors at this meeting tell you that the
11 data were inconsistent with something that you had said
12 previously?

13 A. No. We did not hear from any physician that this data
14 was in any inconsistent with anything that Puma had said in
15 the public domain or that I had said in the public domain.

16 Q. Did any of the doctors tell you that you had overstated
17 the efficacy of neratinib, in words or in substance?

18 A. No. We did not hear from any breast cancer physician
19 that we, that anyone in the company had ever overstated
20 anything regarding the data.

21 Q. And did you hear from any of the doctors in words or in
22 substance that you had understated the safety results?

23 A. No, we had never heard from any physician that we had
24 understated safety results.

25 Q. Was neratinib then accepted for presentation into ASCO?

1 A. Yes, it was.

2 MS. JOHNSON: If we could turn to Exhibit 119.

3 It's the 2015 ASCO acceptance for the ExteNET abstract.

4 I'll move it -- I don't know if it's in evidence.

5 I'll move it into evidence -- I apologize. I did move 115.

6 I'd now like to turn to 119, and I would move 119

7 into evidence. I believe there's no objection.

8 MR. COUGHLIN: No objection, Your Honor.

9 THE COURT: All right. 119 is admitted.

10 **(Exhibit 119 received)**

11 MS. JOHNSON: If you could blow up the first
12 paragraph.

13 THE COURT: Wait. We're talking about 119?

14 MS. JOHNSON: Yes.

15 THE COURT: Did I hear you say 115 was in? Did you
16 say that? I just -- because it's not on my list.

17 MS. JOHNSON: I did say that.

18 THE CLERK: I have it, Judge.

19 THE COURT: You have it in, Ms. Bredahl, 115?

20 THE CLERK: I do.

21 THE COURT: I missed that. Okay. So 115 is in,
22 and now 119 is in.

23 Just hold on one second, please.

24 (Pause in proceedings)

25 THE COURT: Okay.

1 Go ahead.

2 BY MS. JOHNSON:

3 Q. The first paragraph -- the letter is directed to
4 Dr. Chan. Again, she is -- Mr. Auerbach?

5 A. Yes.

6 Q. Remind us of who Dr. Chan is.

7 A. Dr. Arlene Chan is the chairperson of the academic
8 steering committee.

9 Q. All right. And ASCO says to Dr. Chan: Thank you for
10 submitting your abstract.

11 Going to the second sentence: This year we
12 received more than 5,900 abstracts which were reviewed by our
13 scientific program committee and ASCO leadership. Then in
14 bold and underlined: I'm pleased to inform you that your
15 abstract was selected for oral presentation as part of an
16 oral abstract session.

17 Do you see that?

18 A. Yes, I do.

19 Q. All right. You earlier testified about the different
20 levels that a study can be accepted for. Of the 5,900
21 abstracts submitted, do you have any idea of a percentage of
22 how many get in?

23 A. I don't know the number in terms of the percent that get
24 to present at the conference. The way it works is those
25 5,900 abstracts are submitted to the ASCO committee. Their

1 review committee reviews all of those abstracts and gives
2 them a score. The highest ones get what is referred to as an
3 oral presentation.

4 Of the 5,900, I don't know what percent of them get
5 an oral presentation. My guess is it's a single-digit
6 percentage. But they rank those. The highest ranked ones
7 will typically get to what's called the plenary session which
8 is something held on a Sunday afternoon.

9 Then the others will usually get separated into
10 disease categories. So they'll have, you know, one breast
11 cancer one, one prostate cancer one, one lung cancer, et
12 cetera. But it's certainly not the -- it's the minority of
13 them that get to get that oral presentation.

14 Q. And which type of oral presentation was ExteNET selected
15 for, the plenary or the rest of the oral presentations?

16 A. We were selected for the breast cancer presentation
17 which was on a Monday that that occurred.

18 Q. Exhibit 119 contains a reminder of the confidentiality
19 policy, that paragraph that starts with all abstracts are
20 confidential. Do you see that?

21 A. Yes.

22 Q. What did that reminder mean to you about the
23 confidentiality of the ExteNET data?

24 A. Well, as the confidentiality policy states, all
25 abstracts are confidential from the time of submission until

1 the time of public release by ASCO. So what that meant was
2 that you could not disclose the data contained in it. And if
3 did you, you were at risk of being kicked out and not being
4 able to present the data at ASCO.

5 Q. And did you understand that you were still bound by that
6 policy?

7 A. Yes, I did.

8 MS. JOHNSON: Let's jump without further ado to the
9 conference call on July 22nd, 2014. The transcript is
10 Exhibit 103. If you could put up the first page of the
11 transcript, second page of the document.

12 BY MS. JOHNSON:

13 Q. We talked about risk disclosures in the press release.
14 Were there risks also disclosed in connection with the
15 conference call?

16 A. Yes, I believe there was.

17 Q. All right. Ms. Collett -- who is Cheryl Collett?

18 A. Cheryl Collett works in the finance defendant at Puma,
19 and she at the time was our controller. She has since been
20 promoted to the vice president of finance.

21 Q. Ms. Collett says on the conference call: Please refer
22 to documents that we file from time to time with the SEC,
23 including -- you can read it there -- our form 10K. Do you
24 see that?

25 A. Yes, I do.

1 Q. What is a 10K?

2 A. The 10K is the annual report that is filed with the
3 Securities and Exchange Commission. It's available on the
4 Securities and Exchange Commission website. It's the annual
5 report on the financials of the company and also an update on
6 the status of our business.

7 Q. All right.

8 If you turn in your binder to Exhibit 979. This is
9 Puma's form 10K for 2013 filed on March 3rd, 2014, which was
10 before the July 22nd, 2014, conference call.

11 MS. JOHNSON: I would move 979 into evidence. I
12 believe there's no objection.

13 THE COURT: With no objection 979 is admitted.

14 **(Exhibit 979 received.)**

15 BY MS. JOHNSON:

16 Q. Were you involved in putting together Puma's 10K for
17 year end 2013?

18 A. Yes, I was.

19 Q. If you would turn to page 24, there's a section entitled
20 risk factors, risks related to our business.

21 A. Correct.

22 Q. Once we have it up -- I'll read it while it's being put
23 up and you tell me if I'm doing this correctly: We currently
24 have no product revenue and no products approved for
25 marketing and will need to raise additional capital to

1 operate our business.

2 Why did you put that particular risk factor into
3 this 10K?

4 A. We put that risk factor into the 10K because it's a
5 reminder to the investors that this is not a company with
6 products on the market. We are not a profitable company. We
7 don't make money due to research and development having very,
8 very high expenses.

9 The cost of bringing a drug to market is estimated
10 to be anywhere between, you know, \$900 million and \$1
11 billion. Clearly in order to get our drug from where it was
12 to the market was going to require a significant amount of
13 capital.

14 Q. All right. The risk factors go on for some pages. If
15 we could turn to page 38. There's a risk factor that's
16 entitled: The price of our common stock could be subject to
17 volatility related or unrelated to our operations.

18 Do you see that?

19 A. Yes.

20 Q. And there are a number of factors listed under the risk
21 about our trading price could be subject to volatility,
22 right?

23 A. That is correct.

24 Q. And going down a few of the bullets, one of them is
25 timing and announcement of regulatory approvals.

1 Do you see that?

2 A. Yes.

3 Q. And any -- the next one, any future sales of our common
4 stock or other securities in connection with raising
5 additional capital or otherwise. Do you see that?

6 A. Yes, I do.

7 Q. Why did you put that particular bullet point about
8 warning investors about raising additional capital?

9 A. Well, oftentimes when a company announces that it's
10 raising additional capital, sometimes the stock price can
11 drop, and that tends to be a general market reaction.

12 So as we had said previously, we knew we would need
13 additional capital at some point, and this was just a
14 reminder to investors that oftentimes when you raise capital,
15 the stock does drop in relation to that.

16 Q. And why did you expect the need to raise additional
17 capital?

18 A. Well, at the time obviously Puma was still a
19 development-stage company, and we had a lot of expenses, the
20 ExteNET trials as well as other ones, and we knew we would
21 need additional capital at some point.

22 Q. All right. Let's go back to Exhibit 103 where we
23 started when we started talking about risk factors.

24 You've been asked extensively about Dr. Werber's
25 questions, so I wanted to give you a chance to explain what

1 you meant. His first question was: So in terms -- you
2 probably have it memorized by now.

3 A. Yes. Correct.

4 Q. On page 5 -- all right. I'll just read it: So in term
5 of the DFS of the placebo arm -- now I did it wrong. Okay.
6 I will read Dr. Werber's questions. First one. One, give us
7 a little bit of a sense what was the DFS on the control arm
8 first. Do you recall that question?

9 A. Yes, I do.

10 Q. And your answer is: Okay. So in terms of the DFS of
11 the placebo arm of the trial, it was in line with other
12 reported trials. So it's in line with the Herceptin adjuvant
13 studies.

14 Describe what Herceptin adjuvant studies you were
15 referring to or that existed at this time period.

16 A. So as we discussed previously and again this morning,
17 for the patients who have HER2-positive early-stage breast
18 cancer, the standard of care is they receive surgery, and
19 then they receive one year of treatment with chemotherapy and
20 the drug Herceptin.

21 And the idea is to try to prevent the disease from
22 coming back, and Herceptin has been very effective in doing
23 this. Herceptin has been tested in four trials in this
24 setting which is known as adjuvant breast cancer, and those
25 four trials have some interesting names, so I'll go through

1 them slowly.

2 One of them we refer to as the joint analysis
3 because it was actually two different trials that were merged
4 together. The two trials, one was called NCCTG. The other
5 one was called NSABP. So they merged the two together into
6 one long acronym there.

7 The second trial was referred to as HERA, H-E-R-A.
8 The third one was called BCIRG. And the fourth one, which
9 was actually the most recent one, was called BETH just like
10 the girl's name, B-E-T-H.

11 Q. All right.

12 A. What we were trying to do was to say that the placebo
13 arm of our study was similar to the DFS rates that were seen
14 in those four adjuvant trials.

15 Q. All right. Let's look first at Exhibit 300.

16 Exhibit 300 is a printout from a website entitled Herceptin.

17 MS. JOHNSON: I would move 300 into evidence.
18 There's no objection.

19 THE COURT: Without objection 300 is admitted.

20 **(Exhibit 300 received.)**

21 BY MS. JOHNSON:

22 Q. So on this page it looks like three of the studies that
23 you described are listed here.

24 MS. JOHNSON: If we could blow up that box.
25

1 BY MS. JOHNSON:

2 Q. Are these three of the four studies that you just
3 mentioned -- the joint analysis, the HERA study, and BCIRG?

4 A. Yes, those are those three studies.

5 Q. And what is the DFS rate of the treatment arm in the
6 joint study? Can you tell from this?

7 A. I believe it says at -- in joint analysis it looks like
8 at three and a half years, 86.7 percent.

9 Q. And you're looking at the right -- the pink shaded
10 columns, you're looking at the right-hand one under
11 disease-free survival, right?

12 A. That's correct.

13 Q. For at least the published point of the joint analysis,
14 you see 86.7, right?

15 A. That is correct.

16 Q. And then what was the disease-free survival in the HERA
17 study?

18 A. In the HERA study it was was 85.8.

19 Q. And in the BCIRG study what were the DFS rates?

20 A. It was -- for the last one, which is the standard of
21 care, is 88.0.

22 Q. What do you mean by the standard of care?

23 A. There's two arms there. One is called TCH and the other
24 is called ACTH. Because it's more effective, the ACTH tends
25 to be the one more people use.

1 Q. All right. Then let's turn to 922 in your binder. You
2 mentioned a fourth study. If you take a look at 922, it's a
3 presentation on BETH, a randomized phase III study evaluating
4 a number of things, including trastuzumab. Do you see that?

5 A. Yes, I do.

6 Q. And where was this study presented?

7 A. This study was presented at the San Antonio breast
8 cancer meeting that took place in December of 2013. So this
9 was actually the most recent Herceptin adjuvant study that
10 had presented results prior to the ExteNET study.

11 Q. Were you in attendance at that meeting?

12 A. Yes, I was.

13 Q. San Antonio 2013?

14 A. Yes, I was.

15 Q. Is this document a true and correct copy of the
16 presentation on the BETH study that was presented in San
17 Antonio Breast Cancer Symposium in 2013 which you attended?

18 A. Yes, that appears to be correct.

19 MS. JOHNSON: Your Honor, I would move Exhibit 922
20 into evidence.

21 MR. COUGHLIN: No objection, Your Honor.

22 THE COURT: 922 is admitted.

23 **(Exhibit 922 received)**

24 BY MS. JOHNSON:

25 Q. First of all, if you'll turn to slide six. You

1 mentioned this was the most recent Herceptin study as of this
2 July 2014 time period?

3 A. Correct.

4 Q. All right. On slide six it talks about the BETH trial
5 design, and I wanted to ask you a question about central
6 testing which we've talked about before.

7 At the top it says node-positive or high-risk
8 node-negative breast cancer, HER2-positive by central
9 testing. Were the data in the BETH study that studied, of
10 course, Herceptin, not neratinib but Herceptin, was that
11 study a centrally confirmed study?

12 A. Yes. All of the patients had to have their HER2 status
13 determined by a central lab. So, yes, it was centrally
14 confirmed.

15 Q. Let's jump to slide 26 that shows some of the efficacy
16 results in the BETH study. The first column there is marked
17 BETH. What were the efficacy results in the all-patients
18 line?

19 A. The efficacy was 92 percent disease-free survival rate.

20 Q. So putting those two exhibits that we've looked at
21 together, what was the range of the Herceptin studies that
22 had been published by the time of your July 2014 comments
23 with respect to the DFS rates of the Herceptin studies?

24 A. Yes. If you look at the all-patients line on the slide
25 going across all of those Herceptin studies, you can see that

1 the prior -- the previously shown DFS rates for the Herceptin
2 adjuvant studies ranged anywhere from 86 to 92 percent.

3 Q. Just based on your experience, why were the rates
4 getting better over time with the same drug?

5 A. That's a very good question. The Herceptin adjuvant
6 studies as you're seeing on the right-hand side of the slide,
7 so this would be the B31, N9831, BCIRG, and HERA, these were
8 all completed somewhere in the 2005 time frame. BETH was
9 completed in 2013.

10 When it comes to new drugs, you know, you can think
11 of this like any technology. So, for example, when you, you
12 know, first bought your iPhone, it was probably difficult.
13 You were probably, you know, not very comfortable with it. A
14 few months later, years later, you've become very comfortable
15 with it. You're much more, you know, technology
16 user-friendly with it. It's very easy to use.

17 The same thing can happen with new cancer drugs
18 where when a new drug comes out, the doctor is just learning
19 how to give it, how to give it to patients, to balance out
20 the side effects of it, to balance out the efficacy. Ten
21 years later they really optimized that, so they're really
22 able to deliver it and achieve the best results.

23 So what you're really seeing is that, you know,
24 increase in the technology user-friendly nature of the drugs
25 and doctors being able to give it and maximize the benefits

1 for the patients.

2 Q. So when you gave the answer to Dr. Werber and you
3 referred to the placebo arm of the ExteNET trial being in
4 line with other reported Herceptin adjuvant studies, are
5 these the studies that you had in mind?

6 A. Yes, absolutely.

7 Q. And where within the range of those Herceptin adjuvant
8 studies did the DFS for the control arm of ExteNET fall?

9 A. So the disease-free survival for both the all-comers,
10 the intent-to-treat, as well as those that were centrally
11 confirmed, so had their HER2 status determined by a central
12 lab, all fell within that range.

13 Q. Now, let me ask you, why didn't you just tell Dr. Werber
14 the actual number of the DFS of the control arm?

15 A. So, as we discussed previously, there's the
16 confidentiality policy that ASCO has. And every medical
17 conference has that exact same policy, which is, you have to
18 swear that the data you are presenting is confidential and
19 you have not put it in any public forum.

20 There are examples where companies violated that
21 policy and actually got kicked out of the medical conference
22 for doing that. So we certainly didn't want to have that
23 happen. So unfortunately in these situations you need to
24 walk kind of a fine line where you can, you know, disclose
25 some things or give some generalities. But if you actually

1 disclose the data, you would be violating that
2 confidentiality policy.

3 Q. You referred to your recollection of companies getting
4 kicked out of the medical conference. Why is that a bad
5 thing?

6 A. Obviously the goal is to bring new drugs to help cancer
7 patients, and a very important step in that process is being
8 able to present that data to doctors, to cancer doctors so
9 that they can get comfortable with the efficacy of the drug
10 as well as the side effects of the drug. The best place to
11 do that is at one of these medical conferences.

12 If you don't do that, there's no way that these
13 doctors are going to have comfort with the drug or be aware
14 of the drug. It would just end up hurting the patients.

15 Q. Let's go back to 103, to your next exchange with
16 Dr. Werber. You knew who Dr. Werber was in this time period?

17 A. Yes, I did. So as I had mentioned previously, I used to
18 be a Wall Street analyst. Yaron and I were actually analysts
19 at the same time. So Yaron is actually a medical doctor, a
20 very smart guy.

21 When we were both analysts, we used to, you know,
22 run into each other at conferences and we would talk about
23 things, et cetera. So I know Yaron very well. I know how
24 his brain thinks. And when I'm talking to him, I kind of
25 know where the conversation is going to be going.

1 Q. Let's look at the four lines that you were asked about
2 earlier in the testimony. At the bottom of page 5, you can
3 see them there. You're thinking -- he says: You're thinking
4 that, if I'm correct, the DFS is probably around mid to high
5 80s, around 86 or so, in the control arm? You say: I would
6 be comfortable with that number. He says: And one would
7 imagine you probably had to show around 90 percent or
8 91 percent? Is that reasonable? You say: Yes. I think you
9 can do a 33 percent improvement in DFS and come up with that
10 calculation given the numbers you gave.

11 I just want to ask you, in your own words what did
12 you understand Dr. Werber to be asking when he asked you this
13 line of questions?

14 A. So again, I've known Yaron for a long time, and when I'm
15 talking to him, I always know where his questioning is going.

16 When he first asked the question of what the
17 placebo arm DFS was, I knew exactly where he was going
18 whereas he was trying to get some ballpark estimate of where
19 the, you know, absolute DFS benefit was.

20 Again, I've known Yaron a long time. I knew
21 exactly where he was going with this. Now, obviously we're
22 in a very challenging situation because we can't just release
23 that information or else it prevents us from presenting this
24 at a medical conference obviously make it difficult for us to
25 bring this drug to the market.

1 So the goal we were trying to achieve here was to
2 give some kind of a ballpark range where we could give
3 investors and Yaron some range as to where the DFS was and
4 therefore give some, you know, general estimates of that
5 range.

6 Q. And what was your understanding about the range that you
7 took from his questions?

8 A. Well, as he said, mid to high 80s. I assumed that was
9 anywhere from 85 to 89 percent. And when he said 90 to 91,
10 you know, again taking the opposite ends of that spectrum,
11 that was, you know, if the placebo arm, the high end, was 89,
12 and the low end of the neratinib arm was 90, that's a one
13 percent benefit.

14 If you take the opposite, which would be the mid
15 range of the placebo with 85 and the high end of the
16 neratinib is 91, that was six percent. I felt comfortable
17 with that kind of guidance range, if you will, of one to
18 six percent.

19 Q. And again, what is the basis for your understanding that
20 Dr. Werber was interested in the range rather than the actual
21 numbers he was asking about?

22 A. He didn't -- his question is specifically, you know, can
23 you give us some type of sense. He doesn't actually ask for
24 me to give him the exact number. He says, can you give us
25 some type of sense.

1 So that triggered me to think he was looking for
2 some type of a range, and he knew that, you know, we couldn't
3 provide him with the actual data because it would inhibit our
4 ability to present this at a medical conference.

5 Q. All right. So you've given us a range of deltas from
6 Dr. Werber's estimates. You've described it as one to
7 six percent. Let's just run through the actual DFS deltas
8 for the different populations that we've talked about. The
9 DFS delta for the entire ITT population was what?

10 A. 2.3 percent.

11 Q. And the DFS delta for the entire population including
12 the DCIS events?

13 A. Was 2.9 percent.

14 Q. And we're probably good for now, but again what is DCIS,
15 just so that we remember, in that population?

16 A. So the DCIS stands for ductal carcinoma in situ. These
17 are the precancerous lesions.

18 Q. So in that population it was again?

19 A. 2.9 percent.

20 Q. All right. And the DFS delta for the centrally
21 confirmed patients in the ITT population?

22 A. It was 4.1 percent.

23 Q. And finally the DFS delta for the centrally confirmed
24 patients with DCIS?

25 A. I believe it was 4.5 percent if I remember correctly.

1 Q. Okay. And why not explain to Dr. Werber on the call
2 what groups of patients you were focusing on in giving the
3 range or agreeing to the range that he articulated?

4 A. When Yaron first mentioned on the call, you know, when
5 we said it was in line with the Herceptin adjuvant studies, I
6 remember having conversation with him where we were comparing
7 the differences between the Herceptin adjuvant studies with
8 the ExteNET trial.

9 And Yaron was certainly not the only one I had
10 those type of conversations with. I remember having them
11 with Matt Roden at UBS and Howard Liang at Leerink as well.
12 One of the things that they all pointed out was that, you
13 know, in the Herceptin adjuvant studies, some of them used an
14 end point that was just DFS. Some included the precancerous
15 lesions as well, the DCIS.

16 But the big one that they all mentioned was that
17 allo of the patients in the Herceptin adjuvant studies had
18 this centrally confirmed test for HER2. And we didn't have
19 that as an entry criteria for the trial so patients could
20 come in with just their doctor's office saying it, but we did
21 measure it in the patients.

22 So the ability to do that kind of, you know,
23 apples-to-apples comparison, that was something we had
24 discussed beforehand with the majority of our analysts.

25 Q. All right. Let's focus one more time on the last line

1 of your exchange with Dr. Werber. You said: Yes, I think
2 you can do a 33 percent improvement in DFS and come up with
3 that calculation given the numbers we gave.

4 Would you just explain what the 33 percent
5 improvement statistic means for the range of absolute rates
6 that you were discussing with Dr. Werber?

7 A. Yeah. The 33 percent improvement is in relation to the
8 hazard ratio. So you get the 33 percent. The hazard ratio
9 we reported was 0.67. You subtract that from one and get
10 0.33. You express that as a percentage, and that's the
11 33 percent.

12 So all of these analysts have got very
13 sophisticated tools, statistical packages, et cetera, where
14 they can run all of these type of simulations, and they
15 can -- you know, using that number and the hazard ratio of
16 0.67 and the range we gave for the placebo arm, they can
17 generate the curves themselves.

18 Q. Okay. After this conference call there were analyst
19 reports issued, and you were shown a couple of them in your
20 testimony. I wanted to go back to one of them because in
21 your questioning you asked to refer to a lower paragraph in
22 the study -- rather, in the analyst report. So I wanted to
23 give you a chance to do that.

24 If you would turn to Exhibit 301, which is in
25 evidence. And go to the Cowen report, Bates 15853. I

1 believe you testified earlier that you would receive these
2 analyst reports and generally reviewed them at the time when
3 you received them?

4 A. That is correct.

5 Q. All right. And the Cowen report from July 23rd, 2014,
6 is that the day after the conference call that we've been
7 discussing?

8 A. Yes. That is correct.

9 Q. Who is the analyst from Cowen?

10 A. Eric Schmidt.

11 Q. And he issues a report saying "the cat with nerati-nib"
12 strikes back. Do you see that?

13 A. Correct.

14 Q. You were asked questions about the first paragraph under
15 ExteNET looks like a home run. You asked to see the second
16 paragraph.

17 MS. JOHNSON: So if we could blow up the "we see
18 few barriers to approval" paragraph.

19 BY MS. JOHNSON:

20 Q. It says: Our consultants have indicated that a two to
21 three absolute improvement in DFS is clinically meaningful as
22 the prevention of recurrence is tantamount to a cure in this
23 setting.

24 You saw this report when it came out?

25 A. Yes, correct. That was the point I was trying to bring

1 up earlier, was that Cowen had previously done a call with a
2 number of doctors and had done a lot of work with doctors
3 asking them, you know, what result would be clinically
4 meaningful.

5 When we say clinically meaningful, what we mean is
6 what would be a result that would make you want to prescribe
7 this to your patients. The number that they had said was two
8 to three percent. And, you know, they importantly bring up
9 that again in this setting, you know, if you can prevent the
10 disease from coming back, you know, that's similar, if you
11 will, to a cure. And that's exactly what these patients want
12 to achieve.

13 So the two to three percent number he's referencing
14 is obviously exactly in line with our ITT population, and the
15 higher numbers he's mentioning is exactly in line with our
16 centrally confirmed HER2.

17 Q. Dr. Werber, he's an analyst as well, right?

18 A. Yes. Correct.

19 Q. You said he was a medical doctor and obviously an
20 analyst. He issued a report as well after the call. I'd
21 like to look at that. It's Exhibit 766.

22 MS. JOHNSON: I would move 766 into evidence. I
23 believe there's no objection.

24 MR. COUGHLIN: No objection.

25 THE COURT: All right. Without objection

1 Exhibit 766 is in.

2 **(Exhibit 766 received.)**

3 BY MS. JOHNSON:

4 Q. So again, 766 is an e-mail you received attaching some
5 analyst reports. If we can go to the first page of the
6 report, which is the second page of the exhibit, it's
7 entitled: Puma technology, even the skeptics make it on
8 board. Key takeaways and transcript from our recent ExteNET
9 physician call.

10 Is this a report by Dr. Werber who at the time
11 worked for Citi?

12 A. Yes. That is correct.

13 THE COURT: All right. Please make a note that 766
14 is not on the exhibit list. We're talking about 766.

15 THE CLERK: Judge, they added a page on the last,
16 the very last page of your exhibit list.

17 MR. COUGHLIN: There was a page added with later
18 exhibits.

19 THE COURT: I don't have that addition. I don't
20 know where it is.

21 MS. JOHNSON: Okay.

22 THE COURT: Just make a note. Maybe you should
23 make sure I get the addition or it gets to me. But 766 is
24 in.

25 MS. JOHNSON: All right. Thank you.

1 BY MS. JOHNSON:

2 Q. And you read this report when it came out most likely?

3 A. Yes, I did.

4 Q. Okay. Middle of that first paragraph under key
5 takeaways, Dr. Werber writes: At this point the KOL -- what
6 is a KOL?

7 A. So KOL is an acronym that stands for key opinion leader.
8 And what this means is that someone who in the breast cancer
9 world is respected by his peers is having a view that can
10 influence other breast cancer doctors as well.

11 Q. So Dr. Werber is having a discussion with the KOL about
12 of the ExteNET trial? Is that what's going on here?

13 A. Yes, that is correct.

14 Q. And Dr. Werber writes: The KOL -- so the key opinion
15 leader -- would like to see the full data to better
16 understand how the placebo arm did, but he admits that the
17 33 percent improvement in DFS suggests that the data is very
18 robust.

19 Do you see that?

20 A. Yes, I do.

21 Q. What did you take away from that about what the key
22 opinion leader understood about how much data you were and
23 were not disclosing at this point in time?

24 A. My understanding was that the physician or the key
25 opinion leader had just seen the press release which was

1 stating the 33 percent improvement in disease-free survival,
2 and his view was very positive on it.

3 Q. Okay. Going down in that page to the third bullet
4 point, ExteNET data is unprecedented. Dr. Werber writes:
5 Our expert noted that the hazard ratio of .67 observed is
6 unprecedented in breast cancer since Herceptin's first study.

7 Do you see that?

8 A. Yes, I do.

9 Q. Did you agree that the ExteNET data and its hazard ratio
10 were unprecedented since Herceptin?

11 A. Yes. So since the introduction of Herceptin, which was
12 somewhere in the 2005 time frame, there had been many, many
13 improvements to try to improve on Herceptin as we still have
14 not cured this disease. Every one of those attempts failed.

15 So this was the first drug in, you know,
16 approximately ten years to be able to improve on that
17 standard of care. So that was one of the reasons I believe
18 Yaron had said in his questioning this was somewhat
19 surprising and unexpected. Every other attempt had failed.
20 This was the first one to succeed.

21 Q. So attached then to the analyst report is what's called
22 a raw transcript a couple pages later. It says moderator,
23 Yaron Werber, of a call, it looks like, July 24th, 2014.

24 And you turn to that page in your binder?

25 A. Yes. (Witness complies.)

1 Q. Okay. That -- it's a transcript. Were you on this
2 call?

3 A. No, I was not. This is for Citi's clients, which are
4 mutual funds and things like that. They do not open this up
5 to the public, and they do not open this up to companies.
6 So, no, I was not aware of this call until I saw this report.

7 Q. Okay. Dr. Werber starts out the call, and then in the
8 third paragraph he says: So today with us we have a very
9 prominent physician who you all know. Hopefully he calls him
10 doctor. He's associate professor of medicine at Harvard
11 medical school.

12 So is that your understanding of who the KOL was
13 who had this conversation with Dr. Werber six days after the
14 July 22nd conference call?

15 A. Yes. It was one of the physicians from Harvard medical
16 school, yes.

17 Q. All right. And if we'll turn to page 6, the
18 conversation goes on for a while. Eventually they start
19 talking about the DFS rates. And at the top of page 6, do
20 you see in the middle of that paragraph, one question? Are
21 you with me?

22 A. Yes.

23 Q. He says: One question -- and this is the doctor
24 talking -- would be, what is the actual magnitude of
25 difference? That is to say, if the control arm had an

1 88 percent disease-free survival at three or four years, what
2 does the neratinib arm look like?

3 Do you see that?

4 A. Yes, I do.

5 Q. He goes on to say: Is it 96 percent, or is it, you
6 know, 90 percent, with such that there's only a two percent
7 difference?

8 What did you understand him to be estimating in
9 this discussion?

10 MR. COUGHLIN: Your Honor, I'd object to his
11 speculation. I mean, we can read it. I don't think he can
12 speculate what another doctor in another phone call with
13 somebody else was thinking.

14 THE COURT: I will sustain unless you can tell me
15 that his understanding has some other significance.

16 MS. JOHNSON: Plaintiffs' counsel has argued that
17 Mr. Auerbach's review of analyst reports was somehow relevant
18 to his state of mind and his actions.

19 THE COURT: The objection is overruled.

20 You may answer.

21 THE WITNESS: When I read this report, my thought
22 was that, you know, the doctor was suggesting that there is
23 a, you know, potential range of outcomes for what the
24 absolute benefit, DFS benefit, was in the trial. He is
25 saying it could be, you know, two percent appears to be the

1 low end of what his expectations would be.

2 BY MS. JOHNSON:

3 Q. Let's go to the next page. Just for the sake of time,
4 let's go to the discussion they had about the difference. On
5 the next page, page 7, the doctor continues, third paragraph:
6 You know, if the control arm did better than you anticipate,
7 then, you know, you might be looking at something like a
8 90 percent baseline risk, and then a 33 percent risk
9 reduction sort of shifts it down to, you know, maybe
10 92 percent. This is arguably the narrower window.

11 Do you see that?

12 A. Yes, I do.

13 Q. What was your reaction to what he was estimating at this
14 point in the call?

15 A. Again, he appears to be guiding to an expectation for
16 that two percent number. This is now the second time we see
17 it, and I believe there's another one as well where he goes
18 to, like, a two to three percent range or something like
19 that.

20 So there are several times on the call where the
21 physician seems to be guiding to around the two percent
22 number.

23 Q. Okay. Let's jump to that next one, the paragraph that
24 starts, in North America. At the end of that paragraph he
25 says -- this is the doctor from Harvard -- you're probably

1 thinking about -- excuse me: You're probably talking about a
2 baseline risk of 90 percent with the hazard you would get to
3 a two to three percent improvement in disease-free survival.

4 Do you see that?

5 A. Yes.

6 Q. Dr. Werber responds and says: So we've actually asked
7 on the call. Let's assume that the object kind of 86, 87 was
8 showing 90, 91. Is that reasonable? And the answer was:
9 Yes. So again we'll have to wait.

10 Do you see that?

11 A. Yes.

12 Q. And the doctor from Harvard responds and says: That
13 seems credible. I wasn't on that -- you know, I didn't
14 listen in on that call. But that seems, you know, that is
15 very much in line with the numbers we just came up with;
16 isn't it?

17 Do you see that?

18 A. Yes, I do.

19 Q. And what was your understanding of what that exchange
20 meant?

21 A. It looked to me as though the physician was basically
22 guiding to, look, there's a range here. It could be two to
23 three percent. It could be a higher range. But it was all
24 kind of the same.

25 Q. Okay. Let's go back. I want to switch with the time we

1 have left to the safety discussion in the conference call.

2 A. Yes.

3 Q. In the conference call Dr. Werber's second question was:
4 Help us understand, what do you know about the safety
5 profile?

6 A. Yes.

7 Q. And you said -- if we can put it up -- that the company
8 had not yet seen the results as the data were still being
9 validated. Do you recall that?

10 A. Yes, I do.

11 Q. You were asked a number of questions about it. Again, I
12 just wanted to give you the opportunity to explain what was
13 the basis for your statement that the safety data had not
14 been validated.

15 A. So the safety data had been validated by Puma's outside
16 vendor, which was a contract organization called Rho. They
17 had validated the data, but we had not internally validated
18 the data.

19 So we've certainly seen in the past that when we
20 get databases that sometimes are validated from an external
21 vendor, when we do them internally, the numbers change. So
22 it's always a little challenging when you're in that
23 in-between, if you will, type of position.

24 Q. You were shown an e-mail from Alvin Wong saying: Here
25 are the safety tables. They are now validated.

1 Do you recall being asked about that Alvin Wong
2 e-mail?

3 A. Yes, I do.

4 Q. Who at Puma are responsible for the statistical
5 validation of the safety tables?

6 A. That would have been done by Claire Sherman and her
7 group.

8 Q. All right. And what is your understanding about the
9 internal statistical safety validation process?

10 A. My understanding of that is that the internal validation
11 of the safety database was not completed until January of
12 2015.

13 Q. Do you know of examples at Puma where the data changed
14 through the validation process?

15 A. Yes. Absolutely.

16 Q. And what -- describe your experience in that regard.

17 A. Oh, we've had studies both where the safety and efficacy
18 data has changed upon validation. And, you know, the change
19 can be, you know, it could be 50 percent lower than you
20 originally thought. It could be 50 percent higher than you
21 originally thought. So the data can definitely change.

22 Q. All right. Let's take a look at the safety tables that
23 you did have as of July 2014. If you could turn to
24 Exhibit 124, which is in evidence. And let's slip to slide
25 five.

1 We talked about this before. This has the diarrhea
2 for neratinib on one side and the placebo on the other. It
3 has the 39.9 percent that we've talked about. It also has
4 diarrhea rates for the placebo arm. Do you see that?

5 A. Yes, I do.

6 Q. And on placebo all grades of diarrhea -- that's one
7 through four, I think is probably the highest that occurred
8 here -- were 35.4 percent. So 498 people in the study had
9 diarrhea of one grade or the other by taking a placebo pill.

10 What was your reaction to that data?

11 A. When we first received this data, what we were most
12 concerned about was this diarrhea data because the 35.4
13 percent diarrhea rate for the placebo arm -- the placebo is
14 basically a sugar pill. There's no reason this should cause
15 diarrhea.

16 If you went and looked at all of the other studies
17 that have ever been done with placebos, the diarrhea rate
18 total was usually around ten percent or so. So the 35 looked
19 quite high to us. We couldn't quite figure that out.

20 So we certainly thought all of the diarrhea data
21 was a little too high, so that's why we wanted to wait for
22 the validation.

23 Q. And in addition, grade-three or higher diarrhea, 23
24 patients in the study experienced grade-three or higher
25 diarrhea, which is, I think you said, seven bowel movements a

1 day, from taking a placebo pill?

2 A. Correct.

3 Q. What was your reaction to that data?

4 A. Again, we found the placebo data both for the all-grade
5 diarrhea and the severe, which is the grade three, it all
6 looked high. So there was certainly reason to be concerned
7 about the high rates.

8 Q. But the 39.9 percent did not end up changing, right?

9 A. That's correct.

10 Q. Did any of the safety results in all of those tables end
11 up changing from the validation process?

12 A. I believe that there were safety data that changed after
13 the validation. I don't recall which specific parameters
14 changed.

15 Q. You testified earlier that you were thinking about
16 diarrhea as a first-cycle effect. Can you explain that
17 testimony?

18 A. Yes. So with neratinib we tend to see that the
19 diarrhea, severe diarrhea, is what we refer to as being a
20 first-cycle effect. So what does a first-cycle effect mean?

21 What a first-cycle effect means is that in the
22 first cycle, which is the first month you're on it, that's
23 when you see the highest incidence, the highest frequency of
24 this severe diarrhea.

25 It then decreases in its frequency over time, and

1 that tends to be the GI tract adjusting. And this is a very
2 interesting thing that happens with neratinib was this very
3 short-term frequency where you tend to see a very high
4 incidence of this severe diarrhea in the first month. And
5 then the longer you're on it, the less likely you are to get
6 it.

7 So we tend to get a lot of questions from investors
8 about that first cycle percent of patients getting
9 grade-three diarrhea because -- especially if they, you know,
10 drop off study or things like that, you can end up having a
11 lot of missing data. So that was where the questions on
12 dropout rates, et cetera, kind of stemmed from, which was
13 that first-cycle grade-three diarrhea.

14 Q. Again, in this context you're using cycle as months?

15 A. That's correct. The first cycle is first month.

16 Q. All right. Let's turn to 176, which is the data as
17 presented at ASCO at the end of the class period. If we
18 could turn to slide 17. You've seen it before.

19 This is out of order. This is my fault.

20 Slide 176 is the ASCO data. And if you have it in
21 front of you, I can orient you to the page as we're talking.
22 Does this page list some of the grade-three diarrhea results
23 as it was presented in June 1, 2015, at ASCO?

24 A. Yes. So slide 17 which is now up on the screen -- thank
25 you for that. So what you're seeing here on the screen is

1 the percent of patients who got diarrhea by month in the
2 ExteNET trial. So as I mentioned, the diarrhea with
3 neratinib tends to be a first-cycle effect. What that means
4 is that in the first month is where you see the highest
5 incidence of it.

6 As you can see on the screen, it's that first month
7 where you see the big spike. That's exactly what I'm
8 referring to. So there's color coding on the slide where
9 each color is a different grade of diarrhea. The
10 grade-three, which is the severe, is the green. So you will
11 notice on the slide the highest green bar is in month one,
12 and then it drops dramatically after that.

13 So that's exactly the phenomena I was talking
14 about, this first-cycle effect, where that first month has a
15 very high rate of the severe diarrhea, and then it goes down
16 over time.

17 If you look closely at that first-cycle effect
18 percentage, you can see that comes out to be, you know,
19 somewhere around 28 percent, is that -- I think they're
20 trying to highlight it -- somewhere around 28 percent.

21 That's that first cycle you're seeing. And that's exactly
22 what we were referring to on the call.

23 Q. All right. Let's walk through that first bar. You say
24 first cycle is the first month?

25 A. Correct.

1 Q. And the X axis there is months?

2 A. Correct.

3 Q. So if we look at month number one, there's a bar for
4 orange, and that's grade one, right?

5 A. That's correct.

6 Q. Where would you put that? How many percentage?

7 A. That appears to be somewhere around what a 38 percent,
8 grade one.

9 Q. All right. Now I'm going to test your math. Grade two
10 brings it up to about where?

11 A. So I got, what, .62 minus .38. That's putting it at
12 about 24 percent, if I'm going that correctly.

13 Q. All right. And then the green bar, which you testified
14 you were thinking of as a first-cycle, grade-three diarrhea,
15 what is that green bar approximately?

16 A. So I'm looking at about a .62 on the low end, and I'm
17 looking at about a 97, I'm guessing, on the high. So it's
18 probably around 25-ish, a little lower.

19 Q. Okay. And that's the -- we'll check that math later.
20 But that was what you were referring to by grade-three
21 diarrhea in the first cycle?

22 A. That's correct.

23 Q. Okay. You are asked some questions about the
24 prophylaxis in the ExteNET trial. Again, can you remind us
25 what prophylaxis means?

1 A. So neratinib, as we know, has the main side effect as
2 you see is severe diarrhea. With the neratinib-related
3 diarrhea, once it starts, stopping it is very, very
4 challenging.

5 So what we looked at doing when we first acquired
6 the drug -- first licensed the drug, I should say -- is
7 trying to find a way to prevent it from happening in the
8 first place. So the idea was to give Imodium or loperamide
9 day one with neratinib. So the very dose of neratinib you
10 take, you're also taking Imodium.

11 Because of that first-cycle effect you see on the
12 screen, you really just need to do that in the first month.
13 If you can do that in the first month, you've kind of gotten
14 over the hardest part. And that was the approach we took was
15 to give a very high dose of the drug, taper it down.

16 So start with a very high dose on the first day,
17 lower the dose every day as you got out over that month, and
18 see if that could have a preventative effect where we
19 prevented the grade-three diarrhea from occurring.

20 Q. Okay. You were asked about whether there was
21 prophylaxis in the statistical analysis plan for the
22 neratinib, and I wanted to give you a chance to explain.

23 If we could go to Exhibit 1043, which is in
24 evidence. It's in the right of the plaintiffs' binder.
25 Exhibit 1043 was the clinical investigation of neratinib

1 protocol that you were asked about under number of subjects
2 in that first set of numbers.

3 It says antidiarrheal medications. People who did
4 not take it, 12.6 percent. Antidiarrheal medication
5 percentage who did take, 87.4.

6 Can you explain what these numbers are with regard
7 to, you know, an Imodium prophylaxis in the study?

8 A. So this is not patients taking it for prophylaxis. This
9 is patients who are taking Imodium when they get diarrhea.

10 Q. But aren't they able to take it from the first day?
11 Doesn't that effectively count as a prophylaxis?

12 A. No. The idea of prophylaxis is preventing the diarrhea
13 from occurring in the first place. This would be treating
14 the diarrhea once it occurs.

15 So if a patient takes neratinib and on the first
16 day they get diarrhea, then, yes, you're just treating
17 existing. The idea of prophylaxis is -- prophylaxis means
18 prevention. You're trying to prevent it from happening in
19 the first place. With, you know, 87 percent of the patients
20 taking it, they're taking it after the diarrhea occurred.
21 That's not prophylaxis.

22 Q. So if these 87.4 percent of patients take a prophylaxis
23 after they get diarrhea, do they nevertheless show up in the
24 numbers for grade-three diarrhea?

25 A. If they get grade-three diarrhea at all, they show up in

1 the numbers for grade-three diarrhea. The prophylaxis that
2 is referred to, I believe it's in the bottom section of the
3 slide where it says number of patients receiving
4 antidiarrheal prophylaxis --

5 THE COURT: Slow down.

6 THE WITNESS: I'm sorry.

7 At the very bottom of the slide, please. So you'll
8 notice that the last part there says number of subjects
9 receiving antidiarrheal prophylaxis following dose hold
10 and/or dose reduction for diarrhea. So what that's saying is
11 it's patients who already got bad diarrhea and now they're
12 trying to prevent it from happening again.

13 That's very different than what we're talking
14 about. What we're talking about is prevent it from ever
15 happening, not from happening again but from the severe
16 diarrhea ever happening.

17 BY MS. JOHNSON:

18 Q. And again, in the ExteNET slide presentation at ASCO,
19 you reported a number -- a range of diarrhea rates when that
20 prophylaxis is actually used preventatively, if that's not
21 duplicative. What results were you presenting there?

22 A. So in the ASCO slides that we presented were results
23 from other studies we had done where again we were trying to
24 prevent the severe diarrhea from ever occurring. This was
25 giving Imodium the very first day with the first dose of

1 neratinib before diarrhea ever occurred to try to prevent it
2 from ever happening.

3 By doing that, we were able to reduce the
4 grade-three diarrhea rates down to anywhere between 0 and
5 17 percent.

6 Q. And briefly, you were shown the statistical analysis
7 plan for the ExteNET trial, Exhibit 129. For time reasons I
8 won't put it up, but you were asked about the sentence:
9 Number of subjects receiving antidiarrheal prophylaxis
10 following dose hold or reduction due to treatment emergent
11 diarrhea will be summarized by the treatment arm.

12 You remember that discussion?

13 A. Yes.

14 Q. Will you explain what that means about the statistical
15 analysis plan's view of diarrhea prophylaxis?

16 A. That was actually just a slide we had up, which again --
17 so that is very different. That was trying to prevent
18 diarrhea from happening again after it had already occurred.

19 So there was -- the technical terms they use is
20 primary prophylaxis, which is preventing it from ever
21 happening in the first place, versus secondary prophylaxis,
22 which is you've already got bad diarrhea and you want to
23 prevent it from happening a second time. That would be
24 secondary prophylaxis, which is what they mentioned on the
25 slide.

1 What we were talking about doing was primary
2 prophylaxis, preventing the bad diarrhea from ever occurring.

3 Q. All right. Let's go back to the conference call and
4 talk about dropout rates. Exhibit 103 at page 9, you are
5 asked one of a couple of questions about the dropout rates in
6 the trial.

7 If you could turn to that in your binder.

8 A. (Witness complies.) Yes.

9 Q. All right. An analyst from Cowen, Mr. Schmidt -- is
10 that the Cowen report we saw earlier with the two to
11 three percent DFS rate mentioned?

12 A. Yes, that is correct.

13 Q. He asks: Thanks. And lastly, I think you probably do
14 know the dropout rate from the trial. Could you remind us of
15 that? You ask: Dropout rate due to side effects? Next
16 page. He says: Sure, or anything if you have it.

17 You say: I don't have that. I apologize. That's
18 part of the stuff being validated. So we anticipate
19 typically in the neratinib studies, the legacy ones that were
20 done before when Pfizer was running it without any
21 prophylaxis, it was usually in the five to ten percent range,
22 was the dropout rate due to AEs. So we'd anticipate it's in
23 the same vein.

24 Do you see that?

25 A. Yes, I do.

1 Q. Would you just explain in your own words to the jury why
2 you said that?

3 A. So I believe we discussed this yesterday and a little
4 bit this morning. We have two distinct definitions here.
5 One is what we refer to as discontinuations. The other one
6 is what we refer to as dropouts.

7 Discontinuations means you stopped taking neratinib
8 but you continued in the study, meaning you stopped taking
9 neratinib but you kept going to your doctor and every three
10 months the doctor was checking you to see if your cancer came
11 back.

12 Dropout means up stopped taking neratinib and said:
13 I'm going away from the study. You're not getting any more
14 data from me. I'm not going to continue to go to my doctor
15 and get my cancer checked. I'm disappearing completely as of
16 this date.

17 The dropouts is always more concerning to investors
18 because in the dropouts, you can end up having a lot of
19 errors because of it -- so if you had, say, a thousand
20 patients who are taking neratinib, and after two years, you
21 know, 90 percent of them didn't have their cancer come back.

22 Well, if of those, you know, 900 hundred patients
23 you had 100 who had dropped out so you didn't have a
24 measurement on them, you can imagine there's an error rate in
25 there where, look, maybe they dropped out of the study but

1 their cancer came back. You just don't know because they
2 disappeared.

3 So it can introduce a lot of error with that type
4 of missing data. That's why the dropouts is a very important
5 aspect that the analysts were concerned about.

6 Q. All right. Let's look at data you had as of the July 22
7 conference call, Exhibit 124.

8 MS. JOHNSON: If we can go to slide seven.

9 Thank you.

10 BY MS. JOHNSON:

11 Q. All right. This is a table on diarrhea. It's where we
12 see the treatment discontinuation line and the withdrawal
13 from the study line. Can you explain what those two
14 statistics mean?

15 A. So, the treatment discontinuations are what I was
16 referring to earlier as discontinuations, meaning they
17 stopped taking neratinib but they continued in the study. So
18 they continued going to their doctor to see whether or not
19 their cancer came back or not.

20 The withdrawal from study, that's the dropouts.
21 Those are the ones who physically dropped out of the study or
22 withdrew from the study, so we're not getting any more data
23 from them.

24 Q. And which of those two categories were you referring to
25 in answering the dropout question?

1 A. So Eric Schmidt's comment was on dropouts, and that
2 would be displayed as withdrawal from study on the slide. So
3 I believe we give a range of five to ten percent. And as you
4 can see on the slide, the withdrawal due to diarrhea, which
5 is the highest side effect, was 1.6 percent.

6 Q. All right. Final set of questions here on the dropout
7 rate. You were asked a second question on the call about the
8 dropout. Do you recall?

9 A. Yes. It was by Matt Roden at UBS.

10 MS. JOHNSON: Go back to 103.

11 BY MS. JOHNSON:

12 Q. Do you know -- is that a Dr. Roden?

13 A. I believe Matt is a Ph.D. I don't think he's a medical
14 doctor. But, yes, I've known Matt a long time.

15 Q. Okay. And he says at the bottom of page 14 -- I'll
16 start reading: I just wanted to clarify an earlier answer to
17 a question. So you were asked about the dropout rate, and I
18 think you wanted to defer to dropouts due to --

19 discontinuations due to adverse events. But can you just
20 mention, or maybe I missed it, how many patients actually
21 completed the year of therapy? Or another way of saying it
22 is, how much missing data is there from the DFS analysis?

23 Do you see that?

24 A. Yes.

25 Q. And you answer: Yes. So in terms of patients who

1 dropped out due to AEs, like I said, historically with
2 neratinib that should be somewhere in the five to ten percent
3 range.

4 He asks: Okay, but do you have a sense for
5 dropouts for any reason across the study? You say: No. The
6 main one we would expect is due to AEs and obviously if they
7 progressed or died.

8 Will you explain in your words what were you saying
9 here about the dropout rates?

10 A. So again, the concern would be in the patients who, you
11 know, dropped out of the study or actually withdraw from the
12 study. There's basically three reasons patients are going to
13 withdraw from the study.

14 One is that they had some type of an adverse event
15 and they don't want to the participate anymore. The second
16 is that, you know, unfortunately their cancer comes back.
17 The third, and more unfortunate, if they happen to pass away.

18 So I didn't have -- obviously I couldn't give the
19 other two numbers because that would be giving what the DFS
20 rates were and things like that. But in terms of the ones
21 due to the adverse event, which the main adverse event is
22 diarrhea, the five to ten percent number was the range we
23 were guiding to.

24 Q. So we saw that 1.6 number in the dropouts due to
25 diarrhea, and the question is dropouts due to all AEs. How

1 does that number in your mind compare to 1.6?

2 A. If diarrhea is the most common side effect, you know, we
3 can probably assume that the dropouts due to the diarrhea
4 would be probably at most half of the dropouts in the study.

5 So if you doubled the 1.6 percent, that would give
6 it a 3.2 percent. I would still be comfortable with the five
7 to ten percent number then.

8 MS. JOHNSON: Is this a good place to stop, Your
9 Honor?

10 THE COURT: Well done. Right on point.

11 So you have a bit of a break here. We won't be
12 returning until Tuesday. Please be here for, quote, starting
13 Tuesday at 9:00. So, four-day weekend. Don't discuss the
14 case. Don't research the case. Keep an open mind.

15 Thank you.

16 THE CLERK: All rise.

17 (Open court - jury not present)

18 THE COURT: Sir, you may step down. We'll see you
19 all on Tuesday.

20 MR. COUGHLIN: Thank you, Your Honor.

21 MS. JOHNSON: Thank you.

22 (Proceedings adjourned at 4:32 p.m.)
23
24
25

CERTIFICATE

I HEREBY CERTIFY THAT THE FOREGOING IS A TRUE AND CORRECT
TRANSCRIPT OF THE STENOGRAPHICALLY RECORDED PROCEEDINGS IN
THE ABOVE MATTER.

FEES CHARGED FOR THIS TRANSCRIPT, LESS ANY CIRCUIT FEE
REDUCTION AND/OR DEPOSIT, ARE IN CONFORMANCE WITH THE
REGULATIONS OF THE JUDICIAL CONFERENCE OF THE UNITED STATES.

/s/ Miriam V. Baird

01/23/2019

MIRIAM V. BAIRD
OFFICIAL REPORTER

DATE

\$	1067 [6] - 3:11, 60:11, 60:12, 60:16, 60:18, 60:19	153 [2] - 23:6, 23:10	152:6, 214:8
\$10 [1] - 174:3	1068 [4] - 3:12, 62:21, 62:23, 62:24	155 [2] - 24:11, 24:12	2.8 [2] - 48:16, 54:20
\$190 [1] - 103:13	108 [3] - 101:21, 102:2, 102:3	157 [3] - 24:16, 24:18	2.9 [2] - 214:11, 214:17
\$200 [2] - 95:18, 163:1	109 [2] - 3:19, 35:17	158 [3] - 3:4, 24:16, 25:1	20 [16] - 16:6, 16:14, 16:15, 18:1, 25:5, 25:6, 25:9, 25:10, 27:8, 29:14, 38:11, 117:2, 174:16, 178:16, 180:10, 185:3
\$218 [1] - 103:11	10:28 [1] - 74:1	15853 [1] - 216:23	2002 [2] - 159:4, 161:3
\$900 [1] - 202:9	10:45 [1] - 74:1	15th [1] - 85:4	2003 [2] - 159:11, 171:24
/	10K [7] - 200:22, 200:25, 201:1, 201:8, 201:15, 202:2, 202:3	16 [3] - 13:16, 115:2	2005 [2] - 209:6, 221:10
/s [1] - 243:9	11 [9] - 15:12, 15:14, 15:17, 16:4, 19:23, 36:12, 48:6, 48:11, 48:12	16.3 [1] - 42:19	2008 [1] - 172:2
0	111 [1] - 3:19	16.6 [1] - 42:18	2009 [2] - 164:2, 174:12
0 [4] - 54:12, 123:11, 124:6, 236:3	112 [1] - 3:20	16.8 [4] - 42:15, 43:24, 194:23, 194:24	201 [1] - 3:25
0.0046 [1] - 181:10	113 [1] - 35:16	160 [2] - 25:4, 25:9	2010 [1] - 164:17
0.33 [1] - 216:8	115 [9] - 3:23, 187:25, 188:3, 188:4, 188:5, 197:3, 197:13, 197:17, 197:19	161 [1] - 25:9	2011 [1] - 164:23
0.5 [1] - 78:20	11893 [1] - 1:22	16th [1] - 131:21	2012 [3] - 73:15, 101:5, 142:10
0.50 [1] - 168:24	119 [9] - 3:24, 196:25, 197:4, 197:7, 197:8, 197:11, 197:20, 199:17	17 [16] - 1:19, 5:1, 13:21, 15:8, 20:13, 45:9, 62:19, 123:12, 124:6, 152:1, 155:6, 230:17, 230:23, 236:4	2013 [7] - 73:15, 201:8, 201:16, 207:6, 207:11, 207:15, 209:7
0.67 [5] - 78:21, 169:1, 181:9, 216:7, 216:14	11:15 [1] - 91:17	175 [5] - 3:13, 69:22, 70:1, 70:2, 70:3	2014 [61] - 32:16, 32:22, 36:8, 39:14, 40:5, 50:22, 51:6, 54:5, 55:10, 55:14, 57:14, 60:22, 62:4, 62:19, 65:10, 66:13, 66:19, 70:19, 75:17, 76:15, 83:14, 83:17, 85:4, 88:25, 104:4, 127:15, 129:18, 140:3, 141:9, 147:24, 149:8, 149:12, 149:21, 150:13, 150:16, 152:2, 153:6, 155:7, 176:7, 176:9, 176:10, 176:19, 176:22, 176:25, 177:7, 177:10, 177:18, 179:12, 179:18, 179:19, 180:6, 193:5, 194:12, 200:8, 201:8, 201:9, 207:25, 208:20, 217:3, 221:21, 227:22
003 [2] - 37:24, 38:1	12 [3] - 91:17, 149:21	176 [2] - 230:15, 230:19	2015 [20] - 65:25, 70:5, 88:8, 88:24, 91:17, 91:22, 94:6, 103:18, 104:4, 106:25, 122:19, 154:20, 182:13, 184:3, 186:21, 186:25, 188:14, 197:1, 227:11, 230:22
01/18/2019 [1] - 243:9	12-month [2] - 45:18, 46:6	177 [1] - 25:19	2018 [6] - 39:12, 89:3, 93:17, 94:1, 94:3, 94:19
1	12.6 [1] - 234:3	179 [4] - 25:21, 26:8, 35:18, 69:22	2019 [2] - 1:19, 5:1
1 [4] - 52:9, 187:6, 202:9, 230:22	12/15 [2] - 85:22, 89:24	17th [5] - 32:11, 42:10, 44:7, 45:20, 50:6	205 [1] - 3:25
1,704 [1] - 70:13	121 [1] - 3:20	18 [3] - 20:14, 38:10	207 [1] - 4:1
1-053 [1] - 1:23	122 [1] - 3:21	180 [2] - 25:21, 26:8	21 [4] - 21:17, 84:3, 84:10, 84:13
1.0 [2] - 54:13, 54:14	123 [4] - 151:16, 151:18, 175:25, 177:22	186 [1] - 35:19	218 [1] - 4:1
1.5 [1] - 45:13	124 [2] - 227:23, 239:6	187 [1] - 3:23	22 [2] - 32:22, 239:5
1.6 [7] - 43:6, 43:10, 44:3, 240:4, 241:23, 241:25, 242:4	126 [3] - 11:14, 11:15, 13:10	188 [2] - 3:23, 26:18	221 [5] - 3:20, 121:11, 121:12, 121:15, 121:16
10 [12] - 15:11, 27:2, 36:8, 48:10, 48:12, 69:1, 84:17, 85:17, 91:5, 105:16, 174:16, 191:18	12670 [1] - 2:14	189 [3] - 26:24, 27:6	225 [2] - 30:6, 30:12
10,000 [1] - 185:14	128 [5] - 13:9, 13:15, 15:7, 75:3, 75:9	18th [1] - 122:19	22nd [6] - 143:3, 149:12,
100 [1] - 238:22	129 [1] - 236:6	19 [8] - 15:12, 15:15, 15:17, 16:4, 19:23, 27:2, 27:6, 28:23	
1007 [5] - 3:21, 122:11, 122:12, 122:16, 122:17	12:02 [1] - 126:1	190 [3] - 27:1, 27:7, 27:9	
1008 [5] - 3:15, 80:5, 80:8, 80:9, 80:11	12th [1] - 47:22	1900 [1] - 2:6	
1012 [6] - 3:13, 70:18, 71:1, 71:6, 71:7	13 [2] - 60:22, 125:10	191 [1] - 27:9	
1014 [12] - 3:14, 3:22, 74:7, 74:11, 74:12, 167:5, 167:12, 167:13, 170:3, 170:4, 170:6, 170:7	130 [3] - 15:8, 15:9, 19:22	193 [1] - 3:24	
102 [2] - 3:18, 180:16	131 [8] - 15:15, 15:18, 19:2, 19:24, 28:3, 28:18, 28:23, 29:14	197 [1] - 3:24	
103 [6] - 3:18, 200:9, 203:21, 211:13, 237:3, 240:9	132 [2] - 19:2, 28:19	19th [1] - 49:8	
1034 [2] - 115:2, 115:6	133 [2] - 19:2, 19:23	1:30 [3] - 125:19, 125:22, 125:25	
1043 [3] - 115:4, 233:22, 233:24	134 [2] - 20:5, 20:9	1:33 [1] - 126:1	
1048 [5] - 3:15, 83:14, 83:23, 83:24, 83:25	138 [2] - 20:25, 26:21	1st [4] - 94:2, 121:18, 122:5, 188:14	
	13th [1] - 34:7		
	14 [4] - 20:12, 125:10, 175:1, 240:14	2	
	140 [3] - 21:4, 21:5, 21:12	2 [8] - 15:8, 20:5, 20:8, 49:24, 63:12, 109:16, 115:22, 150:8	
	141 [2] - 21:5, 21:12	2,800 [1] - 176:11	
	15 [9] - 73:24, 85:10, 85:14, 85:17, 91:5, 105:16, 178:15, 191:18, 194:18	2,840 [1] - 70:13	
	150 [1] - 3:21	2.3 [12] - 45:3, 48:6, 72:4, 76:24, 77:9, 83:8, 94:14, 113:21, 114:3, 120:6,	

182:14, 200:8, 201:9, 222:12 23 [5] - 36:13, 37:19, 38:17, 228:22 23rd [3] - 75:16, 76:15, 217:3 24 [3] - 35:13, 201:18, 232:11 24th [4] - 32:16, 80:13, 83:14, 221:21 25 [4] - 10:18, 20:20, 51:24, 145:25 25-ish [1] - 232:17 25th [1] - 70:19 26 [1] - 208:13 27 [2] - 83:5, 83:7 27.6 [2] - 42:16, 44:1 27th [3] - 70:5, 103:10, 147:24 28 [5] - 34:23, 83:10, 118:25, 231:18, 231:19 28-29 [1] - 94:1 29 [1] - 118:21 290 [2] - 30:6, 30:12 295 [1] - 32:20 2nd [1] - 94:3	396 [7] - 3:10, 44:9, 44:10, 44:13, 44:14, 44:18, 44:22 398 [5] - 3:10, 47:15, 47:16, 47:18, 47:19 3:01 [1] - 190:12 3:15 [1] - 190:9 3:19 [1] - 190:12 3rd [1] - 201:8	5	75 [1] - 3:14 753 [5] - 3:18, 103:4, 103:5, 103:7, 103:8 766 [9] - 4:1, 218:19, 218:20, 218:24, 218:25, 219:2, 219:11, 219:12, 219:21 773 [7] - 3:16, 84:23, 84:25, 85:1, 85:2, 89:5 78 [2] - 75:3, 75:9 795 [7] - 128:12, 131:10, 153:4, 154:25, 157:9, 157:18, 157:19 7th [3] - 88:8, 89:25, 91:7
3	4	5	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2 [1] - 242:5 30 [2] - 118:21, 180:11 30,000 [2] - 184:9, 187:3 300 [7] - 3:25, 165:24, 205:14, 205:15, 205:16, 205:18, 205:19 301 [1] - 216:22 31 [2] - 3:3, 3:4 316 [1] - 11:18 32 [3] - 3:8, 114:9, 114:11 329 [1] - 26:25 33 [12] - 120:1, 169:1, 181:2, 212:7, 215:25, 216:2, 216:5, 216:6, 216:9, 220:15, 220:24, 224:7 33,000 [1] - 187:3 34 [1] - 3:8 35 [2] - 151:19, 228:17 35.4 [2] - 228:7, 228:11 350 [1] - 165:24 36 [2] - 3:9, 48:13 36-month [1] - 54:18 37 [1] - 181:18 38 [3] - 202:14, 232:6, 232:10 384 [3] - 3:8, 31:16, 32:9 39.9 [4] - 119:13, 194:19, 228:2, 229:7 393 [4] - 3:9, 36:2, 36:5, 36:6 394 [6] - 3:9, 39:23, 40:1, 40:2, 41:14, 41:15	4 [7] - 40:5, 48:6, 49:24, 50:1, 53:21, 71:23, 150:8 4.1 [2] - 64:4, 214:20 4.2 [2] - 110:12, 110:13 4.5 [1] - 214:23 4.7 [1] - 64:22 40 [8] - 3:9, 55:23, 68:16, 68:21, 68:24, 69:4, 119:2, 123:6 40-year-old [1] - 175:16 402 [2] - 146:22, 146:24 403 [1] - 146:22 41 [1] - 125:10 411 [1] - 1:23 438 [1] - 172:16 44 [1] - 3:10 451 [4] - 3:8, 34:9, 34:12, 34:13 460 [5] - 3:14, 75:2, 75:6, 75:7, 172:15 47 [4] - 3:10, 83:5, 83:7, 83:10 475 [11] - 3:11, 51:7, 51:9, 51:11, 51:12, 51:13, 52:4, 52:9, 53:13, 54:1, 54:4 480 [12] - 3:21, 128:11, 128:15, 128:19, 129:12, 129:22, 130:25, 149:18, 150:1, 150:3, 150:4, 157:7 481 [7] - 128:11, 131:10, 131:15, 150:24, 152:8, 157:16, 157:21 482 [5] - 5:15, 5:19, 48:22, 49:3, 49:5 486 [10] - 127:21, 128:12, 131:10, 146:4, 146:16, 146:21, 147:7, 147:22, 148:6, 148:16 491 [9] - 3:17, 86:24, 87:1, 87:15, 87:17, 89:5, 89:6, 91:15, 91:19 492 [6] - 3:17, 97:25, 98:5, 98:6, 98:14, 98:16 494 [4] - 3:12, 65:13, 65:22, 65:23 498 [1] - 228:7 4:32 [1] - 242:21	6	75 [1] - 3:14 753 [5] - 3:18, 103:4, 103:5, 103:7, 103:8 766 [9] - 4:1, 218:19, 218:20, 218:24, 218:25, 219:2, 219:11, 219:12, 219:21 773 [7] - 3:16, 84:23, 84:25, 85:1, 85:2, 89:5 78 [2] - 75:3, 75:9 795 [7] - 128:12, 131:10, 153:4, 154:25, 157:9, 157:18, 157:19 7th [3] - 88:8, 89:25, 91:7
3	4	6	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2 [1] - 242:5 30 [2] - 118:21, 180:11 30,000 [2] - 184:9, 187:3 300 [7] - 3:25, 165:24, 205:14, 205:15, 205:16, 205:18, 205:19 301 [1] - 216:22 31 [2] - 3:3, 3:4 316 [1] - 11:18 32 [3] - 3:8, 114:9, 114:11 329 [1] - 26:25 33 [12] - 120:1, 169:1, 181:2, 212:7, 215:25, 216:2, 216:5, 216:6, 216:9, 220:15, 220:24, 224:7 33,000 [1] - 187:3 34 [1] - 3:8 35 [2] - 151:19, 228:17 35.4 [2] - 228:7, 228:11 350 [1] - 165:24 36 [2] - 3:9, 48:13 36-month [1] - 54:18 37 [1] - 181:18 38 [3] - 202:14, 232:6, 232:10 384 [3] - 3:8, 31:16, 32:9 39.9 [4] - 119:13, 194:19, 228:2, 229:7 393 [4] - 3:9, 36:2, 36:5, 36:6 394 [6] - 3:9, 39:23, 40:1, 40:2, 41:14, 41:15	4	6	8
3	4	6	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2 [1] - 242:5 30 [2] - 118:21, 180:11 30,000 [2] - 184:9, 187:3 300 [7] - 3:25, 165:24, 205:14, 205:15, 205:16, 205:18, 205:19 301 [1] - 216:22 31 [2] - 3:3, 3:4 316 [1] - 11:18 32 [3] - 3:8, 114:9, 114:11 329 [1] - 26:25 33 [12] - 120:1, 169:1, 181:2, 212:7, 215:25, 216:2, 216:5, 216:6, 216:9, 220:15, 220:24, 224:7 33,000 [1] - 187:3 34 [1] - 3:8 35 [2] - 151:19, 228:17 35.4 [2] - 228:7, 228:11 350 [1] - 165:24 36 [2] - 3:9, 48:13 36-month [1] - 54:18 37 [1] - 181:18 38 [3] - 202:14, 232:6, 232:10 384 [3] - 3:8, 31:16, 32:9 39.9 [4] - 119:13, 194:19, 228:2, 229:7 393 [4] - 3:9, 36:2, 36:5, 36:6 394 [6] - 3:9, 39:23, 40:1, 40:2, 41:14, 41:15	4	6	8
3	4	6	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2 [1] - 242:5 30 [2] - 118:21, 180:11 30,000 [2] - 184:9, 187:3 300 [7] - 3:25, 165:24, 205:14, 205:15, 205:16, 205:18, 205:19 301 [1] - 216:22 31 [2] - 3:3, 3:4 316 [1] - 11:18 32 [3] - 3:8, 114:9, 114:11 329 [1] - 26:25 33 [12] - 120:1, 169:1, 181:2, 212:7, 215:25, 216:2, 216:5, 216:6, 216:9, 220:15, 220:24, 224:7 33,000 [1] - 187:3 34 [1] - 3:8 35 [2] - 151:19, 228:17 35.4 [2] - 228:7, 228:11 350 [1] - 165:24 36 [2] - 3:9, 48:13 36-month [1] - 54:18 37 [1] - 181:18 38 [3] - 202:14, 232:6, 232:10 384 [3] - 3:8, 31:16, 32:9 39.9 [4] - 119:13, 194:19, 228:2, 229:7 393 [4] - 3:9, 36:2, 36:5, 36:6 394 [6] - 3:9, 39:23, 40:1, 40:2, 41:14, 41:15	4	6	8
3	4	6	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2 [1] - 242:5 30 [2] - 118:21, 180:11 30,000 [2] - 184:9, 187:3 300 [7] - 3:25, 165:24, 205:14, 205:15, 205:16, 205:18, 205:19 301 [1] - 216:22 31 [2] - 3:3, 3:4 316 [1] - 11:18 32 [3] - 3:8, 114:9, 114:11 329 [1] - 26:25 33 [12] - 120:1, 169:1, 181:2, 212:7, 215:25, 216:2, 216:5, 216:6, 216:9, 220:15, 220:24, 224:7 33,000 [1] - 187:3 34 [1] - 3:8 35 [2] - 151:19, 228:17 35.4 [2] - 228:7, 228:11 350 [1] - 165:24 36 [2] - 3:9, 48:13 36-month [1] - 54:18 37 [1] - 181:18 38 [3] - 202:14, 232:6, 232:10 384 [3] - 3:8, 31:16, 32:9 39.9 [4] - 119:13, 194:19, 228:2, 229:7 393 [4] - 3:9, 36:2, 36:5, 36:6 394 [6] - 3:9, 39:23, 40:1, 40:2, 41:14, 41:15	4	6	8
3	4	6	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2 [1] - 242:5 30 [2] - 118:21, 180:11 30,000 [2] - 184:9, 187:3 300 [7] - 3:25, 165:24, 205:14, 205:15, 205:16, 205:18, 205:19 301 [1] - 216:22 31 [2] - 3:3, 3:4 316 [1] - 11:18 32 [3] - 3:8, 114:9, 114:11 329 [1] - 26:25 33 [12] - 120:1, 169:1, 181:2, 212:7, 215:25, 216:2, 216:5, 216:6, 216:9, 220:15, 220:24, 224:7 33,000 [1] - 187:3 34 [1] - 3:8 35 [2] - 151:19, 228:17 35.4 [2] - 228:7, 228:11 350 [1] - 165:24 36 [2] - 3:9, 48:13 36-month [1] - 54:18 37 [1] - 181:18 38 [3] - 202:14, 232:6, 232:10 384 [3] - 3:8, 31:16, 32:9 39.9 [4] - 119:13, 194:19, 228:2, 229:7 393 [4] - 3:9, 36:2, 36:5, 36:6 394 [6] - 3:9, 39:23, 40:1, 40:2, 41:14, 41:15	4	6	8
3	4	6	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2 [1] - 242:5 30 [2] - 118:21, 180:11 30,000 [2] - 184:9, 187:3 300 [7] - 3:25, 165:24, 205:14, 205:15, 205:16, 205:18, 205:19 301 [1] - 216:22 31 [2] - 3:3, 3:4 316 [1] - 11:18 32 [3] - 3:8, 114:9, 114:11 329 [1] - 26:25 33 [12] - 120:1, 169:1, 181:2, 212:7, 215:25, 216:2, 216:5, 216:6, 216:9, 220:15, 220:24, 224:7 33,000 [1] - 187:3 34 [1] - 3:8 35 [2] - 151:19, 228:17 35.4 [2] - 228:7, 228:11 350 [1] - 165:24 36 [2] - 3:9, 48:13 36-month [1] - 54:18 37 [1] - 181:18 38 [3] - 202:14, 232:6, 232:10 384 [3] - 3:8, 31:16, 32:9 39.9 [4] - 119:13, 194:19, 228:2, 229:7 393 [4] - 3:9, 36:2, 36:5, 36:6 394 [6] - 3:9, 39:23, 40:1, 40:2, 41:14, 41:15	4	6	8
3	4	6	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2 [1] - 242:5 30 [2] - 118:21, 180:11 30,000 [2] - 184:9, 187:3 300 [7] - 3:25, 165:24, 205:14, 205:15, 205:16, 205:18, 205:19 301 [1] - 216:22 31 [2] - 3:3, 3:4 316 [1] - 11:18 32 [3] - 3:8, 114:9, 114:11 329 [1] - 26:25 33 [12] - 120:1, 169:1, 181:2, 212:7, 215:25, 216:2, 216:5, 216:6, 216:9, 220:15, 220:24, 224:7 33,000 [1] - 187:3 34 [1] - 3:8 35 [2] - 151:19, 228:17 35.4 [2] - 228:7, 228:11 350 [1] - 165:24 36 [2] - 3:9, 48:13 36-month [1] - 54:18 37 [1] - 181:18 38 [3] - 202:14, 232:6, 232:10 384 [3] - 3:8, 31:16, 32:9 39.9 [4] - 119:13, 194:19, 228:2, 229:7 393 [4] - 3:9, 36:2, 36:5, 36:6 394 [6] - 3:9, 39:23, 40:1, 40:2, 41:14, 41:15	4	6	8
3	4	6	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2 [1] - 242:5 30 [2] - 118:21, 180:11 30,000 [2] - 184:9, 187:3 300 [7] - 3:25, 165:24, 205:14, 205:15, 205:16, 205:18, 205:19 301 [1] - 216:22 31 [2] - 3:3, 3:4 316 [1] - 11:18 32 [3] - 3:8, 114:9, 114:11 329 [1] - 26:25 33 [12] - 120:1, 169:1, 181:2, 212:7, 215:25, 216:2, 216:5, 216:6, 216:9, 220:15, 220:24, 224:7 33,000 [1] - 187:3 34 [1] - 3:8 35 [2] - 151:19, 228:17 35.4 [2] - 228:7, 228:11 350 [1] - 165:24 36 [2] - 3:9, 48:13 36-month [1] - 54:18 37 [1] - 181:18 38 [3] - 202:14, 232:6, 232:10 384 [3] - 3:8, 31:16, 32:9 39.9 [4] - 119:13, 194:19, 228:2, 229:7 393 [4] - 3:9, 36:2, 36:5, 36:6 394 [6] - 3:9, 39:23, 40:1, 40:2, 41:14, 41:15	4	6	8
3	4	6	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2 [1] - 242:5 30 [2] - 118:21, 180:11 30,000 [2] - 184:9, 187:3 300 [7] - 3:25, 165:24, 205:14, 205:15, 205:16, 205:18, 205:19 301 [1] - 216:22 31 [2] - 3:3, 3:4 316 [1] - 11:18 32 [3] - 3:8, 114:9, 114:11 329 [1] - 26:25 33 [12] - 120:1, 169:1, 181:2, 212:7, 215:25, 216:2, 216:5, 216:6, 216:9, 220:15, 220:24, 224:7 33,000 [1] - 187:3 34 [1] - 3:8 35 [2] - 151:19, 228:17 35.4 [2] - 228:7, 228:11 350 [1] - 165:24 36 [2] - 3:9, 48:13 36-month [1] - 54:18 37 [1] - 181:18 38 [3] - 202:14, 232:6, 232:10 384 [3] - 3:8, 31:16, 32:9 39.9 [4] - 119:13, 194:19, 228:2, 229:7 393 [4] - 3:9, 36:2, 36:5, 36:6 394 [6] - 3:9, 39:23, 40:1, 40:2, 41:14, 41:15	4	6	8
3	4	6	8
3 [10] - 1:17, 41:15, 44:21, 44:23, 50:1, 52:9, 70:10, 109:16, 188:17, 188:20 3.2			

<p>952 [6] - 3:24, 192:20, 192:22, 192:25, 193:2, 193:3</p> <p>96 [1] - 223:3</p> <p>97 [1] - 232:16</p> <p>975 [1] - 69:25</p> <p>979 [5] - 3:25, 201:7, 201:10, 201:12, 201:13</p> <p>98 [1] - 3:17</p> <p>983 [1] - 186:10</p> <p>987 [10] - 3:22, 170:1, 170:9, 170:12, 170:13, 170:17, 170:19, 170:20, 171:2, 172:18</p> <p>99.9 [1] - 185:16</p> <p>9:00 [5] - 5:6, 9:2, 31:2, 31:6, 242:12</p> <p>9:25 [1] - 31:7</p> <p>9th [1] - 98:18</p>	<p>198:20, 198:24, 198:25, 199:18, 199:24</p> <p>abused [1] - 13:5</p> <p>academic [23] - 104:9, 104:18, 122:23, 182:24, 187:12, 189:20, 190:19, 190:22, 190:23, 190:25, 191:6, 191:15, 192:8, 192:9, 192:17, 193:4, 193:19, 194:11, 195:8, 195:12, 195:15, 195:20, 198:6</p> <p>accelerated [2] - 100:21, 172:9</p> <p>accept [1] - 187:24</p> <p>acceptable [1] - 27:6</p> <p>acceptance [2] - 173:16, 197:1</p> <p>accepted [5] - 185:8, 185:9, 185:11, 196:23, 198:19</p> <p>accepting [1] - 31:22</p> <p>accepts [1] - 25:13</p> <p>access [11] - 32:21, 32:22, 32:24, 32:25, 33:3, 33:5, 39:5, 62:5, 62:7, 67:16, 176:9</p> <p>accomplish [1] - 158:19</p> <p>according [2] - 172:6, 182:17</p> <p>accurate [5] - 53:3, 96:10, 170:22, 181:7, 181:14</p> <p>accusations [2] - 17:19, 132:24</p> <p>achieve [4] - 73:6, 209:20, 212:24, 218:10</p> <p>achieving [1] - 172:4</p> <p>acquired [5] - 162:17, 164:5, 165:14, 174:25, 233:4</p> <p>acquiring [2] - 163:18, 164:1</p> <p>acquisition [1] - 164:3</p> <p>acronym [3] - 183:4, 205:5, 220:5</p> <p>ACTH [2] - 206:22</p> <p>acting [1] - 87:21</p> <p>actions [1] - 223:16</p> <p>active [4] - 155:10, 174:20, 174:23, 175:4</p> <p>acts [1] - 87:22</p> <p>actual [21] - 46:1, 55:3, 58:13, 72:1, 72:7, 81:5, 93:11, 113:21, 119:6, 119:22, 120:10, 120:23, 121:22, 153:11, 153:12, 186:21, 210:12, 213:18, 214:1, 214:5, 222:22</p> <p>Adage [1] - 114:21</p> <p>Adam [1] - 111:14</p> <p>add [3] - 19:25, 27:23, 148:9</p> <p>added [3] - 71:24, 219:13, 219:15</p>	<p>adding [3] - 108:4, 108:6, 108:8</p> <p>addition [6] - 177:21, 189:20, 194:6, 219:17, 219:21, 228:22</p> <p>additional [13] - 33:22, 36:19, 142:15, 143:16, 177:16, 178:1, 201:24, 203:4, 203:7, 203:9, 203:12, 203:15, 203:20</p> <p>address [1] - 146:2</p> <p>adequate [1] - 36:19</p> <p>adjourned [1] - 242:21</p> <p>adjust [1] - 123:9</p> <p>adjusting [1] - 229:25</p> <p>adjuvant [15] - 168:21, 182:12, 204:11, 204:13, 204:23, 205:13, 207:7, 208:25, 209:3, 210:2, 210:5, 215:3, 215:5, 215:11, 215:15</p> <p>admission [23] - 23:25, 39:25, 44:11, 47:16, 60:17, 62:20, 65:20, 65:21, 69:24, 70:22, 71:3, 84:24, 86:25, 98:4, 101:22, 103:6, 106:6, 109:1, 111:7, 112:19, 116:2, 120:13, 122:12</p> <p>admit [4] - 36:4, 84:19, 86:2, 87:6</p> <p>admits [1] - 220:14</p> <p>admitted [61] - 12:2, 12:11, 12:14, 12:15, 21:23, 31:4, 31:5, 31:18, 31:23, 32:3, 32:8, 34:11, 34:12, 36:5, 40:1, 44:10, 44:11, 44:13, 47:18, 48:25, 49:5, 51:8, 51:11, 52:11, 53:13, 60:18, 62:23, 65:15, 65:16, 65:18, 65:19, 65:22, 70:2, 71:6, 74:10, 74:11, 75:6, 80:9, 83:24, 85:1, 86:5, 87:15, 98:14, 102:3, 102:7, 103:7, 106:7, 109:2, 111:9, 112:23, 121:15, 122:16, 150:3, 151:17, 170:6, 170:19, 188:4, 197:7, 201:12, 205:18, 207:20</p> <p>admitting [4] - 12:5, 12:7, 52:12, 52:18</p> <p>ado [1] - 200:7</p> <p>adoption [4] - 117:9, 117:11, 117:13, 117:14</p> <p>advance [2] - 88:13, 167:20</p> <p>advanced [1] - 161:4</p> <p>advantage [2] - 72:23, 92:19</p> <p>advantages [1] - 73:20</p> <p>adverse [8] - 43:18, 43:22, 43:25, 194:18, 240:18, 241:13, 241:20</p>	<p>advice [2] - 7:1, 7:3</p> <p>advise [1] - 191:1</p> <p>AEs [5] - 42:16, 237:21, 240:25, 241:5, 241:24</p> <p>afflicts [1] - 77:18</p> <p>afford [3] - 173:21, 173:24, 174:1</p> <p>afield [1] - 164:25</p> <p>afraid [1] - 156:25</p> <p>after-hours [1] - 114:13</p> <p>afternoon [5] - 149:3, 149:4, 158:12, 158:13, 199:7</p> <p>afterwards [2] - 83:1, 104:23</p> <p>aggressive [1] - 138:25</p> <p>ago [2] - 143:6, 175:6</p> <p>agree [10] - 13:25, 16:5, 20:23, 23:5, 68:21, 69:1, 69:4, 105:14, 188:21, 221:7</p> <p>agreed [5] - 12:3, 106:3, 141:3, 141:4, 195:10</p> <p>agreeing [2] - 189:13, 215:1</p> <p>agreement [12] - 86:19, 104:16, 105:6, 134:25, 136:8, 137:8, 137:12, 137:15, 138:4, 144:3, 154:16, 195:9</p> <p>ahead [22] - 12:17, 16:11, 16:14, 21:20, 32:7, 53:14, 54:1, 54:2, 66:16, 68:1, 92:24, 130:11, 131:24, 137:19, 143:18, 146:3, 154:11, 157:22, 168:15, 170:24, 191:7, 197:24</p> <p>AI [1] - 70:7</p> <p>AL [2] - 1:10, 2:12</p> <p>Alan [9] - 3:3, 13:17, 13:20, 19:11, 31:10, 116:15, 155:10, 155:19, 156:13</p> <p>Alan's [1] - 93:9</p> <p>alive [1] - 161:12</p> <p>all-comers [1] - 210:7</p> <p>all-grade [1] - 229:3</p> <p>all-patients [2] - 208:15, 208:22</p> <p>allo [1] - 215:15</p> <p>allow [8] - 11:2, 11:3, 23:19, 24:8, 97:7, 97:21, 133:1, 168:23</p> <p>allowed [14] - 11:1, 19:23, 55:13, 79:9, 79:15, 82:20, 82:25, 107:5, 136:10, 145:12, 145:13, 177:7, 179:5, 179:24</p> <p>allowing [11] - 15:17, 16:1, 21:22, 21:24, 22:8, 24:20, 25:6, 26:14, 27:1, 27:8, 27:9</p> <p>allows [1] - 72:17</p> <p>alluded [1] - 155:20</p>
A			
<p>A-S-C-O [1] - 183:4</p> <p>A.M [1] - 5:1</p> <p>a.m [2] - 74:1</p> <p>abandoned [1] - 161:10</p> <p>ability [4] - 109:22, 110:1, 214:2, 215:20</p> <p>Abiraterone [5] - 159:12, 161:21, 162:1, 162:21, 164:20</p> <p>able [24] - 9:17, 17:8, 23:8, 37:15, 39:11, 40:13, 55:21, 110:10, 112:15, 133:23, 138:1, 167:17, 173:15, 177:8, 180:3, 180:5, 189:1, 200:3, 209:20, 209:23, 211:6, 221:14, 234:9, 236:2</p> <p>ABOVE [1] - 243:4</p> <p>absolute [24] - 45:3, 48:16, 50:14, 54:20, 63:12, 64:4, 72:4, 74:22, 108:16, 108:20, 109:11, 111:12, 113:6, 113:14, 113:20, 121:25, 131:17, 137:3, 152:5, 152:10, 212:17, 216:3, 217:19, 223:22</p> <p>absolutely [10] - 28:8, 94:14, 101:8, 134:8, 142:4, 154:5, 160:20, 189:20, 210:4, 227:14</p> <p>abstract [19] - 106:20, 108:15, 109:18, 111:14, 112:5, 113:2, 113:5, 120:21, 187:22, 188:1, 188:10, 188:15, 189:8, 191:14, 197:1, 198:9, 198:14, 198:15</p> <p>abstracts [7] - 107:1, 198:11,</p>			

<p>almost [1] - 125:18</p> <p>alone [2] - 43:7, 75:23</p> <p>alter [5] - 94:21, 94:22, 95:2, 95:8, 95:9</p> <p>altered [5] - 27:20, 94:15, 95:4, 95:7, 95:10</p> <p>altering [2] - 94:24, 95:1</p> <p>Alvin [6] - 34:7, 34:15, 34:16, 193:14, 226:23, 226:25</p> <p>ambiguous [5] - 9:24, 10:1, 10:6, 10:19, 10:25</p> <p>amendment [4] - 34:18, 34:20, 34:21, 69:19</p> <p>America [5] - 86:11, 87:23, 195:22, 224:23</p> <p>American [3] - 106:13, 106:15, 183:3</p> <p>amount [3] - 163:15, 174:2, 202:11</p> <p>ANA [3] - 1:18, 1:23, 5:1</p> <p>analogy [1] - 107:7</p> <p>analyses [17] - 39:4, 39:5, 39:6, 39:8, 62:13, 109:23, 111:1, 111:4, 111:5, 150:19, 177:8, 177:16, 177:20, 177:23, 178:2, 179:15, 194:6</p> <p>analysis [24] - 9:7, 33:13, 33:21, 41:23, 42:1, 42:3, 42:5, 42:9, 50:14, 64:17, 68:14, 150:8, 156:12, 179:11, 179:18, 179:19, 205:1, 206:1, 206:5, 206:11, 233:20, 236:5, 236:14, 240:21</p> <p>analyst [28] - 8:14, 12:1, 12:2, 12:6, 12:8, 12:19, 109:8, 109:22, 111:22, 112:6, 149:12, 158:25, 159:1, 159:6, 160:16, 160:21, 162:12, 211:16, 216:16, 216:20, 216:25, 217:7, 218:15, 218:18, 219:3, 221:19, 223:15, 237:8</p> <p>analysts [9] - 111:13, 111:21, 111:22, 112:12, 211:16, 211:19, 215:22, 216:10, 239:4</p> <p>analyzing [1] - 160:23</p> <p>AND [2] - 2:13, 243:2</p> <p>AND/OR [1] - 243:6</p> <p>ANDREW [2] - 1:3, 2:12</p> <p>Angeles [4] - 62:11, 160:9, 162:5, 191:13</p> <p>angry [1] - 161:11</p> <p>animals [2] - 81:7, 82:19</p> <p>annotations [1] - 96:7</p> <p>announced [2] - 180:21, 180:25</p>	<p>announcement [2] - 24:20, 202:24</p> <p>announces [2] - 180:19, 203:8</p> <p>annual [2] - 201:1, 201:3</p> <p>answer [22] - 24:20, 39:21, 41:4, 62:13, 67:3, 69:5, 73:4, 76:10, 79:3, 97:15, 107:17, 130:5, 142:3, 152:16, 154:10, 185:4, 204:9, 209:25, 223:18, 225:7, 240:15, 240:24</p> <p>answered [1] - 13:24</p> <p>answering [2] - 137:18, 239:24</p> <p>anticipate [5] - 40:12, 118:12, 224:5, 237:17, 237:21</p> <p>anticipated [1] - 145:1</p> <p>anticipating [1] - 148:13</p> <p>anticipation [1] - 148:10</p> <p>antidiarrheal [5] - 234:2, 234:3, 235:3, 235:8, 236:8</p> <p>Antonio [9] - 104:5, 187:14, 187:15, 189:24, 191:8, 193:4, 207:5, 207:11, 207:15</p> <p>ANY [1] - 243:5</p> <p>anytime [1] - 22:11</p> <p>anyway [1] - 167:15</p> <p>apart [3] - 140:2, 140:10, 140:24</p> <p>apologize [10] - 22:6, 31:7, 53:17, 60:13, 61:5, 61:7, 143:12, 151:20, 197:3, 237:16</p> <p>apologized [1] - 29:21</p> <p>appeal [1] - 22:19</p> <p>appear [2] - 17:11, 169:19</p> <p>appeared [1] - 16:19</p> <p>apple [1] - 180:3</p> <p>apples [3] - 180:3, 215:21</p> <p>apples-to-apple [1] - 180:3</p> <p>apples-to-apples [1] - 215:21</p> <p>application [10] - 77:15, 77:24, 82:21, 83:2, 84:21, 169:4, 169:15, 171:20, 173:4</p> <p>applies [2] - 10:17, 189:8</p> <p>apply [8] - 56:6, 77:13, 82:25, 99:6, 101:3, 101:6, 106:11</p> <p>applying [2] - 81:3, 97:9</p> <p>appreciate [7] - 10:16, 21:15, 22:5, 22:22, 27:25, 137:23, 146:4</p> <p>approach [4] - 115:13, 115:16, 157:24, 233:13</p> <p>approached [3] - 163:5,</p>	<p>163:17</p> <p>approaching [1] - 46:16</p> <p>appropriate [4] - 10:25, 14:1, 21:8, 168:19</p> <p>approval [28] - 72:18, 72:24, 73:5, 77:13, 77:24, 78:13, 78:14, 81:3, 82:24, 83:1, 97:9, 99:8, 99:12, 99:14, 99:17, 100:19, 100:21, 153:16, 164:20, 168:6, 168:16, 169:5, 172:4, 172:9, 182:12, 195:18, 196:1, 217:16</p> <p>approvals [1] - 202:24</p> <p>approve [1] - 173:5</p> <p>approved [2] - 169:7, 201:23</p> <p>April [1] - 174:12</p> <p>arbitration [3] - 134:19, 134:24, 135:21</p> <p>arbitrator [1] - 139:13</p> <p>ARE [1] - 243:6</p> <p>area [3] - 82:12, 105:22, 166:22</p> <p>arguably [1] - 224:9</p> <p>argue [1] - 138:20</p> <p>argued [2] - 52:17, 223:14</p> <p>argument [9] - 11:23, 12:14, 13:1, 13:8, 15:19, 117:13, 117:14, 128:25, 131:9</p> <p>arguments [4] - 130:13, 136:18, 143:14, 143:16</p> <p>Arlene [4] - 122:20, 192:10, 195:23, 198:6</p> <p>Arlene's [1] - 124:4</p> <p>arm [34] - 37:9, 37:24, 37:25, 38:6, 38:9, 38:10, 90:4, 119:19, 119:22, 119:25, 120:4, 204:4, 204:6, 204:10, 205:12, 206:3, 210:1, 210:6, 210:12, 212:3, 212:15, 213:9, 213:10, 216:14, 220:14, 222:23, 222:25, 224:5, 228:3, 228:12, 236:10</p> <p>arms [3] - 122:1, 155:11, 206:21</p> <p>arrow [2] - 30:22, 30:23</p> <p>articulated [1] - 215:1</p> <p>articulating [1] - 8:19</p> <p>ASCO [44] - 106:12, 107:1, 112:5, 117:3, 119:11, 120:23, 121:19, 122:1, 122:5, 122:8, 176:23, 183:4, 184:2, 184:7, 184:8, 185:7, 186:21, 186:25, 187:10, 187:20, 187:25, 188:10, 188:15, 188:25, 189:15, 189:18, 190:18, 191:7, 191:11, 192:16, 195:4, 196:23, 197:1,</p>	<p>198:8, 198:12, 198:24, 199:25, 200:3, 210:14, 230:16, 230:19, 230:22, 235:17, 235:21</p> <p>ASCO's [1] - 195:6</p> <p>Asia [1] - 195:23</p> <p>aside [1] - 117:11</p> <p>aspect [1] - 239:4</p> <p>asserted [1] - 116:23</p> <p>assertion [2] - 22:13, 139:24</p> <p>asset [3] - 55:13, 162:18, 174:25</p> <p>assist [1] - 188:9</p> <p>assistance [2] - 11:4, 174:2</p> <p>associate [1] - 222:8</p> <p>assume [8] - 20:1, 33:13, 40:24, 95:6, 95:7, 225:6, 242:2</p> <p>assumed [1] - 213:6</p> <p>assuming [4] - 32:4, 35:6, 40:23, 56:6</p> <p>assumption [3] - 36:13, 36:18, 153:12</p> <p>assumptions [1] - 59:19</p> <p>assure [1] - 170:21</p> <p>attach [1] - 53:10</p> <p>attached [7] - 54:9, 58:19, 58:23, 88:11, 88:20, 142:5, 221:19</p> <p>attaching [1] - 219:2</p> <p>attachment [3] - 5:22, 5:24, 51:14</p> <p>attempt [2] - 73:17, 221:17</p> <p>attempted [1] - 96:24</p> <p>attempting [1] - 97:10</p> <p>attempts [1] - 221:12</p> <p>attend [1] - 125:6</p> <p>attendance [3] - 184:8, 186:23, 207:9</p> <p>attended [3] - 186:25, 193:9, 207:15</p> <p>attendees [1] - 76:16</p> <p>attention [4] - 36:12, 41:16, 125:20, 172:15</p> <p>attorney [5] - 58:6, 58:8, 58:10, 58:12, 87:20</p> <p>attorneys [5] - 58:1, 58:3, 58:5, 146:7, 153:1</p> <p>audience [1] - 185:5</p> <p>Auerbach [50] - 3:3, 5:25, 6:2, 29:24, 31:10, 31:13, 32:13, 40:4, 49:7, 54:4, 70:18, 71:9, 74:7, 75:11, 79:3, 80:4, 80:13, 94:23, 96:14, 97:24, 100:4, 102:10, 106:10, 108:18, 109:5, 114:20, 114:25, 115:8, 116:15, 117:15, 118:3, 126:9, 127:5, 127:15, 127:21, 129:17,</p>
---	---	---	---

131:4, 139:22, 142:9,
143:2, 143:23, 146:5,
149:3, 152:16, 153:5,
154:8, 155:1, 158:12,
190:17, 198:3
Auerbach's [1] - 223:15
August [23] - 34:7, 35:24,
55:14, 57:12, 57:13, 57:14,
60:7, 70:19, 119:7, 127:15,
129:18, 131:20, 131:21,
140:3, 140:14, 140:22,
141:9, 149:8, 149:20,
150:13, 150:16, 153:6,
155:12
Australia [1] - 192:11
author [5] - 23:13, 91:25,
93:2, 93:5, 93:6
available [6] - 33:18, 39:13,
142:10, 164:22, 180:14,
201:2
aware [11] - 27:8, 27:11,
65:9, 67:2, 67:12, 89:2,
94:17, 105:24, 154:15,
211:11, 222:4
axis [2] - 60:3, 231:25

B

B-E-T-H [1] - 205:9
B31 [1] - 209:5
babies [3] - 55:25, 56:1
bachelor's [1] - 160:4
back-door [1] - 129:4
background [2] - 8:20,
105:10
bad [6] - 135:19, 139:2,
211:2, 235:10, 236:21,
237:1
BAIRD [2] - 1:22, 243:10
Baird [1] - 243:9
balance [2] - 209:17, 209:18
ball [1] - 104:14
ball-parking [1] - 104:14
ballpark [3] - 180:10, 212:16,
212:25
Bank [2] - 86:10, 87:23
banking [2] - 86:10
banks [3] - 102:21, 102:25,
105:3
bar [7] - 168:21, 169:2,
231:10, 231:22, 232:2,
232:12, 232:14
barely [1] - 78:22
barriers [1] - 217:16
based [13] - 9:6, 28:5, 30:14,
40:17, 50:13, 110:2, 111:1,
111:5, 112:16, 173:5,
182:10, 209:1
baseline [3] - 150:7, 224:7,
225:1

basing [1] - 16:7
basis [3] - 62:12, 213:17,
226:12
Bates [1] - 216:23
BCIRG [4] - 205:7, 206:1,
206:17, 209:5
Bebchuk [4] - 62:6, 75:11,
75:12, 79:23
became [5] - 89:2, 94:17,
120:22, 160:15, 161:11
become [4] - 20:13, 143:7,
182:1, 209:12
becomes [2] - 25:12, 25:13
beforehand [1] - 215:22
beg [1] - 26:23
begin [3] - 5:3, 29:16, 117:17
beginning [4] - 19:22, 21:10,
27:1, 145:5
begins [1] - 90:12
BEHALF [2] - 2:3, 2:11
believes [1] - 33:18
below [6] - 35:15, 41:22,
72:1, 77:16, 107:22, 169:2
Ben [2] - 113:4, 149:14
benefit [6] - 101:6, 159:14,
212:17, 213:11, 223:22
benefits [3] - 72:18, 73:11,
209:23
Benjamin [1] - 113:3
best [9] - 10:12, 53:2, 97:19,
163:21, 186:6, 186:9,
187:18, 209:20, 211:8
BETH [8] - 205:8, 207:1,
207:14, 208:2, 208:7,
208:14, 208:15, 209:6
better [7] - 46:12, 64:11,
68:14, 80:23, 209:2,
220:13, 224:5
between [20] - 41:2, 64:2,
81:25, 93:19, 100:20,
109:11, 112:3, 114:5,
116:25, 120:5, 151:5,
152:14, 152:25, 165:24,
166:3, 178:15, 202:9,
215:5, 226:22, 236:3
beyond [9] - 9:13, 33:17,
33:19, 34:2, 36:21, 38:20,
73:9, 155:20, 156:1
biased [1] - 33:17
big [9] - 8:15, 18:25, 30:12,
78:24, 185:2, 185:25,
186:7, 215:14, 231:6
biggest [2] - 99:23, 117:5
Bill [4] - 17:21, 17:23, 87:20,
98:22
billion [1] - 202:10
Bin [19] - 32:14, 32:15, 36:8,
39:1, 39:2, 39:4, 39:8,
40:5, 45:6, 47:23, 66:2,
66:8, 131:22, 140:6,

141:20, 149:14, 155:2
binder [13] - 31:15, 51:22,
51:23, 51:25, 52:3, 157:25,
167:6, 170:2, 201:7,
206:24, 221:22, 233:23,
237:6
binders [4] - 51:24, 51:25,
167:4
binding [1] - 166:16
binds [1] - 166:23
bio [1] - 69:10
biologics [1] - 170:11
biomedical [2] - 160:5, 160:7
biostatisticians [1] - 180:7
biostatistics [2] - 32:15, 36:9
biotech [2] - 158:25, 183:17
BIOTECHNOLOGY [2] -
1:10, 2:12
Biotechnology [1] - 159:12
bit [14] - 9:2, 10:7, 75:20,
78:16, 144:10, 144:20,
158:18, 160:25, 169:2,
182:19, 184:2, 204:6,
238:3, 242:10
black [1] - 49:15
blinded [1] - 33:2
block [2] - 166:18, 166:19
blood [1] - 160:11
blow [6] - 188:6, 188:7,
188:12, 197:9, 205:23,
217:15
BLUFF [1] - 2:14
board [1] - 219:6
bogie [1] - 78:19
boilerplate [1] - 10:13
bold [1] - 198:13
book [7] - 26:8, 107:6, 107:7,
115:1, 126:16, 184:18
books [1] - 115:19
born [1] - 159:21
Boston [2] - 159:23, 159:25
bottom [21] - 28:3, 28:18,
37:25, 40:9, 45:6, 54:8,
59:10, 61:3, 74:23, 76:23,
89:6, 89:24, 90:10, 93:7,
102:15, 107:20, 172:25,
211:25, 235:1, 235:6,
240:14
bought [5] - 133:10, 161:21,
162:4, 162:16, 209:10
bound [1] - 200:4
bowel [1] - 228:24
box [4] - 188:12, 188:20,
189:2, 205:23
boy [1] - 161:23
Bradley [2] - 86:8, 86:9
brain [3] - 7:19, 81:14,
211:22
break [8] - 73:23, 116:17,
117:10, 125:16, 125:17,

190:6, 190:9, 242:10
breaking [1] - 73:21
breakthrough [48] - 71:12,
72:14, 72:17, 73:1, 73:14,
74:15, 75:17, 75:21, 75:22,
76:25, 77:9, 77:18, 77:25,
78:3, 78:11, 78:25, 80:15,
99:1, 99:3, 99:13, 99:16,
100:1, 100:16, 100:18,
100:22, 101:1, 101:11,
101:15, 101:17, 166:25,
167:9, 167:25, 168:3,
168:5, 168:14, 168:23,
169:6, 169:9, 169:14,
169:16, 169:22, 171:9,
171:10, 171:15, 172:4,
173:12
breast [36] - 38:4, 40:20,
55:21, 56:2, 77:21, 81:13,
104:7, 104:12, 104:19,
154:13, 166:9, 166:11,
173:9, 174:24, 175:5,
175:14, 175:19, 181:22,
186:1, 187:12, 187:15,
189:22, 189:24, 190:24,
191:9, 192:10, 196:16,
199:9, 199:15, 204:16,
204:23, 207:5, 208:6,
220:6, 220:8, 221:4
Breast [2] - 104:6, 207:15
Bredahl [2] - 148:19, 197:17
brief [2] - 36:10, 126:24
briefing [1] - 80:19
briefly [5] - 128:13, 162:9,
166:9, 180:17, 236:5
bring [16] - 5:12, 6:14, 8:3,
8:9, 104:25, 105:1, 128:8,
133:6, 135:11, 147:1,
162:23, 190:4, 211:4,
212:23, 217:23, 218:6
bringing [3] - 105:7, 133:7,
202:8
brings [1] - 232:9
British [1] - 161:24
broad [4] - 7:7, 9:15, 10:24,
13:5
BROADWAY [1] - 2:6
broken [2] - 45:5, 61:2
brought [5] - 105:7, 128:7,
141:15, 162:5, 170:15
Bryce [2] - 193:11
BRUCE [1] - 193:11
BTG [1] - 161:23
building [3] - 163:6, 163:11,
163:12
built [2] - 162:6, 162:12
bullet [6] - 33:9, 155:7,
156:10, 171:18, 203:6,
221:1
bullets [1] - 202:23

<p>bunch ^[1] - 27:3</p> <p>business ^[10] - 114:20, 116:15, 116:18, 116:19, 116:21, 117:7, 132:11, 201:5, 201:19, 201:25</p> <p>busy ^[1] - 99:24</p> <p>button ^[1] - 92:20</p> <p>BY ^[79] - 31:12, 32:12, 34:14, 36:7, 40:3, 44:15, 47:20, 49:6, 49:20, 54:3, 60:21, 63:1, 65:24, 68:5, 70:4, 71:8, 74:6, 74:13, 75:8, 79:11, 79:22, 80:12, 82:9, 84:1, 85:3, 86:7, 87:18, 92:4, 92:12, 93:1, 97:23, 98:17, 100:10, 102:9, 103:9, 106:9, 107:14, 107:19, 109:4, 111:11, 113:1, 113:24, 118:2, 118:17, 118:20, 119:5, 119:10, 119:17, 120:18, 121:17, 122:18, 149:2, 150:5, 154:17, 158:11, 165:9, 167:14, 170:8, 171:3, 172:24, 186:20, 187:8, 188:8, 190:16, 193:6, 193:23, 198:1, 200:11, 201:14, 205:20, 205:24, 207:22, 217:17, 219:1, 219:24, 224:1, 235:16, 239:9, 240:10</p>	<p>182:25, 185:19, 185:23, 186:1, 187:12, 187:15, 189:22, 189:24, 190:24, 191:9, 191:24, 192:10, 196:16, 199:10, 199:15, 204:17, 204:23, 207:6, 208:6, 209:15, 211:4, 211:6, 220:6, 220:8, 221:4, 238:9, 238:14, 238:20, 238:25, 239:18, 241:15</p> <p>cancerous ^[2] - 181:23, 182:2</p> <p>cancers ^[3] - 82:1, 82:8, 82:17</p> <p>candidate ^[1] - 183:22</p> <p>cannot ^[2] - 129:3, 195:6</p> <p>capability ^[1] - 15:3</p> <p>capital ^[10] - 163:23, 201:24, 202:12, 203:4, 203:7, 203:9, 203:12, 203:13, 203:16, 203:20</p> <p>Capital ^[1] - 114:21</p> <p>carcinogenicity ^[4] - 81:11, 85:19, 97:7</p> <p>carcinoma ^[3] - 181:19, 181:25, 214:14</p> <p>care ^[9] - 27:18, 73:7, 78:9, 164:8, 168:13, 204:17, 206:19, 206:20, 221:15</p> <p>cared ^[1] - 99:7</p> <p>career ^[1] - 162:11</p> <p>careful ^[4] - 11:2, 22:23, 26:13, 139:5</p> <p>carefully ^[4] - 16:13, 17:25, 24:17, 53:5</p> <p>Carlo ^[4] - 40:22, 41:1, 41:3, 41:5</p> <p>carrying ^[2] - 48:10, 48:20</p> <p>case ^[13] - 7:6, 7:8, 19:16, 21:25, 25:25, 73:13, 125:21, 145:6, 145:11, 147:1, 242:13</p> <p>cash ^[1] - 192:5</p> <p>casino ^[1] - 41:3</p> <p>cat ^[1] - 217:9</p> <p>categories ^[3] - 107:4, 199:9, 239:23</p> <p>categorize ^[2] - 107:3, 184:17</p> <p>caused ^[3] - 82:1, 93:22, 196:6</p> <p>causes ^[5] - 81:14, 81:15, 81:16, 144:21</p> <p>causing ^[1] - 82:5</p> <p>caution ^[1] - 133:2</p> <p>caveat ^[7] - 47:6, 56:20, 80:7, 83:20, 98:9, 98:13, 141:19</p> <p>CCRA ^[1] - 1:22</p> <p>CDA ^[2] - 132:12, 195:9</p> <p>cell ^[4] - 166:12, 166:13,</p>	<p>166:14, 166:17</p> <p>censoring ^[3] - 46:19, 76:25, 77:10</p> <p>central ^[10] - 70:11, 111:24, 112:3, 178:19, 178:20, 179:1, 208:3, 208:6, 208:11, 210:9</p> <p>Central ^[1] - 195:22</p> <p>CENTRAL ^[1] - 1:2</p> <p>centrally ^[26] - 66:3, 68:6, 68:12, 69:9, 69:13, 108:1, 108:8, 108:13, 109:12, 110:18, 114:7, 178:3, 178:18, 179:3, 179:11, 179:14, 179:20, 179:24, 180:5, 208:9, 208:11, 210:8, 214:18, 214:21, 215:16, 218:14</p> <p>CEO ^[3] - 8:13, 95:17, 139:1</p> <p>certain ^[9] - 14:7, 72:18, 82:14, 118:9, 135:3, 137:9, 141:11, 153:7</p> <p>certainly ^[17] - 18:14, 18:17, 33:5, 82:16, 94:21, 95:4, 95:6, 109:15, 146:11, 163:24, 191:25, 199:11, 210:20, 215:7, 226:18, 228:19, 229:5</p> <p>CERTIFICATE ^[1] - 243:1</p> <p>CERTIFY ^[1] - 243:2</p> <p>cetera ^[21] - 13:18, 19:20, 26:13, 27:4, 27:8, 55:19, 56:25, 93:22, 94:20, 96:8, 141:24, 147:10, 160:2, 160:6, 199:11, 211:21, 216:11, 230:11</p> <p>chairperson ^[1] - 198:6</p> <p>challenge ^[1] - 68:1</p> <p>challenging ^[3] - 212:20, 226:21, 233:3</p> <p>Chan ^[8] - 122:20, 192:10, 195:24, 198:3, 198:5, 198:6, 198:8</p> <p>chance ^[12] - 20:8, 50:19, 87:10, 87:13, 96:14, 116:3, 130:2, 144:11, 147:2, 203:24, 216:21, 233:21</p> <p>change ^[9] - 17:24, 90:6, 90:7, 90:8, 91:8, 91:11, 226:20, 227:17, 227:20</p> <p>changed ^[8] - 90:3, 91:8, 94:12, 161:9, 227:12, 227:17, 229:11, 229:13</p> <p>changes ^[3] - 38:13, 91:12, 96:1</p> <p>changing ^[3] - 91:10, 229:7, 229:10</p> <p>CHARGED ^[1] - 243:5</p> <p>chart ^[23] - 35:9, 35:12, 35:13, 37:20, 42:8, 42:9,</p>	<p>44:23, 44:24, 45:15, 48:12, 57:7, 63:14, 66:2, 84:12, 85:10, 90:24, 91:1, 91:2, 91:3, 131:18, 151:1, 171:6</p> <p>charts ^[5] - 35:2, 44:23, 48:10, 74:23, 151:18</p> <p>chase ^[2] - 6:12, 7:4</p> <p>check ^[5] - 31:24, 31:25, 127:11, 189:2, 232:18</p> <p>checked ^[3] - 43:13, 188:21, 238:14</p> <p>checking ^[1] - 238:9</p> <p>chemotherapy ^[1] - 204:18</p> <p>Cheryl ^[2] - 200:16, 200:17</p> <p>Chicago ^[2] - 122:9, 159:21</p> <p>chief ^[1] - 193:12</p> <p>children ^[3] - 175:17, 175:18</p> <p>choose ^[1] - 182:25</p> <p>Christine ^[3] - 71:19, 85:4, 88:25</p> <p>CIRCUIT ^[1] - 243:5</p> <p>circumstances ^[1] - 154:10</p> <p>Citi ^[1] - 219:9</p> <p>Citi's ^[1] - 222:1</p> <p>claim ^[3] - 14:25, 139:17, 144:3</p> <p>claiming ^[1] - 144:5</p> <p>claims ^[1] - 183:22</p> <p>Claire ^[19] - 38:25, 39:2, 39:3, 39:7, 39:15, 55:2, 57:18, 60:23, 62:4, 62:8, 62:10, 64:25, 65:1, 65:2, 65:6, 66:8, 66:9, 227:5</p> <p>clarified ^[1] - 53:19</p> <p>clarify ^[3] - 77:12, 121:24, 240:15</p> <p>class ^[1] - 230:16</p> <p>clear ^[16] - 9:7, 10:10, 14:14, 23:12, 26:7, 26:19, 29:6, 46:24, 47:2, 73:16, 96:25, 101:5, 144:14, 169:3, 172:7, 192:7</p> <p>clearly ^[1] - 202:10</p> <p>clerk ^[1] - 30:19</p> <p>CLERK ^[9] - 73:25, 74:2, 125:23, 148:20, 190:10, 197:16, 197:18, 219:13, 242:15</p> <p>client ^[1] - 133:25</p> <p>clients ^[1] - 222:1</p> <p>clinical ^[24] - 34:16, 35:1, 76:5, 78:4, 78:24, 81:4, 96:25, 97:5, 97:10, 160:12, 160:19, 160:20, 162:23, 163:4, 168:8, 173:6, 174:14, 175:1, 176:21, 179:23, 180:20, 183:21, 233:24</p> <p>Clinical ^[3] - 106:13, 106:16, 183:3</p>
<p style="text-align: center;">C</p> <p>CA ^[2] - 2:7, 2:14</p> <p>calculate ^[1] - 112:15</p> <p>calculated ^[1] - 37:4</p> <p>calculation ^[2] - 212:8, 216:1</p> <p>calculations ^[2] - 110:17, 110:21</p> <p>California ^[4] - 165:25, 166:1, 166:3, 166:4</p> <p>CALIFORNIA ^[4] - 1:2, 1:18, 1:23, 5:1</p> <p>Cancer ^[2] - 104:6, 207:15</p> <p>cancer ^[81] - 38:4, 40:20, 43:14, 55:21, 55:24, 56:2, 77:21, 80:23, 81:12, 81:13, 81:14, 82:5, 104:7, 104:12, 104:19, 154:13, 158:22, 159:3, 159:5, 159:6, 159:10, 159:13, 159:15, 160:12, 160:13, 160:17, 160:23, 161:3, 161:19, 162:8, 162:24, 163:2, 163:7, 163:21, 164:22, 166:10, 166:11, 166:12, 166:17, 166:19, 173:9, 174:24, 175:5, 175:15, 175:19, 178:13, 181:22,</p>	<p>182:25, 185:19, 185:23, 186:1, 187:12, 187:15, 189:22, 189:24, 190:24, 191:9, 191:24, 192:10, 196:16, 199:10, 199:15, 204:17, 204:23, 207:6, 208:6, 209:15, 211:4, 211:6, 220:6, 220:8, 221:4, 238:9, 238:14, 238:20, 238:25, 239:18, 241:15</p> <p>cancerous ^[2] - 181:23, 182:2</p> <p>cancers ^[3] - 82:1, 82:8, 82:17</p> <p>candidate ^[1] - 183:22</p> <p>cannot ^[2] - 129:3, 195:6</p> <p>capability ^[1] - 15:3</p> <p>capital ^[10] - 163:23, 201:24, 202:12, 203:4, 203:7, 203:9, 203:12, 203:13, 203:16, 203:20</p> <p>Capital ^[1] - 114:21</p> <p>carcinogenicity ^[4] - 81:11, 85:19, 97:7</p> <p>carcinoma ^[3] - 181:19, 181:25, 214:14</p> <p>care ^[9] - 27:18, 73:7, 78:9, 164:8, 168:13, 204:17, 206:19, 206:20, 221:15</p> <p>cared ^[1] - 99:7</p> <p>career ^[1] - 162:11</p> <p>careful ^[4] - 11:2, 22:23, 26:13, 139:5</p> <p>carefully ^[4] - 16:13, 17:25, 24:17, 53:5</p> <p>Carlo ^[4] - 40:22, 41:1, 41:3, 41:5</p> <p>carrying ^[2] - 48:10, 48:20</p> <p>case ^[13] - 7:6, 7:8, 19:16, 21:25, 25:25, 73:13, 125:21, 145:6, 145:11, 147:1, 242:13</p> <p>cash ^[1] - 192:5</p> <p>casino ^[1] - 41:3</p> <p>cat ^[1] - 217:9</p> <p>categories ^[3] - 107:4, 199:9, 239:23</p> <p>categorize ^[2] - 107:3, 184:17</p> <p>caused ^[3] - 82:1, 93:22, 196:6</p> <p>causes ^[5] - 81:14, 81:15, 81:16, 144:21</p> <p>causing ^[1] - 82:5</p> <p>caution ^[1] - 133:2</p> <p>caveat ^[7] - 47:6, 56:20, 80:7, 83:20, 98:9, 98:13, 141:19</p> <p>CCRA ^[1] - 1:22</p> <p>CDA ^[2] - 132:12, 195:9</p> <p>cell ^[4] - 166:12, 166:13,</p>	<p>166:14, 166:17</p> <p>censoring ^[3] - 46:19, 76:25, 77:10</p> <p>central ^[10] - 70:11, 111:24, 112:3, 178:19, 178:20, 179:1, 208:3, 208:6, 208:11, 210:9</p> <p>Central ^[1] - 195:22</p> <p>CENTRAL ^[1] - 1:2</p> <p>centrally ^[26] - 66:3, 68:6, 68:12, 69:9, 69:13, 108:1, 108:8, 108:13, 109:12, 110:18, 114:7, 178:3, 178:18, 179:3, 179:11, 179:14, 179:20, 179:24, 180:5, 208:9, 208:11, 210:8, 214:18, 214:21, 215:16, 218:14</p> <p>CEO ^[3] - 8:13, 95:17, 139:1</p> <p>certain ^[9] - 14:7, 72:18, 82:14, 118:9, 135:3, 137:9, 141:11, 153:7</p> <p>certainly ^[17] - 18:14, 18:17, 33:5, 82:16, 94:21, 95:4, 95:6, 109:15, 146:11, 163:24, 191:25, 199:11, 210:20, 215:7, 226:18, 228:19, 229:5</p> <p>CERTIFICATE ^[1] - 243:1</p> <p>CERTIFY ^[1] - 243:2</p> <p>cetera ^[21] - 13:18, 19:20, 26:13, 27:4, 27:8, 55:19, 56:25, 93:22, 94:20, 96:8, 141:24, 147:10, 160:2, 160:6, 199:11, 211:21, 216:11, 230:11</p> <p>chairperson ^[1] - 198:6</p> <p>challenge ^[1] - 68:1</p> <p>challenging ^[3] - 212:20, 226:21, 233:3</p> <p>Chan ^[8] - 122:20, 192:10, 195:24, 198:3, 198:5, 198:6, 198:8</p> <p>chance ^[12] - 20:8, 50:19, 87:10, 87:13, 96:14, 116:3, 130:2, 144:11, 147:2, 203:24, 216:21, 233:21</p> <p>change ^[9] - 17:24, 90:6, 90:7, 90:8, 91:8, 91:11, 226:20, 227:17, 227:20</p> <p>changed ^[8] - 90:3, 91:8, 94:12, 161:9, 227:12, 227:17, 229:11, 229:13</p> <p>changes ^[3] - 38:13, 91:12, 96:1</p> <p>changing ^[3] - 91:10, 229:7, 229:10</p> <p>CHARGED ^[1] - 243:5</p> <p>chart ^[23] - 35:9, 35:12, 35:13, 37:20, 42:8, 42:9,</p>	<p>44:23, 44:24, 45:15, 48:12, 57:7, 63:14, 66:2, 84:12, 85:10, 90:24, 91:1, 91:2, 91:3, 131:18, 151:1, 171:6</p> <p>charts ^[5] - 35:2, 44:23, 48:10, 74:23, 151:18</p> <p>chase ^[2] - 6:12, 7:4</p> <p>check ^[5] - 31:24, 31:25, 127:11, 189:2, 232:18</p> <p>checked ^[3] - 43:13, 188:21, 238:14</p> <p>checking ^[1] - 238:9</p> <p>chemotherapy ^[1] - 204:18</p> <p>Cheryl ^[2] - 200:16, 200:17</p> <p>Chicago ^[2] - 122:9, 159:21</p> <p>chief ^[1] - 193:12</p> <p>children ^[3] - 175:17, 175:18</p> <p>choose ^[1] - 182:25</p> <p>Christine ^[3] - 71:19, 85:4, 88:25</p> <p>CIRCUIT ^[1] - 243:5</p> <p>circumstances ^[1] - 154:10</p> <p>Citi ^[1] - 219:9</p> <p>Citi's ^[1] - 222:1</p> <p>claim ^[3] - 14:25, 139:17, 144:3</p> <p>claiming ^[1] - 144:5</p> <p>claims ^[1] - 183:22</p> <p>Claire ^[19] - 38:25, 39:2, 39:3, 39:7, 39:15, 55:2, 57:18, 60:23, 62:4, 62:8, 62:10, 64:25, 65:1, 65:2, 65:6, 66:8, 66:9, 227:5</p> <p>clarified ^[1] - 53:19</p> <p>clarify ^[3] - 77:12, 121:24, 240:15</p> <p>class ^[1] - 230:16</p> <p>clear ^[16] - 9:7, 10:10, 14:14, 23:12, 26:7, 26:19, 29:6, 46:24, 47:2, 73:16, 96:25, 101:5, 144:14, 169:3, 172:7, 192:7</p> <p>clearly ^[1] - 202:10</p> <p>clerk ^[1] - 30:19</p> <p>CLERK ^[9] - 73:25, 74:2, 125:23, 148:20, 190:10, 197:16, 197:18, 219:13, 242:15</p> <p>client ^[1] - 133:25</p> <p>clients ^[1] - 222:1</p> <p>clinical ^[24] - 34:16, 35:1, 76:5, 78:4, 78:24, 81:4, 96:25, 97:5, 97:10, 160:12, 160:19, 160:20, 162:23, 163:4, 168:8, 173:6, 174:14, 175:1, 176:21, 179:23, 180:20, 183:21, 233:24</p> <p>Clinical ^[3] - 106:13, 106:16, 183:3</p>

<p>clinically [3] - 217:19, 218:1, 218:3</p> <p>close [2] - 25:18, 26:18</p> <p>closely [1] - 231:16</p> <p>closest [2] - 137:17, 147:8</p> <p>CLUBOK [69] - 2:12, 13:25, 14:7, 14:10, 14:14, 14:18, 14:21, 14:24, 15:3, 15:25, 16:3, 16:10, 16:12, 16:15, 17:6, 17:11, 17:22, 18:3, 19:7, 19:25, 20:4, 20:22, 21:15, 21:21, 21:25, 22:5, 22:8, 22:10, 22:14, 22:17, 22:20, 22:22, 23:3, 24:13, 24:24, 25:16, 25:24, 26:6, 26:16, 26:23, 27:14, 27:23, 27:25, 28:14, 28:18, 28:21, 29:3, 29:8, 29:10, 53:23, 137:21, 137:23, 138:17, 141:2, 142:7, 142:19, 143:12, 143:19, 144:8, 144:13, 144:17, 145:21, 146:4, 146:10, 146:18, 146:22, 146:25, 148:8, 148:12</p> <p>coding [1] - 231:7</p> <p>coffee [1] - 29:19</p> <p>cohort [1] - 112:3</p> <p>collecting [4] - 69:6, 69:9, 69:17, 69:19</p> <p>COLLEEN [1] - 2:11</p> <p>college [1] - 159:22</p> <p>Collett [4] - 200:16, 200:17, 200:20</p> <p>color [2] - 231:7, 231:8</p> <p>colors [1] - 8:17</p> <p>column [2] - 171:9, 208:14</p> <p>columnist [1] - 111:17</p> <p>columns [3] - 89:23, 172:9, 206:8</p> <p>combination [1] - 75:23</p> <p>comers [1] - 210:7</p> <p>comfort [1] - 211:11</p> <p>comfortable [10] - 82:7, 82:10, 119:18, 124:12, 209:11, 209:12, 211:7, 212:4, 213:14, 242:5</p> <p>coming [10] - 12:19, 37:23, 40:21, 55:21, 110:3, 124:14, 132:9, 175:22, 204:21, 218:8</p> <p>commend [2] - 10:13, 169:11</p> <p>comment [10] - 113:10, 113:13, 113:19, 113:22, 124:4, 124:10, 125:3, 173:7, 195:15, 239:25</p> <p>commentary [1] - 169:21</p> <p>commented [1] - 127:22</p> <p>comments [3] - 84:4, 138:23, 208:20</p>	<p>Commission [2] - 201:2, 201:3</p> <p>commitments [1] - 102:16</p> <p>committee [30] - 102:16, 104:9, 104:18, 122:22, 122:24, 182:25, 187:13, 189:21, 190:19, 190:22, 190:23, 190:25, 191:6, 191:16, 192:8, 192:9, 192:18, 193:4, 193:20, 194:1, 194:12, 195:5, 195:8, 195:13, 195:16, 195:21, 198:7, 198:12, 198:24, 198:25</p> <p>common [5] - 61:9, 95:24, 202:15, 203:2, 242:1</p> <p>communicate [2] - 62:12, 123:16</p> <p>communicated [3] - 152:20, 153:2, 153:25</p> <p>communicating [2] - 117:1, 124:17</p> <p>communication [2] - 40:5, 60:1</p> <p>communications [2] - 95:22, 152:25</p> <p>community [1] - 104:12</p> <p>companies [14] - 99:22, 159:2, 160:16, 160:22, 160:24, 161:6, 161:15, 168:6, 168:15, 168:18, 183:18, 210:18, 211:1, 222:3</p> <p>Company [1] - 11:20</p> <p>company [39] - 39:1, 55:10, 55:16, 58:5, 65:1, 67:7, 67:13, 67:14, 67:17, 75:12, 95:24, 102:18, 105:16, 114:21, 117:6, 154:3, 158:21, 159:11, 160:9, 160:11, 161:22, 161:23, 162:6, 162:19, 162:25, 163:5, 163:9, 163:18, 164:1, 164:13, 168:20, 183:9, 196:17, 201:4, 202:4, 202:5, 203:8, 203:18, 226:6</p> <p>company's [1] - 183:21</p> <p>compare [4] - 78:8, 89:4, 89:5, 241:25</p> <p>comparing [2] - 180:4, 215:4</p> <p>comparison [2] - 180:4, 215:21</p> <p>compartmentalizing [1] - 143:15</p> <p>compensation [2] - 191:23, 192:15</p> <p>complained [1] - 138:7</p> <p>complaining [1] - 18:10</p> <p>complete [2] - 68:15, 176:16</p>	<p>completed [9] - 73:8, 82:23, 168:15, 171:16, 185:12, 209:6, 209:7, 227:10, 240:20</p> <p>completely [3] - 100:22, 129:7, 238:14</p> <p>completeness [1] - 11:10</p> <p>completing [2] - 42:18, 42:22</p> <p>completion [1] - 159:18</p> <p>complicated [4] - 9:3, 10:2, 10:7, 97:14</p> <p>complication [1] - 9:23</p> <p>complies [5] - 36:11, 44:20, 75:10, 221:23, 237:7</p> <p>compound [4] - 14:15, 79:9, 79:15, 79:19</p> <p>computer [5] - 57:20, 61:14, 67:10, 67:12, 103:25</p> <p>computers [2] - 67:15, 92:19</p> <p>concept [1] - 78:2</p> <p>concern [4] - 133:5, 133:14, 135:22, 241:9</p> <p>concerned [7] - 124:24, 134:2, 134:13, 134:15, 228:11, 229:5, 239:4</p> <p>concerning [3] - 9:10, 129:23, 238:16</p> <p>concerns [7] - 82:17, 132:22, 135:13, 135:16, 147:8, 147:21, 196:6</p> <p>conclusion [2] - 28:10, 37:23</p> <p>condition [1] - 75:25</p> <p>conditions [1] - 170:10</p> <p>conduct [1] - 179:17</p> <p>confer [1] - 52:7</p> <p>conference [61] - 6:8, 8:13, 8:19, 31:20, 32:23, 56:18, 69:18, 102:20, 104:5, 106:12, 106:23, 107:2, 120:23, 121:20, 122:1, 129:16, 139:1, 140:1, 141:14, 141:15, 141:16, 142:11, 143:3, 155:9, 183:1, 184:3, 184:10, 184:12, 184:15, 184:19, 185:25, 186:21, 186:25, 187:10, 187:18, 187:19, 187:23, 188:1, 189:2, 189:15, 189:19, 190:19, 191:4, 192:1, 198:23, 200:8, 200:14, 200:20, 201:9, 210:15, 210:19, 211:2, 212:22, 214:2, 216:16, 217:4, 222:12, 225:25, 226:2, 237:2, 239:6</p> <p>CONFERENCE [1] - 243:7</p> <p>conferences [5] - 124:11, 184:6, 184:7, 211:9,</p>	<p>211:20</p> <p>conferring [3] - 7:25, 30:19, 111:13</p> <p>confident [2] - 68:15, 68:19</p> <p>confidential [8] - 189:4, 189:12, 189:13, 195:10, 195:11, 199:19, 199:24, 210:16</p> <p>confidentiality [16] - 104:15, 105:4, 105:5, 154:16, 188:18, 188:21, 188:25, 189:8, 189:10, 195:7, 195:9, 199:17, 199:22, 199:23, 210:14, 210:25</p> <p>confirm [2] - 157:6, 178:21</p> <p>confirmation [2] - 25:8, 179:1</p> <p>confirmed [27] - 33:1, 66:3, 68:6, 68:12, 69:10, 69:13, 108:1, 108:9, 108:13, 109:12, 110:19, 114:7, 178:3, 178:18, 179:4, 179:12, 179:14, 179:20, 179:25, 180:5, 208:9, 208:12, 210:9, 214:19, 214:21, 215:16, 218:14</p> <p>confirming [1] - 25:6</p> <p>conflicts [2] - 191:25, 192:7</p> <p>CONFORMANCE [1] - 243:6</p> <p>confuse [1] - 143:8</p> <p>confused [1] - 8:22</p> <p>confusing [1] - 142:8</p> <p>CONN [26] - 2:4, 11:17, 11:24, 12:9, 12:12, 12:18, 12:23, 13:12, 14:9, 15:20, 15:23, 19:3, 19:6, 20:11, 20:18, 21:3, 23:12, 23:16, 23:21, 24:1, 24:4, 25:3, 26:2, 27:17, 29:17, 30:16</p> <p>connection [2] - 200:13, 203:3</p> <p>conscious [1] - 159:5</p> <p>consensus [2] - 16:19, 28:4</p> <p>consideration [2] - 102:16, 189:9</p> <p>considered [1] - 188:15</p> <p>considering [1] - 76:7</p> <p>considers [1] - 117:7</p> <p>consistent [2] - 24:6, 24:7</p> <p>constant [1] - 36:20</p> <p>constantly [1] - 18:10</p> <p>consultants [1] - 217:18</p> <p>contained [3] - 112:5, 118:6, 200:1</p> <p>containing [1] - 177:6</p> <p>contains [6] - 74:19, 90:19, 121:22, 121:25, 183:7, 199:17</p> <p>content [2] - 18:23, 96:8</p> <p>contentions [1] - 132:20</p>
--	--	---	---

context [37] - 6:10, 6:24, 7:21, 8:7, 8:12, 9:4, 10:5, 10:8, 12:20, 14:4, 17:1, 21:11, 21:19, 22:13, 24:21, 25:7, 25:12, 27:25, 50:7, 50:17, 55:6, 72:20, 121:1, 123:7, 130:14, 130:16, 130:21, 131:2, 132:1, 132:3, 132:7, 132:12, 132:16, 135:2, 135:24, 139:10, 230:13

contingent [1] - 26:13

continue [9] - 31:8, 43:12, 74:5, 77:2, 100:5, 100:9, 106:18, 148:25, 238:13

continued [4] - 155:21, 238:7, 239:16, 239:17

continues [2] - 181:14, 224:4

continuing [2] - 40:12, 175:9

contract [3] - 137:25, 164:9, 226:15

contractors [1] - 180:10

control [9] - 119:22, 155:11, 186:3, 204:6, 210:6, 210:12, 212:3, 222:23, 224:5

controller [1] - 200:18

controls [1] - 9:6

conversation [11] - 7:23, 18:9, 110:11, 119:20, 121:1, 124:25, 137:19, 211:23, 215:4, 222:11, 222:16

conversations [3] - 16:17, 19:15, 215:8

coordinated [1] - 167:18

copayment [3] - 173:24, 174:1

copies [4] - 53:24, 95:12, 95:20, 95:22

copious [1] - 105:9

copy [18] - 61:15, 85:8, 94:11, 104:20, 106:3, 115:17, 126:15, 150:17, 150:18, 153:11, 153:12, 155:16, 155:17, 155:23, 155:24, 155:25, 156:17, 207:13

core [1] - 136:2

Corporation [1] - 160:10

correct [291] - 12:9, 12:12, 14:25, 32:17, 32:18, 33:5, 33:6, 33:14, 33:15, 34:24, 35:3, 37:11, 37:13, 37:14, 37:22, 38:24, 40:17, 41:11, 41:13, 41:18, 41:20, 41:21, 41:24, 42:6, 42:11, 43:17, 43:19, 44:5, 44:7, 44:8, 45:1, 45:3, 45:4, 45:8, 45:11, 45:16, 45:17, 45:22,

46:3, 46:13, 46:17, 46:18, 46:24, 47:5, 47:9, 47:11, 47:12, 48:3, 48:4, 48:7, 48:8, 48:21, 49:22, 49:23, 50:3, 50:4, 50:16, 51:4, 52:10, 54:6, 54:7, 54:11, 54:15, 54:18, 54:19, 54:23, 55:1, 55:3, 58:24, 59:6, 60:6, 60:10, 60:25, 61:2, 61:3, 61:24, 63:4, 63:5, 63:6, 63:8, 63:15, 63:17, 63:20, 63:22, 64:1, 64:2, 64:5, 64:6, 64:9, 64:10, 64:13, 64:16, 64:22, 64:23, 64:25, 66:1, 66:3, 66:6, 69:7, 70:8, 70:11, 70:13, 71:13, 71:14, 71:16, 71:17, 71:25, 72:9, 72:12, 72:19, 74:17, 74:21, 74:25, 75:1, 75:15, 75:21, 79:24, 80:17, 80:20, 80:21, 80:24, 82:12, 82:21, 82:22, 83:3, 83:6, 83:8, 83:9, 83:11, 83:12, 83:17, 83:18, 84:4, 84:5, 84:8, 84:10, 84:11, 84:14, 84:21, 84:22, 85:6, 85:7, 85:13, 85:15, 85:16, 85:22, 85:23, 86:13, 86:14, 86:16, 86:17, 86:21, 88:3, 88:4, 88:6, 88:7, 88:9, 88:15, 88:17, 88:18, 88:20, 88:21, 89:10, 89:11, 89:13, 89:15, 89:16, 89:18, 89:21, 91:21, 92:1, 92:2, 92:13, 93:3, 98:1, 98:20, 98:21, 98:24, 98:25, 102:14, 102:25, 103:11, 103:12, 103:15, 103:17, 103:19, 104:1, 104:17, 105:12, 106:17, 108:4, 108:6, 108:11, 108:12, 108:14, 108:22, 108:23, 109:9, 109:12, 109:20, 111:15, 111:16, 111:18, 114:10, 118:7, 118:10, 119:23, 119:24, 120:7, 120:8, 120:12, 120:25, 121:21, 121:23, 122:2, 122:6, 122:22, 122:23, 123:2, 123:3, 124:23, 125:12, 127:17, 132:10, 136:19, 137:1, 149:6, 149:7, 149:9, 149:10, 149:15, 149:22, 149:24, 150:10, 150:11, 150:14, 150:22, 152:2, 152:3, 152:6, 152:7, 152:12, 155:14, 155:21, 158:7, 158:8, 167:11, 167:21, 169:24, 178:4, 179:16, 182:6, 182:7, 184:3, 184:4, 186:24,

188:11, 188:16, 190:21, 192:14, 193:1, 193:18, 194:2, 194:5, 194:8, 194:13, 195:1, 201:20, 202:22, 204:2, 206:10, 206:13, 207:13, 207:16, 208:1, 212:2, 217:2, 217:6, 217:11, 217:23, 218:16, 219:10, 220:11, 229:1, 229:8, 230:14, 231:24, 232:1, 232:4, 232:21, 237:11

CORRECT [1] - 243:2

corrected [3] - 111:3, 181:6, 181:13

correcting [1] - 112:10

correctly [8] - 49:4, 68:9, 93:25, 174:11, 191:19, 201:22, 214:23, 232:11

correlation [1] - 41:2

correspondence [6] - 7:15, 86:18, 95:13, 95:20, 98:19, 98:24

Cortazar [3] - 77:20, 173:8

cost [2] - 173:19, 202:8

costs [1] - 163:13

couches [1] - 8:17

Cougar [17] - 8:14, 158:21, 159:11, 159:18, 159:19, 161:2, 161:20, 162:9, 163:3, 164:3, 164:5, 164:10, 165:4, 165:5, 165:10, 165:14

Coughlin [4] - 74:5, 92:22, 138:10, 172:12

COUGHLIN [190] - 2:4, 12:7, 29:20, 30:8, 31:9, 31:12, 31:17, 32:10, 32:12, 34:9, 34:14, 36:3, 36:7, 39:24, 40:3, 44:10, 44:15, 47:16, 47:20, 48:24, 49:3, 49:6, 49:20, 51:7, 51:10, 51:21, 52:2, 52:13, 52:15, 52:23, 53:15, 54:3, 60:15, 60:21, 62:20, 63:1, 65:16, 65:19, 65:21, 65:24, 67:24, 68:2, 68:5, 69:23, 70:1, 70:4, 70:21, 71:1, 71:8, 73:22, 74:6, 74:8, 74:13, 75:4, 75:8, 79:11, 79:22, 80:6, 80:10, 80:12, 82:9, 83:19, 83:23, 84:1, 84:24, 85:3, 86:1, 86:4, 86:7, 86:25, 87:4, 87:8, 87:12, 87:16, 87:18, 92:4, 92:8, 92:11, 92:12, 92:23, 93:1, 97:16, 97:23, 98:4, 98:7, 98:9, 98:12, 98:17, 100:10, 101:23, 102:1, 102:4, 102:9, 103:3, 103:9, 106:5,

106:8, 106:9, 107:11, 107:14, 107:19, 108:25, 109:4, 111:7, 111:11, 112:19, 112:22, 113:1, 113:24, 114:15, 114:19, 114:24, 115:4, 115:9, 115:24, 116:4, 116:8, 116:14, 116:20, 116:22, 117:12, 117:14, 117:20, 117:23, 118:1, 118:2, 118:14, 118:16, 118:17, 118:20, 119:5, 119:10, 119:17, 120:13, 120:18, 121:12, 121:17, 122:12, 122:18, 125:15, 126:3, 126:7, 126:12, 126:15, 126:19, 127:3, 127:8, 127:14, 127:25, 128:3, 128:6, 128:12, 128:23, 129:14, 129:21, 131:15, 137:3, 139:20, 141:8, 145:9, 147:12, 148:2, 148:5, 149:1, 149:2, 150:1, 150:5, 154:17, 156:23, 157:2, 157:5, 157:7, 157:9, 157:11, 157:14, 157:16, 157:18, 157:21, 157:23, 164:24, 170:18, 172:19, 186:13, 192:24, 197:6, 207:19, 218:22, 219:15, 223:8, 242:19

coughlin's [1] - 29:19

counsel [28] - 7:1, 7:3, 7:5, 7:25, 14:9, 31:8, 31:21, 46:20, 47:1, 50:9, 67:19, 72:23, 87:21, 92:18, 93:8, 96:20, 97:21, 100:9, 121:6, 123:8, 134:4, 135:10, 142:24, 152:17, 156:10, 156:21, 170:21, 223:14

count [1] - 234:10

countries [1] - 196:2

couple [9] - 44:16, 47:21, 159:19, 178:1, 181:15, 183:8, 216:17, 221:20, 237:4

course [11] - 30:5, 114:20, 116:15, 116:18, 137:5, 143:22, 146:6, 162:19, 190:3, 193:17, 208:8

COURT [327] - 1:1, 1:22, 5:3, 5:6, 5:16, 5:19, 5:23, 6:11, 6:22, 7:3, 7:12, 7:17, 7:22, 8:1, 8:8, 8:24, 11:18, 12:5, 12:10, 12:13, 12:22, 13:1, 13:13, 14:2, 14:8, 14:11, 14:17, 14:19, 14:23, 15:1, 15:5, 15:22, 15:24, 16:2, 16:8, 16:11, 16:13, 16:18, 17:10, 17:21, 17:24, 19:1,

19:4, 19:18, 20:3, 20:5,
20:12, 20:19, 20:24, 21:4,
21:16, 21:24, 22:3, 22:7,
22:9, 22:11, 22:16, 22:18,
22:21, 22:23, 23:5, 23:15,
23:20, 23:22, 24:2, 24:5,
24:15, 24:25, 25:4, 25:17,
26:4, 26:7, 26:17, 26:24,
27:15, 27:18, 27:24, 28:8,
28:17, 28:20, 28:22, 29:5,
29:9, 29:13, 29:18, 30:2,
30:9, 30:18, 30:20, 30:25,
31:19, 32:11, 34:12, 36:5,
40:1, 44:13, 47:18, 49:2,
49:4, 49:10, 49:17, 49:19,
51:9, 51:11, 51:16, 51:19,
51:23, 52:8, 52:11, 52:14,
52:17, 52:22, 52:24, 53:20,
53:25, 60:18, 62:23, 65:15,
65:18, 65:20, 65:22, 67:19,
67:25, 68:3, 69:25, 70:2,
70:25, 71:5, 73:21, 73:23,
74:4, 74:11, 75:6, 79:13,
79:18, 79:20, 80:9, 81:16,
83:22, 83:24, 85:1, 86:5,
87:3, 87:5, 87:10, 87:13,
92:14, 92:24, 97:17, 98:6,
98:8, 98:11, 98:14, 100:9,
101:22, 102:3, 102:5,
102:7, 103:7, 106:7,
106:15, 106:18, 107:10,
107:12, 107:16, 109:2,
111:9, 112:21, 112:23,
113:16, 114:23, 114:25,
115:6, 115:8, 115:10,
115:14, 115:18, 115:22,
116:1, 116:5, 116:10,
116:17, 116:21, 117:10,
117:13, 117:17, 117:21,
117:24, 118:13, 118:15,
118:19, 119:4, 119:9,
119:15, 120:15, 120:17,
121:15, 122:14, 122:16,
125:18, 125:25, 126:2,
126:5, 126:10, 126:13,
126:17, 126:21, 127:2,
127:6, 127:9, 127:24,
128:2, 128:5, 128:10,
128:14, 128:19, 128:22,
128:24, 129:6, 129:19,
129:22, 130:2, 130:9,
130:15, 130:23, 131:8,
131:14, 131:24, 132:2,
132:6, 132:17, 133:10,
133:18, 133:25, 134:5,
134:7, 134:9, 134:12,
134:20, 135:12, 136:1,
136:5, 136:10, 136:13,
136:16, 136:20, 136:24,
137:2, 137:4, 137:7,
137:17, 137:22, 138:16,

139:18, 141:1, 142:18,
143:10, 143:13, 144:7,
144:9, 144:14, 145:2,
145:10, 145:24, 146:9,
146:16, 146:20, 146:24,
147:4, 147:6, 147:19,
148:3, 148:6, 148:11,
148:16, 148:22, 150:3,
154:9, 156:21, 156:25,
157:3, 157:6, 157:8,
157:10, 157:12, 157:15,
157:17, 157:19, 157:22,
158:1, 158:5, 158:9, 165:1,
165:5, 165:8, 170:6,
170:12, 170:14, 170:17,
170:19, 170:21, 172:20,
186:12, 186:16, 188:4,
190:6, 190:8, 190:14,
192:25, 197:7, 197:11,
197:13, 197:17, 197:19,
197:23, 201:12, 205:18,
207:20, 218:23, 219:11,
219:17, 219:20, 223:12,
223:17, 235:4, 242:9,
242:17
court [13] - 9:12, 11:21,
13:19, 18:5, 18:23, 29:21,
30:24, 74:3, 125:24,
148:21, 190:11, 190:13,
242:16
Court [6] - 30:19, 53:2, 53:7,
53:8, 53:9, 147:5
Court's [1] - 53:7
covered [1] - 78:24
Cowen [8] - 11:20, 25:20,
216:23, 217:3, 217:7,
217:24, 237:8, 237:9
crazy [1] - 126:17
create [2] - 62:14, 62:15
created [5] - 55:3, 91:16,
91:22, 92:5, 148:10
creates [1] - 63:2
credibility [1] - 24:19
credible [1] - 225:12
criteria [1] - 215:17
CROSS [2] - 3:4, 158:10
cross [14] - 9:17, 9:18, 9:20,
17:14, 18:4, 18:18, 19:18,
19:19, 20:6, 23:8, 23:14,
37:9, 97:20, 116:7
CROSS-EXAMINATION [2] -
3:4, 158:10
cross-examination [4] -
19:18, 19:19, 97:20, 116:7
cross-examine [8] - 9:17,
9:18, 9:20, 18:4, 18:18,
20:6, 23:8, 23:14
crosses [1] - 37:9
crossing [1] - 45:16
crystal [1] - 47:2

CSR [1] - 1:22
cure [8] - 17:8, 17:13, 18:6,
18:20, 19:16, 29:11,
217:20, 218:9
cured [1] - 221:12
curiosity [1] - 40:18
current [3] - 36:21, 40:23,
73:7
curve [10] - 40:11, 47:7,
50:23, 54:10, 54:17, 54:18,
63:16, 66:5, 141:20, 155:2
curves [49] - 33:16, 33:19,
38:2, 38:8, 38:20, 38:23,
40:25, 41:19, 44:24, 47:9,
47:25, 49:25, 50:15, 54:12,
54:13, 55:18, 58:19, 59:25,
61:2, 62:2, 63:3, 64:25,
65:11, 66:18, 66:19, 67:1,
67:5, 67:8, 72:10, 74:25,
75:14, 83:11, 110:1,
110:10, 131:22, 140:6,
141:6, 142:14, 143:4,
147:15, 149:13, 149:14,
149:15, 155:2, 155:5,
155:21, 194:10, 216:15
curvy [1] - 18:13
cut [9] - 7:4, 7:9, 126:5,
142:8, 152:10, 152:24,
153:21, 153:22, 154:4
cutoff [1] - 34:23
cuts [3] - 12:16, 77:2, 142:6
cutting [2] - 6:12, 153:7
cycle [19] - 118:24, 118:25,
229:15, 229:19, 229:20,
229:21, 230:7, 230:12,
230:13, 230:14, 231:2,
231:13, 231:16, 231:20,
231:23, 232:13, 232:20,
233:10

D

dad [1] - 161:12
Daniell [1] - 59:9
dash [1] - 36:17
data [208] - 6:2, 6:4, 6:6, 6:7,
7:16, 8:6, 8:18, 32:24,
32:25, 33:2, 33:4, 33:5,
33:23, 34:25, 35:2, 35:7,
35:14, 35:19, 36:22, 37:5,
39:4, 39:13, 40:11, 43:4,
43:15, 43:21, 47:5, 47:10,
50:2, 50:5, 50:11, 50:21,
50:23, 55:3, 55:9, 55:15,
56:16, 56:17, 56:20, 56:23,
57:4, 57:5, 57:6, 57:13,
58:13, 62:5, 68:8, 68:16,
68:20, 68:22, 68:24, 68:25,
69:6, 69:10, 69:18, 69:19,
83:1, 96:25, 97:6, 97:10,

102:17, 102:20, 103:23,
103:24, 104:7, 104:8,
104:13, 104:16, 105:5,
105:6, 105:9, 106:11,
106:21, 107:5, 110:2,
112:4, 112:6, 122:8, 122:9,
124:8, 127:23, 129:16,
130:22, 131:18, 131:22,
131:23, 139:4, 139:25,
140:5, 140:8, 140:12,
140:14, 140:19, 140:21,
141:10, 141:12, 141:13,
141:14, 141:18, 141:22,
142:2, 142:3, 142:5, 142:6,
142:9, 142:10, 142:12,
142:13, 142:14, 143:1,
143:2, 143:5, 144:2, 144:4,
147:15, 149:11, 150:7,
150:19, 153:15, 154:7,
154:13, 154:15, 154:16,
154:19, 155:3, 155:12,
155:13, 155:15, 168:10,
168:11, 169:9, 172:11,
173:5, 176:5, 176:8, 176:9,
176:22, 177:6, 177:9,
177:12, 177:17, 177:21,
179:20, 180:13, 181:15,
183:1, 187:16, 187:18,
189:1, 189:3, 189:11,
189:18, 189:21, 190:4,
190:18, 191:7, 191:11,
192:1, 194:7, 195:4, 195:6,
195:13, 196:3, 196:5,
196:9, 196:11, 196:18,
199:22, 200:1, 200:3,
208:7, 210:16, 210:24,
211:6, 214:1, 220:13,
220:15, 220:20, 221:2,
221:7, 226:7, 226:12,
226:14, 226:16, 226:17,
227:12, 227:17, 227:20,
228:9, 228:10, 228:11,
228:19, 229:2, 229:3,
229:11, 230:10, 230:15,
230:19, 238:13, 239:3,
239:5, 239:21, 240:21
database [11] - 35:1, 62:7,
176:10, 176:16, 176:18,
176:21, 176:24, 177:4,
177:6, 177:9, 227:10
databases [1] - 226:19
DATE [1] - 243:10
date [11] - 32:23, 68:7, 69:3,
70:11, 94:1, 105:11,
188:13, 188:14, 189:11,
192:17, 238:15
dated [11] - 11:19, 36:8,
47:21, 49:8, 54:5, 62:18,
75:16, 83:14, 122:19,
131:20, 155:6

<p>dates [1] - 35:24</p> <p>DAY [1] - 1:17</p> <p>days [4] - 34:23, 47:21, 92:18, 222:11</p> <p>DCI [2] - 47:25, 62:15</p> <p>DCIS [8] - 33:11, 41:12, 64:20, 214:10, 214:12, 214:14, 214:22, 215:13</p> <p>deadly [2] - 124:14, 175:22</p> <p>deal [2] - 127:15, 185:20</p> <p>dealing [2] - 148:23, 159:1</p> <p>deals [1] - 71:15</p> <p>dealt [1] - 160:22</p> <p>decaf [1] - 29:19</p> <p>December [9] - 85:4, 88:25, 104:4, 187:14, 189:25, 191:9, 193:5, 194:12, 207:6</p> <p>decided [3] - 9:8, 102:20, 162:11</p> <p>decides [1] - 45:23</p> <p>decision [1] - 159:5</p> <p>deck [6] - 69:16, 69:17, 104:2, 104:8, 193:19, 194:20</p> <p>declarant [1] - 116:6</p> <p>declarants [1] - 18:2</p> <p>decline [1] - 114:9</p> <p>decreases [1] - 229:24</p> <p>deemed [1] - 22:25</p> <p>deep [1] - 49:10</p> <p>defendant [1] - 200:17</p> <p>DEFENDANT [1] - 2:11</p> <p>defendants [1] - 1:12</p> <p>defense [25] - 5:8, 11:13, 16:9, 19:5, 20:20, 21:13, 23:8, 24:2, 24:13, 24:17, 24:23, 25:22, 26:9, 26:11, 26:12, 26:15, 31:24, 52:5, 52:19, 97:19, 116:2, 127:9, 135:19, 145:13, 145:14</p> <p>defense's [1] - 26:4</p> <p>defer [1] - 240:17</p> <p>defined [1] - 156:14</p> <p>definitely [3] - 57:24, 148:10, 227:20</p> <p>definition [2] - 76:9, 182:3</p> <p>definitions [1] - 238:3</p> <p>deflect [1] - 53:17</p> <p>degree [4] - 159:23, 160:4, 160:6, 178:11</p> <p>delay [2] - 31:1, 97:9</p> <p>delete [2] - 140:13, 147:17</p> <p>deleted [2] - 67:15, 140:11</p> <p>deliver [2] - 124:15, 209:20</p> <p>delta [8] - 113:21, 131:18, 152:5, 152:10, 214:7, 214:9, 214:18, 214:21</p> <p>deltas [2] - 214:3, 214:5</p>	<p>demand [1] - 6:15</p> <p>demonstrate [3] - 76:6, 76:8, 186:17</p> <p>demonstrated [3] - 144:1, 181:1, 181:17</p> <p>demonstrative [4] - 186:11, 186:14, 186:16, 187:5</p> <p>denial [3] - 99:1, 101:10, 101:12</p> <p>denied [2] - 77:25, 78:25</p> <p>denotes [1] - 94:11</p> <p>denying [3] - 91:12, 92:5, 94:7</p> <p>dependent [1] - 11:20</p> <p>deponent [2] - 21:10, 24:22</p> <p>deposed [1] - 12:1</p> <p>DEPOSIT [1] - 243:6</p> <p>deposition [15] - 5:7, 7:10, 8:1, 9:4, 9:8, 9:11, 9:12, 9:13, 9:19, 39:17, 89:2, 93:17, 93:25, 94:4, 94:19</p> <p>describe [5] - 80:25, 166:5, 176:8, 204:13, 227:15</p> <p>described [5] - 80:9, 173:10, 190:19, 205:22, 214:4</p> <p>describing [1] - 173:11</p> <p>description [1] - 122:3</p> <p>design [2] - 191:2, 208:3</p> <p>designated [1] - 101:2</p> <p>designating [1] - 11:7</p> <p>designation [27] - 15:13, 19:22, 23:18, 71:12, 72:14, 72:17, 73:1, 73:14, 77:25, 78:3, 78:11, 80:15, 99:14, 99:17, 100:18, 100:22, 166:25, 167:9, 168:1, 168:3, 168:5, 168:14, 168:23, 169:9, 169:14, 169:16, 171:15</p> <p>designations [1] - 19:2</p> <p>designed [1] - 143:8</p> <p>desire [1] - 169:11</p> <p>detail [2] - 72:22, 129:20</p> <p>detailed [3] - 6:1, 6:24, 122:3</p> <p>details [1] - 102:17</p> <p>determination [4] - 111:24, 187:19, 191:10, 191:11</p> <p>determine [2] - 168:2, 187:24</p> <p>determined [5] - 161:8, 181:8, 182:23, 208:11, 210:9</p> <p>determining [1] - 191:4</p> <p>devastating [1] - 159:8</p> <p>develop [4] - 81:20, 159:2, 161:19, 162:21</p> <p>developed [4] - 159:12, 161:13, 161:22, 162:1</p> <p>developer [1] - 174:13</p> <p>developing [4] - 160:17, 160:22, 161:7, 163:2</p>	<p>development [5] - 100:25, 165:7, 183:17, 202:6, 203:18</p> <p>development-stage [2] - 183:17, 203:18</p> <p>DF [1] - 33:16</p> <p>DFS [56] - 33:10, 33:11, 33:21, 35:15, 38:20, 40:11, 41:10, 41:12, 47:25, 50:14, 62:15, 64:20, 72:2, 76:24, 77:9, 83:7, 110:18, 111:23, 113:14, 113:20, 119:14, 155:9, 155:10, 155:20, 194:3, 204:4, 204:6, 204:9, 205:12, 206:3, 206:17, 208:21, 208:24, 210:6, 210:12, 212:2, 212:7, 212:15, 212:17, 213:1, 214:5, 214:7, 214:9, 214:18, 214:21, 215:12, 215:25, 217:19, 220:15, 222:17, 223:22, 237:10, 240:21, 241:18</p> <p>DFS-DCI [2] - 47:25, 62:15</p> <p>DFS-DCIS [3] - 33:11, 41:12, 64:20</p> <p>diagnosed [3] - 159:4, 161:3, 175:14</p> <p>diagnoses [1] - 179:8</p> <p>Diagnostic [1] - 160:10</p> <p>diagnostics [2] - 160:11, 160:13</p> <p>diarrhea [74] - 42:15, 43:5, 43:7, 43:8, 43:11, 43:25, 118:21, 119:1, 119:6, 119:11, 123:5, 123:11, 123:17, 123:23, 123:25, 124:6, 194:16, 194:19, 227:25, 228:3, 228:5, 228:8, 228:11, 228:12, 228:14, 228:16, 228:19, 228:22, 228:24, 229:4, 229:15, 229:18, 229:23, 230:3, 230:8, 230:12, 230:21, 230:25, 231:1, 231:8, 231:14, 232:13, 232:20, 233:1, 233:2, 233:18, 234:8, 234:11, 234:13, 234:15, 234:19, 234:22, 234:23, 234:24, 234:25, 235:9, 235:10, 235:15, 235:18, 235:23, 235:25, 236:3, 236:10, 236:14, 236:17, 236:21, 237:1, 239:10, 240:3, 241:21, 241:24, 242:1, 242:2</p> <p>dicey [1] - 22:4</p> <p>died [1] - 241:6</p>	<p>DIEGO [2] - 2:7, 2:14</p> <p>differ [1] - 183:10</p> <p>difference [25] - 45:3, 48:16, 50:14, 54:21, 63:13, 64:4, 72:4, 74:22, 81:25, 93:19, 94:14, 100:20, 108:16, 108:20, 111:12, 111:23, 112:2, 113:6, 113:25, 114:1, 194:4, 222:23, 223:5, 224:3</p> <p>differences [5] - 82:3, 109:11, 110:4, 121:25, 215:5</p> <p>different [37] - 6:8, 7:15, 7:18, 8:19, 18:1, 23:22, 39:6, 43:9, 50:11, 50:21, 66:6, 76:19, 76:22, 88:24, 94:18, 96:3, 100:22, 108:4, 110:23, 113:7, 125:9, 125:11, 128:2, 130:22, 132:8, 132:15, 136:18, 137:10, 172:8, 176:5, 198:18, 205:2, 214:6, 231:8, 235:12, 236:16</p> <p>differentiating [1] - 156:15</p> <p>differently [1] - 15:14</p> <p>difficult [5] - 59:18, 113:17, 115:11, 209:10, 212:22</p> <p>digit [1] - 199:4</p> <p>diligence [8] - 86:16, 88:2, 88:13, 88:17, 94:16, 95:18, 102:24, 103:1</p> <p>DIRECT [2] - 3:4, 31:11</p> <p>direct [9] - 10:5, 10:8, 10:18, 21:5, 24:22, 36:12, 41:16, 80:2, 144:11</p> <p>directed [2] - 172:15, 198:2</p> <p>director [1] - 86:9</p> <p>disagree [1] - 105:19</p> <p>disagrees [1] - 148:3</p> <p>disappear [1] - 67:13</p> <p>disappeared [3] - 67:11, 67:21, 239:1</p> <p>disappearing [1] - 238:14</p> <p>disclose [7] - 102:19, 108:15, 108:18, 108:20, 200:1, 210:22, 210:24</p> <p>disclosed [4] - 102:17, 146:10, 181:15, 200:13</p> <p>disclosing [1] - 220:21</p> <p>disclosure [1] - 183:23</p> <p>disclosures [1] - 200:12</p> <p>discontinuation [11] - 42:13, 42:14, 42:15, 43:8, 43:11, 43:23, 43:24, 43:25, 194:24, 239:11</p> <p>discontinuations [5] - 238:4, 238:6, 239:14, 239:15, 240:18</p> <p>discontinued [3] - 42:18,</p>
--	---	---	--

42:21, 42:23
discontinues [1] - 43:12
discovered [2] - 102:18, 185:14
discuss [18] - 37:15, 50:8, 50:9, 50:18, 50:19, 72:16, 72:20, 72:22, 96:2, 96:24, 97:5, 99:5, 123:7, 125:21, 135:6, 191:7, 195:18, 242:12
discussed [18] - 40:10, 43:4, 50:22, 55:15, 55:17, 56:4, 59:4, 64:20, 71:14, 73:18, 78:2, 96:10, 158:24, 168:4, 204:15, 210:13, 215:22, 238:2
discussing [3] - 123:18, 216:4, 217:5
discussion [11] - 50:7, 85:11, 126:24, 149:20, 195:11, 220:9, 223:7, 224:3, 225:25, 236:11
discussions [6] - 16:19, 18:24, 22:24, 28:4, 28:5, 28:15
disease [21] - 75:24, 124:14, 127:23, 147:14, 147:24, 168:13, 175:22, 179:25, 181:3, 181:18, 199:9, 204:20, 206:9, 206:14, 208:17, 210:7, 218:8, 220:24, 221:12, 222:24, 225:2
disease-free [12] - 127:23, 147:14, 147:24, 181:3, 181:18, 206:9, 206:14, 208:17, 210:7, 220:24, 222:24, 225:2
displayed [1] - 240:1
dispute [22] - 6:10, 6:25, 7:21, 8:7, 8:18, 8:21, 126:4, 127:4, 127:5, 129:2, 133:8, 134:23, 134:25, 136:7, 137:10, 138:5, 138:6, 140:2, 143:19, 143:25, 145:19
distinct [1] - 238:3
distracted [2] - 125:5, 142:20
distributing [1] - 85:5
DISTRICT [3] - 1:1, 1:2, 1:22
diversion [1] - 94:5
doctor [20] - 43:12, 178:13, 178:20, 190:4, 209:16, 211:17, 218:17, 222:8, 222:21, 223:10, 223:20, 224:4, 224:24, 225:11, 238:8, 238:9, 238:13, 239:17, 240:13
doctor's [6] - 178:9, 178:11,

178:24, 179:6, 180:1, 215:18
doctors [25] - 104:15, 104:19, 124:12, 124:17, 162:4, 182:24, 185:5, 186:1, 187:12, 189:22, 190:24, 191:15, 195:8, 195:21, 196:3, 196:8, 196:14, 196:19, 209:23, 211:6, 211:11, 217:25, 220:8
document [134] - 10:4, 10:20, 21:9, 21:23, 21:24, 32:13, 34:9, 34:10, 34:19, 35:4, 36:8, 36:10, 37:19, 40:8, 40:9, 42:8, 44:23, 47:11, 47:14, 47:21, 47:22, 48:5, 48:22, 49:8, 49:11, 49:15, 51:8, 52:12, 52:13, 52:16, 52:18, 53:8, 53:9, 53:13, 54:1, 54:4, 54:12, 54:13, 54:22, 55:2, 59:2, 60:4, 60:22, 62:18, 62:21, 63:14, 69:7, 69:24, 70:22, 70:25, 71:1, 71:9, 71:15, 71:22, 74:10, 74:14, 74:18, 74:19, 80:18, 83:21, 83:22, 84:2, 84:3, 84:25, 88:1, 90:9, 90:13, 90:14, 90:18, 91:4, 91:5, 91:7, 91:16, 91:19, 91:22, 91:25, 92:5, 92:13, 92:15, 92:16, 93:3, 93:6, 93:11, 93:16, 94:1, 94:3, 94:8, 94:10, 94:12, 94:15, 94:17, 94:21, 94:22, 95:1, 95:3, 95:5, 95:7, 95:9, 95:10, 96:18, 96:22, 102:10, 109:5, 114:19, 114:21, 114:23, 117:19, 117:22, 119:15, 120:14, 121:10, 127:20, 139:9, 140:24, 147:3, 147:5, 148:1, 149:17, 149:18, 152:9, 152:18, 153:4, 153:5, 154:6, 155:6, 157:6, 167:19, 171:5, 188:17, 200:10, 207:13
documentation [1] - 153:6
documentations [1] - 151:6
documents [47] - 6:6, 23:17, 23:25, 49:11, 53:2, 53:6, 54:24, 59:6, 67:7, 67:10, 67:12, 67:20, 67:21, 67:25, 90:17, 92:19, 93:19, 97:18, 98:13, 105:1, 126:3, 126:8, 126:13, 126:21, 126:25, 127:12, 127:14, 127:17, 129:4, 133:21, 135:23, 136:11, 136:21, 136:22, 136:24, 137:24, 138:24,

140:7, 142:4, 145:7, 145:22, 147:6, 149:5, 149:23, 156:24, 200:21
domain [2] - 196:13
done [49] - 36:25, 37:3, 38:18, 38:23, 39:3, 39:18, 41:15, 45:7, 45:19, 57:10, 61:25, 62:2, 62:9, 65:5, 65:6, 65:7, 66:20, 68:12, 70:11, 72:2, 78:24, 81:7, 82:11, 82:15, 82:16, 111:2, 123:17, 128:1, 143:4, 151:11, 157:10, 159:16, 165:16, 168:20, 168:21, 177:24, 178:9, 178:10, 178:24, 179:15, 179:21, 184:25, 217:24, 217:25, 227:5, 228:16, 235:22, 237:19, 242:9
door [2] - 129:3, 129:4
dose [8] - 233:8, 233:14, 233:15, 233:16, 235:8, 235:9, 235:24, 236:9
doses [1] - 81:23
double [2] - 16:16, 31:25
double-check [1] - 31:25
doubled [1] - 242:4
doubling [1] - 82:4
doubt [3] - 134:7, 134:8, 134:9
DOWD [1] - 2:5
down [48] - 5:13, 5:18, 9:21, 10:23, 27:2, 27:3, 27:5, 27:7, 30:22, 30:23, 33:7, 35:12, 35:14, 35:15, 37:25, 40:9, 41:22, 42:2, 45:5, 45:6, 45:12, 62:11, 72:1, 74:23, 76:23, 109:13, 110:8, 110:11, 110:21, 113:16, 114:10, 116:17, 117:11, 128:4, 128:7, 150:7, 172:25, 174:2, 191:13, 202:23, 221:1, 224:8, 231:14, 233:14, 235:4, 236:3, 242:17
download [2] - 125:7, 125:8
DPC [2] - 160:10, 160:21
Dr [36] - 37:14, 122:20, 155:8, 173:8, 192:10, 193:11, 193:13, 193:14, 195:23, 198:3, 198:5, 198:6, 198:8, 203:23, 204:5, 209:25, 210:11, 211:14, 212:10, 213:18, 214:4, 214:24, 215:24, 216:4, 218:15, 219:8, 220:3, 220:9, 220:12, 221:2, 222:5, 222:11, 225:5, 226:2, 240:11
draft [2] - 146:5, 146:15

drafts [1] - 146:8
dramatic [1] - 175:5
dramatically [5] - 56:21, 56:24, 141:21, 141:23, 231:11
drawn [1] - 63:16
dream [2] - 55:25, 175:20
drive [9] - 93:9, 93:10, 93:12, 93:14, 93:24, 94:2, 94:4, 94:9, 94:10
DRIVE [1] - 2:14
driver [2] - 13:23, 14:13
drives [1] - 93:16
drop [5] - 21:8, 35:14, 203:10, 203:14, 230:9
dropoff [1] - 120:19
dropout [18] - 42:25, 43:2, 43:5, 43:7, 43:10, 43:14, 230:11, 237:3, 237:4, 237:13, 237:14, 237:21, 238:11, 239:24, 240:5, 240:7, 240:16, 241:8
dropouts [13] - 42:12, 238:5, 238:16, 238:17, 239:3, 239:19, 239:25, 240:17, 241:4, 241:23, 241:24, 242:2, 242:3
dropped [8] - 27:9, 27:12, 42:23, 238:22, 238:24, 239:20, 240:25, 241:10
dropping [5] - 43:20, 56:21, 56:23, 141:19, 141:23
drops [2] - 45:12, 231:11
drug [75] - 34:22, 42:23, 55:11, 55:20, 75:23, 76:6, 77:13, 77:14, 77:15, 77:24, 78:8, 78:12, 81:4, 81:5, 81:12, 81:19, 81:23, 82:1, 82:5, 82:7, 82:21, 82:24, 99:18, 100:7, 100:11, 123:16, 124:12, 124:13, 159:12, 159:13, 161:20, 162:1, 162:16, 162:23, 163:2, 163:3, 163:22, 163:24, 166:15, 169:5, 169:6, 169:20, 171:22, 172:3, 173:5, 174:5, 174:13, 174:18, 174:20, 174:23, 174:24, 175:4, 175:20, 179:21, 179:22, 183:21, 185:12, 185:19, 186:1, 202:8, 202:10, 204:19, 209:2, 209:16, 211:7, 211:8, 211:11, 211:12, 212:23, 221:13, 233:5, 233:14
drugs [25] - 73:2, 73:4, 75:24, 78:4, 78:14, 99:18, 99:21, 100:2, 101:2, 159:2, 160:22, 161:7, 161:12,

<p>161:18, 165:17, 169:8, 169:12, 169:14, 169:23, 170:10, 185:14, 209:8, 209:15, 209:22, 211:4</p> <p>dry [1] - 125:22</p> <p>ductal [4] - 64:19, 181:19, 181:25, 214:14</p> <p>due [24] - 42:14, 43:5, 43:8, 43:11, 86:15, 88:2, 94:16, 95:18, 102:24, 103:1, 183:10, 202:6, 236:9, 237:14, 237:21, 240:3, 240:17, 240:18, 240:25, 241:5, 241:20, 241:23, 241:24, 242:2</p> <p>dummy [1] - 81:24</p> <p>uplicative [1] - 235:20</p> <p>during [1] - 167:25</p> <p>duty [1] - 137:24</p>	<p>211:8, 237:14</p> <p>efficacious [1] - 96:17</p> <p>efficacy [33] - 37:21, 38:7, 42:9, 45:19, 50:5, 63:23, 63:24, 73:6, 78:7, 78:8, 81:13, 107:22, 122:4, 123:16, 124:13, 140:13, 150:7, 150:22, 150:25, 151:18, 156:13, 168:11, 174:24, 176:1, 186:2, 193:24, 196:15, 208:13, 208:15, 208:17, 209:18, 211:7, 227:16</p> <p>efficient [1] - 153:24</p> <p>effort [1] - 53:9</p> <p>eight [2] - 33:20, 34:4</p> <p>either [6] - 78:7, 104:25, 106:25, 139:12, 141:4, 161:7</p> <p>elaborate [1] - 13:21</p> <p>electronic [1] - 57:16</p> <p>elmo [6] - 92:9, 92:10, 92:14, 92:15, 92:21, 92:23</p> <p>embarrassed [2] - 8:13, 8:15</p> <p>emergent [1] - 236:9</p> <p>emphasize [1] - 11:25</p> <p>employ [1] - 165:23</p> <p>employee [1] - 164:11</p> <p>employees [4] - 164:7, 164:14, 165:25, 191:20</p> <p>encouraged [5] - 77:21, 99:10, 101:19, 169:4, 195:14</p> <p>encouraging [2] - 77:23, 195:17</p> <p>end [30] - 47:7, 48:13, 53:10, 83:16, 91:19, 137:14, 138:19, 150:25, 158:3, 164:20, 169:15, 171:13, 171:25, 181:16, 182:8, 182:9, 201:16, 211:12, 213:9, 213:10, 213:13, 215:12, 223:24, 224:23, 229:7, 229:9, 230:9, 230:16, 232:15, 238:17</p> <p>ended [5] - 138:9, 159:13, 164:1, 164:16, 183:2</p> <p>endorsing [2] - 120:3, 120:5</p> <p>ends [1] - 213:8</p> <p>engineering [2] - 160:5, 160:7</p> <p>enter [3] - 179:5, 179:24, 180:2</p> <p>entered [1] - 178:8</p> <p>entire [9] - 6:10, 32:25, 62:11, 168:16, 191:14, 194:3, 194:10, 214:7, 214:9</p> <p>entitled [13] - 129:7, 137:11, 137:25, 138:5, 138:8,</p>	<p>138:11, 138:13, 139:11, 144:2, 201:18, 202:15, 205:15, 219:5</p> <p>entity [1] - 100:23</p> <p>entrepreneur [1] - 161:17</p> <p>entrepreneurial [1] - 67:14</p> <p>entry [1] - 215:17</p> <p>ER [1] - 64:15</p> <p>ER/PR [2] - 108:8, 108:10</p> <p>Eric [2] - 217:8, 239:25</p> <p>error [3] - 69:2, 238:23, 239:2</p> <p>errors [1] - 238:18</p> <p>especially [3] - 175:13, 185:18, 230:8</p> <p>essentially [2] - 77:22, 184:1</p> <p>establish [1] - 22:13</p> <p>estimate [3] - 30:14, 34:3, 212:16</p> <p>estimated [1] - 202:8</p> <p>estimates [4] - 36:25, 158:2, 213:2, 214:4</p> <p>estimating [3] - 38:10, 223:6, 224:12</p> <p>estimation [1] - 174:15</p> <p>estrogen [2] - 63:7, 63:9</p> <p>ET [2] - 1:10, 2:12</p> <p>et [21] - 13:18, 19:20, 26:13, 27:4, 27:8, 55:19, 56:25, 93:22, 94:20, 96:7, 141:24, 147:10, 160:2, 160:6, 199:10, 211:21, 216:11, 230:11</p> <p>Europe [2] - 195:22, 196:1</p> <p>evaluating [1] - 207:1</p> <p>evaluation [1] - 13:23</p> <p>evening [1] - 120:22</p> <p>evenly [1] - 166:3</p> <p>event [6] - 43:18, 43:22, 44:24, 241:13, 241:20</p> <p>events [14] - 33:1, 33:20, 34:2, 34:4, 35:16, 35:20, 35:21, 35:25, 40:18, 43:25, 56:7, 194:18, 214:10, 240:18</p> <p>eventually [1] - 222:16</p> <p>evidence [34] - 12:2, 12:16, 12:19, 31:18, 36:4, 76:5, 133:12, 144:15, 145:12, 145:14, 151:17, 156:24, 157:4, 170:4, 172:18, 172:21, 175:25, 180:16, 186:11, 186:17, 187:6, 188:3, 192:23, 197:2, 197:3, 197:5, 201:10, 205:16, 207:18, 216:23, 218:20, 227:23, 233:23</p> <p>evidentiary [1] - 31:3</p> <p>exact [11] - 39:13, 122:7, 133:6, 143:2, 143:5,</p>	<p>165:21, 174:15, 180:9, 191:17, 210:15, 213:22</p> <p>exactly [17] - 80:25, 96:10, 110:6, 131:25, 144:25, 162:13, 171:14, 177:9, 184:1, 212:15, 212:19, 218:9, 218:12, 218:13, 231:6, 231:12, 231:20</p> <p>examination [5] - 19:18, 19:19, 97:20, 116:7, 148:25</p> <p>EXAMINATION [4] - 3:4, 3:4, 31:11, 158:10</p> <p>examine [9] - 9:17, 9:18, 9:20, 18:4, 18:18, 20:6, 23:8, 23:14, 61:18</p> <p>example [4] - 10:20, 21:16, 81:12, 209:9</p> <p>examples [2] - 210:18, 227:12</p> <p>exams [1] - 35:5</p> <p>excellent [1] - 31:3</p> <p>except [2] - 19:23, 137:25</p> <p>exception [3] - 9:10, 9:19, 16:24</p> <p>exceptions [1] - 17:9</p> <p>excerpt [1] - 13:22</p> <p>Exchange [2] - 201:2, 201:3</p> <p>exchange [8] - 17:17, 28:2, 103:17, 135:6, 143:22, 211:13, 215:24, 225:18</p> <p>excited [2] - 32:19, 153:15</p> <p>excitement [1] - 185:20</p> <p>exclude [1] - 129:8</p> <p>excluded [4] - 127:10, 127:13, 133:14, 148:17</p> <p>excuse [6] - 6:20, 16:10, 26:24, 27:18, 130:10, 224:25</p> <p>exhibit [32] - 20:25, 23:7, 31:17, 49:11, 65:13, 65:14, 69:21, 70:17, 75:3, 80:5, 83:13, 86:2, 89:6, 103:3, 106:2, 108:24, 112:17, 112:20, 114:16, 114:25, 115:5, 115:6, 117:24, 118:3, 127:2, 127:7, 135:4, 151:20, 167:16, 219:4, 219:12, 219:14</p> <p>Exhibit [157] - 3:8, 3:8, 3:9, 3:9, 3:10, 3:10, 3:11, 3:11, 3:12, 3:12, 3:13, 3:13, 3:14, 3:14, 3:15, 3:15, 3:16, 3:16, 3:17, 3:17, 3:18, 3:18, 3:19, 3:19, 3:20, 3:20, 3:21, 3:21, 3:22, 3:22, 3:23, 3:23, 3:24, 3:24, 3:25, 3:25, 4:1, 4:1, 5:15, 11:18, 26:25, 31:16, 32:9, 34:13, 36:2,</p>
E			
<p>e-mail [30] - 10:1, 10:4, 10:8, 11:19, 12:24, 23:13, 54:9, 56:10, 61:4, 85:9, 88:20, 93:11, 93:13, 93:22, 104:23, 109:10, 109:14, 111:16, 117:16, 118:7, 118:9, 122:19, 127:21, 132:15, 146:5, 147:10, 152:14, 219:2, 226:23, 227:1</p> <p>e-mailed [2] - 6:3, 110:20</p> <p>e-mailing [1] - 110:22</p> <p>e-mails [3] - 6:25, 23:19, 151:6</p> <p>eager [2] - 55:18, 165:20</p> <p>early [6] - 78:14, 93:17, 101:4, 173:19, 175:14, 204:16</p> <p>early-stage [1] - 204:16</p> <p>earth [1] - 145:7</p> <p>easier [1] - 92:8</p> <p>easily [1] - 81:9</p> <p>easy [2] - 163:20, 209:14</p> <p>edit [4] - 71:23, 74:19, 95:25, 96:1</p> <p>editing [1] - 71:16</p> <p>edits [2] - 71:22</p> <p>educate [2] - 185:25, 186:9</p> <p>effect [16] - 118:24, 118:25, 162:7, 178:13, 229:15, 229:19, 229:20, 231:2, 231:13, 231:16, 232:25, 233:10, 233:17, 240:4, 242:1</p> <p>effective [4] - 81:6, 148:4, 204:21, 206:22</p> <p>effectively [1] - 234:10</p> <p>effects [4] - 186:4, 209:18,</p>	<p>211:8, 237:14</p> <p>efficacious [1] - 96:17</p> <p>efficacy [33] - 37:21, 38:7, 42:9, 45:19, 50:5, 63:23, 63:24, 73:6, 78:7, 78:8, 81:13, 107:22, 122:4, 123:16, 124:13, 140:13, 150:7, 150:22, 150:25, 151:18, 156:13, 168:11, 174:24, 176:1, 186:2, 193:24, 196:15, 208:13, 208:15, 208:17, 209:18, 211:7, 227:16</p> <p>efficient [1] - 153:24</p> <p>effort [1] - 53:9</p> <p>eight [2] - 33:20, 34:4</p> <p>either [6] - 78:7, 104:25, 106:25, 139:12, 141:4, 161:7</p> <p>elaborate [1] - 13:21</p> <p>electronic [1] - 57:16</p> <p>elmo [6] - 92:9, 92:10, 92:14, 92:15, 92:21, 92:23</p> <p>embarrassed [2] - 8:13, 8:15</p> <p>emergent [1] - 236:9</p> <p>emphasize [1] - 11:25</p> <p>employ [1] - 165:23</p> <p>employee [1] - 164:11</p> <p>employees [4] - 164:7, 164:14, 165:25, 191:20</p> <p>encouraged [5] - 77:21, 99:10, 101:19, 169:4, 195:14</p> <p>encouraging [2] - 77:23, 195:17</p> <p>end [30] - 47:7, 48:13, 53:10, 83:16, 91:19, 137:14, 138:19, 150:25, 158:3, 164:20, 169:15, 171:13, 171:25, 181:16, 182:8, 182:9, 201:16, 211:12, 213:9, 213:10, 213:13, 215:12, 223:24, 224:23, 229:7, 229:9, 230:9, 230:16, 232:15, 238:17</p> <p>ended [5] - 138:9, 159:13, 164:1, 164:16, 183:2</p> <p>endorsing [2] - 120:3, 120:5</p> <p>ends [1] - 213:8</p> <p>engineering [2] - 160:5, 160:7</p> <p>enter [3] - 179:5, 179:24, 180:2</p> <p>entered [1] - 178:8</p> <p>entire [9] - 6:10, 32:25, 62:11, 168:16, 191:14, 194:3, 194:10, 214:7, 214:9</p> <p>entitled [13] - 129:7, 137:11, 137:25, 138:5, 138:8,</p>	<p>138:11, 138:13, 139:11, 144:2, 201:18, 202:15, 205:15, 219:5</p> <p>entity [1] - 100:23</p> <p>entrepreneur [1] - 161:17</p> <p>entrepreneurial [1] - 67:14</p> <p>entry [1] - 215:17</p> <p>ER [1] - 64:15</p> <p>ER/PR [2] - 108:8, 108:10</p> <p>Eric [2] - 217:8, 239:25</p> <p>error [3] - 69:2, 238:23, 239:2</p> <p>errors [1] - 238:18</p> <p>especially [3] - 175:13, 185:18, 230:8</p> <p>essentially [2] - 77:22, 184:1</p> <p>establish [1] - 22:13</p> <p>estimate [3] - 30:14, 34:3, 212:16</p> <p>estimated [1] - 202:8</p> <p>estimates [4] - 36:25, 158:2, 213:2, 214:4</p> <p>estimating [3] - 38:10, 223:6, 224:12</p> <p>estimation [1] - 174:15</p> <p>estrogen [2] - 63:7, 63:9</p> <p>ET [2] - 1:10, 2:12</p> <p>et [21] - 13:18, 19:20, 26:13, 27:4, 27:8, 55:19, 56:25, 93:22, 94:20, 96:7, 141:24, 147:10, 160:2, 160:6, 199:10, 211:21, 216:11, 230:11</p> <p>Europe [2] - 195:22, 196:1</p> <p>evaluating [1] - 207:1</p> <p>evaluation [1] - 13:23</p> <p>evening [1] - 120:22</p> <p>evenly [1] - 166:3</p> <p>event [6] - 43:18, 43:22, 44:24, 241:13, 241:20</p> <p>events [14] - 33:1, 33:20, 34:2, 34:4, 35:16, 35:20, 35:21, 35:25, 40:18, 43:25, 56:7, 194:18, 214:10, 240:18</p> <p>eventually [1] - 222:16</p> <p>evidence [34] - 12:2, 12:16, 12:19, 31:18, 36:4, 76:5, 133:12, 144:15, 145:12, 145:14, 151:17, 156:24, 157:4, 170:4, 172:18, 172:21, 175:25, 180:16, 186:11, 186:17, 187:6, 188:3, 192:23, 197:2, 197:3, 197:5, 201:10, 205:16, 207:18, 216:23, 218:20, 227:23, 233:23</p> <p>evidentiary [1] - 31:3</p> <p>exact [11] - 39:13, 122:7, 133:6, 143:2, 143:5,</p>	<p>165:21, 174:15, 180:9, 191:17, 210:15, 213:22</p> <p>exactly [17] - 80:25, 96:10, 110:6, 131:25, 144:25, 162:13, 171:14, 177:9, 184:1, 212:15, 212:19, 218:9, 218:12, 218:13, 231:6, 231:12, 231:20</p> <p>examination [5] - 19:18, 19:19, 97:20, 116:7, 148:25</p> <p>EXAMINATION [4] - 3:4, 3:4, 31:11, 158:10</p> <p>examine [9] - 9:17, 9:18, 9:20, 18:4, 18:18, 20:6, 23:8, 23:14, 61:18</p> <p>example [4] - 10:20, 21:16, 81:12, 209:9</p> <p>examples [2] - 210:18, 227:12</p> <p>exams [1] - 35:5</p> <p>excellent [1] - 31:3</p> <p>except [2] - 19:23, 137:25</p> <p>exception [3] - 9:10, 9:19, 16:24</p> <p>exceptions [1] - 17:9</p> <p>excerpt [1] - 13:22</p> <p>Exchange [2] - 201:2, 201:3</p> <p>exchange [8] - 17:17, 28:2, 103:17, 135:6, 143:22, 211:13, 215:24, 225:18</p> <p>excited [2] - 32:19, 153:15</p> <p>excitement [1] - 185:20</p> <p>exclude [1] - 129:8</p> <p>excluded [4] - 127:10, 127:13, 133:14, 148:17</p> <p>excuse [6] - 6:20, 16:10, 26:24, 27:18, 130:10, 224:25</p> <p>exhibit [32] - 20:25, 23:7, 31:17, 49:11, 65:13, 65:14, 69:21, 70:17, 75:3, 80:5, 83:13, 86:2, 89:6, 103:3, 106:2, 108:24, 112:17, 112:20, 114:16, 114:25, 115:5, 115:6, 117:24, 118:3, 127:2, 127:7, 135:4, 151:20, 167:16, 219:4, 219:12, 219:14</p> <p>Exhibit [157] - 3:8, 3:8, 3:9, 3:9, 3:10, 3:10, 3:11, 3:11, 3:12, 3:12, 3:13, 3:13, 3:14, 3:14, 3:15, 3:15, 3:16, 3:16, 3:17, 3:17, 3:18, 3:18, 3:19, 3:19, 3:20, 3:20, 3:21, 3:21, 3:22, 3:22, 3:23, 3:23, 3:24, 3:24, 3:25, 3:25, 4:1, 4:1, 5:15, 11:18, 26:25, 31:16, 32:9, 34:13, 36:2,</p>

<p>36:6, 39:23, 40:2, 44:9, 44:14, 44:22, 47:15, 47:19, 51:7, 51:12, 52:9, 53:13, 60:11, 60:16, 60:19, 62:24, 65:13, 65:23, 69:22, 70:3, 70:18, 71:1, 71:7, 74:7, 74:12, 75:2, 75:7, 80:5, 80:11, 83:14, 83:25, 84:23, 85:2, 85:25, 86:6, 86:24, 87:17, 89:5, 89:6, 97:25, 98:16, 101:21, 102:4, 102:8, 103:4, 103:8, 106:3, 107:15, 109:3, 111:6, 111:10, 112:18, 112:24, 114:16, 115:2, 121:10, 121:12, 121:16, 122:11, 122:17, 127:21, 146:4, 149:18, 150:1, 150:4, 150:24, 151:16, 152:8, 154:25, 157:9, 157:11, 167:5, 167:13, 170:1, 170:7, 170:20, 172:15, 172:18, 175:25, 177:22, 180:16, 186:10, 187:6, 187:7, 187:25, 188:3, 188:5, 193:2, 196:25, 197:8, 199:17, 200:9, 201:7, 201:13, 203:21, 205:14, 205:15, 205:19, 207:17, 207:21, 216:22, 218:19, 218:24, 218:25, 227:23, 233:22, 233:24, 236:6, 237:3, 239:6</p> <p>exhibits [8] - 3:7, 5:8, 5:10, 5:11, 5:14, 8:24, 208:18, 219:16</p> <p>exist [4] - 6:4, 6:7, 8:6, 57:7</p> <p>existed [4] - 67:9, 176:18, 177:18, 204:14</p> <p>existing [3] - 56:5, 177:21, 234:16</p> <p>expand [3] - 29:2, 121:5, 121:6</p> <p>expect [4] - 6:5, 158:4, 203:15, 241:5</p> <p>expectation [1] - 224:14</p> <p>expectations [3] - 113:14, 113:19, 223:24</p> <p>expedite [4] - 73:4, 73:11, 100:24, 115:21</p> <p>expedited [6] - 99:12, 99:14, 100:7, 100:11, 100:17, 170:10</p> <p>expenses [2] - 202:7, 203:18</p> <p>experience [5] - 159:17, 160:19, 165:16, 209:1, 227:15</p> <p>experienced [2] - 163:23, 228:23</p> <p>experiences [1] - 160:18</p>	<p>expert [1] - 221:3</p> <p>expertise [1] - 105:21</p> <p>explain [28] - 6:9, 37:23, 46:20, 50:24, 80:23, 130:1, 130:3, 133:1, 135:5, 135:23, 138:23, 146:6, 146:12, 152:17, 156:10, 161:1, 203:24, 214:24, 216:2, 226:11, 229:15, 233:21, 234:5, 236:13, 237:25, 239:12, 241:7</p> <p>explained [2] - 160:25, 168:17</p> <p>explaining [1] - 8:7</p> <p>explains [5] - 8:17, 135:2, 135:3, 135:7, 135:8</p> <p>explanation [4] - 18:11, 26:12, 134:21, 140:11</p> <p>expound [1] - 158:15</p> <p>express [1] - 216:8</p> <p>extended [1] - 182:12</p> <p>ExteNET [70] - 39:4, 54:10, 55:9, 55:15, 58:19, 72:7, 73:3, 75:15, 78:18, 83:3, 84:10, 85:14, 90:19, 96:16, 103:23, 104:7, 104:13, 104:16, 105:5, 105:11, 122:22, 123:5, 123:17, 124:7, 124:8, 124:21, 129:16, 147:16, 174:9, 174:10, 174:11, 175:10, 175:12, 175:24, 176:2, 176:7, 178:8, 178:23, 179:2, 180:13, 180:20, 180:21, 182:11, 182:20, 185:7, 187:10, 188:10, 188:15, 189:18, 191:7, 192:17, 193:4, 197:1, 199:13, 199:22, 203:19, 207:8, 210:1, 210:6, 215:6, 217:13, 219:6, 220:10, 221:2, 221:7, 231:1, 232:23, 235:17, 236:6</p> <p>extensive [3] - 149:25, 150:18, 156:12</p> <p>extensively [1] - 203:23</p> <p>extent [3] - 10:4, 39:19, 97:18</p> <p>external [1] - 226:19</p> <p>extra [2] - 53:4, 53:9</p> <p>extraordinarily [1] - 123:6</p> <p>extrapolating [1] - 38:20</p> <p>extrapolation [1] - 36:20</p> <p>extremely [7] - 6:1, 109:24, 153:14, 156:15, 161:4, 175:17, 184:7</p>	<p>103:18, 103:22, 141:22</p> <p>face-to-face [4] - 56:22, 57:8, 103:22, 141:22</p> <p>facilities [2] - 163:12, 163:19</p> <p>fact [8] - 17:4, 25:12, 120:6, 129:14, 135:8, 145:15, 147:20, 162:7</p> <p>factor [6] - 183:19, 183:24, 183:25, 202:1, 202:3, 202:14</p> <p>factors [7] - 33:12, 183:11, 183:16, 201:19, 202:13, 202:19, 203:22</p> <p>facts [1] - 16:23</p> <p>failed [3] - 169:10, 221:12, 221:17</p> <p>failure [4] - 100:3, 169:13, 185:14, 185:16</p> <p>fair [2] - 133:15, 184:2</p> <p>fall [1] - 210:6</p> <p>falloff [1] - 120:19</p> <p>false [6] - 138:2, 142:4, 142:6, 147:2, 178:12, 178:15</p> <p>falsity [1] - 13:4</p> <p>families [3] - 159:7, 159:10, 161:19</p> <p>family [4] - 159:8, 161:5, 164:7</p> <p>far [9] - 40:12, 53:18, 79:1, 79:6, 79:12, 79:24, 119:25, 164:25, 171:13</p> <p>fashion [1] - 153:20</p> <p>fast [5] - 29:22, 107:12, 113:17, 169:12, 172:9</p> <p>fast-track [1] - 169:12</p> <p>father [3] - 159:4, 159:9, 161:3</p> <p>fault [2] - 53:12, 230:18</p> <p>favor [1] - 18:13</p> <p>FDA [66] - 71:12, 72:8, 72:16, 72:25, 73:14, 74:16, 75:17, 76:2, 76:9, 77:12, 77:21, 77:24, 81:3, 82:23, 82:25, 83:16, 84:15, 85:6, 86:18, 88:12, 88:19, 88:22, 93:20, 94:19, 95:12, 95:20, 95:23, 95:25, 96:11, 96:25, 97:9, 98:20, 98:23, 99:3, 99:8, 99:9, 99:21, 99:23, 100:11, 100:16, 100:19, 100:24, 101:17, 101:18, 103:17, 105:22, 140:16, 153:16, 154:13, 154:19, 164:20, 167:9, 167:10, 167:19, 167:20, 168:4, 169:15, 169:21, 171:20, 172:4, 173:4, 173:9, 195:18, 195:20, 196:1</p> <p>FDA's [7] - 84:3, 84:20, 85:5,</p>	<p>85:18, 169:25, 173:11, 173:16</p> <p>February [5] - 93:17, 94:2, 106:25, 188:14</p> <p>FEE [1] - 243:5</p> <p>feedback [2] - 104:12, 195:14</p> <p>FEES [1] - 243:5</p> <p>fell [3] - 35:6, 114:7, 210:10</p> <p>fellowship [1] - 160:5</p> <p>fellowships [1] - 160:2</p> <p>felt [7] - 68:15, 68:19, 73:17, 120:24, 124:7, 187:19, 213:14</p> <p>Feuerstein [1] - 111:14</p> <p>few [12] - 8:8, 34:25, 49:8, 71:21, 125:4, 142:15, 158:14, 194:17, 194:22, 202:23, 209:12, 217:16</p> <p>field [2] - 166:1, 166:2</p> <p>fifth [2] - 89:22, 89:23</p> <p>figure [5] - 30:12, 53:10, 59:24, 152:5, 228:18</p> <p>figured [1] - 101:6</p> <p>file [12] - 77:23, 82:23, 94:11, 97:8, 99:10, 168:2, 169:4, 171:15, 173:15, 182:11, 200:21</p> <p>filed [3] - 171:23, 201:1, 201:8</p> <p>files [1] - 67:15</p> <p>filing [5] - 77:12, 169:15, 173:14, 195:25, 196:1</p> <p>filling [1] - 188:9</p> <p>final [4] - 27:23, 76:23, 156:10, 240:5</p> <p>finally [2] - 64:14, 214:21</p> <p>finance [2] - 200:17, 200:19</p> <p>financials [1] - 201:4</p> <p>financing [1] - 95:21</p> <p>fine [5] - 15:20, 20:22, 24:4, 41:8, 210:22</p> <p>finish [7] - 79:9, 79:15, 97:15, 107:17, 140:17, 144:9, 154:10</p> <p>finished [1] - 143:13</p> <p>firm [1] - 86:10</p> <p>first [118] - 5:7, 5:20, 9:10, 11:5, 11:16, 13:9, 24:21, 32:19, 37:22, 38:10, 39:7, 39:15, 42:14, 44:21, 44:22, 45:10, 54:12, 54:16, 54:17, 59:9, 63:12, 63:14, 64:24, 73:15, 79:25, 84:2, 89:12, 91:6, 93:18, 94:17, 99:2, 108:10, 115:4, 115:6, 116:5, 116:10, 118:12, 118:24, 118:25, 120:21, 122:25, 125:4, 129:24, 133:7, 146:18, 148:14,</p>
		F	
		face [10] - 56:22, 57:8,	

<p>159:11, 160:8, 161:20, 162:17, 171:18, 171:20, 173:1, 173:23, 174:7, 174:25, 182:13, 188:7, 191:8, 193:3, 195:3, 197:9, 198:2, 200:9, 203:25, 204:5, 204:7, 205:14, 207:23, 208:14, 209:10, 212:14, 215:2, 217:12, 219:3, 220:2, 221:4, 221:13, 221:18, 228:10, 229:15, 229:19, 229:20, 229:21, 230:3, 230:7, 230:12, 230:14, 231:2, 231:3, 231:5, 231:13, 231:16, 231:20, 231:22, 231:23, 232:13, 232:20, 233:4, 233:5, 233:7, 233:10, 233:11, 233:12, 233:15, 234:1, 234:9, 234:12, 234:14, 234:18, 235:24, 236:20</p> <p>first-cycle [10] - 229:15, 229:19, 229:20, 230:12, 231:2, 231:13, 231:16, 232:13, 233:10</p> <p>five [18] - 52:6, 53:8, 53:9, 53:13, 54:1, 55:19, 132:8, 136:17, 156:7, 156:8, 175:2, 175:6, 227:24, 237:20, 240:2, 241:1, 241:21, 242:5</p> <p>five-page [4] - 53:8, 53:9, 53:13, 54:1</p> <p>flash [9] - 93:9, 93:14, 93:16, 93:24, 94:2, 94:4, 94:9, 94:10</p> <p>flashing [1] - 142:20</p> <p>flew [6] - 55:14, 57:12, 57:15, 140:3, 140:14, 141:9</p> <p>flip [32] - 34:6, 36:24, 37:18, 39:22, 44:9, 44:21, 45:23, 47:14, 48:5, 48:10, 48:22, 49:24, 54:16, 63:13, 63:18, 64:7, 64:14, 70:10, 74:18, 75:2, 83:5, 83:13, 84:2, 89:12, 90:17, 91:19, 102:15, 121:10, 122:11, 150:25</p> <p>fly [1] - 191:13</p> <p>focus [4] - 5:7, 23:23, 33:8, 215:23</p> <p>focusing [1] - 214:25</p> <p>folder [1] - 146:15</p> <p>folks [5] - 25:18, 27:20, 30:25, 67:23, 148:22</p> <p>follow [9] - 14:11, 35:1, 44:3, 80:23, 102:13, 141:5, 155:19, 156:11, 158:15</p> <p>follow-on [1] - 102:13</p>	<p>follow-up [7] - 14:11, 35:1, 44:3, 80:23, 141:5, 155:19, 156:11</p> <p>followed [4] - 59:24, 176:12, 176:15, 176:17</p> <p>following [4] - 98:18, 103:16, 235:8, 236:9</p> <p>FOR [1] - 243:5</p> <p>force [2] - 163:13, 166:1</p> <p>FOREGOING [1] - 243:2</p> <p>forest [4] - 61:17, 65:5, 84:12, 90:24</p> <p>FORGE [15] - 2:3, 49:14, 49:18, 52:4, 52:7, 52:10, 53:16, 53:21, 92:3, 92:6, 92:10, 115:13, 115:16, 115:20, 186:14</p> <p>forgive [1] - 16:18</p> <p>form [6] - 57:21, 148:14, 188:1, 188:9, 200:22, 201:8</p> <p>formal [8] - 33:23, 77:12, 80:15, 99:4, 101:12, 150:17, 169:15, 173:4</p> <p>format [1] - 176:24</p> <p>former [1] - 158:25</p> <p>forth [1] - 110:11</p> <p>fortunate [1] - 160:1</p> <p>fortune [1] - 185:18</p> <p>forum [4] - 189:5, 195:7, 210:17</p> <p>forward [7] - 162:22, 163:1, 175:7, 183:15, 187:21, 194:17</p> <p>forward-looking [1] - 183:15</p> <p>foundation [2] - 10:14, 114:17</p> <p>founded [4] - 158:20, 159:11, 159:17, 161:20</p> <p>four [26] - 5:18, 16:20, 16:21, 17:3, 17:4, 55:19, 70:24, 112:4, 113:21, 114:2, 114:5, 125:11, 126:3, 126:7, 126:21, 127:14, 127:16, 147:6, 204:22, 204:24, 205:13, 205:25, 211:24, 222:24, 228:6, 242:12</p> <p>four-day [1] - 242:12</p> <p>FOURTH [1] - 1:23</p> <p>fourth [5] - 67:9, 89:19, 131:19, 205:7, 206:25</p> <p>frame [3] - 38:23, 209:6, 221:10</p> <p>Francisco [1] - 62:10</p> <p>free [17] - 15:19, 21:13, 22:3, 127:23, 147:14, 147:24, 174:5, 181:3, 181:18, 192:7, 206:9, 206:14, 208:17, 210:7, 220:24,</p>	<p>222:24, 225:2</p> <p>frequency [3] - 229:22, 229:24, 230:2</p> <p>frequent [1] - 194:18</p> <p>Friday [2] - 88:13, 164:18</p> <p>friend [1] - 21:6</p> <p>friendly [2] - 209:14, 209:22</p> <p>front [8] - 76:9, 127:7, 147:6, 151:20, 167:4, 170:2, 183:6, 230:20</p> <p>full [6] - 131:25, 132:3, 160:6, 182:17, 192:16, 220:13</p> <p>fully [3] - 17:1, 50:2, 130:3</p> <p>fun [1] - 92:17</p> <p>funds [1] - 222:2</p> <p>future [5] - 56:6, 102:19, 182:18, 182:20, 203:2</p>	<p>236:3</p> <p>grade-three [16] - 123:5, 123:11, 124:6, 228:22, 228:23, 230:8, 230:12, 230:21, 231:9, 232:13, 232:19, 233:18, 234:23, 234:24, 234:25, 236:3</p> <p>grades [1] - 228:5</p> <p>graduate [1] - 160:3</p> <p>graduated [1] - 160:8</p> <p>granted [2] - 33:17, 133:20</p> <p>granting [2] - 9:14, 135:14</p> <p>grants [1] - 160:2</p> <p>grasp [1] - 17:1</p> <p>Gray [1] - 138:14</p> <p>great [5] - 6:18, 55:12, 165:18, 173:24, 185:19</p> <p>greater [2] - 73:7, 194:19</p> <p>greatest [1] - 159:14</p> <p>green [4] - 231:9, 231:10, 232:12, 232:14</p> <p>GRONBORG [2] - 2:3, 5:5</p> <p>gross [9] - 17:18, 17:20, 116:6, 116:7, 116:14, 118:4, 119:1, 120:19, 120:21</p> <p>Gross [8] - 11:19, 17:21, 17:22, 17:23, 18:9, 18:13, 18:14, 114:20</p> <p>Gross's [2] - 18:11, 114:21</p> <p>ground [1] - 46:9</p> <p>grounds [3] - 146:17, 146:18, 146:21</p> <p>group [15] - 73:16, 77:21, 90:12, 101:5, 108:1, 108:3, 108:10, 173:9, 175:13, 178:2, 182:24, 186:9, 187:11, 190:23, 227:6</p> <p>Group [1] - 161:25</p> <p>groups [3] - 109:22, 184:16, 214:25</p> <p>grow [3] - 55:25, 159:20, 175:18</p> <p>growing [1] - 166:20</p> <p>guarantee [2] - 101:8, 163:24</p> <p>guess [9] - 15:16, 21:21, 32:19, 76:16, 80:1, 135:22, 180:11, 194:14, 199:4</p> <p>guessing [1] - 232:16</p> <p>guidance [7] - 114:5, 169:25, 170:9, 171:4, 171:5, 173:11, 213:15</p> <p>guiding [4] - 224:14, 224:20, 225:21, 241:22</p> <p>GUILFORD [1] - 1:3</p> <p>guy [2] - 23:8, 211:18</p>
G			
<p>Gail [1] - 161:24</p> <p>gain [1] - 160:18</p> <p>gambling [1] - 41:1</p> <p>gears [1] - 29:5</p> <p>gee [1] - 139:3</p> <p>GELLER [1] - 2:5</p> <p>gene [6] - 166:12, 178:7, 178:17, 178:22, 178:25, 179:9</p> <p>general [2] - 203:10, 213:2</p> <p>generalities [2] - 7:7, 210:23</p> <p>generally [4] - 38:7, 184:5, 184:17, 216:25</p> <p>generate [1] - 216:15</p> <p>generic [1] - 107:4</p> <p>genetic [1] - 69:11</p> <p>gentleman [1] - 56:8</p> <p>GI [1] - 229:25</p> <p>giant [1] - 185:2</p> <p>girl's [1] - 205:9</p> <p>given [10] - 20:22, 36:21, 73:19, 115:18, 144:1, 152:1, 155:12, 212:8, 214:3, 216:1</p> <p>goal [8] - 38:4, 55:20, 100:13, 158:20, 158:21, 163:21, 211:4, 212:24</p> <p>Gordon [1] - 21:17</p> <p>gosh [4] - 9:15, 9:20, 30:11, 144:9</p> <p>gotta [1] - 79:14</p> <p>grade [24] - 33:12, 123:5, 123:11, 124:6, 228:8, 228:22, 228:23, 229:3, 229:4, 230:8, 230:12, 230:21, 231:8, 231:9, 232:3, 232:7, 232:8, 232:13, 232:19, 233:18, 234:23, 234:24, 234:25,</p>			

H			
<p>H-E-R-A ^[1] - 205:6</p> <p>half ^[5] - 162:2, 182:13, 190:2, 206:6, 242:3</p> <p>hand ^[4] - 26:20, 126:15, 206:8, 209:4</p> <p>handing ^[1] - 26:25</p> <p>hands ^[1] - 163:22</p> <p>hang ^[3] - 41:21, 68:9, 68:10</p> <p>happy ^[5] - 96:12, 145:19, 154:6, 154:12, 175:8</p> <p>Happy ^[1] - 88:10</p> <p>hard ^[4] - 104:20, 150:18, 156:17, 188:6</p> <p>hardest ^[1] - 233:13</p> <p>harm ^[1] - 186:4</p> <p>harmful ^[1] - 129:8</p> <p>Harvard ^[4] - 222:8, 222:13, 224:24, 225:11</p> <p>hazard ^[38] - 36:13, 36:18, 36:20, 36:25, 37:4, 37:9, 37:12, 38:5, 38:9, 38:12, 45:9, 45:16, 45:20, 46:1, 46:5, 46:6, 46:10, 46:12, 46:15, 47:7, 47:24, 56:6, 64:8, 64:11, 78:20, 108:1, 108:10, 110:2, 168:24, 169:1, 181:8, 182:5, 216:6, 216:13, 221:3, 221:7, 225:1</p> <p>head ^[11] - 32:15, 36:9, 122:21, 122:23, 168:12, 173:8, 185:21, 191:18, 192:8, 192:9</p> <p>head-to-head ^[1] - 168:12</p> <p>headed ^[2] - 66:7, 66:8</p> <p>healthcare ^[1] - 86:9</p> <p>hear ^[13] - 7:6, 19:4, 87:3, 115:14, 137:14, 143:10, 154:24, 195:17, 196:5, 196:11, 196:16, 196:19, 197:13</p> <p>heard ^[8] - 77:20, 139:19, 155:9, 166:15, 178:2, 182:19, 195:15, 196:21</p> <p>hearing ^[3] - 7:6, 27:15, 132:8</p> <p>hearsay ^[28] - 9:7, 9:8, 9:10, 9:14, 9:25, 10:14, 10:15, 10:17, 10:20, 10:23, 11:14, 12:3, 16:7, 16:16, 16:24, 17:6, 17:7, 17:9, 18:1, 25:11, 114:18, 116:2, 116:6, 116:11, 116:12, 116:24, 120:16</p> <p>heart ^[1] - 147:14</p> <p>held ^[1] - 199:7</p> <p>help ^[12] - 30:1, 142:18, 158:22, 159:6, 159:7,</p>	<p>159:9, 159:10, 161:19, 185:23, 191:1, 211:4, 226:3</p> <p>helped ^[1] - 191:2</p> <p>helpful ^[2] - 27:21, 125:5</p> <p>helping ^[2] - 148:14, 191:24</p> <p>helps ^[2] - 138:16, 185:19</p> <p>hence ^[1] - 113:21</p> <p>HER2 ^[11] - 70:11, 108:9, 166:12, 178:7, 178:17, 178:22, 178:25, 208:10, 210:9, 215:16, 218:14</p> <p>HER2-positive ^[11] - 166:10, 166:11, 175:14, 178:6, 178:13, 178:17, 179:3, 179:7, 179:9, 204:16, 208:6</p> <p>HERA ^[5] - 205:6, 206:1, 206:14, 206:16, 209:5</p> <p>Herceptin ^[27] - 166:16, 179:22, 204:11, 204:13, 204:19, 204:21, 204:22, 205:15, 207:7, 207:24, 208:8, 208:19, 208:21, 208:23, 208:24, 209:3, 210:2, 210:5, 215:3, 215:5, 215:11, 215:15, 221:8, 221:9, 221:11</p> <p>Herceptin's ^[1] - 221:4</p> <p>HEREBY ^[1] - 243:2</p> <p>Hi ^[1] - 98:22</p> <p>Hicks ^[29] - 87:19, 87:20, 89:8, 89:25, 90:14, 90:19, 91:7, 93:20, 93:23, 94:7, 94:8, 94:16, 94:18, 95:13, 96:9, 98:18, 101:10, 101:15, 102:24, 103:16, 103:20, 104:8, 104:20, 105:5, 105:6, 105:10, 105:14, 154:18</p> <p>hidden ^[2] - 144:5</p> <p>hiding ^[4] - 140:16, 140:17, 140:18, 143:24</p> <p>HIGH ^[1] - 2:14</p> <p>high ^[29] - 8:22, 63:19, 68:17, 68:18, 69:2, 100:3, 119:20, 120:3, 123:6, 151:9, 151:14, 169:13, 178:11, 185:13, 202:7, 208:5, 212:2, 213:6, 213:9, 213:13, 228:18, 228:20, 229:5, 229:6, 230:2, 231:14, 232:16, 233:14, 233:15</p> <p>high-risk ^[1] - 208:5</p> <p>higher ^[7] - 40:24, 47:8, 218:13, 225:22, 227:19, 228:22, 228:23</p> <p>highest ^[11] - 153:18, 184:14, 184:24, 199:1,</p>	<p>199:5, 228:6, 229:22, 231:3, 231:10, 240:4</p> <p>highlight ^[1] - 231:19</p> <p>highlighted ^[4] - 77:16, 113:10, 171:12, 183:8</p> <p>himself ^[4] - 23:13, 127:21, 140:19, 146:5</p> <p>hinting ^[1] - 124:18</p> <p>hire ^[1] - 163:16</p> <p>historically ^[1] - 240:25</p> <p>history ^[2] - 159:14, 162:24</p> <p>hit ^[2] - 92:20, 114:9</p> <p>hits ^[1] - 166:21</p> <p>Ho ^[1] - 56:9</p> <p>Hodgkins ^[2] - 81:15, 81:17</p> <p>hogwash ^[3] - 137:3, 137:5, 138:10</p> <p>Hold ^[2] - 107:10</p> <p>hold ^[16] - 29:5, 29:18, 92:3, 92:6, 106:15, 113:16, 117:10, 118:13, 119:9, 128:14, 143:13, 185:1, 186:8, 197:21, 235:8, 236:9</p> <p>holding ^[1] - 135:10</p> <p>home ^[1] - 217:13</p> <p>Honor ^[121] - 5:4, 5:13, 11:17, 11:24, 12:7, 12:12, 13:12, 13:25, 14:14, 14:21, 15:21, 15:25, 16:6, 17:6, 17:17, 17:22, 19:3, 20:1, 20:11, 20:18, 20:22, 21:3, 21:15, 21:25, 22:6, 22:14, 23:3, 23:12, 24:4, 24:14, 24:24, 25:3, 26:2, 26:16, 27:14, 28:6, 29:3, 29:8, 29:17, 29:20, 30:16, 31:9, 32:5, 32:10, 34:11, 36:4, 39:24, 49:14, 51:21, 52:4, 52:7, 52:21, 53:15, 53:16, 60:15, 62:22, 65:17, 67:24, 69:24, 70:22, 71:2, 73:22, 74:8, 79:8, 80:6, 86:2, 87:4, 87:16, 97:13, 102:6, 103:5, 106:8, 109:1, 114:17, 114:18, 115:13, 115:25, 116:4, 116:8, 116:22, 117:7, 119:3, 120:16, 121:13, 122:13, 125:15, 127:1, 127:3, 128:3, 128:18, 129:1, 137:21, 141:2, 141:7, 141:8, 142:7, 142:19, 144:17, 144:25, 145:9, 147:13, 148:2, 148:8, 150:2, 156:20, 156:22, 156:24, 164:24, 170:18, 170:25, 172:17, 186:13, 186:15, 190:15, 197:6, 207:17, 207:19, 223:8,</p>	<p>242:8, 242:19</p> <p>Honor's ^[1] - 134:3</p> <p>HONORABLE ^[1] - 1:3</p> <p>hope ^[4] - 10:10, 23:22, 26:19, 29:18</p> <p>hopefully ^[2] - 186:2, 222:7</p> <p>hoping ^[2] - 31:6, 82:23</p> <p>hormone ^[4] - 61:18, 63:10, 63:24, 108:7</p> <p>hormone-receptor ^[4] - 61:18, 63:10, 63:24, 108:7</p> <p>hour ^[3] - 5:7, 31:2, 190:2</p> <p>hours ^[1] - 114:13</p> <p>house ^[2] - 109:23, 166:2</p> <p>Howard ^[4] - 109:8, 155:19, 156:11, 215:9</p> <p>HR ^[13] - 33:11, 61:1, 63:3, 63:7, 63:8, 63:18, 63:20, 109:11, 110:13, 110:17, 110:18</p> <p>HR-2 ^[1] - 111:24</p> <p>HR-plus ^[2] - 109:11, 110:13</p> <p>HR2 ^[1] - 33:12</p> <p>HSINGCHING ^[2] - 1:4, 2:3</p> <p>HSU ^[2] - 1:4, 2:3</p> <p>huge ^[2] - 151:7, 163:19</p> <p>human ^[1] - 171:21</p> <p>humans ^[4] - 81:9, 81:20, 82:6, 171:22</p> <p>hundred ^[4] - 104:14, 175:6, 176:14, 238:21</p> <p>hundreds ^[2] - 185:1, 186:8</p> <p>hurting ^[1] - 211:12</p> <p>hurts ^[1] - 9:16</p> <p>hustle ^[1] - 31:24</p>
			<p>I</p> <p>idea ^[9] - 161:15, 162:15, 162:16, 163:17, 198:20, 204:20, 233:7, 234:11, 234:16</p> <p>ideal ^[1] - 187:20</p> <p>ideally ^[3] - 73:1, 171:13, 171:15</p> <p>identification ^[5] - 3:23, 170:1, 170:9, 170:22, 187:7</p> <p>identify ^[1] - 146:1</p> <p>II ^[18] - 73:4, 78:5, 78:6, 78:12, 78:17, 78:19, 99:18, 168:10, 168:15, 168:18, 168:20, 169:9, 169:23, 171:13, 171:16, 172:1, 172:7</p> <p>III ^[26] - 73:2, 73:3, 73:8, 76:4, 78:5, 78:7, 78:12, 78:13, 99:19, 99:22, 100:15, 153:15, 163:10, 168:11, 168:16, 168:18,</p>

<p>168:21, 168:23, 169:10, 171:17, 172:3, 172:11, 180:20, 185:12, 185:17, 207:1</p> <p>ills [2] - 73:5, 163:10</p> <p>imagine [3] - 185:18, 212:5, 238:23</p> <p>immediately [1] - 159:17</p> <p>Imodium [7] - 123:18, 123:22, 233:7, 233:9, 234:6, 234:8, 235:24</p> <p>impact [3] - 100:18, 169:7, 175:5</p> <p>impacted [1] - 164:16</p> <p>impeach [1] - 140:23</p> <p>impeachment [10] - 117:22, 126:4, 126:8, 126:16, 126:22, 126:25, 128:1, 128:8, 148:4, 148:17</p> <p>implicate [5] - 130:4, 135:13, 135:20, 145:4, 147:21</p> <p>implicated [1] - 135:17</p> <p>implicates [4] - 129:22, 130:7, 131:7, 131:11</p> <p>implication [11] - 36:19, 77:11, 134:3, 134:5, 135:10, 138:2, 147:2, 172:3, 173:12, 173:14, 173:16</p> <p>implications [5] - 77:17, 144:15, 144:16, 144:18, 173:3</p> <p>implied [4] - 155:10, 155:19, 156:1, 156:13</p> <p>implies [1] - 156:5</p> <p>imply [2] - 82:5, 192:2</p> <p>important [21] - 6:21, 7:7, 9:3, 12:4, 12:20, 17:3, 17:4, 94:13, 95:16, 104:11, 123:15, 133:22, 142:20, 158:23, 175:10, 175:12, 175:22, 177:5, 180:2, 211:5, 239:3</p> <p>importantly [1] - 218:6</p> <p>impossibly [1] - 143:7</p> <p>impressed [1] - 110:9</p> <p>improper [1] - 135:9</p> <p>improperly [1] - 138:3</p> <p>improve [2] - 221:11, 221:14</p> <p>improved [1] - 64:22</p> <p>improvement [19] - 76:6, 76:8, 76:24, 77:9, 113:14, 113:20, 120:2, 168:25, 169:2, 181:3, 181:18, 212:7, 215:25, 216:3, 216:5, 217:19, 220:15, 220:24, 225:2</p> <p>improvements [1] - 221:11</p> <p>IN [4] - 2:3, 2:11, 243:3, 243:6</p>	<p>in-between [1] - 226:22</p> <p>in-house [2] - 109:23, 166:2</p> <p>inaccuracy [1] - 178:11</p> <p>inappropriate [2] - 5:11, 11:9</p> <p>inappropriately [1] - 144:6</p> <p>incapable [2] - 13:18, 13:20</p> <p>inception [1] - 190:25</p> <p>incidence [4] - 123:11, 229:22, 230:3, 231:4</p> <p>inclined [2] - 11:21, 23:19</p> <p>include [5] - 83:2, 124:20, 124:22, 182:3, 194:3</p> <p>included [4] - 33:21, 56:10, 85:19, 215:12</p> <p>includes [3] - 64:20, 96:7, 150:19</p> <p>including [5] - 153:1, 181:18, 200:22, 207:2, 214:9</p> <p>incomplete [2] - 51:15, 51:17</p> <p>incompleteness [1] - 51:18</p> <p>incomprehensible [1] - 143:8</p> <p>inconsistent [2] - 196:9, 196:12</p> <p>incorrect [3] - 38:25, 93:15, 100:25</p> <p>increase [5] - 30:13, 32:20, 35:20, 209:22</p> <p>increasingly [1] - 11:20</p> <p>incredibly [1] - 142:8</p> <p>IND [3] - 171:18, 171:20, 171:23</p> <p>indeed [9] - 25:12, 63:6, 68:3, 80:21, 82:17, 94:8, 96:10, 178:17, 189:12</p> <p>independent [2] - 16:22, 129:7</p> <p>INDEX [1] - 3:1</p> <p>indicate [2] - 127:17, 156:3</p> <p>indicated [3] - 29:22, 94:14, 217:18</p> <p>indicates [2] - 37:12, 76:5</p> <p>indication [2] - 76:1, 80:16</p> <p>indicative [1] - 33:19</p> <p>individuals [2] - 184:13, 190:2</p> <p>induced [1] - 138:18</p> <p>industry [7] - 100:3, 105:15, 105:16, 170:10, 171:4, 185:13, 185:16</p> <p>influence [1] - 220:8</p> <p>influenced [1] - 46:18</p> <p>influencing [1] - 47:7</p> <p>inform [2] - 105:23, 198:13</p> <p>informal [3] - 101:18, 167:17, 168:1</p> <p>information [43] - 6:19, 6:24, 6:25, 28:24, 28:25, 33:18, 33:22, 49:21, 61:6, 61:8, 93:15, 94:13, 95:17, 96:9,</p>	<p>102:19, 109:19, 117:18, 118:6, 118:15, 127:16, 127:18, 129:6, 129:8, 132:11, 132:13, 132:18, 134:6, 135:3, 135:4, 135:6, 135:9, 135:10, 143:23, 150:10, 150:13, 153:7, 156:19, 181:6, 181:13, 189:12, 193:24, 195:2, 212:21</p> <p>informed [2] - 93:8, 142:15</p> <p>informs [1] - 131:2</p> <p>inhibit [1] - 214:1</p> <p>initial [7] - 78:6, 78:7, 82:14, 82:15, 84:22, 168:10, 168:11</p> <p>innovative [1] - 162:16</p> <p>input [1] - 15:13</p> <p>inside [2] - 63:14, 166:14</p> <p>instead [2] - 125:7, 133:19</p> <p>instruct [1] - 28:22</p> <p>instruction [12] - 12:8, 12:24, 12:25, 17:12, 18:6, 18:19, 19:16, 28:7, 28:9, 28:11, 29:10</p> <p>instructions [1] - 22:24</p> <p>insurance [2] - 173:24, 173:25</p> <p>intend [4] - 80:14, 126:22, 183:13, 183:22</p> <p>intended [1] - 75:23</p> <p>intensive [1] - 123:12</p> <p>intent [6] - 58:23, 60:5, 63:25, 108:21, 114:6, 210:8</p> <p>intent-to-treat [6] - 58:23, 60:5, 63:25, 108:21, 114:6, 210:8</p> <p>interaction [1] - 135:2</p> <p>interest [3] - 99:12, 163:6, 191:25</p> <p>interested [3] - 127:6, 163:8, 213:18</p> <p>interesting [4] - 23:7, 56:12, 204:24, 230:1</p> <p>interests [1] - 173:23</p> <p>internal [6] - 96:6, 96:23, 166:20, 166:21, 227:8, 227:9</p> <p>internally [4] - 146:8, 161:8, 226:16, 226:20</p> <p>interpretation [2] - 36:18, 155:22</p> <p>interpreted [1] - 155:16</p> <p>interpreting [1] - 16:20</p> <p>interrupt [2] - 66:17, 107:11</p> <p>interrupted [1] - 107:16</p> <p>interrupting [1] - 16:18</p> <p>interval [1] - 33:11</p> <p>intervals [3] - 37:4, 45:5,</p>	<p>45:18</p> <p>intriguing [2] - 56:14, 162:17</p> <p>introduce [2] - 158:18, 239:2</p> <p>introduced [1] - 73:15</p> <p>introduction [1] - 221:9</p> <p>investigate [1] - 93:21</p> <p>investigation [2] - 36:25, 233:24</p> <p>investing [1] - 183:17</p> <p>investment [3] - 86:10, 130:24</p> <p>investor [4] - 17:18, 18:9, 113:14, 113:19</p> <p>investors [37] - 16:19, 16:22, 17:3, 17:13, 17:14, 17:15, 17:16, 18:3, 18:7, 18:15, 18:18, 18:24, 19:8, 19:20, 28:4, 28:5, 50:22, 99:7, 99:11, 132:18, 133:3, 162:12, 164:19, 165:11, 165:15, 165:22, 176:23, 183:14, 183:16, 183:24, 183:25, 202:4, 203:7, 203:13, 213:1, 230:6, 238:16</p> <p>invite [1] - 20:20</p> <p>involved [13] - 67:6, 72:13, 72:15, 75:15, 102:21, 132:25, 135:15, 138:14, 138:18, 139:5, 177:11, 190:24, 201:15</p> <p>IP [2] - 86:19, 88:17</p> <p>iPhone [1] - 209:10</p> <p>irrelevant [2] - 17:4, 20:13</p> <p>IS [1] - 243:2</p> <p>issue [11] - 14:2, 23:17, 23:20, 30:2, 30:7, 67:25, 136:2, 143:8, 145:23, 145:25, 147:9</p> <p>issued [2] - 216:17, 218:18</p> <p>issues [11] - 5:7, 31:3, 31:4, 102:16, 133:6, 146:1, 146:2, 147:1, 147:10, 148:23, 217:9</p> <p>items [1] - 88:17</p> <p>itself [2] - 93:11, 166:20</p> <p>ITT [6] - 193:25, 194:3, 194:10, 214:7, 214:19, 218:12</p>
J			
<p>JANUARY [2] - 1:19, 5:1</p> <p>January [19] - 32:11, 88:8, 89:3, 89:25, 91:7, 91:17, 91:22, 94:1, 94:6, 94:19, 98:18, 103:10, 103:18, 104:4, 106:25, 154:20, 164:16, 191:13, 227:10</p> <p>JASON [1] - 2:3</p>			

<p>Jeannette [2] - 85:6, 88:23</p> <p>jeopardizes [1] - 175:20</p> <p>job [3] - 79:13, 160:8, 160:14</p> <p>JOHNSON [132] - 2:12, 5:4, 5:13, 5:17, 5:22, 5:24, 6:21, 6:23, 7:11, 7:13, 7:20, 7:24, 8:5, 8:11, 51:13, 51:18, 52:6, 52:21, 70:23, 79:8, 79:17, 79:19, 97:13, 98:10, 100:8, 101:25, 102:6, 114:18, 119:3, 120:16, 121:14, 122:15, 127:1, 127:10, 128:18, 128:20, 129:1, 129:24, 130:8, 130:12, 130:20, 131:2, 131:12, 131:25, 132:4, 132:10, 133:5, 133:17, 133:24, 134:2, 134:6, 134:8, 134:11, 134:15, 134:23, 135:22, 136:3, 136:7, 136:12, 136:14, 136:19, 136:22, 137:1, 137:5, 137:8, 156:22, 157:24, 158:4, 158:8, 158:11, 165:4, 165:6, 165:9, 167:12, 167:14, 170:3, 170:8, 170:13, 170:15, 170:25, 171:3, 172:17, 172:22, 172:24, 186:10, 186:18, 186:20, 187:5, 187:8, 188:2, 188:6, 188:8, 190:7, 190:15, 190:16, 192:21, 193:1, 193:3, 193:6, 193:22, 193:23, 196:25, 197:9, 197:12, 197:15, 198:1, 200:7, 200:11, 201:10, 201:14, 205:16, 205:20, 205:23, 205:24, 207:17, 207:22, 217:15, 217:17, 218:20, 219:1, 219:19, 219:23, 219:24, 223:14, 224:1, 235:16, 239:7, 239:9, 240:9, 240:10, 242:7, 242:20</p> <p>Johnson [19] - 8:8, 128:16, 147:9, 158:2, 163:5, 163:6, 163:16, 163:17, 163:25, 164:1, 164:4, 164:5, 164:9, 190:14</p> <p>joint [5] - 205:1, 206:1, 206:4, 206:5, 206:11</p> <p>Judge [1] - 197:16</p> <p>JUDGE [1] - 1:3</p> <p>judge [2] - 139:12, 219:13</p> <p>JUDICIAL [1] - 243:7</p> <p>Judith [1] - 75:11</p> <p>Judy [3] - 62:6, 75:12, 172:12</p>	<p>Judy's [1] - 79:25</p> <p>July [47] - 32:16, 32:22, 39:13, 42:10, 44:7, 45:20, 50:6, 50:22, 55:10, 62:4, 65:10, 66:13, 66:15, 66:18, 66:19, 67:1, 67:8, 68:13, 141:14, 142:10, 143:3, 152:1, 164:2, 176:7, 176:9, 176:10, 176:19, 176:22, 176:25, 177:7, 177:10, 177:18, 179:12, 179:18, 179:19, 180:6, 182:14, 182:16, 200:8, 201:9, 207:25, 208:20, 217:3, 221:21, 222:12, 227:22, 239:5</p> <p>jump [6] - 166:24, 168:15, 176:6, 200:7, 208:13, 224:22</p> <p>juncture [2] - 33:3, 94:24</p> <p>June [4] - 121:18, 122:5, 149:12, 230:22</p> <p>jurors [1] - 31:1</p> <p>jury [28] - 7:20, 17:12, 18:6, 18:15, 18:20, 22:24, 29:20, 30:24, 53:6, 74:3, 125:24, 132:4, 132:5, 133:8, 134:15, 135:24, 137:13, 143:9, 148:19, 148:21, 157:13, 158:5, 161:1, 166:6, 190:11, 190:13, 237:25, 242:16</p> <p>JURY [1] - 1:17</p>	<p>kind [23] - 9:5, 40:23, 78:22, 106:20, 146:11, 151:9, 151:11, 152:21, 176:21, 180:3, 184:13, 184:16, 184:24, 187:22, 210:22, 211:22, 212:25, 213:15, 215:20, 225:6, 225:23, 230:11, 233:12</p> <p>kinds [1] - 22:24</p> <p>Kingdom [1] - 161:23</p> <p>KM [9] - 44:24, 61:2, 63:3, 66:5, 72:10, 74:25, 110:1, 152:5, 152:9</p> <p>knowledge [4] - 64:24, 155:20, 156:1, 156:13</p> <p>known [12] - 62:8, 63:10, 81:20, 159:12, 160:9, 160:10, 183:4, 187:12, 204:23, 212:12, 212:18, 240:13</p> <p>knows [2] - 20:1, 105:16</p> <p>KOL [6] - 220:3, 220:4, 220:5, 220:9, 220:12, 222:10</p>	<p>58:10, 138:15, 153:1</p> <p>launching [1] - 13:18</p> <p>lawsuit [2] - 133:20, 139:16</p> <p>lawyer [1] - 87:22</p> <p>lawyers [10] - 6:25, 131:4, 132:14, 132:15, 132:25, 135:6, 135:15, 138:17, 139:5, 139:10</p> <p>lay [2] - 114:17, 137:13</p> <p>lead [1] - 114:4</p> <p>leader [4] - 220:5, 220:13, 220:20, 220:23</p> <p>leadership [1] - 198:12</p> <p>leading [3] - 8:20, 159:19, 190:18</p> <p>leapfrog [4] - 78:12, 168:6, 168:23, 169:12</p> <p>learning [1] - 209:16</p> <p>least [7] - 16:16, 28:6, 113:7, 117:9, 135:9, 143:20, 206:11</p> <p>leave [5] - 67:15, 150:17, 153:10, 155:15, 162:11</p> <p>leaving [1] - 108:17</p> <p>led [1] - 114:2</p> <p>Leerink [4] - 111:21, 112:2, 112:12, 215:9</p> <p>leeway [1] - 165:2</p> <p>left [9] - 43:14, 56:17, 89:6, 89:9, 92:16, 141:13, 164:18, 188:12, 225:25</p> <p>legacy [1] - 237:18</p> <p>legal [5] - 6:24, 8:16, 88:16, 147:17, 148:14</p> <p>length [1] - 190:2</p> <p>lengthy [1] - 140:10</p> <p>lesions [5] - 181:24, 181:25, 182:1, 214:15, 215:13</p> <p>less [1] - 230:4</p> <p>LESS [1] - 243:5</p> <p>letter [2] - 5:24, 198:2</p> <p>letting [4] - 16:4, 97:14, 113:5, 158:5</p> <p>level [2] - 39:3, 133:2</p> <p>levels [1] - 198:19</p> <p>Liang [5] - 109:8, 155:19, 156:11, 215:9</p> <p>license [7] - 55:13, 86:19, 137:8, 137:12, 137:15, 144:2, 161:16</p> <p>licensed [2] - 55:10, 233:5</p> <p>licensing [4] - 34:22, 134:24, 136:8, 175:3</p> <p>licensor [2] - 49:22, 149:6</p> <p>lied [2] - 140:1, 140:20</p> <p>life [1] - 75:24</p> <p>life-threatening [1] - 75:24</p> <p>light [1] - 142:20</p> <p>likelihood [2] - 8:22, 195:18</p> <p>likely [4] - 82:8, 151:15,</p>
L			
<p>lab [7] - 111:24, 112:3, 178:19, 178:20, 208:11, 210:10</p> <p>label [1] - 60:5</p> <p>lack [2] - 44:3, 68:14</p> <p>Lalani [1] - 70:7</p> <p>large [22] - 78:7, 78:17, 81:23, 82:3, 105:8, 107:2, 116:8, 163:5, 163:10, 163:14, 163:16, 166:1, 168:12, 176:10, 176:16, 184:8, 184:9, 184:18, 184:20, 184:25, 186:6</p> <p>largely [1] - 25:12</p> <p>larger [1] - 104:11</p> <p>largest [4] - 114:22, 116:25, 117:1</p> <p>last [32] - 23:18, 24:21, 27:17, 27:22, 31:6, 33:9, 37:8, 37:18, 38:2, 42:7, 46:15, 46:16, 46:19, 47:21, 51:14, 51:16, 51:20, 51:25, 64:7, 107:22, 111:22, 112:5, 127:20, 157:20, 165:4, 193:13, 193:15, 206:18, 215:23, 219:13, 219:14, 235:7</p> <p>lasted [1] - 31:7</p> <p>lastly [2] - 40:10, 237:12</p> <p>late [4] - 68:7, 73:10, 78:16, 145:24</p> <p>LATHAM [1] - 2:13</p> <p>Latham [5] - 58:2, 58:8,</p>			
K			
<p>Kaplan [8] - 54:10, 58:19, 61:22, 62:2, 83:10, 147:15, 151:3, 194:10</p> <p>Kaplan-Meier [8] - 54:10, 58:19, 61:22, 62:2, 83:10, 147:15, 151:3, 194:10</p> <p>Kathy [1] - 59:4</p> <p>keep [9] - 6:22, 125:21, 130:15, 131:8, 161:12, 166:20, 189:13, 195:10, 242:13</p> <p>keeping [3] - 7:22, 140:19, 154:2</p> <p>keeps [1] - 67:19</p> <p>kept [5] - 39:20, 130:4, 140:22, 190:4, 238:8</p> <p>key [13] - 102:16, 131:18, 140:11, 140:13, 142:6, 180:4, 185:24, 219:6, 220:2, 220:5, 220:12, 220:19, 220:22</p> <p>kicked [4] - 195:3, 200:2, 210:19, 211:2</p> <p>kinase [1] - 166:22</p>			

<p>219:25, 230:4</p> <p>limine [14] - 7:18, 7:19, 127:11, 128:17, 128:21, 129:23, 132:23, 133:7, 133:12, 133:18, 133:20, 135:14, 135:16</p> <p>limited [1] - 108:23</p> <p>limiting [13] - 12:8, 12:23, 12:25, 17:12, 18:5, 18:19, 19:16, 28:7, 28:8, 28:9, 28:10, 28:21, 29:10</p> <p>line [57] - 11:19, 13:16, 13:21, 15:7, 15:8, 15:11, 16:6, 16:14, 16:15, 18:1, 20:14, 20:15, 20:17, 21:1, 21:17, 22:6, 23:7, 23:9, 25:5, 25:6, 25:9, 25:10, 25:19, 27:2, 27:6, 27:8, 28:23, 29:14, 65:14, 70:17, 84:6, 87:9, 115:7, 116:5, 116:11, 118:21, 167:2, 171:6, 204:10, 204:11, 208:16, 208:22, 210:2, 210:22, 212:11, 215:3, 215:23, 218:12, 218:13, 225:14, 239:11, 239:12</p> <p>lines [16] - 5:17, 5:18, 10:18, 15:12, 15:14, 15:17, 16:4, 16:5, 20:5, 20:8, 20:12, 26:11, 33:11, 35:13, 125:4, 211:24</p> <p>list [20] - 6:1, 6:24, 41:15, 49:11, 85:9, 127:2, 127:7, 150:19, 151:7, 151:15, 152:21, 153:11, 153:14, 156:7, 170:14, 170:23, 197:14, 219:12, 219:14, 230:21</p> <p>listed [6] - 91:25, 109:16, 127:12, 173:7, 202:19, 205:22</p> <p>listen [3] - 53:5, 153:17, 225:13</p> <p>listening [2] - 144:9, 145:18</p> <p>listing [1] - 7:14</p> <p>lists [2] - 6:25, 76:15</p> <p>literature [1] - 162:3</p> <p>litigate [1] - 134:18</p> <p>litigating [1] - 144:24</p> <p>litigation [46] - 5:11, 5:12, 6:20, 7:5, 8:4, 8:10, 66:25, 67:3, 67:6, 128:22, 129:23, 130:9, 130:16, 130:18, 130:21, 131:1, 131:7, 131:11, 131:16, 132:7, 132:14, 132:20, 132:25, 134:18, 134:22, 135:1, 135:2, 135:14, 135:23, 139:4, 139:10, 140:10, 143:11, 143:20, 144:3,</p>	<p>144:25, 145:4, 145:16, 146:6, 147:10, 148:10, 148:13, 177:2, 177:5, 177:13</p> <p>live [1] - 117:18</p> <p>lives [1] - 162:8</p> <p>LLP [2] - 2:5, 2:13</p> <p>local [2] - 178:24, 179:6</p> <p>located [1] - 93:7</p> <p>lock [1] - 33:23</p> <p>long-term [1] - 155:19</p> <p>longer-term [1] - 55:18</p> <p>look [76] - 14:3, 14:22, 15:16, 16:13, 17:25, 24:17, 31:15, 32:13, 33:7, 35:12, 36:2, 36:10, 38:8, 38:16, 40:4, 40:8, 40:23, 40:25, 41:6, 42:8, 42:17, 44:18, 44:22, 48:12, 49:7, 50:13, 50:23, 51:5, 54:4, 54:8, 55:18, 56:3, 60:11, 61:3, 62:18, 65:13, 69:21, 70:17, 71:9, 74:14, 76:13, 78:5, 78:6, 78:20, 84:16, 84:23, 85:17, 94:20, 102:15, 106:2, 106:4, 107:15, 107:20, 107:21, 108:24, 112:17, 116:3, 126:7, 126:14, 151:16, 183:5, 186:18, 187:25, 205:14, 206:25, 208:22, 211:24, 218:19, 222:25, 225:21, 227:21, 231:16, 232:2, 238:24, 239:5</p> <p>looked [13] - 23:20, 35:16, 42:13, 42:14, 63:23, 175:25, 179:19, 208:18, 225:20, 228:15, 228:17, 229:5, 233:4</p> <p>looking [23] - 5:19, 5:20, 16:14, 37:24, 61:5, 69:11, 82:3, 91:18, 110:12, 114:25, 115:10, 115:12, 115:22, 115:23, 128:15, 158:2, 183:15, 206:7, 206:8, 213:24, 224:6, 232:15, 232:16</p> <p>looks [8] - 30:22, 147:10, 156:7, 166:5, 205:21, 206:5, 217:13, 221:21</p> <p>loperamide [2] - 123:10, 233:7</p> <p>Los [4] - 62:11, 160:9, 162:5, 191:13</p> <p>lose [1] - 161:5</p> <p>loss [1] - 159:8</p> <p>loved [2] - 165:15, 165:16</p> <p>low [5] - 40:18, 174:2, 213:10, 223:24, 232:15</p> <p>lower [9] - 38:6, 38:9, 40:24,</p>	<p>46:12, 153:19, 216:19, 227:18, 232:17, 233:16</p> <p>lung [2] - 81:14, 199:10</p> <p>lymphoma [2] - 81:15, 81:17</p> <p>Lynch [2] - 86:11, 87:23</p>	<p>math [3] - 54:21, 232:8, 232:18</p> <p>Matone [2] - 113:3, 113:4</p> <p>Matt [4] - 215:9, 240:8, 240:12, 240:13</p> <p>matter [4] - 21:18, 97:17, 116:23, 127:4</p> <p>MATTER [1] - 243:4</p> <p>maximize [1] - 209:23</p> <p>mean [27] - 7:4, 14:5, 21:22, 23:9, 32:4, 39:23, 43:16, 44:11, 49:12, 62:4, 66:16, 68:25, 99:9, 135:18, 136:1, 136:17, 138:19, 149:21, 172:7, 174:23, 178:5, 199:21, 206:20, 218:3, 223:9, 229:19, 239:13</p> <p>meaning [5] - 178:12, 181:23, 238:7, 239:15</p> <p>meaningful [3] - 217:19, 218:2, 218:3</p> <p>meaningless [1] - 59:14</p> <p>means [23] - 23:9, 26:8, 35:7, 43:14, 51:17, 51:19, 53:5, 65:18, 87:21, 146:13, 166:12, 176:21, 178:19, 186:16, 216:3, 220:6, 229:20, 231:2, 232:24, 234:16, 236:13, 238:6, 238:11</p> <p>meant [14] - 20:7, 23:3, 73:1, 73:4, 78:4, 156:23, 168:5, 178:24, 183:14, 190:25, 199:25, 203:25, 225:19</p> <p>measure [1] - 215:19</p> <p>measurement [1] - 238:23</p> <p>mechanism [2] - 166:20, 166:21</p> <p>medical [21] - 104:5, 106:12, 107:2, 124:11, 162:3, 184:5, 184:7, 189:2, 191:4, 193:12, 210:14, 210:19, 211:2, 211:9, 211:17, 212:22, 214:2, 218:17, 222:9, 222:13, 240:12</p> <p>medication [1] - 234:3</p> <p>medications [1] - 234:2</p> <p>medicine [1] - 222:8</p> <p>meet [3] - 76:3, 149:8, 191:6</p> <p>meeting [88] - 56:22, 57:8, 57:25, 58:12, 60:7, 75:17, 76:15, 76:17, 77:22, 78:2, 80:3, 80:19, 82:24, 83:15, 85:5, 88:11, 96:1, 96:2, 96:4, 96:7, 96:8, 96:11, 96:19, 97:1, 97:3, 97:5, 99:3, 99:4, 101:13, 101:16, 101:18, 103:16, 103:18, 103:21, 103:22, 103:24, 104:3, 104:6, 104:22,</p>
M			
<p>M&A [3] - 11:20, 13:22, 14:12</p> <p>magnitude [2] - 110:18, 222:22</p> <p>mail [30] - 10:1, 10:4, 10:8, 11:19, 12:24, 23:13, 54:9, 56:10, 61:4, 85:9, 88:20, 93:11, 93:13, 93:22, 104:23, 109:10, 109:14, 111:16, 117:16, 118:7, 118:9, 122:19, 127:21, 132:15, 146:5, 147:10, 152:14, 219:2, 226:23, 227:1</p> <p>mailed [2] - 6:3, 110:20</p> <p>mailing [1] - 110:22</p> <p>mails [3] - 6:25, 23:19, 151:6</p> <p>main [4] - 182:9, 232:25, 241:5, 241:20</p> <p>maintain [1] - 96:6</p> <p>major [1] - 11:19</p> <p>majority [4] - 63:22, 166:1, 174:19, 215:22</p> <p>male [1] - 30:22</p> <p>malignant [2] - 84:7, 181:23</p> <p>managing [1] - 86:9</p> <p>mandate [1] - 191:3</p> <p>manner [2] - 61:13, 124:16</p> <p>manufacturing [2] - 163:12, 163:19</p> <p>March [3] - 65:25, 68:22, 201:8</p> <p>marco [1] - 14:10</p> <p>mark [1] - 187:5</p> <p>marked [7] - 3:23, 26:25, 149:17, 170:1, 170:9, 187:7, 208:14</p> <p>marker [1] - 69:10</p> <p>market [16] - 113:7, 114:2, 114:4, 117:2, 117:4, 140:17, 162:24, 169:12, 169:20, 185:15, 185:21, 202:5, 202:8, 202:11, 203:10, 212:23</p> <p>marketing [2] - 163:13, 201:24</p> <p>marks [2] - 30:21, 49:15</p> <p>married [1] - 30:10</p> <p>master's [1] - 160:6</p> <p>material [1] - 128:8</p> <p>materially [1] - 183:10</p> <p>materials [4] - 63:2, 86:22, 88:6, 103:20</p>			

104:25, 105:3, 106:13,
106:16, 107:1, 107:5,
122:9, 131:5, 132:15,
141:3, 141:4, 141:5,
141:22, 144:21, 150:16,
154:20, 156:8, 167:9,
167:20, 167:22, 167:24,
167:25, 168:1, 171:14,
172:1, 173:6, 173:10,
182:18, 182:20, 183:4,
187:13, 187:15, 189:6,
189:13, 189:23, 189:24,
191:9, 193:7, 193:9,
193:10, 193:12, 193:14,
193:16, 193:20, 196:8,
207:6, 207:9
meetings [4] - 95:25, 99:23,
135:5, 190:1
Meier [8] - 54:10, 58:19,
61:22, 62:2, 83:10, 147:15,
151:3, 194:10
members [1] - 156:6
memo [1] - 9:21
memorized [1] - 204:1
memory [2] - 60:13, 68:18
mention [8] - 95:21, 101:18,
125:1, 129:12, 129:21,
143:11, 157:19, 240:19
mentioned [25] - 9:1, 26:5,
55:6, 57:1, 75:13, 76:1,
77:19, 78:10, 78:17, 88:1,
141:25, 161:22, 168:20,
172:13, 181:21, 187:11,
206:1, 206:25, 207:24,
211:15, 215:2, 215:14,
231:1, 236:23, 237:10
mentioning [3] - 145:15,
171:14, 218:13
mentions [1] - 134:1
merged [2] - 205:2, 205:4
merits [4] - 29:6, 87:11,
87:14, 165:3
Merrill [2] - 86:11, 87:23
met [3] - 120:22, 156:6,
191:8
metadata [4] - 91:16, 93:2,
93:4, 93:10
MICHELE [1] - 2:12
microphone [2] - 53:25,
115:15
Microsoft [1] - 93:6
mid [7] - 119:20, 120:3,
159:2, 160:16, 212:2,
213:6, 213:12
mid-size [2] - 159:2, 160:16
middle [7] - 46:9, 122:25,
131:18, 142:24, 163:4,
220:2, 222:18
midst [1] - 142:24
might [22] - 5:6, 9:1, 10:7,

17:24, 22:25, 26:12, 28:25,
29:1, 32:5, 65:14, 69:4,
117:8, 117:21, 123:19,
125:15, 135:3, 135:5,
140:25, 151:19, 157:10,
224:6
MIL [1] - 70:24
million [4] - 95:18, 103:11,
163:1, 202:9
mind [14] - 12:20, 13:4, 13:5,
13:7, 17:8, 17:25, 116:24,
117:9, 125:22, 143:15,
210:3, 223:16, 241:25,
242:13
minority [1] - 199:11
minus [1] - 232:10
minute [1] - 131:12
minutely [1] - 62:12
minutes [8] - 73:24, 85:5,
88:11, 99:4, 101:13,
103:17, 145:25, 185:3
Miriam [1] - 243:9
MIRIAM [2] - 1:22, 243:10
mis copied [1] - 52:3
misheard [1] - 70:2
misimpression [1] - 134:16
misleading [3] - 59:17,
132:4, 132:5
misleadingly [1] - 139:8
misled [4] - 120:24, 121:2,
121:5, 121:9
misquoting [1] - 154:23
miss [1] - 12:6
missed [3] - 78:22, 197:19,
240:19
missing [9] - 51:14, 67:25,
68:7, 68:16, 68:21, 90:11,
230:10, 239:3, 240:21
mission [1] - 158:23
misspoke [2] - 16:8, 105:20
mistake [2] - 16:11, 32:1
mistakes [2] - 95:15
misunderstand [1] - 133:8
misunderstood [1] - 26:6
mixed [1] - 110:19
moderator [1] - 221:20
modifications [1] - 91:14
modify [1] - 61:21
modus [1] - 146:1
moment [8] - 13:2, 13:8,
22:2, 114:23, 116:3,
128:14, 154:9, 157:12
Monday [2] - 164:18, 199:16
money [10] - 161:8, 162:9,
162:18, 162:19, 162:20,
162:22, 165:11, 165:22,
192:4, 202:6
mono [1] - 118:22
Monte [4] - 40:22, 41:1, 41:3,
41:5

month [19] - 37:4, 45:5,
46:19, 104:4, 140:7, 174:3,
229:21, 230:3, 230:14,
230:25, 231:3, 231:5,
231:10, 231:13, 231:23,
232:2, 233:11, 233:12,
233:16
months [18] - 35:13, 37:8,
37:22, 38:3, 38:10, 38:11,
43:13, 44:16, 45:10, 46:15,
48:13, 70:5, 142:15,
164:13, 209:12, 230:13,
231:25, 238:9
moot [2] - 25:12, 25:13
Moran [1] - 193:13
MORAN [1] - 193:13
morning [18] - 5:5, 29:19,
31:13, 31:14, 129:17,
137:18, 140:3, 140:9,
140:21, 149:5, 149:16,
155:1, 155:4, 156:13,
171:14, 181:22, 204:15,
238:3
most [11] - 6:4, 92:18,
142:20, 194:18, 205:8,
207:7, 207:24, 219:25,
228:10, 242:1, 242:3
motion [15] - 7:18, 7:19,
127:10, 127:11, 128:17,
128:20, 129:22, 129:25,
132:22, 133:7, 133:11,
133:18, 133:20, 135:14,
135:16
mourning [1] - 145:12
mouth [1] - 166:8
move [47] - 7:10, 8:1, 24:15,
30:11, 32:2, 32:6, 34:11,
39:25, 47:16, 60:16, 62:20,
65:20, 65:21, 69:24, 70:22,
80:8, 83:19, 84:24, 86:2,
86:25, 98:4, 101:22, 103:5,
106:6, 109:1, 111:7,
112:19, 116:2, 120:13,
122:12, 146:2, 150:1,
156:23, 157:3, 170:4,
172:18, 175:6, 186:11,
192:23, 197:2, 197:3,
197:4, 201:10, 205:16,
207:17, 218:20
moved [1] - 114:17
movements [1] - 228:24
moving [10] - 20:24, 23:24,
24:11, 25:18, 26:17, 27:15,
44:11, 153:16, 163:11,
187:6
MR [271] - 5:5, 12:7, 13:25,
14:7, 14:10, 14:14, 14:18,
14:21, 14:24, 15:3, 15:25,
16:3, 16:10, 16:12, 16:15,
17:6, 17:11, 17:22, 18:3,

19:7, 19:25, 20:4, 20:22,
21:21, 21:25, 22:5, 22:8,
22:10, 22:14, 22:17, 22:20,
22:22, 23:3, 24:13, 24:24,
25:16, 25:24, 26:6, 26:16,
26:23, 27:14, 27:23, 27:25,
28:14, 28:18, 28:21, 29:3,
29:8, 29:10, 29:20, 30:8,
31:9, 31:12, 31:17, 32:10,
32:12, 34:9, 34:14, 36:3,
36:7, 39:24, 40:3, 44:10,
44:15, 47:16, 47:20, 48:24,
49:3, 49:6, 49:14, 49:18,
49:20, 51:7, 51:10, 51:21,
52:2, 52:4, 52:7, 52:10,
52:13, 52:15, 52:23, 53:15,
53:16, 53:21, 53:23, 54:3,
60:15, 60:21, 62:20, 63:1,
65:16, 65:19, 65:21, 65:24,
67:24, 68:2, 68:5, 69:23,
70:1, 70:4, 70:21, 71:1,
71:8, 73:22, 74:6, 74:8,
74:13, 75:4, 75:8, 79:11,
79:22, 80:6, 80:10, 80:12,
82:9, 83:19, 83:23, 84:1,
84:24, 85:3, 86:1, 86:4,
86:7, 86:25, 87:4, 87:8,
87:12, 87:16, 87:18, 92:3,
92:4, 92:6, 92:8, 92:10,
92:11, 92:12, 92:23, 93:1,
97:16, 97:23, 98:4, 98:7,
98:9, 98:12, 98:17, 100:10,
101:23, 102:1, 102:4,
102:9, 103:3, 103:9, 106:5,
106:8, 106:9, 107:11,
107:14, 107:19, 108:25,
109:4, 111:7, 111:11,
112:19, 112:22, 113:1,
113:24, 114:15, 114:19,
114:24, 115:4, 115:9,
115:13, 115:16, 115:20,
115:24, 116:4, 116:8,
116:14, 116:20, 116:22,
117:12, 117:14, 117:20,
117:23, 118:1, 118:2,
118:14, 118:16, 118:17,
118:20, 119:5, 119:10,
119:17, 120:13, 120:18,
121:12, 121:17, 122:12,
122:18, 125:15, 126:3,
126:7, 126:12, 126:15,
126:19, 127:3, 127:8,
127:14, 127:25, 128:3,
128:6, 128:12, 128:23,
129:14, 129:21, 131:15,
137:3, 137:21, 137:23,
138:17, 139:20, 141:2,
141:8, 142:7, 142:19,
143:12, 143:19, 144:8,
144:13, 144:17, 145:9,
145:21, 146:4, 146:10,

146:18, 146:22, 146:25,
147:12, 148:2, 148:5,
148:8, 148:12, 149:1,
149:2, 150:1, 150:5,
154:17, 156:23, 157:2,
157:5, 157:7, 157:9,
157:11, 157:14, 157:16,
157:18, 157:21, 157:23,
164:24, 170:18, 172:19,
186:13, 186:14, 192:24,
197:6, 207:19, 218:22,
219:15, 223:8, 242:19
MS [156] - 5:4, 5:13, 5:17,
5:22, 5:24, 6:21, 6:23,
7:11, 7:13, 7:20, 7:24, 8:5,
8:11, 11:17, 11:24, 12:9,
12:12, 12:18, 12:23, 13:12,
14:9, 15:20, 15:23, 19:3,
19:6, 20:11, 20:18, 21:3,
23:12, 23:16, 23:21, 24:1,
24:4, 25:3, 26:2, 27:17,
29:17, 30:16, 51:13, 51:18,
52:6, 52:21, 70:23, 79:8,
79:17, 79:19, 97:13, 98:10,
100:8, 101:25, 102:6,
114:18, 119:3, 120:16,
121:14, 122:15, 127:1,
127:10, 128:18, 128:20,
129:1, 129:24, 130:8,
130:12, 130:20, 131:2,
131:12, 131:25, 132:4,
132:10, 133:5, 133:17,
133:24, 134:2, 134:6,
134:8, 134:11, 134:15,
134:23, 135:22, 136:3,
136:7, 136:12, 136:14,
136:19, 136:22, 137:1,
137:5, 137:8, 156:22,
157:24, 158:4, 158:8,
158:11, 165:4, 165:6,
165:9, 167:12, 167:14,
170:3, 170:8, 170:13,
170:15, 170:25, 171:3,
172:17, 172:22, 172:24,
186:10, 186:18, 186:20,
187:5, 187:8, 188:2, 188:6,
188:8, 190:7, 190:15,
190:16, 192:21, 193:1,
193:3, 193:6, 193:22,
193:23, 196:25, 197:9,
197:12, 197:15, 198:1,
200:7, 200:11, 201:10,
201:14, 205:16, 205:20,
205:23, 205:24, 207:17,
207:22, 217:15, 217:17,
218:20, 219:1, 219:19,
219:23, 219:24, 223:14,
224:1, 235:16, 239:7,
239:9, 240:9, 240:10,
242:7, 242:20
multiple [3] - 16:7, 18:1, 61:9

must [3] - 52:3, 52:8, 67:19
mutations [1] - 69:11
mutual [1] - 222:2
MVB11893@aol.com [1] -
1:24

N

N9831 [1] - 209:5
name [6] - 56:9, 58:6, 75:13,
193:13, 193:15, 205:9
named [1] - 77:19
names [2] - 109:7, 204:24
narrower [1] - 224:9
NASDAQ [1] - 113:4
nature [1] - 209:22
NCCTG [1] - 205:3
NDA [17] - 77:11, 77:12,
77:17, 77:23, 82:20, 85:19,
99:10, 101:19, 169:4,
169:21, 173:3, 173:4,
173:12, 173:14, 173:15,
173:17
near [4] - 49:12, 102:19,
115:15, 115:24
necessarily [7] - 24:8, 30:9,
92:22, 131:6, 134:21,
147:20, 194:15
necessary [2] - 7:9, 17:1
need [35] - 5:6, 6:16, 6:17,
6:19, 7:5, 7:8, 7:9, 7:15,
7:22, 8:1, 14:4, 15:16,
20:6, 35:4, 60:13, 68:17,
76:25, 77:10, 129:19,
130:7, 130:16, 130:25,
131:25, 132:3, 132:6,
148:6, 151:12, 195:16,
201:24, 203:11, 203:15,
203:20, 210:21, 233:11
needed [1] - 39:18
needs [1] - 170:21
nefarious [1] - 6:10
negative [8] - 61:1, 63:3,
63:7, 68:2, 71:24, 74:20,
138:23, 208:6
negatively [1] - 164:16
negotiation [1] - 132:11
neighborhood [1] - 162:25
neoplasms [1] - 84:7
nerati [1] - 217:9
nerati-nib [1] - 217:9
neratinib [71] - 37:9, 37:21,
37:24, 38:4, 38:5, 38:7,
38:9, 63:19, 80:16, 82:10,
82:17, 88:12, 90:4, 96:17,
99:8, 99:12, 112:3, 113:14,
113:20, 118:22, 119:25,
120:4, 120:6, 121:19,
165:7, 165:11, 165:21,
166:5, 166:7, 166:9,

166:21, 166:23, 166:25,
171:23, 171:25, 173:20,
173:21, 174:6, 174:14,
174:20, 175:11, 179:23,
181:2, 181:17, 182:12,
196:15, 196:23, 208:8,
213:10, 213:14, 222:25,
228:1, 229:17, 230:1,
231:2, 232:25, 233:1,
233:8, 233:21, 233:24,
234:14, 235:25, 237:18,
238:6, 238:8, 238:11,
238:19, 239:16, 241:1
neratinib-related [1] - 233:1
never [10] - 43:21, 59:22,
59:24, 65:4, 130:5, 146:10,
146:14, 156:3, 189:4,
196:21
nevertheless [1] - 234:22
New [7] - 55:14, 88:10,
129:18, 140:4, 140:15,
141:9, 149:9
new [8] - 77:14, 77:15, 82:21,
102:17, 209:8, 209:15,
209:16, 211:4
newly [1] - 175:14
news [1] - 121:18
next [64] - 13:15, 15:11,
33:16, 34:6, 34:7, 34:9,
35:2, 35:9, 36:24, 38:16,
38:18, 39:22, 41:8, 41:14,
45:23, 47:14, 50:1, 51:2,
62:18, 63:13, 63:16, 63:18,
65:13, 65:14, 69:3, 69:21,
70:17, 72:10, 74:25, 77:3,
80:5, 83:10, 83:13, 83:16,
84:9, 84:12, 90:9, 90:17,
90:18, 90:23, 97:21, 103:3,
106:2, 107:25, 108:24,
112:17, 121:10, 122:11,
147:16, 153:4, 154:25,
155:18, 157:15, 160:14,
164:18, 181:8, 194:23,
203:2, 211:13, 224:2,
224:4, 224:22, 237:14
nib [1] - 217:9
nicely [1] - 113:9
night [6] - 27:22, 91:17,
111:22, 112:5, 114:11,
120:20
nine [5] - 34:18, 34:20,
34:21, 69:19, 193:22
nobody [1] - 164:15
node [7] - 33:11, 71:24,
74:19, 74:20, 208:5, 208:6
node-negative [1] - 208:6
node-positive [1] - 208:5
noise [1] - 47:6
non [3] - 31:21, 36:20, 81:15
Non [1] - 81:17

non-constant [1] - 36:20
non-Hodgkins [1] - 81:15
Non-Hodgkins [1] - 81:17
non-objections [1] - 31:21
noncancerous [1] - 64:21
nonclinical [6] - 80:18, 81:6,
81:7, 97:1, 97:3, 97:5
none [2] - 27:15, 67:5
noon [1] - 125:19
normal [1] - 30:5
North [1] - 224:23
Northern [1] - 166:3
not-formal [1] - 99:4
note [6] - 14:25, 58:18,
111:14, 146:1, 219:11,
219:20
noted [2] - 180:20, 221:3
notepad [1] - 105:8
notes [16] - 26:19, 27:22,
75:16, 76:23, 79:25, 96:1,
96:7, 96:8, 96:19, 96:23,
97:2, 99:9, 105:9, 112:2,
172:12
nothing [6] - 24:13, 69:10,
99:13, 123:17, 133:21,
139:20
notice [5] - 61:7, 97:2,
152:14, 231:10, 235:7
noticing [1] - 51:13
notify [1] - 101:10
notion [1] - 23:1
notions [2] - 9:6, 24:6
November [5] - 51:5, 54:5,
83:14, 83:17, 98:24
nowhere [2] - 59:2, 60:4
NSABP [1] - 205:4
Number [4] - 101:21, 103:4,
121:11, 154:25
number [68] - 6:6, 33:1, 34:5,
40:18, 42:17, 42:19, 42:21,
42:25, 43:2, 46:4, 49:2,
60:2, 68:17, 68:18, 69:19,
78:20, 81:22, 81:25, 84:17,
89:6, 91:4, 91:6, 104:7,
104:19, 112:21, 119:18,
120:1, 125:4, 128:21,
156:14, 169:8, 174:15,
176:3, 180:9, 183:7,
183:11, 183:19, 187:2,
191:17, 194:6, 194:14,
194:19, 194:22, 195:2,
195:14, 198:22, 202:19,
207:2, 210:12, 212:4,
213:22, 216:13, 217:25,
218:5, 218:11, 224:15,
224:21, 226:10, 232:2,
233:25, 235:2, 235:7,
235:18, 236:8, 241:21,
241:23, 241:25, 242:6
numbers [32] - 35:16, 42:13,

44:6, 56:21, 56:23, 90:3,
110:5, 110:6, 110:7,
110:23, 110:25, 111:4,
111:12, 112:16, 115:1,
115:7, 115:11, 121:22,
125:13, 141:19, 141:23,
212:8, 213:19, 216:1,
218:13, 225:14, 226:20,
234:1, 234:5, 234:23,
234:25, 241:18
numerous [1] - 154:13

O

O'Donnell [2] - 85:6, 88:24
object [6] - 24:3, 26:11,
97:13, 100:8, 223:8, 225:6
objected [2] - 11:7, 26:11
objecting [3] - 25:23, 26:3,
32:2
objection [135] - 7:18, 8:24,
9:14, 10:17, 10:23, 11:5,
11:16, 11:25, 12:3, 13:14,
14:15, 14:16, 14:17, 15:2,
15:10, 15:12, 15:15, 20:16,
20:20, 21:2, 22:1, 22:19,
24:10, 24:14, 26:4, 26:9,
26:16, 31:18, 31:23, 32:3,
32:4, 32:6, 32:8, 34:10,
34:12, 36:3, 36:5, 39:24,
44:12, 44:13, 47:17, 47:18,
48:24, 49:1, 51:7, 51:15,
51:17, 52:22, 52:23, 60:16,
60:18, 62:21, 62:23, 65:16,
65:22, 69:23, 70:21, 70:24,
71:2, 71:4, 71:6, 74:9,
74:11, 75:5, 75:6, 79:8,
79:13, 79:18, 80:6, 80:7,
83:20, 84:25, 86:1, 87:1,
87:2, 87:3, 87:6, 87:8,
87:9, 87:11, 87:14, 98:6,
98:7, 101:24, 102:1, 102:5,
103:5, 103:7, 106:6,
108:25, 109:2, 111:8,
112:20, 114:16, 114:18,
116:12, 116:24, 117:24,
119:3, 120:15, 121:12,
121:14, 122:14, 122:15,
128:19, 146:9, 146:16,
146:20, 147:22, 148:7,
150:3, 170:5, 170:6,
170:17, 172:19, 186:12,
186:14, 188:2, 188:4,
192:22, 192:24, 192:25,
197:5, 197:6, 201:11,
201:12, 205:17, 205:18,
207:19, 218:21, 218:22,
218:23, 223:17
objections [13] - 10:13,
11:13, 12:1, 15:5, 25:25,
27:7, 27:19, 31:21, 31:22,

49:4, 70:23, 71:3
objects [1] - 127:9
observed [1] - 221:3
obtained [2] - 165:20, 169:9
obvious [1] - 134:12
obviously [22] - 20:2, 31:7,
55:17, 56:3, 105:8, 110:22,
145:6, 153:14, 163:18,
166:2, 177:4, 182:2,
186:23, 195:23, 203:17,
211:4, 212:19, 212:22,
218:12, 218:17, 241:5,
241:17
occasionally [1] - 9:14
occur [1] - 123:25
occurred [9] - 96:2, 123:23,
159:8, 172:2, 199:16,
228:6, 234:19, 235:25,
236:17
occurring [5] - 46:19,
233:18, 234:12, 235:23,
237:1
occurs [3] - 37:21, 123:25,
234:13
October [11] - 40:5, 44:16,
47:22, 60:22, 62:19, 66:12,
86:16, 127:19, 147:24,
153:8
OF [7] - 1:2, 1:16, 2:3, 2:11,
243:3, 243:7
offered [14] - 10:5, 13:19,
16:21, 17:2, 17:10, 21:17,
22:12, 25:8, 25:11, 28:12,
28:24, 28:25
offering [10] - 13:3, 13:4,
26:9, 86:12, 95:18, 102:13,
103:10, 103:11, 116:22,
116:24
office [7] - 62:10, 178:9,
178:11, 178:24, 179:6,
180:2, 215:18
officer [1] - 193:12
OFFICIAL [2] - 1:22, 243:10
often [2] - 125:4, 139:10
oftentimes [4] - 67:14,
95:25, 203:8, 203:13
old [3] - 55:23, 92:21, 107:9
once [8] - 144:19, 165:20,
166:8, 180:13, 188:20,
201:21, 233:2, 234:13
Oncology [3] - 106:13,
106:16, 183:3
oncology [1] - 160:19
one [128] - 5:14, 5:19, 6:6,
7:24, 11:6, 19:7, 19:25,
22:1, 27:17, 27:23, 28:2,
28:14, 33:18, 39:3, 39:7,
40:24, 41:19, 46:16, 58:5,
64:8, 66:7, 66:8, 68:9,
68:11, 75:23, 80:13, 89:8,

89:9, 89:23, 89:24, 91:7,
92:6, 93:19, 93:20, 94:8,
100:1, 104:22, 106:18,
106:22, 107:4, 110:13,
114:5, 115:18, 120:5,
120:8, 123:24, 123:25,
125:4, 131:12, 132:12,
133:6, 135:7, 142:12,
142:16, 142:23, 145:21,
156:8, 166:18, 183:2,
183:19, 183:20, 184:8,
184:17, 185:15, 186:2,
186:13, 189:3, 190:1,
193:25, 195:15, 197:21,
199:9, 199:10, 202:23,
203:2, 204:5, 204:18,
205:1, 205:3, 205:4, 205:5,
205:7, 205:8, 206:8,
206:18, 206:21, 206:23,
211:9, 212:4, 213:10,
213:15, 214:4, 215:7,
215:10, 215:14, 215:23,
216:7, 216:18, 221:12,
221:15, 221:18, 222:13,
222:18, 222:21, 224:16,
224:22, 228:1, 228:5,
228:8, 231:10, 232:2,
232:3, 232:7, 233:8, 237:4,
238:4, 241:5, 241:13
one-on-one [1] - 190:1
one-page [1] - 106:22
ones [15] - 39:10, 40:16,
40:17, 66:11, 81:10, 82:1,
184:14, 191:2, 191:3,
199:1, 199:5, 203:19,
237:18, 239:20, 241:19
ongoing [1] - 123:10
Open [7] - 30:24, 74:3,
125:24, 148:21, 190:11,
190:13, 242:16
open [7] - 31:15, 125:21,
129:3, 185:4, 222:2, 222:3,
242:13
opened [1] - 93:22
operandi [1] - 146:1
operate [1] - 201:25
operations [1] - 202:16
opinion [5] - 97:11, 220:5,
220:12, 220:20, 220:23
opportunity [2] - 23:14,
226:11
opposite [2] - 213:8, 213:12
optimistic [6] - 45:25, 48:2,
48:9, 48:13, 48:19
optimized [1] - 209:19
options [1] - 132:8
oral [12] - 166:7, 184:25,
185:9, 185:11, 186:6,
198:14, 198:15, 199:2,
199:4, 199:12, 199:13,

199:14
orally [1] - 125:2
orange [1] - 232:3
order [12] - 6:9, 31:20, 115:1,
115:12, 132:1, 147:1,
158:19, 179:2, 189:1,
191:14, 202:10, 230:18
ordinary [3] - 114:19,
116:15, 116:18
organization [1] - 226:15
orient [1] - 230:20
original [7] - 48:6, 58:23,
60:5, 90:11, 90:13, 91:5,
174:12
originally [5] - 123:14, 138:7,
191:2, 227:19, 227:20
originate [1] - 174:10
originated [1] - 174:11
otherwise [3] - 70:24, 73:20,
203:4
ought [2] - 9:16, 23:8
out-of-court [4] - 9:12,
11:21, 13:19, 18:23
outcome [1] - 175:24
outcomes [1] - 223:21
outside [14] - 53:19, 146:15,
148:23, 154:3, 166:13,
166:16, 166:19, 182:23,
187:11, 189:17, 190:18,
190:23, 191:21, 226:14
overall [5] - 9:5, 10:22, 46:2,
64:11, 68:16
overrule [2] - 15:10, 20:19
overruled [10] - 8:25, 15:8,
15:12, 25:10, 25:25, 26:22,
27:7, 30:21, 30:23, 223:17
overruling [8] - 13:16, 15:15,
20:12, 21:4, 24:11, 24:16,
24:18, 25:20
oversee [1] - 191:22
overstated [2] - 196:14,
196:17
own [10] - 26:5, 26:11, 39:5,
56:1, 96:7, 129:10, 175:19,
192:5, 212:9, 237:25
owners [1] - 117:5
ownership [1] - 174:17

P

p-value [2] - 47:24, 181:10
p.m [5] - 126:1, 190:12,
242:21
Pacific [1] - 195:23
package [1] - 80:19
packages [2] - 109:24,
216:11
PAGE [1] - 3:2
page [146] - 5:20, 5:21, 13:9,
13:15, 15:7, 15:9, 15:11,

15:15, 15:18, 19:22, 19:24, 20:5, 20:8, 20:25, 21:12, 23:6, 23:10, 24:12, 25:9, 25:19, 26:18, 26:23, 26:24, 27:1, 27:7, 27:9, 28:3, 28:17, 28:18, 28:19, 29:14, 30:14, 34:7, 35:9, 36:12, 36:24, 37:18, 37:19, 38:15, 38:17, 39:22, 41:14, 41:15, 41:17, 42:7, 44:21, 44:22, 45:23, 46:6, 48:6, 48:10, 49:24, 50:1, 52:9, 52:11, 52:13, 52:18, 53:8, 53:9, 53:13, 54:1, 54:16, 63:13, 63:16, 64:7, 64:14, 70:10, 71:23, 72:10, 72:11, 74:18, 74:25, 75:3, 75:9, 77:3, 83:5, 83:7, 83:10, 84:2, 84:9, 84:10, 84:12, 84:17, 85:10, 85:17, 89:12, 89:15, 89:17, 89:19, 89:22, 89:23, 90:9, 90:10, 90:17, 90:18, 90:23, 91:17, 96:13, 102:15, 106:22, 107:25, 109:16, 122:11, 131:19, 150:8, 150:25, 151:19, 152:8, 171:5, 171:6, 172:15, 175:25, 177:21, 183:6, 188:17, 188:20, 200:9, 200:10, 201:18, 202:14, 204:3, 205:21, 211:25, 219:3, 219:4, 219:13, 219:14, 219:15, 221:1, 221:22, 222:15, 222:17, 224:2, 224:4, 230:20, 230:21, 237:3, 237:15, 240:14

Pages [1] - 107:9

pages [19] - 24:11, 25:20, 26:8, 30:4, 35:3, 51:14, 51:20, 52:1, 52:5, 52:15, 52:19, 52:24, 53:4, 53:18, 53:21, 54:5, 173:2, 202:13, 221:20

paid [1] - 192:3

panel [1] - 184:12

Panthera [1] - 102:12

paper [2] - 57:23, 61:14

paragraph [23] - 5:17, 5:20, 6:1, 42:2, 122:25, 123:1, 167:16, 173:1, 173:2, 180:24, 197:10, 198:2, 199:18, 216:19, 217:12, 217:14, 217:16, 220:2, 222:6, 222:18, 224:4, 224:22, 224:23

parameters [1] - 229:12

pardon [1] - 26:23

parking [1] - 104:14

parse [2] - 10:22, 23:9

part [27] - 9:15, 11:9, 16:1, 24:21, 42:18, 42:22, 52:20, 52:25, 66:20, 77:16, 85:11, 124:6, 124:21, 130:18, 136:7, 145:10, 145:18, 148:12, 166:13, 184:18, 188:7, 198:14, 233:13, 235:7, 237:17

participate [3] - 167:22, 179:2, 241:14

particular [7] - 9:16, 28:21, 175:10, 188:21, 202:1, 203:6

particularly [3] - 18:8, 146:14, 170:22

parties [6] - 9:8, 53:11, 53:12, 134:25, 152:25, 154:14

partner [1] - 105:12

party [1] - 87:14

pass [2] - 102:2, 241:16

past [9] - 33:20, 34:4, 35:7, 35:8, 35:13, 43:21, 48:25, 61:12, 226:18

path [3] - 73:20, 99:15, 169:19

paths [1] - 172:10

patient [18] - 43:11, 56:21, 56:23, 59:5, 59:7, 59:10, 59:21, 124:22, 141:19, 141:23, 166:8, 173:23, 173:25, 174:4, 174:5, 178:16, 179:12, 234:14

patient's [1] - 173:23

patients [89] - 34:25, 40:21, 59:12, 59:14, 59:15, 59:18, 59:23, 60:3, 64:3, 68:13, 70:12, 81:5, 100:13, 108:7, 111:24, 112:4, 123:21, 124:13, 124:16, 124:18, 158:22, 159:6, 159:10, 161:19, 162:8, 162:24, 163:2, 163:22, 163:24, 164:23, 165:18, 166:10, 166:11, 173:20, 174:7, 174:21, 175:5, 175:6, 175:7, 175:13, 175:15, 175:16, 176:11, 176:12, 176:14, 176:16, 178:2, 178:8, 178:23, 179:5, 179:24, 185:19, 185:23, 186:3, 186:5, 191:24, 195:16, 204:16, 208:10, 208:15, 208:22, 209:17, 209:24, 211:5, 211:12, 214:19, 214:22, 214:25, 215:15, 215:17, 215:19, 218:5, 218:9, 228:23, 230:7, 230:25, 234:7, 234:8, 234:18, 234:21,

235:2, 235:10, 238:19, 238:21, 240:19, 240:24, 241:9, 241:11

Patricia [7] - 77:19, 77:20, 173:6, 173:7, 173:8

PATRICK [1] - 2:4

patterns [2] - 40:19, 40:20

Pause [1] - 197:22

pay [5] - 159:25, 174:2, 191:22, 192:3, 192:13

payment [1] - 192:12

PBYI [1] - 27:3

pdf [1] - 93:5

peers [1] - 220:7

pen [1] - 105:8

people [31] - 13:6, 28:25, 55:12, 67:15, 76:22, 113:17, 125:4, 125:6, 125:10, 139:5, 140:18, 143:2, 156:5, 163:15, 164:6, 165:23, 166:2, 184:9, 184:22, 185:1, 186:8, 186:25, 187:3, 189:17, 190:17, 206:23, 228:7, 234:2

per [2] - 45:5, 51:2

percent [134] - 16:20, 16:21, 17:3, 17:4, 32:20, 35:5, 43:6, 45:3, 45:9, 48:16, 50:15, 51:2, 64:2, 64:4, 68:7, 68:16, 68:21, 68:24, 68:25, 69:1, 69:3, 69:4, 70:12, 70:15, 76:24, 77:9, 83:8, 110:12, 110:13, 113:21, 114:2, 114:3, 114:5, 114:6, 114:9, 114:11, 117:2, 118:21, 118:25, 119:2, 119:13, 119:18, 119:21, 120:1, 120:5, 120:6, 120:9, 120:10, 120:11, 123:6, 123:12, 123:21, 124:6, 152:6, 168:24, 169:1, 178:16, 181:2, 181:18, 185:16, 194:18, 194:19, 194:23, 194:24, 198:22, 199:3, 206:6, 208:17, 208:25, 212:5, 212:6, 212:7, 213:7, 213:11, 213:14, 213:16, 214:5, 214:8, 214:11, 214:17, 214:20, 214:23, 215:25, 216:2, 216:5, 216:6, 216:9, 218:6, 218:11, 220:15, 220:24, 222:24, 223:3, 223:4, 223:23, 224:7, 224:9, 224:15, 224:17, 224:20, 225:1, 225:2, 225:22, 227:18, 227:19, 228:2, 228:7, 228:12,

228:17, 229:7, 230:7, 230:25, 231:18, 231:19, 232:6, 232:11, 234:3, 234:18, 234:21, 236:4, 237:10, 237:20, 238:20, 240:2, 240:4, 241:1, 241:21, 242:4, 242:5, 242:6

percentage [10] - 30:12, 30:13, 111:23, 112:4, 198:20, 199:5, 216:8, 231:17, 232:5, 234:4

perception [1] - 96:3

perfect [1] - 77:5

perform [2] - 40:22, 180:6

performed [3] - 34:22, 177:17, 177:25

performing [1] - 56:5

perhaps [6] - 9:1, 62:6, 133:1, 148:17, 158:17, 161:9

period [13] - 35:6, 38:12, 43:22, 48:20, 81:21, 176:17, 179:18, 180:8, 185:4, 204:14, 207:25, 211:14, 230:16

person [4] - 9:17, 24:7, 57:16, 134:25

person's [2] - 22:12, 179:3

personally [2] - 177:11, 185:10

persuading [1] - 130:8

pessimistic [1] - 46:4

Pfizer [80] - 5:25, 6:1, 6:7, 8:12, 8:15, 34:22, 49:22, 51:1, 54:8, 54:24, 55:10, 59:20, 59:22, 60:2, 127:4, 127:12, 127:16, 127:22, 128:22, 129:8, 129:9, 129:10, 129:12, 129:23, 130:4, 130:7, 130:9, 131:1, 132:7, 132:22, 133:8, 133:16, 134:1, 134:17, 135:19, 135:20, 137:10, 137:14, 137:16, 137:24, 138:6, 138:7, 138:10, 138:12, 138:20, 138:25, 139:3, 139:9, 139:16, 139:21, 139:24, 140:2, 140:7, 140:10, 140:19, 140:25, 142:14, 143:11, 143:21, 144:1, 144:25, 145:4, 145:15, 147:14, 147:15, 147:24, 149:6, 149:9, 150:6, 150:10, 152:13, 152:19, 153:23, 156:6, 174:25, 237:19

Ph.D [1] - 240:12

pharmaceutical [1] - 163:5

phase [48] - 73:2, 73:3, 73:4,

73:5, 73:8, 76:4, 78:5,
78:6, 78:12, 78:13, 78:17,
78:19, 99:18, 99:19, 99:21,
100:15, 153:15, 163:10,
168:9, 168:10, 168:11,
168:15, 168:16, 168:18,
168:20, 168:21, 168:23,
169:9, 169:10, 169:23,
171:13, 171:16, 171:17,
172:1, 172:3, 172:7,
172:11, 180:20, 185:12,
185:17, 207:1

Phase [1] - 78:7

phases [2] - 78:4, 168:8

phenomena [1] - 231:12

Phil [7] - 17:23, 18:9, 18:11,
18:13, 18:14, 114:20,
114:21

phone [9] - 76:16, 107:7,
109:21, 109:25, 110:7,
110:15, 112:11, 112:13,
223:10

phonetic [1] - 20:7

phrase [1] - 10:9

phrased [1] - 29:12

physical [6] - 153:11,
153:12, 155:16, 155:17,
155:23, 155:25

physically [4] - 43:14, 107:5,
166:6, 239:20

physician [10] - 192:10,
196:5, 196:11, 196:16,
196:21, 219:7, 220:22,
222:7, 224:20, 225:20

physicians [4] - 104:7,
154:13, 191:21, 222:13

pick [1] - 16:6

picks [1] - 46:9

picture [3] - 186:18, 186:21,
194:9

piece [2] - 57:22, 61:14

pieces [1] - 195:2

pill [6] - 81:24, 166:7, 166:8,
228:8, 228:13, 228:25

pink [1] - 206:7

placate [1] - 18:14

place [10] - 104:3, 133:7,
187:14, 207:6, 211:8,
233:7, 234:12, 234:18,
236:20, 242:7

placebo [31] - 37:10, 37:25,
38:6, 38:9, 81:24, 82:2,
90:4, 90:12, 112:3, 113:6,
119:19, 120:4, 181:3,
181:19, 204:4, 204:10,
205:11, 210:1, 212:15,
213:9, 213:13, 216:14,
220:14, 228:1, 228:3,
228:5, 228:8, 228:12,
228:25, 229:3

placebos [1] - 228:16

places [1] - 195:22

Plaintiff [1] - 1:6

plaintiff [16] - 5:14, 11:7,
13:10, 13:11, 14:3, 15:16,
16:9, 23:11, 25:2, 25:23,
26:10, 133:23, 135:18,
145:6, 177:8

PLAINTIFF [1] - 2:3

plaintiffs [7] - 6:5, 26:2,
143:6, 167:15, 177:2,
177:7, 177:12

plaintiffs' [5] - 52:8, 142:24,
167:4, 223:14, 233:23

plan [4] - 182:14, 182:16,
233:20, 236:6

plan's [1] - 236:14

plans [5] - 102:18, 180:13,
182:11, 195:19, 195:25

pleased [5] - 55:12, 185:8,
185:10, 185:11, 198:13

plenary [2] - 199:6, 199:14

PLO [1] - 113:20

plots [3] - 61:17, 61:22, 65:5

plus [5] - 64:15, 109:11,
110:13, 175:2

point [37] - 12:18, 13:20,
23:15, 57:23, 92:17, 92:20,
111:23, 124:18, 133:13,
133:22, 134:12, 142:12,
142:13, 142:16, 142:21,
147:19, 151:1, 155:7,
156:11, 163:9, 170:1,
171:18, 181:16, 182:8,
182:9, 191:10, 203:6,
203:12, 203:20, 206:11,
215:12, 217:23, 220:3,
220:21, 221:2, 224:13,
242:9

pointed [2] - 173:2, 215:10

points [6] - 9:3, 31:4, 33:9,
112:4, 151:10, 181:15

policy [15] - 173:20, 173:22,
188:18, 188:22, 188:25,
189:8, 189:10, 195:6,
199:18, 199:23, 200:5,
210:14, 210:15, 210:19,
210:25

poor [1] - 26:18

population [25] - 58:23, 60:5,
64:1, 64:12, 108:21,
109:11, 109:12, 110:14,
114:6, 114:7, 124:22,
125:9, 179:12, 179:21,
182:5, 182:7, 193:25,
194:4, 194:10, 214:7,
214:9, 214:13, 214:16,
214:19, 218:12

populations [6] - 59:5, 59:7,
59:10, 59:21, 176:6, 214:6

portfolio [1] - 163:7

position [5] - 7:14, 8:3, 68:4,
138:25, 226:22

positive [17] - 61:1, 63:3,
63:8, 63:11, 63:19, 63:21,
63:24, 71:24, 74:19, 108:7,
108:10, 110:17, 110:18,
178:12, 178:15, 208:5,
220:25

positives [1] - 108:8

possession [2] - 176:19,
176:25

possible [5] - 26:20, 53:3,
100:14, 135:19, 163:25

possibly [3] - 75:13, 102:19,
161:12

post [2] - 99:21, 172:10

poster [1] - 184:20

posters [1] - 184:21

potential [4] - 69:2, 99:8,
175:21, 223:21

PowerPoint [2] - 57:9, 185:3

PR [1] - 64:15

practice [1] - 95:24

pre [3] - 134:24, 135:2,
143:20

pre-arbitration [1] - 134:24

pre-litigation [2] - 135:2,
143:20

precancerous [5] - 181:24,
181:25, 182:1, 214:15,
215:12

prejudicial [2] - 8:5, 146:22

preliminary [5] - 50:14, 76:5,
84:3, 142:11, 155:5

premalignant [2] - 64:21,
182:4

preparation [1] - 66:25

prepared [2] - 127:22,
148:18

preparing [2] - 146:8, 167:8

prescribe [1] - 218:4

presence [2] - 148:24,
178:22

present [29] - 25:22, 30:24,
74:3, 103:23, 107:3, 107:5,
122:21, 123:2, 124:8,
124:11, 125:24, 145:12,
148:21, 178:7, 178:17,
187:18, 189:1, 190:11,
190:13, 192:1, 193:16,
193:19, 194:16, 198:23,
200:3, 211:6, 214:2,
242:16

presentation [22] - 66:20,
66:21, 124:9, 125:6, 153:9,
185:2, 185:3, 185:9,
185:11, 187:10, 188:15,
195:13, 196:23, 198:14,
199:2, 199:4, 199:12,

199:13, 199:15, 207:1,
207:14, 235:17

presentations [6] - 176:23,
184:20, 184:25, 186:7,
199:14

presented [37] - 50:22,
103:23, 103:24, 106:11,
108:3, 121:19, 121:23,
122:1, 122:5, 122:8,
122:10, 129:16, 147:7,
147:8, 149:12, 153:6,
153:9, 182:18, 182:21,
183:1, 183:2, 184:3,
184:15, 189:4, 189:5,
191:5, 191:11, 194:1,
194:19, 195:6, 207:4,
207:5, 207:8, 207:14,
230:16, 230:22, 235:21

presenting [8] - 105:9,
106:22, 122:22, 185:25,
195:4, 210:16, 212:21,
235:20

presently [1] - 147:22

presents [1] - 68:1

preservation [1] - 71:2

preserve [1] - 70:23

preserved [7] - 49:1, 49:5,
51:8, 71:4, 80:7, 83:20,
84:25

preserving [2] - 74:9, 87:9

president [2] - 34:16, 200:19

PRESIDING [1] - 1:3

press [16] - 180:12, 180:16,
180:19, 180:20, 180:25,
182:10, 182:14, 182:16,
182:17, 182:22, 183:5,
183:6, 183:9, 183:14,
200:12, 220:23

pretial [1] - 31:20

pretty [4] - 9:15, 26:21,
164:25, 166:3

prevent [16] - 38:4, 123:17,
124:14, 166:9, 175:21,
182:3, 204:20, 218:7,
233:6, 234:17, 235:11,
235:13, 235:23, 235:25,
236:16, 236:22

preventative [1] - 233:17

preventatively [1] - 235:19

prevented [1] - 233:18

preventing [4] - 81:13,
234:11, 236:19, 237:1

prevention [2] - 217:20,
234:17

prevents [1] - 212:21

preview [1] - 106:21

previous [6] - 7:14, 16:5,
54:21, 64:8, 88:1, 129:11

previously [16] - 3:3, 31:10,
50:12, 64:18, 66:10, 66:11,

<p>144:18, 161:22, 189:23, 196:10, 203:11, 204:15, 208:24, 210:13, 211:15, 217:24</p> <p>price [4] - 27:9, 202:15, 202:20, 203:9</p> <p>primary [6] - 13:23, 14:13, 33:21, 150:7, 236:19, 236:25</p> <p>print [1] - 47:23</p> <p>printout [1] - 205:15</p> <p>priorities [1] - 161:9</p> <p>prioritizes [1] - 99:21</p> <p>priority [3] - 100:21, 153:19, 172:9</p> <p>privilege [2] - 10:15, 130:17</p> <p>problem [9] - 16:5, 18:25, 29:11, 30:9, 68:22, 68:23, 82:12, 99:23</p> <p>proceed [6] - 10:12, 79:21, 98:15, 148:18, 148:24, 165:8</p> <p>proceeded [1] - 171:25</p> <p>PROCEEDINGS [2] - 1:16, 243:3</p> <p>proceedings [1] - 197:22</p> <p>Proceedings [1] - 242:21</p> <p>process [19] - 50:2, 72:13, 72:18, 134:24, 135:1, 136:8, 136:9, 143:21, 143:25, 148:13, 168:6, 172:5, 185:24, 187:9, 189:14, 211:5, 227:8, 227:13, 229:10</p> <p>processed [1] - 69:15</p> <p>produce [6] - 56:1, 56:13, 61:21, 66:2, 66:9, 67:7</p> <p>produced [21] - 52:16, 57:9, 61:18, 64:25, 65:2, 65:4, 65:8, 65:9, 65:10, 65:11, 66:10, 66:13, 66:14, 66:15, 67:2, 67:5, 136:21, 136:22, 136:23, 138:4</p> <p>producing [1] - 66:18</p> <p>product [2] - 163:3, 201:23</p> <p>production [1] - 177:12</p> <p>Products [1] - 160:10</p> <p>products [3] - 160:19, 201:23, 202:5</p> <p>professor [1] - 222:8</p> <p>profile [1] - 226:4</p> <p>profitable [1] - 202:5</p> <p>progesterone [2] - 63:7, 63:9</p> <p>program [4] - 101:4, 112:14, 168:16, 198:12</p> <p>programs [3] - 61:21, 161:10, 170:10</p> <p>progressed [1] - 241:6</p> <p>project [1] - 102:12</p> <p>prominent [1] - 222:7</p>	<p>promising [1] - 78:12</p> <p>promoted [1] - 200:19</p> <p>pronounced [1] - 162:7</p> <p>proof [2] - 28:15, 138:19</p> <p>proper [1] - 26:19</p> <p>properly [3] - 17:13, 19:15, 147:2</p> <p>prophylaxis [25] - 123:10, 123:12, 123:18, 232:23, 232:24, 233:20, 234:6, 234:7, 234:10, 234:11, 234:16, 234:20, 234:21, 234:25, 235:3, 235:8, 235:19, 236:8, 236:14, 236:19, 236:20, 236:23, 237:1, 237:20</p> <p>proportional [1] - 36:13</p> <p>propose [1] - 147:12</p> <p>propriety [1] - 153:18</p> <p>prospectively [1] - 156:14</p> <p>prostate [5] - 159:13, 159:15, 162:8, 164:22, 199:10</p> <p>protect [3] - 105:4, 124:17, 133:25</p> <p>protocol [1] - 233:25</p> <p>proud [1] - 162:7</p> <p>prove [17] - 13:3, 13:19, 16:21, 16:22, 17:2, 17:10, 18:18, 21:17, 22:13, 25:8, 28:12, 28:24, 28:25, 29:4, 68:2, 138:19, 139:13</p> <p>provide [21] - 33:22, 56:11, 86:22, 88:19, 104:20, 111:22, 112:6, 112:9, 115:16, 137:24, 138:1, 139:7, 151:21, 154:6, 154:12, 165:2, 174:1, 177:20, 191:23, 192:14, 214:1</p> <p>provided [25] - 6:7, 7:2, 11:13, 21:10, 88:12, 93:12, 115:19, 127:16, 127:18, 131:6, 135:4, 136:8, 137:9, 137:16, 139:6, 140:4, 140:5, 143:5, 149:11, 149:13, 150:13, 151:15, 177:2, 177:6</p> <p>provides [2] - 9:9, 188:13</p> <p>providing [6] - 6:19, 88:5, 88:23, 132:12, 135:7, 177:11</p> <p>proving [2] - 29:3, 68:1</p> <p>provisional [1] - 25:24</p> <p>public [15] - 8:13, 103:11, 109:19, 112:16, 120:22, 180:14, 189:4, 189:5, 189:12, 195:7, 196:13, 199:25, 210:17, 222:3</p> <p>publicly [1] - 146:10</p>	<p>publish [3] - 107:6, 184:18, 192:21</p> <p>published [2] - 206:11, 208:20</p> <p>pudding [1] - 138:20</p> <p>Puma [57] - 13:23, 17:19, 27:8, 32:15, 34:17, 34:22, 84:4, 86:12, 93:12, 95:16, 102:17, 117:1, 134:6, 134:17, 143:25, 158:19, 158:20, 159:17, 164:19, 165:6, 165:10, 165:22, 165:23, 167:18, 167:20, 169:15, 173:20, 174:17, 174:19, 176:6, 176:7, 176:9, 176:18, 179:17, 180:7, 180:8, 182:11, 182:23, 183:18, 189:17, 190:18, 191:1, 191:20, 191:22, 192:6, 192:13, 193:9, 193:10, 195:9, 196:12, 200:17, 203:17, 219:5, 227:3, 227:12</p> <p>PUMA [2] - 1:10, 2:12</p> <p>Puma's [4] - 93:13, 201:8, 201:15, 226:14</p> <p>purist [1] - 124:7</p> <p>purporting [1] - 28:3</p> <p>purpose [4] - 82:24, 99:16, 105:3, 191:24</p> <p>purposes [3] - 130:24, 162:10, 170:1</p> <p>pursue [1] - 8:16</p> <p>put [40] - 7:13, 29:19, 30:21, 92:18, 104:13, 104:15, 105:3, 107:6, 107:8, 123:9, 123:12, 124:1, 125:1, 136:14, 138:11, 162:22, 163:1, 163:22, 164:9, 167:12, 171:2, 172:14, 173:22, 174:6, 176:1, 183:15, 184:18, 184:21, 186:10, 191:14, 200:9, 201:21, 202:1, 202:3, 203:6, 210:17, 226:6, 232:5, 236:7</p> <p>putting [6] - 8:2, 30:21, 187:21, 201:15, 208:18, 232:10</p>	<p>questions [39] - 6:2, 9:23, 10:18, 30:20, 31:16, 49:25, 50:10, 76:19, 76:22, 97:14, 119:14, 119:16, 129:4, 135:13, 135:16, 142:7, 144:11, 156:20, 158:14, 159:19, 166:24, 167:8, 172:14, 173:19, 174:9, 179:14, 185:6, 192:12, 203:24, 204:5, 212:11, 213:5, 217:12, 226:10, 230:6, 230:10, 232:22, 237:4, 240:5</p> <p>quick [1] - 163:25</p> <p>quicker [7] - 81:20, 99:15, 99:17, 99:20, 101:2, 101:9, 153:21</p> <p>quickly [7] - 7:10, 30:10, 53:24, 92:20, 100:13, 110:10, 166:5</p> <p>quickness [1] - 100:19</p> <p>quit [4] - 69:6, 69:9, 69:17, 69:18</p> <p>quite [19] - 56:24, 57:11, 61:9, 73:16, 77:21, 82:7, 82:10, 99:25, 109:22, 110:9, 141:23, 151:10, 158:14, 163:14, 163:16, 176:17, 184:9, 228:18</p> <p>quote [5] - 13:17, 27:3, 118:12, 144:4, 242:11</p> <p>quoted [1] - 118:10</p> <p>quotes [1] - 118:9</p>
R			
<p>raise [8] - 134:4, 144:15, 145:22, 162:9, 165:11, 201:24, 203:13, 203:15</p> <p>raised [8] - 116:23, 144:18, 159:21, 162:18, 162:22, 162:25, 165:22</p> <p>raising [5] - 134:12, 145:24, 203:3, 203:7, 203:9</p> <p>ran [3] - 47:9, 47:10, 160:12</p> <p>random [1] - 33:18</p> <p>randomization [1] - 35:15</p> <p>randomized [2] - 168:12, 207:1</p> <p>range [36] - 114:5, 114:8, 120:3, 120:5, 120:9, 120:10, 164:11, 174:16, 187:2, 189:22, 191:18, 208:19, 210:5, 210:10, 212:25, 213:1, 213:3, 213:4, 213:13, 213:15, 213:18, 213:25, 214:3, 215:1, 216:3, 216:14, 223:21, 224:17, 225:21, 225:22, 235:18, 237:20,</p>			
Q			
<p>qualification [1] - 105:20</p> <p>qualified [1] - 105:18</p> <p>quantity [2] - 81:23, 81:24</p> <p>question-and-answer [1] - 185:4</p> <p>questioning [6] - 87:9, 167:2, 167:16, 212:13, 216:19, 221:16</p>			

<p>240:2, 241:2, 241:21</p> <p>ranged [1] - 208:25</p> <p>rank [1] - 199:5</p> <p>ranked [1] - 199:5</p> <p>rat [2] - 82:15, 82:22</p> <p>rate [34] - 40:24, 43:7, 43:10, 43:23, 43:24, 43:25, 46:6, 64:22, 100:3, 118:21, 119:1, 119:6, 119:11, 119:22, 123:5, 147:25, 169:13, 178:12, 178:15, 185:14, 185:16, 206:3, 208:17, 228:12, 228:16, 231:14, 237:10, 237:13, 237:14, 237:21, 238:23, 240:6, 240:16</p> <p>rates [28] - 38:9, 48:14, 62:15, 84:7, 151:3, 152:5, 152:9, 152:10, 155:9, 155:10, 155:20, 194:16, 205:12, 206:17, 208:21, 208:24, 209:1, 216:3, 222:17, 228:3, 229:6, 230:11, 235:18, 236:3, 237:3, 237:4, 241:8, 241:19</p> <p>rather [3] - 135:6, 213:18, 216:20</p> <p>rating [1] - 184:14</p> <p>ratings [1] - 184:14</p> <p>ratio [27] - 36:19, 36:20, 37:12, 38:5, 45:9, 45:20, 46:1, 46:5, 46:10, 46:12, 46:15, 47:8, 47:24, 56:6, 64:8, 64:11, 78:20, 108:10, 168:24, 169:1, 181:8, 182:5, 216:6, 216:13, 221:3, 221:7</p> <p>ratios [5] - 37:4, 37:9, 45:16, 108:1, 110:2</p> <p>rats [6] - 81:7, 81:19, 81:22, 82:1, 82:19</p> <p>raw [1] - 221:20</p> <p>re [1] - 25:19</p> <p>reached [1] - 46:1</p> <p>reaching [1] - 88:2</p> <p>reaction [5] - 117:3, 203:10, 224:12, 228:9, 229:2</p> <p>reactions [1] - 195:12</p> <p>read [18] - 21:22, 77:5, 77:6, 77:8, 113:11, 113:16, 113:17, 118:6, 147:4, 180:25, 188:6, 200:22, 201:21, 204:3, 204:5, 219:25, 223:9, 223:19</p> <p>reading [4] - 25:11, 147:5, 148:9, 240:15</p> <p>ready [5] - 5:3, 30:15, 145:3, 189:15, 189:18</p> <p>real [17] - 40:16, 40:17, 47:8,</p>	<p>56:16, 57:4, 57:5, 57:6, 59:15, 140:5, 140:12, 140:14, 141:12, 142:2, 142:3, 149:11, 154:3, 155:2</p> <p>realize [1] - 161:6</p> <p>realized [1] - 161:11</p> <p>really [14] - 16:6, 17:3, 17:15, 30:23, 31:1, 47:2, 55:12, 79:4, 81:9, 151:12, 209:19, 209:21, 233:11</p> <p>reason [17] - 11:10, 43:20, 56:15, 97:1, 97:4, 97:12, 113:7, 124:10, 140:16, 154:4, 154:5, 161:7, 161:10, 192:2, 228:13, 229:5, 241:4</p> <p>reasonable [2] - 212:6, 225:7</p> <p>reasons [7] - 6:13, 18:17, 94:20, 100:1, 221:15, 236:6, 241:11</p> <p>rebut [5] - 19:15, 138:2, 144:22, 144:23, 147:2</p> <p>rebuttal [3] - 11:7, 25:24, 26:5</p> <p>rebuttals [2] - 11:9, 11:12</p> <p>receive [7] - 28:23, 107:1, 118:3, 160:1, 204:17, 204:18, 216:24</p> <p>received [97] - 3:8, 3:8, 3:9, 3:9, 3:10, 3:10, 3:11, 3:11, 3:12, 3:12, 3:13, 3:13, 3:14, 3:14, 3:15, 3:15, 3:16, 3:16, 3:17, 3:17, 3:18, 3:18, 3:19, 3:19, 3:20, 3:20, 3:21, 3:21, 3:22, 3:22, 3:23, 3:24, 3:24, 3:25, 3:25, 4:1, 4:1, 32:9, 34:13, 36:6, 40:2, 42:10, 44:14, 47:19, 51:12, 55:9, 60:19, 62:24, 65:23, 70:3, 71:7, 74:12, 75:7, 80:11, 83:25, 85:2, 85:8, 85:22, 86:6, 87:17, 88:25, 89:9, 89:24, 90:14, 93:20, 98:16, 102:8, 103:8, 109:3, 111:10, 111:14, 111:16, 112:24, 113:2, 114:21, 116:16, 121:16, 122:17, 131:13, 150:4, 153:23, 160:4, 160:6, 169:14, 170:7, 170:20, 188:5, 193:2, 197:8, 198:11, 201:13, 205:19, 207:21, 217:1, 218:25, 219:2, 228:10</p> <p>receives [2] - 117:15, 169:6</p> <p>receiving [3] - 235:2, 235:8, 236:8</p> <p>recent [9] - 86:18, 88:11,</p>	<p>95:12, 95:20, 95:22, 205:8, 207:7, 207:24, 219:6</p> <p>recently [1] - 102:18</p> <p>receptor [6] - 61:18, 63:9, 63:10, 63:24, 108:7</p> <p>Recess [3] - 74:1, 126:1, 190:12</p> <p>recite [1] - 10:14</p> <p>recognize [5] - 60:11, 102:10, 109:5, 121:18, 151:1</p> <p>recognized [2] - 161:5, 177:4</p> <p>recollect [2] - 151:7, 174:3</p> <p>recollection [25] - 34:1, 34:19, 35:24, 44:19, 56:22, 70:14, 79:7, 90:7, 90:8, 91:2, 91:3, 91:10, 91:11, 91:13, 95:1, 95:2, 95:10, 95:11, 109:13, 112:11, 141:21, 150:15, 150:23, 156:18, 211:1</p> <p>record [21] - 15:6, 20:1, 24:9, 39:20, 52:4, 53:16, 53:23, 57:6, 57:10, 57:11, 57:16, 66:24, 87:4, 87:5, 100:8, 116:19, 116:21, 117:8, 126:2, 148:15</p> <p>RECORDED [1] - 243:3</p> <p>recreate [1] - 39:11</p> <p>recreating [1] - 110:1</p> <p>recurrence [6] - 38:5, 40:19, 40:23, 40:24, 56:2, 217:20</p> <p>redacted [3] - 49:16, 49:17, 129:1</p> <p>reduce [3] - 55:20, 124:5, 236:2</p> <p>reduces [1] - 123:11</p> <p>reducing [1] - 56:2</p> <p>reduction [3] - 224:8, 235:9, 236:9</p> <p>REDUCTION [1] - 243:6</p> <p>refer [15] - 59:8, 119:15, 129:13, 129:14, 171:19, 181:20, 183:13, 184:19, 184:24, 200:20, 205:1, 216:19, 229:18, 238:4, 238:5</p> <p>reference [10] - 5:10, 7:8, 21:9, 21:16, 22:11, 31:20, 127:4, 129:9, 132:7</p> <p>referenced [8] - 5:8, 9:21, 12:23, 23:18, 64:17, 128:17, 129:24, 189:23</p> <p>references [3] - 5:25, 128:22, 129:2</p> <p>referencing [4] - 10:2, 148:1, 149:20, 218:11</p> <p>referred [8] - 108:7, 181:25, 183:3, 199:1, 205:6, 210:1, 211:1, 235:1</p>	<p>referring [15] - 17:8, 94:3, 94:9, 100:20, 113:22, 118:24, 125:11, 168:7, 193:7, 204:14, 231:7, 231:21, 232:19, 239:15, 239:23</p> <p>reflect [2] - 53:6, 96:1</p> <p>reflects [2] - 26:21, 96:10</p> <p>refresh [7] - 34:1, 34:19, 35:23, 44:19, 60:13, 68:18, 70:14</p> <p>refute [2] - 144:16, 145:14</p> <p>refuting [1] - 145:15</p> <p>regard [2] - 227:15, 234:5</p> <p>regarding [8] - 6:2, 7:2, 67:2, 127:12, 155:9, 155:19, 156:12, 196:18</p> <p>region [1] - 33:12</p> <p>REGULATIONS [1] - 243:7</p> <p>regulatory [5] - 73:16, 88:13, 101:5, 182:11, 202:24</p> <p>reiterated [1] - 78:3</p> <p>reject [1] - 187:24</p> <p>related [3] - 201:19, 202:16, 233:1</p> <p>relates [2] - 6:20, 7:6</p> <p>relation [2] - 203:14, 216:5</p> <p>relationship [3] - 7:17, 17:19, 55:11</p> <p>relationships [1] - 162:13</p> <p>release [22] - 103:10, 117:3, 119:12, 121:18, 122:7, 180:12, 180:17, 180:19, 180:21, 180:25, 182:10, 182:15, 182:16, 182:17, 182:22, 183:5, 183:6, 183:9, 199:25, 200:12, 212:20, 220:23</p> <p>released [1] - 112:5</p> <p>releases [1] - 183:14</p> <p>relevance [5] - 10:14, 99:7, 146:22, 146:25, 164:25</p> <p>relevant [2] - 117:7, 223:15</p> <p>relied [2] - 56:17, 141:15</p> <p>relies [1] - 166:20</p> <p>relive [1] - 159:16</p> <p>relying [1] - 141:14</p> <p>remaining [1] - 12:1</p> <p>remains [1] - 181:7</p> <p>remedies [1] - 8:16</p> <p>remember [64] - 35:18, 43:5, 46:18, 57:21, 58:3, 58:7, 58:8, 58:11, 59:11, 60:1, 60:20, 64:3, 65:2, 65:11, 66:19, 66:21, 68:9, 68:10, 68:11, 68:18, 69:13, 69:14, 69:20, 73:13, 76:17, 78:10, 78:15, 78:16, 78:21, 93:25, 95:4, 101:17, 107:9, 109:8, 110:8, 114:10, 114:12,</p>
--	---	--	--

<p>114:13, 121:4, 121:7, 121:8, 122:7, 123:5, 124:24, 124:25, 125:13, 125:20, 141:5, 151:5, 151:6, 151:11, 151:14, 155:3, 174:11, 191:17, 191:19, 193:10, 214:13, 214:23, 215:4, 215:8, 236:11</p> <p>remembered [3] - 95:6, 95:7, 95:8</p> <p>remembers [1] - 154:24</p> <p>remind [5] - 28:9, 190:22, 198:5, 232:23, 237:13</p> <p>reminded [1] - 170:3</p> <p>reminder [4] - 199:17, 199:21, 202:4, 203:13</p> <p>reminding [1] - 67:23</p> <p>remove [5] - 15:2, 15:5, 59:10, 91:1, 91:3</p> <p>removed [5] - 59:5, 59:7, 90:21, 90:24, 131:18</p> <p>removing [1] - 91:2</p> <p>repeat [1] - 174:9</p> <p>repeatedly [1] - 142:25</p> <p>repeating [2] - 116:12, 130:12</p> <p>rephrase [1] - 79:21</p> <p>replies [1] - 61:17</p> <p>report [25] - 19:14, 25:20, 28:3, 45:19, 88:19, 88:22, 88:24, 89:24, 89:25, 110:23, 201:1, 201:4, 216:20, 216:23, 217:3, 217:9, 217:22, 218:18, 219:4, 219:8, 219:25, 221:19, 222:4, 223:19, 237:9</p> <p>reported [7] - 107:21, 110:6, 119:11, 204:11, 210:2, 216:7, 235:18</p> <p>REPORTER [2] - 1:22, 243:10</p> <p>reporter [1] - 29:22</p> <p>REPORTER'S [1] - 1:16</p> <p>reporting [6] - 16:17, 18:23, 19:12, 19:14, 28:16, 68:20</p> <p>reports [19] - 12:2, 12:3, 12:6, 12:8, 12:19, 12:21, 12:24, 19:8, 19:9, 65:8, 66:14, 85:18, 89:4, 89:13, 105:13, 216:17, 216:25, 219:3, 223:15</p> <p>representation [1] - 147:18</p> <p>represented [1] - 142:25</p> <p>request [22] - 28:11, 59:22, 74:15, 74:16, 75:17, 80:15, 80:19, 82:25, 99:22, 104:22, 129:15, 132:11, 132:17, 142:4, 149:23,</p>	<p>149:25, 150:6, 153:13, 167:9, 171:7, 171:11</p> <p>requested [17] - 6:4, 7:1, 39:5, 55:4, 55:5, 56:8, 56:10, 57:2, 58:15, 58:25, 60:8, 88:6, 95:19, 133:22, 141:10, 142:1</p> <p>requesting [4] - 61:23, 150:6, 150:10, 156:9</p> <p>requests [4] - 135:4, 136:11, 150:19, 155:7</p> <p>require [5] - 5:12, 31:24, 146:7, 146:25, 202:11</p> <p>required [12] - 136:23, 136:25, 137:4, 137:7, 137:9, 137:15, 138:2, 138:4, 139:8, 139:21, 139:22, 179:2</p> <p>requires [1] - 134:22</p> <p>research [5] - 125:21, 162:23, 184:11, 202:6, 242:13</p> <p>resolution [7] - 129:2, 131:3, 134:24, 135:1, 136:8, 143:19, 143:25</p> <p>resolve [1] - 139:13</p> <p>resolved [1] - 138:6</p> <p>resourced [1] - 99:25</p> <p>resources [1] - 163:19</p> <p>respect [2] - 23:18, 208:21</p> <p>respected [2] - 124:4, 220:7</p> <p>respond [6] - 16:1, 50:1, 79:14, 117:15, 144:19, 175:9</p> <p>responding [5] - 47:22, 76:23, 133:2, 139:14, 175:7</p> <p>responds [2] - 225:5, 225:11</p> <p>response [24] - 8:23, 20:10, 20:16, 21:2, 21:13, 21:19, 23:11, 24:18, 25:1, 25:7, 25:11, 25:15, 27:12, 84:20, 84:22, 85:18, 119:1, 136:11, 139:19, 141:1, 155:8, 155:18, 156:11</p> <p>responses [1] - 97:18</p> <p>responsibility [1] - 53:17</p> <p>responsible [1] - 227:3</p> <p>rest [4] - 15:13, 151:13, 199:14</p> <p>restate [1] - 113:18</p> <p>result [5] - 43:18, 117:3, 169:19, 218:1, 218:4</p> <p>resulted [2] - 181:2, 181:17</p> <p>results [52] - 32:21, 32:22, 41:10, 48:6, 48:9, 68:24, 69:2, 71:11, 72:2, 72:7, 83:3, 84:9, 85:14, 90:19, 90:21, 107:21, 107:22, 108:21, 122:4, 124:4,</p>	<p>139:2, 153:22, 153:23, 154:3, 176:2, 176:7, 177:17, 180:4, 180:5, 180:14, 180:19, 180:21, 180:24, 181:1, 181:16, 182:10, 182:17, 182:20, 183:10, 183:20, 194:22, 196:20, 196:22, 207:8, 208:14, 208:15, 209:20, 226:7, 229:9, 230:21, 235:20, 235:21</p> <p>RESUMED [2] - 3:4, 31:11</p> <p>returning [1] - 242:11</p> <p>returns [1] - 166:19</p> <p>Reuters [2] - 27:2, 27:5</p> <p>reveal [1] - 102:20</p> <p>revenue [1] - 201:23</p> <p>reverse [2] - 72:2, 83:8</p> <p>reversed [1] - 87:7</p> <p>review [12] - 35:4, 63:5, 97:18, 100:20, 100:21, 100:25, 105:13, 105:22, 172:9, 184:13, 198:25, 223:15</p> <p>reviewed [3] - 175:24, 198:11, 216:25</p> <p>reviews [1] - 198:25</p> <p>revised [2] - 49:17, 86:19</p> <p>revisit [2] - 23:17, 28:1</p> <p>Rho [1] - 226:15</p> <p>rhymes [1] - 17:23</p> <p>Richard [1] - 193:11</p> <p>right-hand [2] - 206:8, 209:4</p> <p>rights [5] - 8:16, 161:16, 162:4, 165:21</p> <p>ripe [2] - 140:23</p> <p>rise [6] - 73:25, 74:2, 125:23, 148:20, 190:10, 242:15</p> <p>risk [29] - 55:20, 59:12, 59:14, 59:18, 59:23, 60:3, 82:5, 130:12, 183:7, 183:13, 183:16, 183:19, 183:20, 183:22, 183:24, 183:25, 200:2, 200:12, 201:19, 202:1, 202:3, 202:13, 202:14, 202:19, 203:22, 208:5, 224:7, 225:1</p> <p>risks [4] - 80:23, 183:17, 200:13, 201:19</p> <p>ROBBINS [1] - 2:5</p> <p>robust [2] - 109:24, 220:16</p> <p>Roden [3] - 215:9, 240:8, 240:11</p> <p>rooms [3] - 184:20, 184:25, 186:7</p> <p>Ropes [1] - 138:14</p> <p>roughly [2] - 35:18, 118:25</p> <p>row [1] - 27:4</p> <p>RUDDMAN [1] - 2:5</p>	<p>rule [11] - 9:7, 9:10, 11:8, 11:9, 11:11, 11:12, 87:10, 87:14, 126:11, 143:17, 145:3</p> <p>ruling [12] - 11:12, 19:21, 21:12, 22:15, 24:3, 24:24, 25:15, 27:12, 29:15, 53:7, 128:10</p> <p>rulings [2] - 20:23, 27:20</p> <p>run [8] - 45:24, 46:9, 49:9, 168:7, 211:20, 214:5, 216:12, 217:13</p> <p>running [6] - 78:13, 160:20, 162:22, 163:11, 168:16, 237:19</p> <p>runs [1] - 130:22</p>
S			
<p>SACV15-0865-AG [1] - 1:8</p> <p>safe [1] - 81:5</p> <p>safer [1] - 124:16</p> <p>safety [24] - 69:8, 69:18, 76:25, 77:10, 78:6, 122:4, 124:17, 168:10, 186:3, 194:22, 196:20, 196:22, 225:25, 226:3, 226:12, 226:14, 226:24, 227:4, 227:8, 227:10, 227:16, 227:21, 229:9, 229:11</p> <p>sake [1] - 224:2</p> <p>sales [2] - 163:12, 203:2</p> <p>sample [1] - 178:25</p> <p>samples [1] - 68:13</p> <p>San [10] - 62:10, 104:5, 187:14, 187:15, 189:24, 191:8, 193:4, 207:5, 207:11, 207:14</p> <p>SAN [2] - 2:7, 2:14</p> <p>Sanayha [1] - 20:6</p> <p>SANTA [3] - 1:18, 1:23, 5:1</p> <p>SARAH [1] - 2:13</p> <p>SAS [1] - 112:14</p> <p>sat [1] - 191:13</p> <p>save [1] - 67:14</p> <p>saved [5] - 93:17, 93:24, 94:2, 94:4, 176:21</p> <p>saw [15] - 40:17, 56:17, 63:22, 68:10, 69:7, 99:9, 109:7, 154:21, 154:22, 164:15, 190:18, 217:22, 222:4, 237:9, 241:23</p> <p>scale [2] - 54:12, 54:14</p> <p>scenario [4] - 48:2, 48:9, 48:13, 48:19</p> <p>scenarios [1] - 47:11</p> <p>schedule [2] - 99:24, 167:17</p> <p>scheduled [1] - 190:1</p> <p>Schmidt [6] - 18:12, 19:19, 20:2, 23:13, 217:8, 237:8</p>			

Schmidt's ^[1] - 239:25

scholarships ^[1] - 160:1

school ^[3] - 160:3, 222:9, 222:14

sciences ^[1] - 34:17

scientific ^[3] - 182:18, 182:20, 198:12

score ^[1] - 199:1

screen ^[12] - 92:7, 92:16, 125:5, 151:22, 153:1, 172:8, 184:1, 189:3, 230:23, 230:24, 231:5, 233:11

screens ^[1] - 185:2

SEC ^[1] - 200:21

second ^[43] - 5:17, 5:20, 5:25, 7:24, 27:3, 34:8, 36:17, 37:20, 45:20, 46:5, 46:14, 49:24, 51:14, 54:13, 68:10, 89:15, 92:6, 99:7, 114:22, 115:12, 116:25, 123:19, 129:25, 142:17, 142:21, 142:23, 150:8, 167:5, 167:16, 183:6, 184:19, 186:13, 197:21, 198:10, 200:10, 205:6, 217:13, 219:4, 224:15, 226:2, 236:22, 240:6, 241:14

secondary ^[5] - 181:16, 182:8, 182:9, 236:20, 236:23

section ^[2] - 201:18, 235:1

securities ^[1] - 203:3

Securities ^[2] - 201:2, 201:3

see ^[148] - 5:19, 11:16, 14:3, 14:17, 14:20, 14:23, 18:1, 27:21, 33:24, 35:4, 36:13, 36:22, 37:1, 37:8, 38:21, 40:6, 40:14, 40:25, 42:19, 43:13, 45:6, 45:13, 45:21, 46:10, 47:25, 48:14, 48:17, 49:9, 53:19, 54:10, 56:14, 57:3, 58:13, 58:20, 59:18, 59:21, 60:2, 61:15, 61:19, 61:22, 62:16, 71:23, 72:5, 74:16, 74:19, 75:18, 77:1, 77:3, 78:23, 80:16, 81:24, 82:4, 82:6, 85:20, 86:20, 89:12, 89:25, 90:3, 90:12, 90:14, 90:18, 90:20, 90:21, 90:22, 90:23, 90:25, 91:22, 92:13, 102:22, 107:22, 111:25, 112:7, 116:5, 117:21, 123:6, 125:8, 125:22, 125:25, 131:9, 137:14, 139:3, 142:2, 149:18, 149:20, 150:8, 151:3, 151:24, 152:11, 153:1, 154:1, 157:13,

161:15, 169:3, 171:7, 172:8, 175:9, 175:18, 178:6, 178:7, 181:4, 181:11, 183:11, 188:13, 188:18, 188:22, 189:3, 194:25, 198:16, 199:19, 200:23, 202:17, 202:25, 203:4, 206:12, 207:2, 208:23, 212:1, 217:10, 217:13, 217:15, 220:13, 220:17, 221:5, 222:18, 223:1, 224:10, 224:15, 225:3, 225:9, 225:16, 228:3, 229:17, 229:22, 230:2, 231:3, 231:5, 231:6, 231:17, 233:1, 233:10, 233:17, 237:23, 238:9, 239:11, 239:17, 240:3, 240:22, 242:17

seeing ^[10] - 35:13, 46:14, 65:11, 66:19, 154:24, 176:2, 209:4, 209:21, 230:24, 231:20

seek ^[2] - 19:19, 72:24

seeks ^[1] - 135:11

seem ^[13] - 19:14, 35:18, 46:18, 69:14, 78:16, 89:19, 139:8, 143:14, 146:13, 147:20, 151:6, 151:11, 151:14

Segal ^[3] - 75:11, 172:13, 173:11

selected ^[3] - 198:14, 199:13, 199:15

sell ^[1] - 161:16

selloff ^[3] - 113:8, 113:22, 117:4

send ^[9] - 55:2, 95:13, 95:17, 95:19, 103:20, 127:22, 139:22, 139:24, 153:23

sending ^[8] - 49:21, 49:25, 51:1, 54:8, 54:17, 74:15, 105:12, 105:20

sends ^[2] - 142:5, 178:20

senior ^[1] - 34:16

sense ^[5] - 163:25, 204:6, 213:21, 213:23, 241:3

sensitivity ^[2] - 42:1, 42:3

sent ^[40] - 6:1, 41:15, 54:24, 57:17, 58:17, 58:18, 59:1, 59:6, 60:9, 88:23, 89:8, 89:25, 90:19, 91:7, 93:11, 93:19, 93:23, 94:5, 94:7, 94:8, 94:15, 94:17, 94:19, 95:17, 96:9, 99:1, 105:13, 105:22, 114:20, 139:25, 141:6, 142:14, 149:6, 151:7, 152:21, 153:3, 153:11, 154:18, 178:19, 178:25

sentence ^[11] - 51:16, 90:11, 90:13, 107:22, 107:23, 147:20, 148:4, 181:8, 198:10, 236:7

sentences ^[3] - 147:17, 148:15, 181:1

separated ^[1] - 199:8

separating ^[2] - 50:15, 131:22

separation ^[1] - 155:21

September ^[14] - 36:8, 49:8, 66:12, 75:16, 76:15, 80:13, 127:19, 129:15, 131:21, 140:15, 149:21, 153:7, 155:6, 155:13

sequence ^[1] - 135:7

serious ^[2] - 75:24, 170:10

seriously ^[1] - 22:21

session ^[2] - 198:15, 199:6

set ^[12] - 32:25, 39:13, 50:11, 50:21, 50:23, 142:9, 142:15, 143:1, 143:2, 143:5, 234:1, 240:5

setting ^[5] - 83:15, 182:12, 204:23, 217:21, 218:7

seven ^[5] - 35:20, 35:21, 157:17, 228:24, 239:7

seventh ^[1] - 45:24

several ^[4] - 51:5, 145:22, 176:14, 224:19

severe ^[9] - 229:4, 229:18, 229:23, 230:3, 231:9, 231:14, 233:1, 235:14, 235:23

severity ^[1] - 123:11

shaded ^[1] - 206:7

shaking ^[1] - 145:8

shall ^[2] - 115:2, 115:3

shape ^[1] - 57:21

share ^[3] - 103:13, 105:1, 141:9

shared ^[4] - 57:24, 104:6, 104:8, 105:6

shareholder ^[4] - 114:22, 116:9, 116:25, 117:1

shelf ^[2] - 162:2, 165:17

shelves ^[2] - 161:14, 161:18

Sherman ^[7] - 38:25, 39:2, 55:2, 57:18, 60:23, 227:5

shift ^[1] - 7:19

shifts ^[1] - 224:8

short ^[5] - 35:6, 106:20, 126:5, 153:17, 230:2

short-staffed ^[1] - 153:17

short-term ^[1] - 230:2

shortened ^[1] - 187:22

shorter ^[1] - 125:17

shot ^[1] - 24:19

show ^[24] - 5:9, 41:25, 43:16, 57:9, 58:17, 96:17, 101:1,

131:10, 133:23, 138:3, 138:12, 140:7, 140:21, 141:12, 149:17, 151:22, 154:16, 154:18, 154:20, 186:1, 192:16, 212:5, 234:22, 234:24

showed ^[15] - 47:5, 57:15, 57:22, 58:12, 104:16, 104:17, 104:18, 104:21, 124:5, 140:12, 141:22, 153:10, 167:15, 172:12, 187:16

showing ^[11] - 45:15, 54:17, 55:3, 57:6, 57:17, 57:21, 93:5, 159:14, 190:4, 194:10, 225:7

shown ^[32] - 56:19, 56:20, 57:5, 57:23, 61:12, 61:13, 66:22, 81:13, 93:18, 107:22, 131:21, 131:22, 140:14, 141:17, 141:18, 142:3, 150:15, 150:16, 150:20, 150:21, 155:2, 155:5, 155:15, 155:22, 155:24, 156:16, 156:18, 189:21, 208:24, 216:17, 226:23, 236:5

shows ^[12] - 35:9, 37:20, 54:12, 54:13, 54:20, 91:16, 92:20, 93:2, 93:5, 140:9, 142:5, 208:13

shutdown ^[2] - 67:10, 67:12

sic ^[2] - 26:21, 142:10

sic ^[1] - 85:25

side ^[11] - 9:16, 186:4, 209:4, 209:18, 211:8, 228:1, 232:25, 237:14, 240:4, 242:1

sides ^[4] - 7:2, 31:3, 53:5, 139:12

sideshow ^[2] - 18:13, 143:1

signal ^[1] - 47:8

signed ^[2] - 105:5, 195:8

significance ^[2] - 63:20, 223:13

significant ^[4] - 21:1, 133:13, 181:9, 202:11

significantly ^[1] - 123:10

similar ^[6] - 12:25, 41:22,

68:24, 189:2, 205:12, 218:8

simplifying ^[1] - 132:5

simply ^[2] - 31:22, 158:21

simulate ^[1] - 40:10

simulated ^[2] - 142:13, 143:4

simulation ^[9] - 40:22, 41:3, 41:5, 44:18, 55:5, 141:6, 149:14, 149:15, 155:2

simulations ^[23] - 40:22, 41:1, 41:9, 44:17, 45:24,

49:9, 56:5, 56:11, 56:13, 57:2, 57:3, 58:14, 58:16, 58:18, 58:22, 59:3, 59:9, 59:15, 60:6, 139:25, 142:1, 142:2, 216:12

single [2] - 36:18, 199:4

single-digit [1] - 199:4

sit [3] - 31:1, 128:4, 128:6

sitting [3] - 161:13, 162:2, 165:17

situ [3] - 181:19, 182:1, 214:14

situation [1] - 212:20

situations [1] - 210:21

six [21] - 37:4, 37:8, 37:22, 38:2, 45:5, 45:10, 46:15, 114:6, 120:5, 120:9, 125:10, 156:7, 156:8, 159:1, 164:13, 207:23, 208:2, 213:14, 213:16, 214:5, 222:11

six-month [2] - 37:4, 45:5

size [5] - 107:7, 124:22, 124:24, 159:2, 160:16

skeptics [1] - 219:5

skip [1] - 11:5

slap [1] - 92:16

sleep [1] - 10:14

slide [33] - 57:9, 57:23, 66:22, 69:16, 69:17, 104:2, 104:8, 123:9, 193:3, 193:19, 193:22, 194:11, 194:20, 194:24, 207:23, 208:2, 208:13, 208:22, 209:4, 227:23, 230:17, 230:19, 230:23, 231:7, 231:10, 235:2, 235:6, 235:17, 236:15, 236:24, 239:7, 240:1, 240:3

slides [14] - 123:1, 123:13, 123:14, 124:1, 124:3, 125:1, 125:7, 125:8, 193:25, 194:9, 194:15, 194:17, 194:23, 235:21

slight [1] - 21:9

slightly [1] - 28:1

slip [1] - 227:23

slow [2] - 113:16, 235:4

slowly [2] - 161:1, 204:25

small [7] - 67:13, 67:17, 159:2, 160:16, 163:9, 166:7, 183:17

smaller [1] - 78:18

smart [2] - 166:17, 211:18

SMITH [1] - 2:11

smoothly [1] - 148:24

snapshot [5] - 141:14, 176:20, 177:1, 177:12, 177:17

snippet [1] - 139:8

Society [3] - 106:13, 106:15, 183:3

software [2] - 109:24, 112:14

sold [1] - 165:10

solicited [1] - 7:1

someone [15] - 6:15, 14:7, 29:18, 30:10, 62:1, 62:5, 65:1, 65:11, 66:9, 77:19, 78:17, 95:8, 163:22, 192:2, 220:6

sometime [1] - 73:15

sometimes [5] - 10:17, 22:25, 61:13, 203:9, 226:19

somewhat [2] - 10:10, 221:16

somewhere [15] - 94:2, 162:25, 164:2, 164:11, 165:24, 174:16, 187:2, 189:21, 191:18, 209:6, 221:10, 231:18, 231:19, 232:6, 241:1

sophisticated [2] - 109:22, 216:11

sorry [29] - 12:15, 13:10, 15:25, 16:8, 19:6, 26:6, 29:8, 30:25, 37:25, 39:22, 42:19, 63:13, 64:8, 66:16, 69:22, 77:2, 87:25, 90:10, 91:18, 107:13, 114:12, 115:14, 115:20, 121:24, 137:21, 141:7, 142:19, 143:12, 235:5

Sorry [1] - 157:2

sort [4] - 18:14, 111:19, 147:10, 224:8

sought [2] - 73:12, 100:16

sound [1] - 76:11

South [1] - 195:22

Southern [1] - 166:4

space [1] - 108:23

spans [1] - 173:1

speaking [2] - 25:14, 110:3

specializes [1] - 178:21

specific [10] - 7:8, 8:2, 10:23, 24:19, 129:1, 131:10, 145:23, 145:25, 146:19, 229:12

specifically [13] - 56:12, 58:15, 69:14, 81:10, 127:11, 159:1, 159:7, 160:11, 166:22, 177:24, 185:8, 192:17, 213:20

spectrum [1] - 213:8

speculate [1] - 223:10

speculation [1] - 223:9

speed [4] - 30:3, 30:7, 30:9, 30:14

speeding [1] - 72:18

spelled [3] - 164:21, 193:11,

193:13

spike [1] - 231:6

spits [1] - 30:10

split [1] - 166:3

spoken [1] - 109:21

spontaneous [1] - 81:20

staff [1] - 53:2

staffed [1] - 153:17

stage [6] - 100:2, 168:5, 175:14, 183:17, 203:18, 204:16

stand [1] - 24:7

standard [7] - 73:7, 78:9, 168:13, 204:17, 206:18, 206:20, 221:15

standing [1] - 128:9

stands [6] - 49:16, 77:15, 106:12, 161:24, 214:14, 220:5

start [21] - 5:14, 11:14, 35:13, 48:5, 115:1, 116:10, 144:20, 145:5, 153:15, 158:17, 161:18, 162:9, 163:11, 165:11, 165:22, 168:10, 171:21, 172:7, 222:16, 233:15, 240:15

started [12] - 31:2, 73:2, 76:3, 138:25, 161:6, 171:16, 174:17, 174:19, 175:2, 175:5, 203:22

starting [8] - 11:15, 31:19, 86:15, 158:18, 163:13, 164:19, 193:3, 242:11

starts [5] - 38:1, 199:18, 222:5, 224:23, 233:2

state [10] - 12:20, 13:4, 13:5, 13:6, 17:8, 83:22, 99:13, 116:24, 117:9, 223:16

statement [28] - 8:2, 9:15, 9:17, 10:5, 10:6, 10:21, 10:24, 11:21, 13:14, 13:19, 21:17, 21:18, 21:22, 22:12, 22:25, 24:6, 24:7, 24:22, 25:11, 25:21, 31:25, 105:14, 105:19, 116:6, 123:14, 124:1, 124:3, 226:12

statements [7] - 9:13, 18:4, 18:11, 21:5, 21:14, 183:10, 183:16

States [1] - 195:21

states [4] - 72:25, 127:21, 189:3, 199:23

STATES [2] - 1:1, 243:7

stating [2] - 6:3, 220:24

statistic [2] - 181:20, 216:3

statistical [11] - 41:3, 41:4, 63:20, 66:7, 177:23, 216:11, 227:3, 227:8, 233:20, 236:5, 236:13

statistically [1] - 181:9

statistician [4] - 39:1, 65:3, 66:22, 75:12

statisticians [6] - 39:6, 62:6, 65:7, 109:23, 112:13, 179:17

statistics [2] - 101:1, 239:13

status [7] - 33:11, 33:12, 111:24, 179:3, 201:5, 208:10, 210:9

stay [3] - 125:22, 164:3, 164:6

stayed [1] - 164:13

staying [2] - 136:24, 164:16

steering [25] - 104:9, 104:18, 122:24, 182:24, 187:12, 189:21, 190:19, 190:22, 190:23, 190:25, 191:6, 191:15, 192:8, 192:9, 192:17, 193:4, 193:19, 194:1, 194:12, 195:4, 195:8, 195:12, 195:15, 195:20, 198:7

stemmed [1] - 230:11

STENOGRAPHICALLY [1] - 243:3

step [8] - 53:19, 70:18, 73:9, 116:17, 118:14, 185:24, 211:5, 242:17

steps [2] - 38:16, 38:18

stick [1] - 19:21

still [23] - 33:19, 50:2, 68:12, 69:15, 73:11, 78:13, 89:19, 92:14, 120:13, 127:18, 136:20, 167:4, 173:15, 174:21, 175:7, 175:8, 176:18, 176:25, 200:4, 203:17, 221:11, 226:7, 242:5

stipulation [1] - 164:10

stock [16] - 11:20, 13:23, 14:13, 27:9, 27:12, 32:20, 114:9, 114:10, 120:20, 192:4, 192:5, 192:6, 202:15, 203:3, 203:9, 203:14

stop [8] - 28:23, 29:14, 29:25, 116:17, 123:19, 153:21, 159:5, 242:7

stopped [6] - 69:12, 69:14, 238:6, 238:7, 238:11, 239:16

stopping [1] - 233:2

story [8] - 130:13, 132:5, 137:13, 138:1, 138:22, 139:14, 144:20, 144:21

straight [1] - 125:19

strategy [4] - 130:18, 147:9, 147:11, 148:14

Street [8] - 109:22, 111:17,

158:25, 159:1, 160:15,
160:21, 211:16
STREET [1] - 1:23
strikes [1] - 217:10
stuck [1] - 131:17
studied [1] - 208:7
studies [49] - 80:23, 81:4,
81:6, 81:7, 81:18, 81:19,
81:21, 82:11, 82:14, 82:15,
82:16, 82:18, 82:22, 84:16,
84:19, 85:19, 97:7, 118:22,
123:10, 124:5, 124:11,
124:23, 124:25, 125:10,
125:11, 184:11, 184:17,
204:12, 204:13, 205:21,
205:25, 206:2, 208:19,
208:21, 208:23, 208:25,
209:4, 210:2, 210:3, 210:6,
215:3, 215:5, 215:11,
215:15, 227:16, 228:15,
235:22, 237:18
study [68] - 33:1, 34:21, 38:3,
42:24, 43:15, 43:21, 44:25,
46:2, 72:7, 78:7, 78:19,
83:3, 84:10, 85:18, 96:16,
121:19, 124:7, 124:21,
168:21, 175:10, 175:12,
178:18, 179:3, 179:5,
179:8, 182:11, 185:7,
191:2, 191:4, 198:19,
205:12, 206:1, 206:4,
206:15, 206:16, 206:17,
206:25, 207:1, 207:4,
207:5, 207:7, 207:8,
207:14, 207:24, 208:7,
208:9, 208:14, 216:20,
221:4, 228:7, 228:23,
230:9, 234:6, 238:7,
238:12, 238:24, 239:12,
239:16, 239:19, 239:20,
239:21, 240:1, 241:4,
241:10, 241:11, 241:12,
242:3
stuff [5] - 105:22, 135:19,
140:16, 152:22, 237:17
subgroup [4] - 42:1, 42:2,
63:25, 156:12
subgroups [9] - 33:14,
41:23, 61:2, 61:18, 63:23,
108:4, 108:16, 156:14,
156:15
subject [11] - 9:14, 11:19,
21:1, 23:7, 23:9, 87:2,
116:7, 128:20, 134:17,
202:15, 202:20
subjects [4] - 42:17, 233:25,
235:7, 236:8
submission [6] - 85:20,
101:19, 106:24, 188:1,
188:13, 199:24

submit [10] - 80:15, 83:1,
84:15, 84:16, 84:21,
106:19, 167:8, 171:7,
171:10, 189:8
submitted [11] - 53:6, 82:20,
106:23, 167:19, 184:12,
185:7, 187:23, 188:14,
189:18, 198:20, 198:24
submitting [4] - 80:20,
187:9, 189:11, 198:9
subset [1] - 111:23
substance [2] - 196:15,
196:20
substantial [2] - 76:6, 76:8
subtract [1] - 216:7
succeed [1] - 221:18
success [1] - 8:15
successful [2] - 185:17,
185:21
successfully [1] - 144:1
sucked [1] - 139:14
sudden [1] - 32:1
sue [2] - 138:6, 138:20
sued [1] - 133:16
sufficiently [1] - 18:20
sugar [1] - 228:13
suggest [5] - 25:10, 26:9,
47:8, 123:10, 135:24
suggested [6] - 6:13, 135:18,
136:17, 143:21, 143:22,
145:17
suggesting [2] - 143:22,
223:20
suggests [2] - 30:6, 220:15
SUITE [2] - 1:23, 2:6
summarized [1] - 236:10
summarizing [1] - 129:15
summary [5] - 106:20,
106:22, 151:1, 187:23,
193:24
Sunday [1] - 199:7
super [1] - 139:5
supplied [1] - 56:15
supplying [1] - 6:3
support [1] - 183:21
supports [2] - 93:10, 145:13
supposed [1] - 102:24
supposedly [8] - 16:17, 18:4,
19:8, 19:9, 19:12, 19:13,
28:5, 88:23
surely [1] - 18:6
surgery [1] - 204:17
surprised [1] - 139:1
surprising [1] - 221:17
surprisingly [1] - 145:7
survival [13] - 127:23,
147:15, 147:24, 159:14,
181:3, 181:18, 206:9,
206:14, 208:17, 210:7,
220:24, 222:24, 225:2

Susan [1] - 193:13
SUSANNAH [1] - 2:4
suspicious [1] - 146:14
sustain [5] - 11:22, 13:13,
24:9, 116:12, 223:12
sustained [10] - 15:7, 15:11,
25:9, 25:19, 27:7, 117:25,
119:4, 120:17, 147:23,
148:7
sustaining [21] - 13:15,
13:20, 15:14, 16:4, 20:5,
20:8, 20:14, 20:15, 20:16,
20:25, 21:1, 23:6, 23:10,
24:16, 25:1, 25:4, 25:5,
25:20, 27:1, 27:4, 27:5
sway [1] - 97:11
swear [1] - 210:16
switch [3] - 41:14, 42:7,
225:24
switching [1] - 29:5
sworn [3] - 3:3, 31:10, 67:22
symbol [1] - 30:23
Symposium [2] - 104:6,
207:15
system [2] - 93:13, 105:4

T

table [18] - 46:6, 63:12,
63:14, 84:6, 131:17,
140:13, 150:6, 151:14,
151:18, 151:24, 152:1,
152:10, 152:24, 153:21,
153:22, 154:4, 154:5,
239:10
tables [11] - 62:15, 72:1,
96:16, 96:21, 129:15,
140:11, 150:22, 226:24,
227:4, 227:21, 229:9
takeaways [2] - 219:6, 220:3
talks [7] - 32:21, 33:10,
33:16, 76:19, 107:25,
180:24, 208:2
tangible [1] - 61:15
tantamount [1] - 217:20
taper [1] - 233:14
TCH [1] - 206:21
team [12] - 62:11, 66:7, 66:9,
95:12, 95:14, 95:15, 95:19,
97:19, 177:11, 177:23
technical [2] - 105:11,
236:18
technique [1] - 142:22
Technology [1] - 161:25
technology [5] - 162:17,
209:9, 209:13, 209:22,
219:5
teleconference [4] - 83:15,
167:17, 167:20
telephonic [1] - 85:11

ten [8] - 209:18, 221:14,
228:17, 237:20, 240:2,
241:1, 241:21, 242:6
tend [3] - 229:17, 230:2,
230:6
tended [1] - 168:17
tends [4] - 203:10, 206:22,
229:25, 231:2
tens [2] - 104:14, 104:15
tenuous [1] - 36:21
term [6] - 41:4, 55:18, 56:4,
155:19, 204:3, 230:2
termed [1] - 99:4
terminal [1] - 159:5
terminate [1] - 164:10
terms [11] - 96:8, 105:7,
105:11, 105:18, 151:12,
198:22, 203:25, 204:9,
236:18, 240:24, 241:19
test [11] - 81:9, 178:6, 178:7,
178:9, 178:19, 178:21,
178:24, 179:6, 215:16,
232:8
tested [2] - 171:21, 204:22
testified [12] - 127:5, 131:4,
150:12, 154:21, 154:22,
155:1, 169:22, 189:16,
198:18, 216:24, 229:14,
232:12
testifies [1] - 129:17
testify [1] - 142:9
testimony [14] - 79:4, 79:10,
90:6, 91:1, 95:9, 112:9,
154:23, 154:24, 155:4,
156:16, 170:16, 211:25,
216:18, 229:16
testing [9] - 68:12, 70:11,
81:5, 81:8, 81:10, 81:18,
82:13, 208:4, 208:7
tests [2] - 160:12, 178:10
Texas [1] - 187:14
THAT [1] - 243:2
THE [354] - 2:3, 2:11, 5:3,
5:6, 5:16, 5:19, 5:23, 6:11,
6:22, 7:3, 7:12, 7:17, 7:22,
8:1, 8:8, 8:24, 11:18, 12:5,
12:10, 12:13, 12:22, 13:1,
13:13, 14:2, 14:8, 14:11,
14:17, 14:19, 14:23, 15:1,
15:5, 15:22, 15:24, 16:2,
16:8, 16:11, 16:13, 16:18,
17:10, 17:21, 17:24, 19:1,
19:4, 19:18, 20:3, 20:5,
20:12, 20:19, 20:24, 21:4,
21:16, 21:24, 22:3, 22:7,
22:9, 22:11, 22:16, 22:18,
22:21, 22:23, 23:5, 23:15,
23:20, 23:22, 24:2, 24:5,
24:15, 24:25, 25:4, 25:17,
26:4, 26:7, 26:17, 26:24,

27:15, 27:18, 27:24, 28:8, 28:17, 28:20, 28:22, 29:5, 29:9, 29:13, 29:18, 30:2, 30:9, 30:18, 30:20, 30:25, 31:19, 32:11, 34:12, 36:5, 40:1, 44:13, 47:18, 49:2, 49:4, 49:10, 49:17, 49:19, 51:9, 51:11, 51:16, 51:19, 51:23, 52:8, 52:11, 52:14, 52:17, 52:22, 52:24, 53:20, 53:25, 60:18, 60:20, 62:23, 65:15, 65:18, 65:20, 65:22, 67:19, 67:25, 68:3, 69:25, 70:2, 70:25, 71:5, 73:21, 73:23, 73:25, 74:2, 74:4, 74:11, 75:6, 79:13, 79:18, 79:20, 80:9, 81:16, 81:17, 83:22, 83:24, 85:1, 86:3, 86:5, 87:3, 87:5, 87:10, 87:13, 92:14, 92:24, 97:17, 98:6, 98:8, 98:11, 98:14, 100:9, 101:22, 102:3, 102:5, 102:7, 103:7, 106:7, 106:15, 106:17, 106:18, 106:19, 107:10, 107:12, 107:13, 107:16, 107:18, 109:2, 111:9, 112:21, 112:23, 113:16, 113:18, 114:23, 114:25, 115:6, 115:7, 115:8, 115:10, 115:14, 115:18, 115:22, 116:1, 116:5, 116:10, 116:17, 116:21, 117:10, 117:13, 117:17, 117:21, 117:24, 118:13, 118:15, 118:19, 119:4, 119:9, 119:15, 120:15, 120:17, 121:15, 122:14, 122:16, 125:18, 125:23, 125:25, 126:2, 126:5, 126:10, 126:13, 126:17, 126:21, 127:2, 127:6, 127:9, 127:24, 128:2, 128:5, 128:10, 128:14, 128:19, 128:22, 128:24, 129:6, 129:19, 129:22, 130:2, 130:9, 130:15, 130:23, 131:8, 131:14, 131:24, 132:2, 132:6, 132:17, 133:10, 133:18, 133:25, 134:5, 134:7, 134:9, 134:12, 134:20, 135:12, 136:1, 136:5, 136:10, 136:13, 136:16, 136:20, 136:24, 137:2, 137:4, 137:7, 137:17, 137:22, 138:16, 139:18, 141:1, 142:18, 143:10, 143:13, 144:7, 144:9, 144:14, 145:2, 145:10, 145:24, 146:9, 146:16, 146:20,

146:24, 147:4, 147:6, 147:19, 148:3, 148:6, 148:11, 148:16, 148:20, 148:22, 150:3, 154:9, 154:12, 156:21, 156:25, 157:3, 157:6, 157:8, 157:10, 157:12, 157:15, 157:17, 157:19, 157:22, 158:1, 158:5, 158:9, 165:1, 165:5, 165:8, 170:6, 170:12, 170:14, 170:17, 170:19, 170:21, 172:20, 186:12, 186:16, 188:4, 190:6, 190:8, 190:10, 190:14, 192:25, 197:7, 197:11, 197:13, 197:16, 197:17, 197:18, 197:19, 197:23, 201:12, 205:18, 207:20, 218:23, 219:11, 219:13, 219:17, 219:20, 223:12, 223:17, 223:19, 235:4, 235:5, 242:9, 242:15, 242:17, 243:2, 243:3, 243:4, 243:6, 243:7
theirs [1] - 180:4
themselves [2] - 177:24, 216:15
theory [2] - 145:11, 145:13
therapy [8] - 80:15, 118:23, 169:22, 171:9, 171:10, 172:4, 173:12, 240:20
therefore [3] - 117:16, 178:21, 213:2
they've [6] - 8:12, 43:14, 61:12, 71:3, 129:1, 175:17
thinking [7] - 16:22, 212:1, 223:11, 224:25, 229:14, 232:13
thinks [1] - 211:22
third [11] - 35:21, 35:25, 42:2, 45:24, 89:17, 180:24, 205:7, 221:1, 222:6, 224:4, 241:16
THIS [1] - 243:5
Thomas [2] - 27:2, 27:5
thoughts [1] - 190:5
thousand [1] - 238:18
thousands [5] - 99:22, 107:1, 184:11, 185:1, 186:8
threatened [1] - 139:4
threatening [1] - 75:24
three [74] - 5:17, 32:5, 35:1, 35:6, 35:8, 39:8, 40:10, 40:25, 41:9, 41:20, 43:13, 44:6, 47:10, 47:24, 51:24, 52:5, 52:11, 52:13, 52:18, 53:18, 54:5, 54:25, 55:18, 56:24, 58:14, 78:4, 79:14, 107:4, 110:13, 113:20,

114:2, 114:4, 123:5, 123:11, 124:6, 141:20, 141:24, 142:16, 155:3, 155:7, 156:24, 157:1, 162:2, 164:12, 168:8, 184:16, 205:21, 205:25, 206:2, 206:6, 217:19, 218:6, 218:11, 222:24, 224:17, 225:2, 225:22, 228:22, 228:23, 229:4, 230:8, 230:12, 230:21, 231:9, 232:13, 232:19, 233:18, 234:23, 234:24, 234:25, 236:3, 237:10, 238:8, 241:11
three-page [3] - 52:11, 52:13, 52:18
three-year [5] - 39:8, 40:10, 40:25, 41:9, 141:20
throughout [1] - 48:20
throwing [1] - 10:19
thrown [1] - 132:8
THURSDAY [2] - 1:19, 5:1
tier [1] - 184:24
ties [1] - 130:25
timed [3] - 7:14, 97:19, 165:1
timeline [2] - 41:7, 41:8
timely [1] - 153:20
timers [1] - 92:21
timing [7] - 6:21, 97:17, 100:19, 125:18, 135:3, 135:8, 202:24
today [5] - 5:9, 88:22, 176:19, 181:7, 222:6
together [10] - 38:2, 105:4, 187:13, 187:21, 191:12, 191:14, 201:15, 205:3, 205:4, 208:19
Tom [1] - 161:24
TOMKOWIAK [1] - 2:13
tonight's [1] - 113:21
took [13] - 27:22, 58:12, 59:16, 94:13, 95:16, 96:24, 99:15, 104:3, 105:8, 176:20, 207:6, 213:5, 233:13
tools [1] - 216:11
top [15] - 33:11, 41:6, 41:16, 71:23, 74:22, 84:6, 89:22, 89:23, 97:3, 110:12, 110:13, 171:6, 191:17, 208:5, 222:17
topic [1] - 67:3
topline [13] - 41:10, 41:12, 44:24, 72:2, 83:2, 83:7, 84:9, 85:14, 108:21, 153:22, 177:17, 180:21, 194:6
TOR [1] - 2:3
total [1] - 228:17

tough [1] - 68:2
toward [3] - 93:7, 153:16, 163:11
track [3] - 169:12, 172:9, 179:8
tract [1] - 229:25
trading [2] - 114:13, 202:20
transaction [1] - 102:21
transcript [10] - 8:25, 9:4, 14:22, 30:17, 80:2, 200:8, 200:10, 219:6, 221:20, 221:24
TRANSCRIPT [3] - 1:16, 243:3, 243:5
transcripts [1] - 23:23
translating [1] - 165:18
trastuzumab [1] - 207:2
treat [7] - 58:23, 60:5, 63:25, 75:24, 108:21, 114:6, 210:8
treating [2] - 234:12, 234:15
treatment [14] - 159:3, 160:12, 160:23, 169:6, 174:24, 181:2, 181:17, 194:24, 204:18, 206:3, 236:9, 236:10, 239:11, 239:14
treatments [1] - 160:17
trend [1] - 46:14
trends [1] - 40:11
triage [2] - 152:21, 153:17
triaging [1] - 151:11
trial [57] - 7:14, 30:5, 54:10, 58:19, 73:2, 73:3, 75:15, 78:18, 78:24, 114:1, 118:25, 119:8, 122:3, 123:17, 133:11, 133:12, 133:15, 139:15, 147:16, 165:1, 171:17, 173:6, 173:19, 174:9, 174:10, 174:11, 175:8, 175:23, 176:2, 178:8, 180:20, 180:22, 181:1, 181:16, 182:8, 182:9, 187:10, 190:24, 191:1, 191:7, 192:17, 204:10, 205:6, 208:2, 210:1, 215:6, 215:17, 220:10, 223:22, 231:1, 232:23, 236:6, 237:5, 237:13
TRIAL [1] - 1:17
trials [29] - 76:4, 78:4, 78:13, 124:9, 160:13, 160:19, 160:20, 160:23, 162:23, 163:4, 165:11, 168:8, 168:12, 169:10, 171:21, 174:14, 175:1, 175:24, 179:23, 183:21, 191:22, 203:19, 204:11, 204:22, 204:24, 205:2, 205:3,

<p>205:13 tried ^[1] - 97:5 triggered ^[1] - 213:24 tripling ^[1] - 82:4 trouble ^[1] - 137:23 troubled ^[1] - 17:18 troubling ^[2] - 196:4, 196:6 TRUE ^[1] - 243:2 true ^[13] - 6:10, 10:6, 17:15, 18:11, 18:16, 18:21, 29:1, 67:21, 67:22, 138:24, 139:25, 192:12, 207:13 truncated ^[1] - 36:22 truncation ^[2] - 33:17, 34:21 trust ^[1] - 95:14 truth ^[11] - 13:3, 13:19, 18:7, 18:22, 21:18, 22:13, 28:15, 28:24, 29:3, 33:19, 116:23 truthful ^[1] - 19:14 truthfully ^[1] - 18:23 try ^[6] - 29:24, 29:25, 30:11, 204:20, 221:11, 235:25 trying ^[27] - 12:18, 14:25, 18:12, 18:13, 26:19, 40:10, 53:17, 72:13, 72:24, 97:6, 99:22, 99:24, 110:23, 115:20, 130:1, 134:4, 135:18, 205:11, 212:16, 212:24, 217:23, 231:19, 233:6, 234:17, 235:11, 235:22, 236:16 Tuesday ^[4] - 158:7, 242:11, 242:12, 242:18 tuition ^[1] - 160:6 tumor ^[3] - 33:12, 63:10, 178:7 tumors ^[5] - 64:21, 81:20, 181:22, 182:4 turn ^[31] - 71:22, 74:7, 75:9, 85:10, 85:25, 86:24, 103:3, 111:6, 114:15, 117:22, 142:16, 150:24, 165:6, 167:5, 171:4, 192:20, 193:22, 196:25, 197:4, 201:7, 201:18, 202:14, 206:24, 207:23, 216:22, 221:22, 222:15, 227:22, 230:15, 230:17, 237:6 turned ^[2] - 8:14, 187:17 Twitter ^[4] - 113:10, 113:13, 113:19, 113:23 two ^[97] - 5:14, 6:7, 33:9, 33:11, 33:17, 33:19, 33:20, 34:2, 34:4, 34:23, 35:2, 35:6, 35:7, 35:19, 36:21, 36:22, 38:3, 38:8, 38:21, 39:6, 41:19, 43:9, 46:2, 51:14, 51:20, 51:24, 51:25, 52:15, 52:19, 52:24, 53:4, 55:22, 56:2, 56:24, 62:14,</p>	<p>62:15, 63:23, 66:6, 69:6, 70:5, 81:22, 82:6, 82:15, 82:22, 84:17, 89:4, 89:22, 91:4, 91:6, 93:19, 97:9, 108:4, 108:16, 115:8, 115:19, 117:5, 128:21, 139:12, 140:4, 141:24, 142:13, 147:16, 148:14, 155:3, 155:20, 156:6, 160:18, 163:10, 164:11, 173:1, 176:13, 176:15, 179:8, 181:1, 194:9, 205:2, 205:3, 205:4, 206:21, 208:18, 217:18, 218:5, 218:11, 223:4, 223:23, 224:15, 224:17, 224:20, 225:2, 225:21, 232:8, 237:9, 238:3, 238:19, 239:12, 239:23, 241:18 two-year ^[8] - 33:17, 35:6, 35:19, 38:3, 62:14, 62:15, 82:15, 82:22 type ^[14] - 41:1, 60:1, 80:19, 179:17, 183:15, 199:13, 213:21, 213:23, 213:25, 215:8, 216:12, 226:22, 239:2, 241:13 types ^[3] - 130:22, 179:8, 184:5 typical ^[1] - 16:24 typically ^[5] - 96:6, 168:7, 168:22, 199:6, 237:18 tyrosine ^[1] - 166:22</p>	<p>understated ^[2] - 196:20, 196:22 understood ^[6] - 61:11, 68:6, 130:3, 144:8, 148:16, 220:20 undertake ^[1] - 86:15 underwriter's ^[1] - 87:21 underwriters ^[2] - 87:22, 154:22 unexpected ^[1] - 221:17 unfortunate ^[1] - 241:16 unfortunately ^[11] - 99:25, 108:17, 159:4, 161:4, 166:17, 169:13, 175:20, 178:10, 210:21, 241:15 uniformly ^[1] - 11:13 uninsured ^[1] - 174:4 United ^[2] - 161:23, 195:21 UNITED ^[2] - 1:1, 243:7 University ^[2] - 159:24, 159:25 unless ^[2] - 8:2, 223:12 unnamed ^[3] - 18:3, 18:24, 19:15 unprecedented ^[3] - 221:2, 221:4, 221:8 unrelated ^[4] - 10:20, 132:20, 147:1, 202:16 untenable ^[1] - 7:13 untimed ^[1] - 18:24 up ^[102] - 5:12, 6:14, 8:3, 8:9, 8:20, 13:15, 14:11, 15:7, 16:6, 23:22, 25:5, 31:15, 32:1, 35:1, 37:24, 38:1, 43:16, 44:3, 45:13, 48:14, 51:2, 53:5, 53:11, 55:25, 59:24, 62:10, 64:2, 66:7, 66:8, 72:18, 80:23, 83:15, 91:6, 92:7, 98:18, 110:3, 115:7, 125:4, 125:19, 128:7, 128:8, 128:9, 133:6, 136:18, 138:9, 141:5, 144:14, 148:17, 155:19, 156:11, 158:15, 158:17, 159:13, 159:19, 159:20, 163:12, 164:1, 164:16, 164:20, 167:12, 169:15, 170:15, 171:2, 172:14, 175:18, 176:1, 183:2, 184:21, 185:5, 186:10, 188:7, 188:12, 190:18, 191:15, 195:21, 197:9, 200:9, 201:21, 201:22, 205:23, 211:12, 212:7, 215:25, 217:15, 217:24, 218:6, 222:2, 222:3, 225:14, 226:6, 229:7, 229:10, 230:9, 230:23, 232:9, 234:22, 234:24, 236:7, 236:15, 238:11,</p>	<p>238:17 upcoming ^[1] - 102:20 update ^[6] - 55:16, 86:19, 88:13, 98:24, 99:1, 201:4 upset ^[6] - 120:24, 121:2, 121:4, 121:7, 121:8, 121:9 upside ^[1] - 11:20 USC ^[1] - 160:5 user ^[2] - 209:14, 209:22 user-friendly ^[2] - 209:14, 209:22</p>
V			
<p>vague ^[1] - 14:15 validated ^[10] - 50:6, 50:12, 226:8, 226:13, 226:14, 226:16, 226:19, 226:24, 237:17 validating ^[1] - 50:2 validation ^[8] - 227:4, 227:8, 227:9, 227:13, 227:17, 228:21, 229:10, 229:12 value ^[3] - 47:24, 146:23, 181:10 various ^[7] - 9:6, 33:14, 41:23, 81:8, 81:23, 152:25, 158:2 Vat ^[1] - 56:9 Vat-Ho ^[1] - 56:9 Vatnak ^[5] - 56:9, 56:12, 59:4, 149:9, 149:11 vein ^[1] - 237:22 vendor ^[2] - 226:15, 226:20 venture ^[1] - 80:1 version ^[8] - 14:19, 26:20, 78:18, 93:15, 93:23, 94:18, 96:6, 96:23 versus ^[9] - 29:25, 42:13, 82:1, 96:4, 114:3, 120:10, 181:3, 181:19, 236:20 viable ^[1] - 87:6 vice ^[2] - 34:16, 200:19 videographer ^[6] - 15:1, 26:18, 27:21, 28:22, 29:14, 30:16 videotape ^[1] - 28:10 view ^[4] - 9:5, 220:7, 220:25, 236:14 viewed ^[1] - 38:7 vigorous ^[1] - 28:2 violated ^[3] - 36:18, 37:13, 210:18 violating ^[1] - 210:24 vis-à-vis ^[1] - 134:17 visit ^[1] - 43:12 visually ^[1] - 61:15 volatility ^[2] - 202:16, 202:20 volume ^[3] - 115:10, 115:12, 176:8</p>			

Volume ^[1] - 115:22 volumes ^[2] - 115:2, 115:8 Vs ^[1] - 1:8	withdrawal ^[4] - 239:11, 239:19, 240:1, 240:3 withdrawn ^[1] - 5:14 withdrew ^[1] - 239:21 withheld ^[9] - 130:17, 130:18, 133:21, 134:6, 135:25, 136:4, 136:6, 138:2, 145:7 withhold ^[1] - 136:10 withholding ^[1] - 135:9 Witness ^[5] - 36:11, 44:20, 75:10, 221:23, 237:7 WITNESS ^[13] - 3:2, 60:20, 81:17, 86:3, 106:17, 106:19, 107:13, 107:18, 113:18, 115:7, 154:12, 223:19, 235:5 witness ^[25] - 3:3, 9:9, 9:18, 9:24, 9:25, 10:6, 10:19, 14:12, 20:2, 27:11, 31:10, 37:15, 51:24, 67:22, 97:15, 115:23, 116:7, 117:18, 119:16, 129:4, 138:12, 145:17, 147:23, 157:24, 158:3 witnesses ^[2] - 136:14, 138:18 Wolff ^[2] - 86:8, 86:9 woman's ^[1] - 55:20 women ^[3] - 55:22, 55:23, 55:24 wonderful ^[3] - 55:11, 55:22, 56:3 wondering ^[1] - 155:13 WONG ^[1] - 193:15 Wong ^[6] - 34:8, 34:15, 34:16, 193:15, 226:23, 226:25 Woods ^[3] - 71:19, 85:4, 88:25 woods ^[2] - 74:14, 89:10 Word ^[1] - 93:6 word ^[4] - 10:1, 68:14, 80:2, 179:9 words ^[9] - 53:21, 61:7, 113:17, 186:19, 196:15, 196:19, 212:9, 237:25, 241:7 works ^[4] - 113:4, 166:16, 198:23, 200:17 world ^[1] - 220:7 worldwide ^[1] - 195:20 worried ^[3] - 76:25, 144:25, 195:3 worry ^[2] - 77:10, 129:2 worth ^[1] - 68:20 would've ^[1] - 95:6 write ^[4] - 25:5, 79:23, 110:12, 110:23 writer ^[1] - 9:20	writes ^[4] - 32:16, 220:3, 220:12, 221:2 writing ^[9] - 12:21, 60:23, 71:18, 96:4, 96:5, 116:14, 139:10, 146:5, 146:13 written ^[4] - 110:8, 110:10, 110:21, 110:24 wrongfully ^[2] - 136:3, 136:5 wrote ^[3] - 21:10, 23:8, 50:20 Wyeth ^[1] - 174:12	young ^[5] - 55:22, 55:24, 175:13, 175:15, 175:17 yourself ^[1] - 158:18 yourselves ^[1] - 26:14
W		X	Z
wait ^[8] - 32:5, 34:8, 51:13, 101:25, 102:1, 197:11, 225:8, 228:20 waive ^[2] - 12:3, 22:19 waived ^[1] - 14:15 waiver ^[1] - 22:25 walk ^[4] - 180:17, 189:17, 210:22, 231:22 walked ^[2] - 176:5, 194:11 Wall ^[7] - 109:21, 158:25, 159:1, 160:15, 160:21, 211:16 walls ^[1] - 184:22 wants ^[5] - 25:22, 134:10, 134:13, 134:14, 135:19 warned ^[1] - 183:9 warning ^[2] - 183:13, 203:7 warnings ^[1] - 183:7 watch ^[1] - 55:25 WATKINS ^[1] - 2:13 Watkins ^[1] - 138:15 website ^[6] - 72:25, 76:2, 100:24, 111:19, 201:3, 205:15 Wednesday ^[1] - 41:8 week ^[1] - 190:3 weekend ^[1] - 242:12 weeks ^[2] - 49:8, 51:5 welcome ^[2] - 30:25, 148:22 Werber ^[21] - 155:8, 209:25, 210:11, 211:14, 212:10, 213:18, 214:24, 215:24, 216:4, 218:15, 219:8, 220:3, 220:9, 220:12, 221:2, 221:21, 222:5, 222:11, 225:5 Werber's ^[4] - 203:23, 204:5, 214:4, 226:2 WEST ^[2] - 1:23, 2:6 whereas ^[1] - 212:16 whole ^[13] - 9:7, 22:8, 55:16, 87:8, 99:16, 114:1, 137:13, 138:1, 138:22, 139:14, 143:7, 184:12, 186:9 wholly ^[3] - 140:2, 140:9, 140:24 widening ^[1] - 38:1 William ^[1] - 87:19 william ^[1] - 87:20 window ^[2] - 78:14, 224:9 wish ^[1] - 88:10 WITH ^[1] - 243:6 withdraw ^[2] - 241:10, 241:12		X1 ^[3] - 3:23, 187:6, 187:7	Z-y-t-i-g-a ^[1] - 164:22 Zytiga ^[2] - 159:13, 164:21
		Y	
		Yao ^[19] - 32:14, 32:15, 36:9, 37:3, 37:14, 38:17, 39:1, 40:5, 45:6, 45:23, 47:23, 66:2, 131:22, 140:6, 141:20, 149:14, 155:2 Yaron ^[10] - 211:16, 211:17, 211:21, 212:12, 212:18, 213:1, 215:2, 215:7, 221:16, 221:21 year ^[30] - 33:17, 35:6, 35:19, 35:21, 35:25, 38:3, 39:8, 40:10, 40:25, 41:9, 45:20, 45:24, 45:25, 46:5, 46:14, 46:16, 50:15, 51:2, 62:14, 62:15, 82:15, 82:22, 141:20, 143:6, 179:23, 198:10, 201:16, 204:18, 240:20 Year ^[1] - 88:10 years ^[48] - 33:19, 33:20, 34:2, 34:4, 34:23, 35:1, 35:7, 35:8, 36:21, 36:22, 38:21, 41:20, 46:2, 47:24, 54:25, 55:18, 55:19, 55:22, 55:23, 56:3, 56:24, 58:14, 69:7, 78:24, 78:25, 81:22, 97:9, 105:16, 141:24, 155:3, 155:20, 159:1, 162:2, 164:12, 174:22, 175:2, 175:6, 176:13, 176:15, 206:6, 209:12, 209:19, 221:14, 222:24, 238:19 Yellow ^[1] - 107:9 yellow ^[2] - 25:22, 26:8 yesterday ^[14] - 5:9, 6:13, 26:5, 29:22, 30:5, 30:6, 35:17, 41:24, 42:12, 43:4, 64:20, 106:7, 181:21, 238:2 York ^[6] - 55:14, 129:18, 140:4, 140:15, 141:9, 149:9	